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‘The liver has always been an important symbol in occult physiology. As the largest 
organ, the one containing the most blood, it was regarded as the darkest, least penetrable 
part of man's innards. Thus it was considered to contain the secret of fate and was used 
for fortune-telling. In Plato, and in later physiology, the liver represented the darkest 
passions, particularly the bloody, smoky ones of wrath, jealousy, and greed which drive 
men to action. Thus the liver meant the impulsive attachment to life itself ‘ 
 ~~~~~~~~~~~~~~~~~~~~~~~~  
 
James Hillman 
 
 
 
 
 
 
 
 
Abstract 
Abstract  
Liver cirrhosis and/or liver malignancies have been nominated as the 5th leading cause of 
death worldwide. The WHO reported, in 2006, that 20 million people around the globe 
suffer from some form or other of severe liver illness. The ultimate fate of end-stage liver 
disorders is hepatic dysfunction and eventually organ failure. The only curative mode of 
management for liver failure is liver transplantation, which is subject to many limitations. 
Novel alternatives, such as artificial and bio-artificial support devices only aid in temporary 
replacement of some liver function until an organ is available for transplantation. These 
newer modalities also have drawbacks or remain experimental and still demand further 
controlled trials to allow proof of concept and safety before transferring them to the bedside.  
Regenerative medicine and stem cell therapy has recently shown promise in the 
management of various human diseases. Recent reports of stem cell plasticity and its 
multipotentiality has raised hopes of stem cell therapy offering exciting therapeutic 
possibilities for patients with chronic liver disease. With the understanding that stem cells 
might not just be about making organs ex vivo, but also regenerating a patients own tissues; 
a concept is now developing to use stem cells to treat patients with serious disease 
conditions that are terminal or where conventional modes of treatment are insufficient.  
There exists a choice of stem cells that have been reported to be capable of self-renewal and 
differentiation to hepato-biliary cell lineages both in vitro and in vivo. These include: rodent 
and human embryonic stem cells, bone marrow haematopoietic stem cells, mesenchymal 
stem cells, umbilical cord blood stem cells, foetal liver progenitor cell and adult liver 
progenitor cells. It may, however, be argued that with a global population of 6 billion people 
and a global birth rate in access of 130 million per year, the products of birth ,umbilical cord 
and cord blood, possibly provide the most readily accessible and ethically sound alternative 
source of stem cells. The differentiated stem cells can be potentially exploited for gene 
therapy, cellular transplant, bio-artificial liver-assisted devices, drug toxicology testing and 
use as an in vitro model to understand the developmental biology of the liver.  
 
In this study UCB-derived nucleated cells and umbilical cord-derived Mesenchymal stem 
cells were exploited for liver differentiation ex vivo. These cells were cultured on 
extracellular matrix (ECM) protein-coated dishes and inserted into ECM incorporated 
scaffold 3D culture systems. Stimulation with exogenous mitogens and morphogens to 
induce hepatic histogenesis was experimented.  Immunofluorescence analysis revealed the 
expression of markers specific for: hepatic stem cells (CK-19), hepatoblasts (AFP) and 
  4 
mature hepatic and biliary epithelium markers including: albumin (ALB), and cytokeratin-
18 (CK-18) and cytokeratin-19 (CK-19) and cytokeratin-7 (CK-7) respectively. The 
differentiated cells displayed several features of hepatic cell kinetics and metabolic 
activities, including glycogen synthesis, uptake of Indocyanine green dye and cytochrome 
P450 activity.   
These cells may prove to have potential in developing cellular therapy for various liver 
disorders for which the current mode of therapy is inadequate and also provide an adequate 
in vitro model of parenchymal liver cells in toxicology and in bioartificial liver research. 
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The following section is a brief insight into the biology of stem cells.  
1 Introduction  
1.1 Definition of stem cell  
The concept of stem cell arose from pioneering studies of Till and McCullogh on the 
haematopoietic stem cell and those of Leblond on spermatogenesis and intestinal crypt 
(Handbook of Stem Cells, volume1- Embryonic Stem Cells, Lanza 2004).  
Stem cells can be defined as single cells that are clonal precursors of both more identical 
stem cells and a defined set of differentiated progeny (Till and McCulloch 1961) 
(Weissman, Anderson et al. 2001) (Smith 2001).  
More explicitly, stem cells are capable of generating daughter cells identical to their mother 
(self-renewal) as well as produce progeny with more restricted potential (differentiated 
cells) (Handbook of Stem Cells , Volume 1, embryonic stem cells, Lanza 2004). This board 
definition may be acceptable for embryonic and foetal stem cells that do not remain in 
existence for the life-time of an organism. But this definition proves inadequate in trying to 
discriminate between transient adult progenitor cells that have a reduced capacity of self-
renewal and adult stem cells. Hence, it is important when describing adult stem cells to 
further restrict this definition to cells that self-renew through-out the life span of the 
organism (van der Kooy and Weiss 2000) (Handbook of Stem Cells, volume1- Embryonic 
Stem Cells, 2004). 
Parameters that play a pivotal role in defining ‘stemness’ include the following: self renewal 
(replication capacity), clonality, and potency.  
 
 Self renewal 
Most in vitro cultures of somatic cells demonstrate a finite number of population doubling 
(less than 80) prior to undergoing senescence or replication arrest, and this can be contrasted 
to the seemingly unrestricted proliferation capacity of stem cells in culture (Hayflick 1973; 
Hayflick 1974; Sherr and DePinho 2000).  Therefore, if a cell that can undergo more than 
twice this number of population doublings (160) without tumour transformation may 
possibly be regarded as ‘capable of extensive proliferation’. (Handbook of Stem Cells, 
Volume 1, embryonic stem cells, Lanza 2004).  
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 Clonality 
Stem cells are referred to as clonal entities: single cells that are capable of creating more 
stem cells.  This phenomenon is essential for any definitive characterisation of self-renewal, 
potential and lineage (Weissman, Anderson et al. 2001).  
 Potency 
Stem cells can be classified by the extent to which they can differentiate into different cell 
types, this is defined as potency. A lineage hierarchy classification of stem cells based on 
potency is as follows:   
A. Totipotent stem cell - controversial and changing area 
Totipotent stem cells- are capable of differentiating into any cell type in the body in addition 
to the placenta which nourishes the embryo i.e. both embryonic and extra-embryonic 
tissues. A fertilized egg (zygote) is by definition the only totipotent stem cell. Embryonic 
stem (ES) cells which represent a model for investigation of the fundamental aspects of cell 
stemness are therefore not exactly totipotent. ES cells are derived from the inner cell mass 
(ICM) of the blastocyst and are equivalent to ICM- pluripotent. Hence, they can generate 
tissues of all three germ layers: ectoderm, mesoderm and endoderm; but cannot produce the 
extra-embryonic tissues (De Felici, Farini et al. 2009). There is a substantial debate 
surrounding this area and concepts of totipotency and ES cells are swiftly changing.  
B. Pluripotent stem cell 
Pluripotent stem cells- are descendants of the totipotent stem cells of the embryo. These 
cells can differentiate into any cell type, except for totipotent stem cells and extra-
embryonic membranes. A single pluripotent stem cell has the ability to give rise to tissues of 
all three germ layers (endoderm, mesoderm and ectoderm) from which all the cells of the 
body arise. Embryonic stem cells (derived from inner cell mass), embryonic germ cells and 
recently cord and cord blood-derived stem cells (McGuckin, Forraz et al. 2005; McGuckin, 
Forraz et al. 2006) (Harris and Rogers 2007) are examples. 
C. Multipotent stem cell 
Oligopotent/multipotent stem cells- are descendants of pluripotent stem cells and 
antecedents of specialized cells in particular tissues. Adult stem cells are multipotent stem 
cells with a more constraint differentiation potential and capacity for self-renewal. Examples 
include haematopoietic stem cells (HSCs) which give rise to all the cells in the blood and 
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neural stem cells which contribute to nerve cells (neurons) and neural support cells 
(oligodendrocytes and astrocytes). 
D. Unipotent stem cell  
Unipotent/Progenitor cells- have a very limited differentiation potential and can produce 
only one cell type. For example erythroid progenitor cells differentiate into red blood cells 
only.  
 
1.1.1 Source of stem cells  
Stem cells may be sourced from the blastocyst in the developing embryo prior to 
implantation (embryonic stem cells) or derived from the foetus (foetal stem cells) or, from 
blood and tissues postnatally (‘adult’ stem cells),  each forming a unique component of the 
revolution in stem cell research and therapies (Watt and Contreras 2005). Adult Stem Cells 
(ADS) or somatic stem cells are immature cell groups capable of tissue repair, maintaining 
tissue homeostasis and repair in a niche-specific controlled microenvironment (Heissig, 
Ohki et al. 2005) (Li and Xie 2005). Although, ADS have been characterized in many 
tissues (including neural, muscular, hepatic and cardiovascular tissues), hematopoietic stem 
cells remain the most characterized ADS population with clinical evidence. General 
experimental approaches and paradigms applicable to adult or tissue-specific mammalian 
stem cells have been defined in the haemopoietic system (Till and McCulloch 1961; Jones, 
Wagner et al. 1990; Morrison, Wright et al. 1997; McCulloch 2003). .  
ADS have more therapeutic potential than ES cells. There are no current clinical treatments 
based on ES cells, and there are in fact only few modest published successes using animal 
models. On the other had, ADS therapies are well established and in clinical practice for 
over 3 decades. The most commonly utilized sources of ADS cell is the bone marrow, 
although most tissues of the body harbour lineage-restricted stem cells. Cord blood derived 
stem cells enjoy a special niche between ES cells and ADS cells. ES cells are occasionally 
considered to be totipotent, while ADS cells are more restricted in their potential and more 
likely to be multipotent. Cord blood-derived stem cells have been characterized to be 
pluripotent with ES cell-like properties (McGuckin, Forraz et al. 2005; McGuckin, Forraz et 
al. 2006). These stem cells may safely be regarded as comparable to foetal stem cells, as 
they are derived from foetal tissues (extra-embryonic membranes).  
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Figure 1. Sources of stem cells. ES cell are derived from the inner cell mass (ICM) of the 
blastocyst and may be considered totipotent. Primordial germ cells are derived from 
embryonic germ cells and are pluripotent. Foetal cell stems are derived from the developing 
foetus and are pluripotent or multipotent. All stem cells derived after birth is defined as adult 
stem cells (ADS). These cells have restricted potential and are usually multipotent. Cord blood-
derived stem cells occupy a niche between ES cell and ADS. These have been characterized to 
be pluripotent and exhibit some ES cell-like properties. Adapted from 
www.stemcellresearch.org/testimony/images/20040929prentice.htm 
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In this study umbilical cord blood was used as the tissue source for primitive haematopoietic 
stem cells and primitive progenitor cells. The following section elaborates briefly on the 
identification and characterization of these primitive cells in blood.  
 
1.1.2 Characterization of haematopoietic stem cells 
Haematopoietic stem cells (HSCs) resemble lymphocytes in morphology. Examined 
microscopically they are non-adherent and rounded cells, with a rounded nucleus and low 
cytoplasm-to-nucleus ration.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2. Differential interference contrast (DIC) image of haematopoietic stem cells by laser-
scanning confocal microscope. Haematopoietic stem cells derived from cord blood (CB) and 
bone marrow (BM). (A) Shows a low magnification picture of CB MNCs (x630). (B) Reveals 
haemopoietic progenitor cells from CB at a medium magnification (x630x6). (C) and (D) are 
DIC images of haemopoietic progenitor cells from CB and BM respectively, at high 
magnification (x630x8). Both BM and CB progenitor cells have typical "blast" morphology 
with a discrete cytoplasm and a large nucleus. Interestingly, BM progenitor cells reveal 
increased membrane activity with multiple protrusions, reflecting their physiological 
interacting status in the marrow when compared to normally circulating CB progenitor cells. 
Membrane contours represented in yellow (computer generated). White scale bar is equivalent 
to 10 µm. Adapted from McGuckin et al, 2003b. 
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Since haematopoietic stem cells cannot be isolated as a pure population, it is not possible to 
identify them microscopically. The above description is based on the morphological 
characteristics of a heterogeneous population, of which haematopoietic stem cells are a 
component.  
The frequency of HSCs in any tissue is extremely low. This quality coupled with the lack of 
a single molecular marker that is expressed exclusively by HSC has made purification and 
characterization of these cells a highly challenging goal. After many exhaustive studies 
researchers have been able to identify several markers whose expression is gained (or lost) 
at different rates as primitive haematopoietic cells differentiate. It has been possible to 
subdivide the functionally heterogeneous mixture of cells found in blood into more 
homogenous subpopulations by targeting various combinations of markers. In the absence 
of reliable direct markers for HSCs, the better route for the their identification and 
enumeration depends on functional long-term, multilineage, in vivo repopulation assays 
(Wognum, Eaves et al. 2003).  
1.1.2.1 Cell surface markers associated with the haematopoietic system  
The cluster of differentiation (cluster of designation) (CD) is a system of cell markers 
commonly used to identify cells. This protocol allows cells to be defined based on what 
molecules are present on their surface. CD molecules can act in numerous ways, often 
acting as receptors or ligands (the molecule that activates a receptor) and associated with 
cell signaling. Some CD proteins do not play a role in cell signaling, but have other 
functions, such as cell adhesion (Zola, Swart et al. 2005; Zola, Swart et al. 2007). CD for 
humans is numbered up to 350 most recently (as of 2009) (HCDM, responsible for HLDA 
workshop and CD molecules) (Human Cell Differentiation Molecules Council (successor to 
the HLDA Workshops) (http://www.hcdm.org/MoleculeInformation/tabid/54/Default.aspx. 
Retrieved 2009-06-01). Cell populations are usually identified by using a combination of 
CD markers.  
Terminal differentiation of haematopoietic stem/progenitor cells is associated with the 
expression of a variety of surface markers. Thus, lack of expression of these lineage (lin) 
markers, which in combination include all of the mature haematopoietic cell subtypes 
(erythrocytes, T-cells, B-cells, natural killer cells, monocytes and granulocytes)  can be used 
to distinguish immature and immuno-naive cells from the more abundant differentiated cells 
in blood. The selected cell population is commonly referred to as Lin- (Linage negative) 
cells.  The following table highlights some of the more commonly used CD antigens used in 
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characterization of differentiated blood cells. In vitro isolation of haematopoietic primitive 
stem/progenitor cells involves identification and subsequent removal of these linage 
committed cells leaving behind the enriched lineage negative cell fraction.  
Table 1. Table of human HSC CD cellular antigens. 
(http://www.ebioscience.com/ebioscience/whatsnew/pdf/HumanCD_Poster.pdf) 
Antigen 
Name  
Other Names  Molecular 
Weight (MW)  
Structure  Distribution  Function  
CD2  T11, LFA-2, 
SRBC-R 
50kD IgSF Thymocytes, 
T, NK 
CD58 ligand, adhesion, T 
cell activation  
CD3γ, 
CD3δ 
T3  IgSF T, thymocyte 
subset  
w/TCR, TCR surface 
expression/signal 
transduction  
CD3ε T3 20kD IgSF T, thymocyte 
subset  
w/TCR, TCR surface 
expression/signal 
transduction 
CD4 T4 55kD IgSF Thymocyte 
subset, T 
subset, 
mono, mac  
MHC class II coreceptor, 
HIV receptor, T cell 
differentiation/activatio-n  
CD8a T8, Leu-2 32-34kD IgSF Thymocyte 
subset, T 
subset, NK 
MHC class I coreceptor, 
receptor for some mutated 
HIV-1, T-cell 
differentiation/activatio-n  
CD8b  32-34kD IgSF Thymocyte 
subset, T 
subset  
 
CD11c P150, 95, 
CR4, integrin 
αX 
150kD Integrin 
family  
DC, myeloid 
cells, NK, B, 
T subset  
Binds CD54, fibrinogen 
and iC3b 
CD14 LPS-R 53-55kD GPI-linked  Mono, mac, 
langerhans 
cells, granlow  
Receptor for LPS/LBP, 
LPS recognition  
CD15 Lweis-x, Lex  CHO Neutrophils, 
eosinophils, 
mono 
Adhesion  
CD16a FcyRIIIA 50-65kD IgSF Neutrophils, 
mac, NK 
Component of low affinity 
Fc receptor, phagocytosis 
and ADCC 
CD16b FcyRIIIB 48kD IgSF Neutrophils  Component of low affinity 
Fc receptor, phagocytosis 
and  AADCC 
Introduction: Stem Cell Biology 
 29 
Antigen 
Name  
Other Names  Molecular 
Weight (MW)  
Structure  Distribution  Function  
CD19 B4 95kD IgSF B, FDC Complex w/CD21 and 
CD81, BCR coreceptor, B 
cell 
activation/differentiatio-n 
CD20 B1, Bp35 33-37kD TM4SF B, T subset B cell activation  
CD24 BA-1 35-45kD GPI-linked Thymocytes, 
erythrocytes, 
peripheral 
lymph, 
myeloid  
Binds P-selectin  
CD25 Tac, p55 55kD Type I TM  Tact, Bact, 
Lymph 
progenitors  
IL-2Rα, w/IL-2Rβ and γ to 
form high affinity complex  
CD36 GPIV 88kD  Platelets, 
mono, mac, 
endoth, early 
erythrocytes 
ECM receptor, adhesion, 
phagocytosis 
CD38 T10 45kD  Variable 
levels on 
majority of 
haematopoiet
i-c cells, high 
expression 
on plasma 
cells, B and 
Tact 
Ecto-ADP-ribosyl cyclise, 
cell activation  
CD45 LCA, T200, 
B220 
180-240kD  Haematopoie
t-ic cells, 
multiple 
isoforms 
from 
alternative 
splicing  
Tyrosine phosphatise, 
enhanced TCR and BCR 
signals 
CD45RA  205-220kD  B, T subset 
(naïve), 
mono  
Exon A isoform of CD45 
CD56  NCAM 175-185kD IgSF NK, T 
subset, 
neurons, 
some large 
granular 
lymphocyte 
leukemias, 
myeloid 
leukemias 
Adhesion  
CD66b CD67, CGM6 95-100kD IgSF, CEA 
family  
Gran Cell adhesion, neutrophils 
activation  
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Antigen 
Name  
Other Names  Molecular 
Weight (MW)  
Structure  Distribution  Function  
CDw123 IL-3R 70kD CRSF Lymph 
subset, 
basophils, 
haematopoiet
ic 
progenitors, 
Mac, DC, 
megakaryocy
t-es 
IL-3Rα, w/CDw131 
 
CD235a 
 
Glycophorin 
A 
 
36kD 
  
Erythrocytes 
 
HLA-ABC  45, 11-12kD  Nucleated 
cells  
Cell-mediated immune 
response and tumour 
surveillance  
HLA-DR    APC, Tact  Presentation of peptides to 
CD34+ T lymphocytes  
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Cell surface profile of human haematopoietic stem cells (HSCs) 
 
 CD34 
The first identified marker to be recognized on primitive haematopoietic cells was CD34. 
CD34 is still the most commonly used marker to obtain enriched populations of 
haematopoietic stem/progenitor cells for both laboratory based research and clinical 
application (Wognum, Eaves et al. 2003). CD34 is expressed on approximately 1-4% of the 
nucleated cells in the normal human bone marrow aspirate samples and <0.1% of the 
nucleated cells in steady-state human peripheral blood (Civin, Strauss et al. 1984; Strauss, 
Rowley et al. 1986; Andrews, Bryant et al. 1992; Saeland, Duvert et al. 1992).  
CD34+ have been shown to be capable of producing multilineage haematopoietic 
engraftment in myeloablated recipients (Andrews, Bryant et al. 1992; Civin, Trischmann et 
al. 1996; Larochelle, Vormoor et al. 1996; Zanjani, Almeida-Porada et al. 1997; Vogel, 
Scheding et al. 2000). However, it is worth noting that even in a highly purified CD34+ cell 
population (>90% pure) the frequency of cells possessing progenitor activity (Colony 
forming unit potential) is <20%, the frequency of Long-term culture initiating cells (LTC-
IC) and HSCs is <0.1% (Wang, Doedens et al. 1997; Holyoake, Nicolini et al. 1999). CD34+ 
cell population can be subdivided into HSCs, primitive progenitor cells and lineage 
committed progenitor cells. The different expression patterns of other markers on these cells 
allow these cells to be distinguished from one another.  
CD34- primitive haematopoietic cells have also been identified in human cord blood and 
adult peripheral blood (Goodell, Rosenzweig et al. 1997; Bhatia, Bonnet et al. 1998; 
Zanjani, Almeida-Porada et al. 1998). These cells are identified by the lack of CD38 
expression and the positive expression of CD133. Only 0.2% of lineage negative CD34− 
cells in human cord blood were found to express CD133 (Gallacher, Murdoch et al. 2000).  
 
 CD133 
 
CD133 (also known as AC133) is expressed on majority of, but not all CD34+ cells. These 
include repopulating cells, immature progenitors, and monocyte/granulocyte progenitors, 
but not most erythroid progenitors. As noted previously, CD133 also appears to be 
expressed on the CD34− HSCs identified in human cord blood (Miraglia, Godfrey et al. 
1997; Yin, Miraglia et al. 1997).  
CD34 and CD133 are very frequently used for the isolation and enrichment of HSCs. Other 
markers that have also been applied include: CD90 (also known as Thy1) which is a 
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member of the immunoglobulin superfamily and is expressed on CD34+ cell populations; 
CDCP1 (Cub-domain containing protein) which has a pattern of expression on adult human 
bone marrow cells similar to that of CD133 (Conze, Lammers et al. 2003); Stem cell factor 
receptor (C-KIT or CD117) expressed on approximately 2/3 of CD34+ cells including most 
lineage-committed progenitor cells, and is selectively up regulated in terminally 
differentiating erythroid cells but is absent from virtually all circulating mature blood cells 
(Kawashima, Zanjani et al. 1996; Wognum, de Jong et al. 1996); Vascular endothelial 
growth factor receptor 1 (VEGFR-1) expressed on approximately 5% of CD34+ cells in 
human cord blood and fœtal liver (Hattori, Heissig et al. 2002). 0.1-0.5% of CD34+ cells in 
adult bone marrow express vascular endothelial growth factor 2 (VEGFR-2) also known as 
KDR (Ziegler, Valtieri et al. 1999).  
A combination of cell surface markers noted above are usually used to identify and isolate 
rare population of primitive haematopoietic stem/progenitor cells, This, however, does not 
equate to a definitive HSC phenotype, which must identify only cells with HSC function 
(long-term, multi-lineage repopulation). It is this lack of a definitive phenotype that poses 
significant challenges to the development of techniques to isolate sufficiently pure yields of 
HSCs reproducibly for research and clinical transplantation purposes. Interestingly, even the 
purest human HSC-containing populations are likely to be heterogeneous. The frequency of 
human cord blood cells capable of repopulating NOD/SCID mice has been estimated at 1 
per 600–1,000 lin−CD34+CD38− cells after intravenous injection and 1 per 44 CD34+CD38− 
cells after direct intra-bone marrow injection (Wognum, Eaves et al. 2003).  
Considerable work has been carried out to characterize and classify primitive cells in the 
haematopoietic system. One such work is by Gotze et al who demonstrated that CD34 
expression is acquired at a later stage in the development of the haematopoietic system and 
is preceded by CD133 (Gallacher, Murdoch et al. 2000; Gotze, Schiemann et al. 2007). 
Based on similar reported work (McGuckin, Pearce et al. 2003; Christina Basford 2010), 
HSCs may be classified as: 
 
- Early-stage HSC (CD45+/CD34-/CD133+) 
- Mid-stage HSC (CD45+/CD34+/CD133+) 
- Late-stage HSC (CD45+/CD34+) 
 
This classification was used for the analysis of HSCs in this study.  
 
 
Introduction: Stem Cell Biology 
 33 
In addition to haematopoietic stem cells, non-haematopoietic stem cells have also been 
identified in cord blood. A well known population of non-haematopoietic stem cells are the 
Mesenchymal stem cells. These progenitor cells are multipotent in their differentaitive 
capacity and are identified and isolated based on a distinct profile. These cells are negative 
for haematopoietic cell markers: CD45, CD34 and HLA-DR. They test positive for the 
various markers elaborated in the table 2. It should be noted, however, that the isolation of 
MSCs from UCB is not associated with 100% success; previous studies have demonstrated 
that only in 63% of UCB units could MSCs be isolated in culture with a frequency of MSC-
like cells ranging from 0 to 2.3 clones per 1x 108 MNC cells (Bieback, Kern et al. 2004), 
and the isolation is very much dependent on the quality and volume of the cord blood. 
Lineage negative cells, on the other hand, could prove to be an easier  alternative to MSCs, 
as irrespective of the size of the cord blood units these cells can be isolated from nearly 
every cord blood specimens processed, albeit at very low yields.   
Irrespective of their source, all MSCs share a core MSC profile distinct from that of other 
foetal organs. These cells have the same morphology, similar population doubling time, all 
are negative for CD34, CD45 and HLA-DR, all are positive for CD29, CD44 (adhesion 
markers), CD105, CD73 (Mesenchymal markers) and HLA-A-, B-, and C- (Class I 
histocompatibility complex). Some MSC sources have been shown to express stem cell 
markers, including c-kit, Nanog, Oct4 and Sox2 (Mitchell, Weiss et al. 2003; Weiss, 
Medicetty et al. 2006). Regulation of extracellular matrix (ECM) and adhesion is a 
prominent feature of all MSCs. This feature is one of the main determinants of 
differentiation of stromal cells to somatic Mesenchymal cells.  
Although all MSCs are considered multipotent, disparate differentiation tendencies of MSCs 
from different sources should be considered (Chang, Shih et al. 2006).  This phenomenon 
may result from the function of the MSCs in their prime location of isolation. For example, 
the most prominent functions of amniotic fluid MSCs may be involvement in uterine 
contraction and its related signaling transduction pathways. Amniotic membrane MSCs play 
a role in homeostasis of fluid and electrolytes. Cord blood MSCs are an important part of 
the innate immune system against viruses and bacteria. One major difference between UCB 
MSCs and other MSC sources is their reported down-regulation of some genes including 
homeobox genes, probably because cord blood is taken from term babies. Other genes are 
up regulated in amniotic fluid and BM MSCs, related to the important feature of frequent 
renewal (Tsai, Hwang et al. 2007). Furthermore, BM MSCs participate in skeletal 
development, BMP signaling, ossification, bone mineralization, dopamine biosynthesis, 
synaptic transmission and regulation of neurotransmitter secretion. The BM has been 
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proposed to be a source of neural stem cells because some bone marrow stroma is 
innervated and contains nerve terminal which maybe responsible for the synapse-related 
protein (Safford, Safford et al. 2004).  
 
Table 2. Mesenchymal stem cell markers. 
Antigen 
Name  
Other 
Name  
Molecular 
Weight  
Structure  Distribution  Function  
CD29 Integrin β1 130kD Integrin 
family  
Lymph, mono, 
gran, platelets, 
mast cells, 
fibroblasts, 
endoth 
w/CD49a 
(VLA-1) 
receptor for 
VCAM-1, 
MAdCAM-1 
and ECM 
CD44 H-CAM, 
Pgp-1 
80-95kD Hyaladherin  
family  
Haematopoietic 
and non-
haematopoitic 
cells, except 
platelets, 
hepatocytes, 
testis 
Binds 
hyaluronic 
acid, adhesion 
` 
CD73  69kD GPI-linked B subset, T 
subset, FDC, 
epith 
Ecto-5’-
nucleotidase, 
nucleoside 
uptake, T 
costimulation, 
lymph 
adhesion  
CD105  Endoglin 95kD Homodimer Endoth, bone 
marrowsubset, 
activated mac 
Cellular 
response to 
TGF-β1) 
CD106 VCAM-1 110kD IgSF Activated 
endoth, FDC 
VLA-4 
(CD49d/Cd29) 
receptor, 
leukocyte  
CD166 ALCAM 105kD IgSF Neurons, 
mono, epith, 
fibroblast, Tact  
CD6 ligand, 
adhesion  
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1.1.2.2 Molecular definition of stem cells  
 
Stem cells have the unique ability to self-renew and to differentiate into specialized cell 
types. This is one of the most important characteristics of stem cells and a part of their 
molecular definition.  For a long time embryos or germ-cell derived cells were thought to 
be the only source of pluripotency- a dogma that has been challenged in the last decade. 
The unique stem cell machinery that drives the molecular mechanisms underlying 
pluripotency and self-renewal is governed by a set of transcription factors centered on the 
triumvirate of Oct4, Sox2 and Nanog. All three proteins are co-localized in the chromatin 
and are associated with other transcriptional modulators that have been more recently 
identified to play a role in the transcriptional control of pluripotency. Expression levels of 
these pivotal transcription factors impact the eventual developmental potential of stem 
cells (Bosnali, Munst et al. 2009). Mechanisms of action of this core transcriptional 
network regulating stem cell machniery are illustrated in Figure 3 and 4.  
 
Table 3. Key transcription factors of pluripotency.  
Name of Transcription 
Factor  
Explanation  Gene Family 
Oct4 Octamer binding transcription 
factor 4 
POU (Pit, Oct, Unc) domain TF 
Sox2 SRY (sex determining region 
Y)-related HMG box2 
transcription factor 
HMG (High Mobility Group) 
of DNA-binding proteins 
Nanog Named after ‘Tir na nOg’ 
(celtic mythology= land of the 
ever young)  
Homeodomain transcription 
factor  
(Bosnali, Munst et al. 2009) 
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Figure 3. Oct4, Sox2 and Nonog form the core transcriptional network regulating stem cell 
machinery. Several hundred downstream genes are associated with this core network. These 
can be classified into two groups of genes exerting opposing functions. One group includes 
genes associated with maintenance of stemness while the other group activates pathways that 
lead to inhibition of differentiation. Adapted from (Bosnali, Munst et al. 2009) 
 
 
 
 
 
 
 
 
Figure 4. Expression levels of key transcription factors inpact on the developmental potential 
of embryonic stem cells. ES cells exhibit pluripotent differentiation potential that is regulated 
by three main transcription factors: Oct4, Sox2 and Nanog. Alterations in the expression levels 
of these factor in vitro (over expression indicated by blue arrows, and loss of function indicated 
by red arrows) results in differentiation of ES cells toward the indicated lineage (Bosnali, 
Munst et al. 2009). 
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These pluripotency determining factors have also been shown to induce pluripotency in 
somatic cells. Takahashi and Yamanka demonstrated for the first time that over expression 
of Oct4 and Sox2, together with two other transcription factors c-Myc and Klf4 was 
sufficient to reprogramme fibroblast cells into ES-like cells. These cells have been referrred 
to induced pluripotent stem cells (iPS) (Takahashi and Yamanaka 2006).  
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1.1.3 Haemopoiesis and ontology of haemopoiesis  
Much of our current knowledge and scientific concepts about stem cells comes from 
haematology. The following section sheds light on the key concepts of haemopoiesis and 
haematopoietic cell hierarchy.   
Blood production is a complex task. The normal human body generates 200 billion 
erythrocytes and 70 billion granulocytes per kilogram of body weight daily (Ogawa 1993; 
Weissman, Anderson et al. 2001). Blood production is achieved by means of a process 
termed 'haemopoiesis' 
Haemopoiesis (from the Greek ' haima': blood; and ' poiein': to make) provides a reliable 
and efficient blood cell system that consists of a dynamic and complex developmental 
process capable of continuous blood cell generation and also rapid cell proliferation in 
response to haemorrhage, infection or hypoxia (Ogawa 1993; Weissman, Anderson et al. 
2001) (Weissman, 2000). 
1.1.3.1 Ontogeny of Haemopoiesis  
 
In mammalian development haemopoiesis occurs in two distinct phases: primitive and 
definitive phases (Figure 5). The two stages occur at different anatomical sites and generate 
different cell types, probably through divergent genetic programs (Tavassoli 1991). 
Primitive haemopoiesis (also termed as mesoblastic phase) instigates during embryonic life 
within yolk sac blood islands at approximately embryonic day 15-28 (E 15-18) (Figure 6). 
These blood island cells originate from the ventral mesoderm. Erythrocytes and myeloid 
lineage cells are produced during this stage of development (Palis, Robertson et al. 1999).  
Primitive haemopoietic cells and endothelial cells are believed to have a common precursor 
cell, termed hemangioblasts (from the Greek 'haima': blood and 'angio': blood vessel)  (Choi 
1998). This theory of common origin is supported by several lines of evidence. First, 
primitive haemopoietic and endothelial cells express similar markers, such as CD34 (Wood, 
May et al. 1997) and vascular endothelial growth factor receptor VEGFR2, also known as 
Flk-1 (mouse) and KDR (human) (Labastie, Cortes et al. 1998; Lugus, Park et al. 2005) . 
Moreover, in vitro studies have shown that haemopoietic cells and endothelial cells can be 
cultured from the same bi-potential cell type, termed colony forming blast cell (Choi 1998).  
Some controversy, however, surrounds the origin of cells responsible for the definitive 
phase of haemopoiesis. It was originally believed that cells migrated from the yolk sac into 
the blood stream and colonized the foetal liver. This long held view was founded upon in 
vitro proof which demonstrated that yolk sac progenitors contained spleen colony forming 
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units (CFU-S), progenitor cells capable of generating all haemopoietic lineages (Hollands 
1987) . However, there are arguments that surround the contribution of the yolk sac to 
haemopoiesis. It is questionable whether there is a long term contribution from the yolk sac 
or whether the progenitors found there have a transient role and then migrate to intra-
embryonic regions of haemopoiesis and the foetal liver (Orkin and Zon 2002). These views 
have been proven to be overly simplified through experiments involving grafting of quail 
embryos into chick yolk sac which demonstrated that the embryo is itself a chief 
independent source of definitive haematopoietic stem cells (Dieterlen-Lievre 1975). Studies 
have demonstrated the presence of lympho-myeloid precursors in the embryo proper at time 
before the establishment of circulation in the yolk sac. These precursors have been 
demonstrated to originate from a paraoartic region within the embryo termed, aorto-gonad-
mesonephros (AGM) (Cumano, Furlonger et al. 1993). 
The definitive stage of haemopoiesis consists of two phases: 
The hepatic phase: occurs at week 6 in the foetal liver. At this stage the spleen also starts to 
contribute towards granulopoiesis and primitive lymphopoiesis begins in the foetal thymus 
and lymphoid tissues until birth.  
The myeloid (medullary) phase: occurs from week 22 of gestation, in the bone marrow and 
eventually becomes the major site of life-long haemopoiesis.  
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Figure 5. Graphical representation of the different phases of haemopoiesis. The y-axis 
illustrates the contribution of different tissues towards haemopoiesis during the various stages 
of gestation and then eventually after birth (postpartum). The Primitive (mesoblastic) phase is 
predominantly dependent on the input of the yolk sac and AGM region. The Definitive phase 
initially involves mainly the liver and to some extend the spleen (Hepatic phase) and then the 
bone marrow which continues to be a source of life-long haemopoiesis (myeloid or Medullary 
phase). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Saggital section of an early embryonic development (E18). Embryo (6) lying in the 
amnion and connected to the yolk sac (2). Blood islands are visible in the yolk sac at this stage 
of development (1 and 3). These islands constitute bi-potent stem cells that eventually 
contribute to the formation of the haemopoietic and vascular system. Primitive blood vessels in 
the yolk sac converge to form the umbilical vessels; umbilical vein (8) and umbilical arteries 
(9) that allow exchange of nutrients and gases in the placenta (10). The figure also illustrates 
the contribution of the aorto-gonad-mesonephros (AGM) (7) paraortic regions towards 
haemopoiesis. Cardiogenic mesoderm (5), (4). 
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1.1.3.2 Haematopoietic stem cells  
 
The haemopoietic system comprises a hierarchy of cells with different potentials. At its 
zenith are rare heterogeneous populations of immature haemopoietic precursor cells, 
occurring at a frequency of approximately 1 in 104–1 in 105 cells postnatally (Watt and 
Contreras 2005). These are multipotent haematopoietic stem cells (Figure 7). HSCs were 
discovered in the early sixties because of their ability to regenerate blood cells in animals 
suffering from bone marrow suppression. HSCs are capable of constant movement from the 
bone marrow to the blood stream and vice versa, a process known as 'Homing' (Orkin and 
Zon 2002). 
HSCs are characterized by self-renewal, proliferation and differentiation into all the cells of 
the haematopoietic system (Wagers, Sherwood et al. 2002). This balance between self-
renewal and differentiation has to be maintained at a steady state but must be capable of 
swift adaptation upon stress. Their genetic and phenotypic heterogeneity resides in their 
different proliferative and differentaitng abilities, and activation of cell cycle states. HSCs 
are multipotent, with the ability to commit to one of 10 or 11 functional haemopoietic 
lineages (Watt and Contreras 2005). The 'true' HSC has probably not been identified to date, 
however, HSC are typically described as blast cells, with a large nucleus surrounded by a 
thin cytoplasm (McGuckin et al, 2003b) (Figure 2). Their multipotent and long-term 
repopulating ability enables these cells to populate the whole haemopoietic system at least 
once over an individual's lifespan (Martin-Rendon and Watt 2003; Martin-Rendon and Watt 
2003). Self renewal and quiescence are two specific cell cycle features that enable HSC to 
continuously replenish the haemopoietic system.  Self renewal consists of HSC division 
giving rise to identical daughter cells, hence maintaining a sufficient pool of HSC to sustain 
continuous haemopoiesis throughout life (Lajtha 1975; Ogawa 1993). Quiescence was first 
defined by Lajtha and he suggested that HSCs were at a steady state in quiescence (G0 
state). The genetic and pluripotent integrity of HSCs is maintained in this dominant stage 
thus allowing cell growth and DNA-repair prior to the entry of the cells for self-renewal or 
differentiation (Metcalf 1999).  
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Figure 7. Schematic representation of the hierarchy involved in the development of the 
haemopoietic system. A haemopoietic stem cell (HSC) balances self-renewal with lineage 
commitment and differentiation, giving rise to more HSCs and differentiated blood 
components, that is, myeloid and lymphoid lineages. CLP (common lymphoid progenitor); 
CMP (common myeloid progenitor); B cells (B lymphocytes); T cells (T lymphocytes); NK cells 
(natural killer cells); Lymphoid DC (lymphoid dendritic cell); Plat (platelets); RBCs (red 
blood cells); Eosin (eosinophils); Baso (basophils); Neutr (neutrophils); Monoc (monocytes) 
and Myeloid DC (myeloid dendritic cells) (Martin-Rendon and Watt, 2003). 
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In the late 90's and early 2000 an increasing body of evidence suggested the phenomenon of 
plasticity in HSCs. In most mammalian species the HSC compartment contains a continuum 
of stem cell types and these cells are believed to be 'plastic' in their proliferative and 
differentiation capacities. Current studies on haematopoietic and other tissue derived stem 
cells have challenged one of the main dogmas in biology, namely that mammalian cell 
differentiation follows established programmes in a hierarchical fashion, and once 
committed to a particular somatic cell lineage cells do not change into another somatic 
lineage. The proposed newer concepts of stem cell plasticity or potentiality (Martin-Rendon 
and Watt 2003) facilitate a better understanding of plasticity, especially for HSCs which 
seem to have extraordinary abilities to generate or switch between haematopoietic and non-
haematopoietic lineages (Orkin and Zon 2002; Poulsom, Alison et al. 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction: Stem Cell Biology 
 44 
1.1.4 Stem cell plasticity  
Plasticity is defined as the ability of stem cells to adopt to new fates. Environmental factors 
(microenvironment), to which the stem cells are exposed to, have a pivotal role in cell fate 
decisions. This strengthens the case that stem cell fate is not completely intrinsically 
determined and emphasizes the importance of the microenvironment. 
Embryonic stem (ES) cells are defined as being totipotent and are able of generating all or 
most tissue types in an organism (Smith 2001; Wilmut 2002). ES cells may be regarded as 
being truly 'plastic' in their development potential. However, the requirement of human 
embryos to obtain these stem cells has resulted in many ethical concerns and debate 
surrounding this area of research. In contrast, ADS are a lot more ethically accepted 
worldwide and have been applied in clinical practice for many years (Lemischka 1999; 
Metcalf 1999; McCulloch 2003). As HSC is the best-characterized adult mammalian ADS 
type it has been used to define 'stemness' of cells in other mammalian adult tissues (Martin-
Rendon and Watt 2003). 
The exact mechanisms via which cell fate reprogramming occurs are still not fully 
understood, however, five pathways have been suggested (Martin-Rendon and Watt 2003) 
(Figure 8): 
 Dedifferentiation of mature or lineage-restricted cell to a more immature or 
precursor cell. 
 Transdetermination whereby stem cell potential is redirected giving rise to cell types 
of a different stem/precursor cell. 
 Transdifferentiation where a differentiated cell gains the phenotypic characteristics 
of another differentiated cell. 
 Cell fusion the physical union of two cells  
 The presence of very primitive or multiple stem cell types in a tissue whose potential 
is expressed when the stem cell enters and interacts with the appropriate 
microenvironment.  
 
 
 
 
 
 
Introduction: Stem Cell Biology 
 45 
 
 
 
 
 
Figure 8. Pathways proposed for stem cell plastity. The pathways to new cell identities may be 
explained by the following processes: (1) dedifferentiation of mature or lineage-restricted cell 
to a more immature progenitor or precursor, followed by differentiation to another lineage. (2) 
Transdetermination, whereby stem cell potential is redirected giving rise to cell types of a 
different stem/precursor cell. (3) Transdifferentiation, the mechanism via which a 
differentiated cell can gain the phenotype of another differentiated cell. (4) Cell fusion and (5) 
a totipotent or pluripotent stem cell gives rise to a multipotent stem cell or a stem cell with 
restricted potential (Martin-Rendon and Watt, 2003).  
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1.1.4.1 Stem Cell Plasticity within haemopoietic tissues 
 
Stem cells that generate the haemopoietic system are developmentally mesodermal in origin 
and, until recently it was commonly accepted in biology, that once committed to 
haemopoietic lineage should be unable to switch between lineages. However, recent studies 
have provided evidence that stem cells in haemopoietic tissues have the potential to generate 
cell types other than those of the tissues in which they reside and this potential of stem cells 
has been extensively reviewed (Orkin and Zon 2002) . A few selected examples of stem cell 
plasticity or potentiality demonstrated in human studies are described in the table 4. This 
non-hierarchical reversible phenotype of stem cells in haemopoietic tissues is an advantage 
that can be exploited extensively in regenerative medicine. 
Mesoderm-Endoderm Conversions 
 
Since one of the goals of this research was the generation of hepatocytes from haemopoietic 
stem cells (cord blood derived stem cells), an appropriate example of germ layer transition 
would be mesoderm-endoderm conversions (Table 4).  
In the liver, hepatocytes and biliary epithelium are endodermal in origin. The capability of 
haematopoietic stem cells of mesodermal origin to gain the phenotype of endodermal cell 
lineages has been reported both in vitro and in vivo in both rodent and human studies 
(Petersen, Bowen et al. 1999; Lagasse, Connors et al. 2000; Theise, Badve et al. 2000; 
Theise, Nimmakayalu et al. 2000; Schwartz, Reyes et al. 2002; Kakinuma, Tanaka et al. 
2003; Lee, Kuo et al. 2004; Kang, Zang et al. 2005; McGuckin, Forraz et al. 2005).  
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Table 4. Examples of adult stem cell plasticity. 
Stem cell 
origin 
Lineage 
'plasticity' 
Somatic 
lineage 
transition? 
Reference 
Marrow Neural cells Mesoderm-
ectoderm 
(Mezey 
2003) 
Marrow Liver 
hepatocytes 
Mesoderm-
endoderm 
(Alison, 
Poulsom et 
al. 2000) 
(Theise, 
Nimmakayal
u et al. 2000) 
Marrow Pancreatic 
endocrine 
cells 
Mesoderm-
endoderm 
(Ianus, Holz 
et al. 2003) 
Marrow Glomerular 
mesangial 
cells 
Mesoderm-
endoderm 
(Masuya, 
Drake et al. 
2003) 
Marrow Epithelial 
and liver 
hepatocytes 
Mesoderm-
ectoderm 
(Kleeberger, 
Rothamel et 
al. 2002) 
(Korbling 
and Estrov 
2003) 
Marrow Blood vessel 
endothelium 
and vascular 
cells 
Mesoderm-
mesoderm 
(Strauer, 
Brehm et al. 
2001) 
(Assmus, 
Schachinger 
et al. 2002) 
(Stamm, 
Westphal et 
al. 2003) 
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1.1.5 Stem cell niches  
Cell fate is regulated by complex and complementary successions of external and intrinsic 
stimuli (Phillips, Ernst et al. 2000). The external stimuli activate complex signaling 
pathways which in turn module intrinsic regulatory pathways via production of transcription 
factors (Shivdasani and Orkin 1996; Tenen, Hromas et al. 1997; Zhang and Li 2008). 
1.1.5.1 Microenvironment ('Niches') 
 
Recent studies demonstrate that in addition to intrinsic control of cell survival, self-renewal 
and differentiation (lineage determination); the surrounding environment plays a crucial role 
in cell fate decisions. These privileged microenvironments are also referred to as 'niches' 
(Watt and Hogan 2000; Spradling, Drummond-Barbosa et al. 2001; Fuchs, Tumbar et al. 
2004; Li and Xie 2005; Xie and Li 2007) (Figure 9). These niches may be viewed as 
specific anatomic locations that regulate how stem cells participate in tissue generation, 
maintenance and repair. In tissue engineering such niches can be modeled or re-created in 
vitro to culture tissues better or mimic a physiological environment. Such niches protect 
stem cells from depletion, while protecting the host from over-exuberant stem-cell 
proliferation and hence consequent pathologies, such as tumours (Scadden 2006). The 
theory of a niche as a specialized microenvironment was first proposed almost 30 years ago 
by Schofield in reference to mammalian haematology, although experimental evidence was 
first provided by invertebrate models (Schofield 1978). 
The regulatory elements in these niches include heterologous cells, non-cellular  and 
extracellular matrix (ECM) constituents (Scadden 2006). ECM constituents include: 
cytokines, cell adhesion molecules (CAM), and extracellular non-protein elements, such as 
Calcium and 'homing' molecules (which may themselves be modulated by cytokines) with 
their corresponding receptors. Interactions between the stem cells and their 
microenvironments are presumably a prerequisite for enabling the stem cells to lodge in 
specific regions and then to respond to the localized developmental stimuli (Hoffbrand AV 
2001). The importance of this environmental control is considered greater for stem cells 
then for mature cells (Hoffbrand AV 2001). Establishment of ‘Niches’ is needed for organ 
regeneration. Disease conditions may be associated with destruction of or absence of the 
stem cell niche and this has to be restored, so that the organ can repair itself. Examples 
include: benign age related conditions like hair graying which is proposed to be associated 
with defective self-maintenance of melanocyte stem cells within their niche in the hair 
follicle (Nishimura, Granter et al. 2005); pathological age related degenerative disorders 
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such as Parkinson’s disease and Alzheimer’s disease (Carlson and Conboy 2007)  and 
malignant diseases such as Leukemias (Lane, Scadden et al. 2009),  
 
 
 
 
 
Figure 9. Cellular and  non-cellular components of stem cell niche. The stem cell system is 
regulated by architectural space, physical interactions with neighboring cells, neural signals, 
paracrine (hormonal factors produced by neighboring cells) and endocrine (hormonal factors 
produced by distant glands and secreted into the circulation) signals from local or distant 
sources and metabolic products of tissue activity. Stem cell is depicted in dark green (Scadden, 
2006).  
 
 
 
 
 
 
 
 
 
 Stem/progenitor cells utilized in this study were derived from the umbilical cord and 
umbilical cord blood. The following section is an introduction to the afterbirth and its 
various components.  
 
1.2 Introduction to the Umbilical cord and cord blood  
Afterbirth comprises: the placenta, umbilical cord and chorioamnion (‘foetal membranes’). 
The structures are collectively known as the ‘foetal adnexa’. The placenta and cord are 
extra-embryonic tissues derived from the trophoblast. The placenta connects the foetus to 
the uterine wall via the umbilical cord, and is the organ by means of which the nutritive, 
respiratory, and excretory functions of the foetus are carried on. It is composed of foetal and 
maternal portions (The Bartleby.com edition of Gray's Anatomy of the Human Body). The 
umbilical cord connects the foetus to the placenta. Umbilical cord blood (UCB) is the blood 
that is obtained from the umbilical vessels.  
 
A. The Placental  
The placenta is an intra-uterine organ formed by the fusion of extra-embryonic and maternal 
tissues. The word placenta comes from the Latin for cake, from Greek plakóenta/plakoúnta, 
accusative of plakóeis/plakoús - πλακόεις, πλακούς, "flat, slab-like", referring to its round, 
flat appearance in humans. Except from a small maternal contribution to the placenta, the 
foetal adnexa develop from the extra-embryonic tissues of conceptus. During the embryonic 
period, the precursors of the fetal adnexa are the developmental adnexa, which include the 
extra-embryonic membranes (amnion, chorion, umbilical vesicle, also known as the yolk sac 
or vitelline sac, and allantoic diverticulum) and the connecting (or body) stalk. Later during 
embryonic develop the connecting stalk becomes covered by amnion to form the umbilical 
cord. In humans, the placenta averages 22 cm (9 inch) in length and 2–2.5 cm (0.8–1 inch) 
in thickness (greatest thickness at the center and become thinner peripherally). It typically 
weighs approximately 500 grams (1 lb). It has a dark reddish-blue or maroon color. It 
connects to the fetus by an umbilical cord.  
The placenta also illustrates metabolic and endocrine functions. It produces both protein as 
well as steroid protein hormones. Protein hormones including: human placental lactogen 
(hPL) also known as somatomammotropin, human chorionic gonadotropin (hCG), human 
chorionic thyrotropin (hCT) and human chorionic corticotrpin (hCACTH). Steroid 
hormones including: progesterone and oestrogen.  
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The placenta and the fetus might also be regarded as foreign allografts in the mother and 
hence must escape the maternal immune system. The placenta serves in several ways to 
avoid immune rejection; it avoids detection through secretion of Neurokinin B containing 
phosphocholine molecules. This mechanism is applied by parasitic nematodes to avoid 
detection by the immune system. There are small lymphocytic suppressor cells in the foetus 
that inhibit maternal cytotoxic T cells. This is done through inhibiting the response to 
interleukin 2 (Il-2) (Clark, Chaput et al. 1986). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction: The Umbilical Cord and Cord Blood  
 52 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
Figure 10. Development of the 
placenta and the umbilical cord. 
(A) Conceptus at approximately 
3.5 weeks. All the fetal adnexa are 
visible at this stage. (B) A later 
stage in the development of the 
umbilical cord. The umbilical cord 
embryonically constituents the 
vitelline vessels, vitelline duct, 
right and left umbilical veins, and 
a pair of umbilical arteries. As 
development progresses the 
vitelline vessels and duct, together 
with the right umbilical vein, 
undergo atrophy and disappear; 
and thus the cord, at birth, 
contains a pair of umbilical 
arteries and one (the left) umbilical 
vein. (C) Foetus in utero, near 
term gestation. The diagram 
illustrates the structure of the 
umbilical cord near full term. Note 
the presence of one umbilical vein 
(blue vessel) and two umbilical 
arteries (red) wound around the 
vein. (The Bartleby.com edition of 
Gray's Anatomy of the Human 
Body) 
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B. The umbilical cord  
The human umbilical cord (UC) is embryologically derived at day 26 of gestation. The 
umbilical cord at full term, as a rule, is about equal to the length of the foetus, i.e., about 50 
cm, but it may be greatly diminished or increased. The umbilical cord is essentially 
composed of amniotic epithelium covering mucoid mesenchymal connective tissue 
(Wharton’s jelly). Sarugaser et al postulated that this connective tissue was derived from a 
mesenchymal precursor cell population located within the umbilical cord. They reported that 
these cells were most likely located in close vicinity to the vasculature, thus close to their 
source of oxygen and nutrients. They called these cells human umbilical cord perivascular 
(HUCPV) cells (Sarugaser, Lickorish et al. 2005).  
The umbilical cord inserts into the chorionic plate of the placenta. It is composed of two 
arteries and a single umbilical vein. These vessels are developmentally derived from the 
allantoic vessels. At the junction of umbilical cord and placenta, the umbilical arteries 
branch radially to form chorionic arteries (Figure 11). The chorionic arteries further branch 
before they enter into the villi. In the villi, they form an extensive arteriocapillary venous 
system, bringing the fetal blood extremely close to the maternal blood; but no intermingling 
of fetal and maternal blood occurs. This is defined as the placental barrier and allows 
selective movement of endogenous and exogenous compounds across the placenta. This 
protects the developing foetus from the harmful effects of toxins, chemicals, cytokines, 
micro-organisms etc. The umbilical vessels are responsible for exchange of gases, nutrients 
and waste products between fetal and maternal circulations across the placental membranes. 
The umbilical arteries deliver deoxygenated blood to the capillaries of the placental villi 
where gaseous exchange takes place between maternal and fetal circulations. Oxygenated 
blood is returned to the fetus via the umbilical vein. Maternal blood in the intervellous 
spaces is supplied and drained by maternal vessels.  
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Figure 11. Cross section of the placenta illustrating branching of the umbilical arteries to form 
the chorionic arteries. These vessels branch further before they enter into the villi. In the villi 
the extensive arteriocapillary venous system allows communication between foetal and 
maternal circulation without direct mixing of blood. This is know as the placenta barrier. (The 
Bartleby.com edition of Gray's Anatomy of the Human Body) 
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1.2.1 The afterbirth as a stem /progenitor cell resource 
Foetal stem cells, comprises a broad stem cell class and can be isolated from two distinct 
sources, the foetus proper and the extra-embryonic structures. The extra-embryonic tissues 
are a rich stem cell reservoir with many advantages over both embryonic and adult stem cell 
sources. The afterbirth is routinely discarded at parturition, thus allowing little ethical 
controversy over harvesting of the resident stem cell populations. In addition, the 
extracorporeal nature of these stem cell sources assist isolation, eliminating patient risk that 
may accompany adult stem cell isolation. Further more, the relatively large volume of extra-
embryonic tissues and the ease of physical manipulation theoretically interprets as an 
increase in the number of stem cells isolated.  
1.2.1.1 Umbilical cord blood  
The first isolated foetal stem cells were haematopoietic, derived from human umbilical cord 
blood. Thus, cord blood represents the prototypic foetal stem cell source. UCB-derived stem 
cells enjoys an intermediate niche between ES and ADS with the added advantages of being 
ethically sound and associated with completely non-invasive methods for collection of the 
cord blood. Until the advent of cord blood banking in the mid 90s, placenta and umbilical 
cord were considered clinical by-products, but ever since cord blood has created hope as a 
new alternative in the management of various disease conditions for which there is no cure 
or the current treatment options are inefficient. Cord blood provides an easily available and 
rich source of haemopoietic and non-haemopoietic stem cells. Term and preterm umbilical 
cord blood contains an equal or significantly higher number of early and committed 
progenitor cells when compared with bone marrow and greatly surpasses that of adult 
peripheral blood (Mayani, Gutierrez-Rodriguez et al. 1998). A lot of work has been done in 
the area of exploring the potential of stem cells in cord blood. One of such exciting studies 
is the work done by Mcguckin et al, who investigated the multipotential capability of cord 
blood-derived stem cells (Forraz, Pettengell et al. 2002; McGuckin, Forraz et al. 2004). In 
2005, McGuckin et al reported the world’s first reproducible production of cord blood-
derived stem cells expressing embryonic stem cell markers (McGuckin et al, 2005). Their 
work was supported by other reports concerning the existence of circulating embryonic stem 
cell-like cells during foetal development (Jiang et al, 2002; Korbling and Estov, 2003). 
Another population of non-haematopoietic multipotent stem cells termed, mesenchymal 
stem cells (MSCs) has been identified in UCB (Erices, Conget et al. 2000; Mareschi, Biasin 
et al. 2001; Bieback, Kern et al. 2004; Kogler, Sensken et al. 2004; Markov, Kusumi et al. 
2007). These multipotent  cells (Kang, Zang et al. 2006) have unique immunoregulatory 
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features that suppress lymphocyte proliferation in vitro (Gerson 1999) and exhibit high self 
renewal potential (Bartholomew, Sturgeon et al. 2002). MSCs have potential to differentiate 
into tissues of all three germ layers: including bone, cartilage, fat, muscle, endothelial cells, 
neuronal, glial cells and liver (Bruder, Jaiswal et al. 1997; Kopen, Prockop et al. 1999; 
Pittenger, Mackay et al. 1999; Erices, Conget et al. 2000; Woodbury, Schwarz et al. 2000; 
Campagnoli, Roberts et al. 2001; Horwitz, Gordon et al. 2002; Krampera, Glennie et al. 
2003; O'Donoghue, Choolani et al. 2003; Lee, Kuo et al. 2004; Hong, Gang et al. 2005; Li, 
Qu et al. 2005; Chien, Yen et al. 2006; Lange, Bruns et al. 2006; Ong, Dai et al. 2006; 
Snykers, Vanhaecke et al. 2006; Lu, Teng et al. 2007; Paunescu, Deak et al. 2007; 
Tamagawa, Oi et al. 2007; Yen, Chien et al. 2007; Lu, Dong et al. 2008). 
Although, term UCB is reported to be a source of MSCs (Erices, Conget et al. 2000; 
Mareschi, Biasin et al. 2001; Bieback, Kern et al. 2004; Kogler, Sensken et al. 2004; 
Markov, Kusumi et al. 2007), this source of MSC is subjected to a lot of controversy 
(Gutierrez-Rodriguez, Reyes-Maldonado et al. 2000; Campagnoli, Roberts et al. 2001; 
Mareschi, Biasin et al. 2001; Wexler, Donaldson et al. 2003; Kogler, Sensken et al. 2004; 
Lee, Kuo et al. 2004; Yu, Xiao et al. 2004; Kern, Eichler et al. 2006).  Kogler et al, reported 
that the amount of MSC in UCB was one MSC in every 20ml of UCB (Kogler, Sensken et 
al. 2004). Additionally, previous studies have demonstrated that only in 63% of UCB units 
could MSCs be isolated in culture with a frequency of MSC-like cells ranging from 0 to 2.3 
clones per 1x 108 MNC cells (Bieback, Kern et al. 2004). This makes the isolation of UCB 
sourced MSCs very much dependent on the quality and volume of the cord blood, hence 
making cord blood not a very efficient resource for MSC compared to the umbilical cord.  
1.2.1.2 Umbilical cord  
The umbilical cord (UC) has recently been recognized as a rich source of stem/progenitor 
cells, namely Mesenchymal stem cells (Romanov, Svintsitskaya et al. 2003; Wang, Hung et 
al. 2004; Sarugaser, Lickorish et al. 2005) (Figure 13). Wharton’s jelly, first described by 
Thomas Wharton in 1656 (Wharton 1996) is the matrix filling the umbilical cord and is a 
rich source of MSCs. Chacko and Reynolds (Chacko AW 1945) described these cells 
residing in Wharton’s jelly as smooth muscles, but Takechi et al (Takechi, Kuwabara et al. 
1993) refined the description to ‘myofibroblats’ after insitu labelling of vimetin, desmin, α-
actin, and myosin, which was confirmed by Kadner et al (Kadner, Hoerstrup et al. 2002). 
These cells are present in relatively high numbers, with an average of 400,000 cells isolated 
per umbilical cord (Karahuseyinoglu, Cinar et al. 2007). This is significantly greater that the 
yield from adult bone marrow. These cells grow adherent to plastic and express specific 
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pattern of cell surface determinants (CD105, CD90, CD73, and CD44). This cell fraction is 
distinct from the haematopoietic and pluripotent stem cells present in cord blood and do not 
express blood-cell determinants (CD34, CD45). These Mesenchymal cells can be expanded 
very efficiently in vitro and have been propagated in culture for more than 80 population 
doublings (Marcus and Woodbury 2008). 
In vivo studies involving the transplantation of UC MSCs are limited, but encouraging. 
These cells have been transplanted into animal models of disease (severe muscle damage, 
ischemic rodent brain and hemiparkinsonian) and have demonstrated very promising results 
(Conconi, Burra et al. 2006; Weiss, Medicetty et al. 2006; Ding, Shyu et al. 2007) 
1.2.1.3 Amniotic fluid  
Of all the extra-embryonic sources, amniotic fluid is the only one where harvest occurs prior 
to parturition. This trait may prove increasingly important as in utero cell-based therapies 
progress (Muench 2005). Amniotic fluid contains a heterogeneous population of cells 
displaying a range of morphologies. Most of these cells are epithelial in nature and have a 
limited capacity to proliferate in nature. These cells are predominantly derived from the fetal 
skin, urogenital, respiratory and digestive tract. Additional cells derived from the inner 
surface of the amniotic membrane add to the mix. The cellular composition of amniotic 
fluid changes with gestation, coinciding with the maturation of the foetus (Torricelli, Brizzi 
et al. 1993). Stem cells with the characteristics of HSCs within amniotic fluid were first 
isolated and described in 1993 by Toricelli et al (Torricelli, Brizzi et al. 1993). However, 
non-haematopoietic Mesenchymal stem cell population within amniotic fluid was only 
recently reported (In 't Anker, Scherjon et al. 2003). A subset of these cells have reportedly 
tested positive for Oct4 expression  highlighting their possible pluripotent nature (Prusa, 
Marton et al. 2003). It has been reported that these MSCs express both mesodermal and 
ectodermal gene products. This characteristic is consistent with the emerging concept that 
stem cell populations exist in a multi-differentiated state. The proliferation capacity of these 
cells meets or exceeds that described for adult human MSCs. Additionally, these cells have 
demonstrated the ability to differentiate into various tissues derived from all three germ 
layers (In 't Anker, Scherjon et al. 2003; Bossolasco, Montemurro et al. 2006; Tsai, Hwang 
et al. 2006; coppi, Georg Bartsch et al. 2007). Amniotic fluid cells have been transplanted 
into animal models of disease but have produced contradictory results (Sartore, Lenzi et al. 
2005; Chiavegato, Bollini et al. 2007). More work is demanded to resolve these apparently 
contradictory outcomes and to pronounce amniotic fluid MSCs as a possible alternative for 
cell transplantation therapies.  
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1.2.1.4 Placenta  
This large fetomaternal organ is an attractive tissue for the isolation of stem/progenitor cells. 
The sheer volume of a full term placenta, weighing more than 500g, almost 15 times the 
weight of the average umbilical cord makes it a rich source of multipotent cells. MSCs have 
been isolated from dissociated placental tissue based on plastic adherence. These cells 
express the pluripotency markers Oct4 and Rex1. These cells exist in a multi-differentiated 
state- simultaneously expressing ectodermal, mesodermal and endodermal genes. These cell 
have demonstrated tremendous ex vivo proliferation capacity and the ability to differentiate 
into tissue representing all three germ layers (Fukuchi, Nakajima et al. 2004; Yen, Huang et 
al. 2005; Chien, Yen et al. 2006). Placental-derived MSCs have also demonstrated the 
ability to support the growth of exogenous HSCs derived from cord blood in culture (Zhang, 
Li et al. 2004).  
Placental-derived MSCS have been utilized in ex vivo engineering of complex biological 
structures such as artificial heart valves (Schmidt, Mol et al. 2006). Additionally, these cells 
have also been exploited in in vivo studies on animal models and demonstrated interesting 
results (Kogler, Sensken et al. 2004).  
1.2.1.5 Amniotic membrane  
The amniotic membrane or the amnion is one of the first recognizable tissues derived from 
the epiblast. This tissue is an avascular structure generated early in development from 
multipotent cells residing in two distinct areas of the developing blastocyst. During 
subsequent development, the cells of the amnion are not exposed to the same signals 
responsible for the gradual fate restriction of cells within the embryo proper. It is thus 
postulated that the stem cell populations sequestered within the amnion might retain the 
potency of the epiblast cells from which they are derived.  Several multipotent cells have 
been isolated from the amnion, including MSCs (Marcus and Woodbury 2008). Amniotic 
membrane has been extensively used as a biological dressing to treat chemical and thermal 
burns. The clinical success of amniotic membrane transplantation is greatly due to its 
immunoprivileged characteristics. If this trait is indeed shared by its constituent stem cell 
populations, they may prove very useful for allogeneic transplantation strategies (Akle, 
Adinolfi et al. 1981; Adinolfi, Akle et al. 1982). In addition, these cells secrete a number of 
immunosuppressive factors that target the innate and adaptive immune systems, which may 
support longterm survival of grafts following transplantation (Kamiya, Wang et al. 2005; Li, 
Niederkorn et al. 2005).  
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Some of the isolated stem cell populations were reported to be positive for pluripotency 
markers and demonstrated the capacity to differentiate into tissue derived from all three 
germ layers (Miki, Lehmann et al. 2005).  
Amnion-derived stem/progenitor cells have been transplanted in animal models of brain 
diseases and have illustrated promising results (Kakishita, Elwan et al. 2000; Kosuga, 
Sasaki et al. 2001; Sankar and Muthusamy 2003) 
 
1.2.1.6 Umbilical vessels 
MSCs have also been identified in umbilical vessels (Butler, Nolan et al.; Ishige, Nagamura-
Inoue et al. 2009).  
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Stem/progenitor cells derived from cord blood have been extensively studieds and have 
demonstrated clinical utility. More recently the umbilical cord has gained a lot of attention 
over other extra-embryonic tissues as an alternative stem cell source for cell transplantation 
approaches.  
It may be safely concluded that, cord and cord blood-derived stem/progenitor cells offer 
multiple advantages over truly adult stem cells and over embryonic stem cells. With a global 
population of 6 billion people and a global birth rate in access of 130 million per year, 
umbilical cord and cord blood possibly provide the most readily accessible and ethically 
sound alternative source of stem cells (McGuckin, Forraz et al. 2005). Although UCB 
contains fewer primitive haemopoietic precursor cells than earlier trimester fetal bone 
marrow, it still provides a source of stem cells at a younger stage than mobilized peripheral 
blood (MPB) and bone marrow (Tocci, Roberts et al. 2003).  
Other differences between these stem cell sources include UCB and MPB (Mobilized 
Peripheral Blood) haemopoietic precursors are slowly cycling, whereas those in foetal and 
adult bone marrow have a higher proportion in G2, M and S phases. In terms of ontogeny, 
UCB cells are at the intermediate point between embryonic and adult life and have longer 
telomeres and high proliferation potential. In addition, UCB has an increased capacity for 
self-renewal (Emerson 1996). UCB units also have a reduced risk of viral contaminations 
(cytomegalovirus or Epstein Barr virus) (Chang and Seto 1979; Stagno, Pass et al. 1986; 
Bertolini, Lazzari et al. 1995). 
Haematological transplantation using UCB further demonstrated a lower incidence of graft-
versus host disease for allogeneic graft (Gluckman and Rocha 2006; Rubinstein 2006). UCB 
induces better tolerance for human leukocyte antigen (HLA) mismatches when compared to 
bone marrow, probably due to the immaturity of the immune cells or controlled by UCB 
dendritic cells and/or natural killer cells (Cohen and Nagler 2004; Liu, Law et al. 2004). 
They may be the only source of allogeneic HSCs (Hematopoeitic stem cells) available to 
patients with rare HLA types and hence to ethnic minorities, to siblings suffering from 
diagnosed haematological disorders and for urgent unrelated donor transplants.  
The past 30-40 years has seen great successes in HSC therapies. These provide curative 
therapies for patients with haematological and non-haematological disorders. Currently 
more than 85 diseases are either treatable with or ameliorated with the use of umbilical cord 
blood.  
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Figure 12. Extra-embryonic stem cell sources. The diagram illustrates that stem/progenitor 
cells have been isolated from all extra-embryonic tissues including: the amniotic membrane, 
amniotic fluid, Wharton’s jelly and placenta.  Adapted from (Marcus and Woodbury 2008) 
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Figure 13. Stem/progenitor cells derived from the umbilical cord. (A) Populations of cord blood cells, 
these cells have a tendency to form aggregates upon culture in vitro. (B) Cord vessel progenitor cells with 
star-like phenotype. This phenotype is lost after the first passage subsequent to which the cells take on a 
standard MSC phenotype as shown in (C). 
(A) Cord Blood progenitor 
cells 
(B)  Cord vessels progenitor 
cells 
(C) Wharton’s jelly progenitor 
cells 
Wharton’s 
Jelly
Cord arteries 
Cord Vein 
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1.2.2 Clinical application of cord blood 
The present day is witness to more than 2400 stem cell based therapies in early human trials 
around the world, based on the Clinical Trials Database (www.clinicaltrials.gov).  The 
beginning of stem cell research dates back to 1866, when Ernst Neumann first postulated the 
bone marrow as a blood forming organ with a common stem cell for all haematopoietic 
cells. Further studies followed to increase the understanding of early mammalian 
development and more recently substantial work has been done in the area of stem cell 
biomedical research to help improve our understanding of how stem cells influence the 
organism to maintain its homeostasis. 
The clinical application of stem cell transplantation in the management of disease has made 
tremendous development in the past 3 decades. 20 years ago, it was one disease treatable 
with cord blood; 10 years ago about 10-15 and now over 85 diseases are treatable with cord 
blood.  
The first clinical use of cord blood was in 1930s, where is was safely used as a substitute for 
peripheral blood for performing transfusions (Halbrecht 1939). HLA-matching was not 
available then and no adverse effects were noted; hence the feasibility of cord blood 
administration to a non pre-conditioned host was suggested.   
The first traceable umbilical cord blood transplant was performed in 1970 in a 16-year boy 
with acute lymphoblastic leukemia (Ende M 1972). This procedure is less reported in 
literature. The boy received cord blood units from 8 different unrelated donors, untested for 
HLA compatibility. Only one unit engrafted, but the patient remained in remission with 
maintenance chemotherapy until his last follow-up appointment at 9 months. The results of 
this transplant fuelled research into umbilical cord blood as a stem cell resource and in 
1980s it was reported that umbilical cord blood contained haematopoietic stem cells that 
may be suitable for transplantation. 
 In 1988, the first reported cord blood transplantation was executed to cure Fanconi’s 
anemia in a 5-year boy, using blood from his HLA-identical baby sister’s umbilical cord, in 
Paris, France (Gluckman, Broxmeyer et al. 1989). This report lead to the establishment of 
cord blood banks worldwide for the collection and cryopreservation of cord blood for 
allogeneic haematopoietic stem cell transplants. 
 Since the first reported cord blood transplantation 20 years ago, the number of umbilical 
cord blood transplantations (UCBT) from siblings and unrelated donors has increased 
dramatically. In 2006, it was estimated that more than 5000 patients had undergone UCBT 
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from unrelated donors (Rocha and Gluckman 2006). By 2009, 20,000 UCBT were 
performed in children and in adults (Gluckman and Rocha 2009). 
 In 2006, the inventory of Netcord, the cooperative network of large experienced UCB 
banks, had over 100,000 cryopreserved UCB units ready for clinical use and a reasonably 
accurate worldwide estimate would be 250,000 UCB units (Rocha and Gluckman 2006). By 
2009 that number had increased to 400,000 in more than 50 banks worldwide 
(www.bmdw.org) (Gluckman and Rocha 2009). A survey of the International Bone Marrow 
Transplant Registry (CIBMTR) estimates that after 1998, 20% of stem cell transplants 
performed in young patients (<20 years) were cord blood transplants. In Japan, 
approximately 50% of haematopoietic stem cell transplants from unrelated donors were 
performed with cord blood cells. This development is due to the organization of 
international registries for outcome data collection named Eurocord (www.eurocord.org) 
and CIBMTR (www.cibmtr.org) and of cord blood banks network named Netcord 
(www.netcord.org) and NMDP (www.nmdp.org) (Gluckman and Rocha 2009).  
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Figure 14. History of cord blood clinical applications. 
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UCB stem/progenitor cells display several advantages over other ADS sources (BM being 
the most commonly used resource). These benefits include: 
- Logistical and clinical advantage: prompt availability of transplant; patients receive UCB 
transplants in a median of 25-36 days earlier than those receiving BM) (Barker, Krepski et 
al. 2002). 
- Less frequent and less severe acute graft-versus-host disease (GVHD) than BM which 
contains a higher number of activated T cells.  
- Less stringent criteria for HLA donor-recipient selection; tolerance of 1-2 HLA 
mismatches out of 6. This allows extension of the donor pool.  
- Lower incidence of infections by latent viruses. 
- Lack of risk to the donor. 
- Higher frequency of rare haplotypes compared to bone marrow registries, thus allowing 
easier targeting of ethnic minorities.  
-Umbilical cord blood transplantation criteria iclude:  
Two factors that are the key determining factors for engraftment are the number of 
nucleated cells (NC) and CD34+ cells infused  and the number of HLA differences 
(Gluckman, Rocha et al. 2004; Kamani, Spellman et al. 2008). The latest recommendations 
are: to choose UCB units with ≤ 2HLA disparities and >2.5 x 10^7 NC/kg or ≥2x 10^5 
CD34+ cells/kg. In non-malignant diseases where the risk of rejection is higher the dose 
should be increased and units with <3.5 x 10^7 NC/kg and 2 or more HLA incompatibility 
avoided. If a single UCB unit proves insufficient than, two units with a combined total dose 
of  ≥3x 10^7 NC/kg and if possible not more than 1 HLA difference between the two units 
and the patient should be used (Gluckman and Rocha 2009).  
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Cord blood application was initially limited to the treatment of paediatric haematological 
malignancies due to the low cell yield from cord blood units of modest volume. Discovery 
of the need for less strict HLA donor-recipient selection permitted cord blood to be applied 
in adult patients lacking BM donors (Sanz, Saavedra et al. 2001; Schonberger, Niehues et al. 
2004; Cornetta, Laughlin et al. 2005; Lekakis, Giralt et al. 2006). Additionally, outside the 
area of oncology, the clinical use of cord blood has expanded into various areas of disease 
management, such as : reconstitution of a defective immune system, correction of congenital 
haematological abnormalities and inducing angiogenesis. Table 5 illustrates some of the 
cord blood clinical studies concentrating on non-malignant diseases. The examples provided 
here are by no means exhaustive, but merely demonstrate the remarkable advances that have 
been made in the area of cord blood stem cell engineering and re-enforce the fact that stem 
cells hold tremendous promise for the future of regenerative medicine and cellular therapy. 
Chronic diseases such as diabetes mellitus, stroke, ischemic heart disease, 
haemoglobinopathies and chronic liver cirrhosis are a social repercussion and have a huge 
impact on the health care system. They are a global priority of health and demand definite 
attention. The statistical incidence and prevalence of some of these chronic disease 
conditions is shocking. For example, in 2006 the International Diabetes Federation indicated 
that 6% of adults in the world (246 million people worldwide) suffer from diabetes. The 
highest prevalence was found in Eastern Mediterranean and Middle East region where 9.2% 
of adults are affected (BMJ 2006; 333:1191 (9 December), 
doi:10.1136/bmj.39055.608507.DB). It was predicted that the worldwide prevalence of 
diabetes will increase to 7.1% of adults, totaling 380 million people, by 2025. The Eastern 
Mediterranean and Middle East region will continue to have the highest overall prevalence, 
with 10.4% of the adult population having diabetes by 2025. Despite its long history the 
only curative treatment available for diabetes today, especially type 1 diabetes, is pancreatic 
beta cell transplantation. 
Another common killer is liver cirrhosis. The WHO calculated that 20 million people 
worldwide have cirrhosis of the liver and/or liver cancer, arising predominantly among the 
estimated 500 million people (nearly 10% of the world population) who suffer from 
hepatitis B (HBV) and hepatitis C (HCV) viral infections. Each year an estimated 2 million 
people die of liver disease (www.hepalfe.com/images/chronic liver disease) (Rozga 2006).  
In the present day the only management available for such chronic diseases is supportive or 
palliative therapy ultimately demanding cell transplantation for cure in some cases; beta cell 
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transplantation in the case of diabetes, bone marrow transplantation for thalassemia and 
hepatocyte transplantation for liver cirrhosis. However, the scarcity of available donors and 
the complications associated with the operative procedure justifies the requirement for 
alternative treatment options for these illnesses. Cord blood stem cells could prove to have 
potential in developing cellular therapy for treatment of these and other similar disease 
conditions 
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Table 5. Non-malignant disorders treated with cord blood. 
Disorder 
 
Number Treated Outcome Reference  
Hurler’s disease 20 17 out of 20 children 
alive a median of 905 
days after 
transplantation with 
complete donor 
chimerism and normal 
peripheral blood α- L-
iduronidase activity 
(Staba, Escolar et al. 
2004) 
Duchenne Muscular 
Dystrophy  
1 On day 42 post 
transplantation, 
obvious improvement 
in walking, turning the 
body over and standing 
up was noted  
(Zhang, Chen et al. 
2005; Zhang, Feng et 
al. 2005) 
Malignant infantile 
osteoporosis  
1 Normalization of spine 
bone mineral density 
was noted  
(Jaing, Hou et al. 
2006) 
Buerger’s disease  4 Ischemic rest pain 
suddenly disappeared. 
Digital capillaries were 
increased in number 
and size  
(Kim, Han et al. 2006) 
Spinal cord injury 1 Within 41 days post 
transplantation, 
improvement in 
sensory perception and 
movement in the SPI 
patient’s hips and 
thighs was noted. 
Regeneration of the 
spinal cord at the 
injured site 
(Kang, Kim et al. 
2005) 
Krabbe’s disease 25 Progressive central 
myelination and 
continued gains in 
developmental skills, 
and most had age-
appropriate cognitive 
function and receptive 
language skills in 
patient subset  
(Escolar, Poe et al. 
2005) 
Omenn Syndrome  1 T cell reconstitution  (Tomizawa, Aoki et al. 
2005) 
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Disorder 
 
Number Treated Outcome Reference  
Non-healing wounds  2 Accelerated healing  (Valbonesi, Giannini et 
al. 2002) 
Refactory anaemia  3 All patients were alive 
and free of disease at 
between 17 and 59 
months after UCBT 
(Ooi, Iseki et al. 2005) 
Diamond-Blackfan 
anaemia  
1 Successful 
seroconversion to 
vaccines (Diphtheria, 
pertussis, tetanus, 
rubella, measles and 
BCG) administered 
22-34 months post 
transplant  
(Azuma, Hirayama et 
al. 2001) 
Severe chronic active 
Epstein Barr virus  
1 Complete remission 
without circulating 
EBV-DNA continued 
for 15 months post 
transplant  
(Ishimura, Ohga et al. 
2005) 
Behcet’s disease  1 23 months post UCBT, 
the patient was doing 
well and no signs or 
symptoms were noted  
(Tomonari, Tojo et al. 
2004) 
Mucopolysaccharidosis 
type IIB (Hunter’s 
symdrome) 
1 2 years post UCBT ~ 
55% normal plasma 
iduronase sulfarase 
activity was restored 
and abnormal urinary 
excretion of 
glycosaminoglycans 
was nearly completed 
resolved 
(Mullen, Thompson et 
al. 2000) 
Wiskott-Aldrich 
syndrome 
  (Slatter, Bhattacharya 
et al. 2006) 
Chronic 
Granulomatous 
Disease  
  (Bhattacharya, Slatter 
et al. 2003) 
Adapted from (Riordan, Chan et al. 2007) 
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1.2.3 Cord blood banking  
Scientific data generated from research into the pluripotent nature of UCB-derived stem 
cells greatly highlights the need and importance of cord blood banking.   
Banking is the process whereby UCB stem cells are saved for potential medical uses in the 
future. The procedure includes the process of cord blood collection from the umbilical cord 
which can be performed in utero (during third stage of labour, prior to delivery of the 
placenta) or ex utero (after the umbilical cord has been clamped and completely detached 
from the baby). Both procedures can yield similar amounts of cord blood (on average 
between 70-120ml per unit). It is encouraged that unless there is a very strong medical 
indication otherwise, that only ex utero collection is warranted. The procedure poses no 
harm in any way to the mother or the baby. It is a completely non-invasive process. The 
blood collected is then subjected to plasma depletion and removal of red blood cell 
compartment and is tested to determine whether it meets the eligibility standards. The 
processed cord blood unit (buffy cells) which contains, in very low quantity, the stem cells 
is then cryopreserved by freezing in liquid nitrogen at -196° C with a cryopreservative 
mixture. This enables cellular aging and damage to be halted.  
Thus far, two main types of cord blood banks exist: 
(i) Public cord blood banks storing anonymized units that can be released to any patients 
with a partial or total HLA match;  
(ii) Private ‘family’ banks which against a fee, store units for exclusive use by the family 
paying for the service. 
Public banks have come into existence in many countries since the early 1990’s. These 
banks usually meet strict quality control criteria and national/international accreditation. The 
rationale behind public banking is that they offer the advantage of having the sample already 
stored in a bank, and if there is a match the unit can be shipped to the hospital immediately. 
On the other hand, bone marrow banks are subject to complexity of HLA and 
immunological matching and other logistical complications that hinder the timely 
localisation of a potential bone marrow donor.  
However, when compared to a world registry exceeding 11 million bone marrow donors, 
only 700,000 cord blood units are stored in approximately 50  cord blood banks in about 20 
countries. 
Private cord blood banks charge a fee to store umbilical cord blood samples for about 20-25 
years. It has been estimated that approximately 700,000 units are stored in private banks 
worldwide, including 500,000 in the USA and just over 135,000 in Europe. An issue 
associated with private banking is that not enough private cord blood banks are complying 
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with regulations and accreditations for processing quality control. So there is a rigorous 
need for strict regulatory frameworks to better prevent unreliable service. Additionally, 
some cord blood banks are struggling financially so it is of critical importance to find the 
most effective and economical processing and storage methods (McGuckin and Forraz 
2008; Christina Basford 2010). Many factors affect the success of processing and the yield 
of stem cells generated (McGuckin, Basford et al. 2007), so it remains an important priority 
to find the best possible methods of cord blood separation, that will allow even cord blood 
units of small volumes to prove clinically viable.  
More recently, in addition to cord blood, cryopreservation of the umbilical cord has also 
been made available to the public in some countries. An example of such a facility is the 
Tissue Regeneration Therapeutics (TRT) in Toronto, in collaboration with Create Cord 
Blood Bank (CCBB) that was launched in 2006. The focus of this tissue bank lays in cell 
therapy applications of MSCs for regenerative therapy in cell transplantation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 One of the chief goals of this study was the in vitro differentiation of cord and cord blood 
derived stem/progenitor cells toward hepatobilary lineage.  The aim was to try to produce an 
in vitro model for application in biomedical research and extracorporeal liver assist devices 
and eventually to be applied in cell therapy.  
The following sections provide a concise introduction to liver structure and development.  
 
1.3 Introduction to the liver- a unique organ 
The liver is a intricate organ composed of cells, such as hepatocytes, hepatocyte precursor 
cells (Scadden 2006) , stellate cells, Kupffer cells, epithelial cells, sinusoidal epithelial cells, 
biliary epithelial cells, and fibroblasts (Volker 2007). The liver is involved in over 150 
different vital functions including: metabolism, detoxification, and maintenance of 
homeostasis in the body. The liver also possesses endocrine functions, production of many 
serum proteins into the blood, blood clotting factors and an exocrine function, secreting 
large amounts of bile into the digestive tract (Lemaigre and Zaret 2004; Volker 2007). 
Correct liver functions are fundamental to human health and loss of these can be severely 
compromising.  
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1.3.1 Gross anatomy and physiology of the liver  
The Liver (Hepar) is the largest gland in the body. It is situated in the upper and right part of 
the abdominal cavity, occupying almost the whole of the right hypochondrium, the greater 
part of the epigastrium and not uncommonly extending into the left hypochondrium as far as 
the mammary line. The anatomical details of the liver illustrated below were taken from the 
online version of Gray’s Anotomy of the Human Body (Bartleby.com) 
 
 
 
Figure 15. Surface anatomy of the liver. View from front of abdomen, showing surface 
markings of the liver, stomach and great intestines. Bartleby.com; Anatomy of the Human 
Body (Henry Gray- 1821-1865) 
 
 
Right hypochondrium  Left hypochondrium  
Epigastrium 
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Weight- In adult males the liver weighs from 1.4 to 1.6 kg and in adult females from 1.2 to 
1.4 kg. It is relatively much larger in the fetus than in the adult, constituting, in the former, 
about one-eighteenth, and in the latter about one thirty-sixth of the entire body weight.  
Shape- it presents the appearance of a wedge, the base of which is directed to the right and 
the thin edge towards the left (Figure 15).  
Measurements- the greatest transverse measurement of the liver is from 20 to 22.5cm. 
Vertically, near its lateral right surface, it measures 15-17.5cm.  
Consistency- soft solid and friable 
Color- dark reddish brown 
Specific gravity- 1.05  
Structure of the liver- the substance of the liver is composed of lobules, held together by 
an extensively fine areolar tissue, in which ramify the portal vein, hepatic ducts, hepatic 
artery, hepatic veins, lymphatics and nerves. The entire structure is invested by a serous and 
a fibrous coat.  
Structural unit of the liver- the lobules (lobuli hepatis) constitutes the chief mass of the 
hepatic structure. Each lobule consists of a mass of hepatic cells, arranged in irregular 
radiating columns between which run the blood channels (sinusoids) and minute bile 
capillaries (Figure 17). Each lobule measures approximately 1 to 2.5 mm in diameter.  
Functional unit of the liver- the hepatic acinus is the functional unit of the liver. The 
acinus is oriented around the afferent vascular supply of the liver lobules and hence 
represents a unit that is of more relevance to liver function (Figure 18).  
Hepatocyte- or liver cells make up about 80% of the liver mass and are the functional cells. 
Hepatocytes are polyhedral in form and measure from 12-25 µ in diameter. These cells 
contain one or two distinct nuclei. The nucleus exhibits an intranuclear network and one or 
two refractile nucleoli. The cells are usually granular, some of which are protoplasmic, 
while others contain glycogen, fat or an iron compound.  
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(a) Superior surface of the liver  
 
 
 
 
 
 
(b) Inferior surface of the liver  
 
 
 
 
 
 
(c) Inferior and posterior surface of the liver  
 
 
 
 
 
 
 
 
Figure 16. Surfaces of the liver. (a) 
Superior surface (facies superior) is 
attached to the diaphragm and the 
anterior abdominal wall by the 
falciform ligament. The line of 
attachment of the falciform ligament 
divides the liver into two parts, the 
right and left lobes. (b) Inferior 
surface of the liver (facies inferior; 
visceral surface). (c) Inferior anf 
posterior surface of the liver  
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Figure 17. Structure of a single liver lobule. Image from porcine liver (x60) 
 
 
 
 
 
 
Figure 18. Liver acinus of porcine liver. The acinus is the functional unit of the liver and is 
oriented around the afferent vascular supply of the liver lobule.  
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1.3.2 Liver Development  
The liver is derived from the endoderm, one of the three germ layers during gastrulation. 
The endoderm defines the primitive gut and gives rise to the epithelial compartment of the 
gastrointestinal tract. The endoderm also gives rise to other organs including the pancreas 
and the thyroid gland (Figure 19A) (Lemaigre 2009). Fate mapping studies in mice where 
endodermal cells were labeled with a dye showed that liver progenitor cells originate from 
three endodermal domains: two domains are paired and located laterally, and the third 
domain is found along the ventral midline (Figure 19B) (Tremblay and Zaret 2005; Zaret 
2008).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Formation and patterning of the endoderm associated with development of the 
liver. (A) The figure depicts a parasagittal section of a mouse embryo at the six-somite stage (~ 
8.25 days gestation), at the time when endodermal patterning begins (Zaret 2002). (B) A 
schematic representation of a mouse embryo (4 to 10 somite stage) with a ventral view on the 
anterior intestinal portal showing the blue areas that correspond to the hepatic progenitor 
domains in the ventral endoderm. (Lemaigre 2009) 
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Both the endocrine as well as the exocrine parenchyma of the liver is derived from the 
endoderm. The ultimate fate of endodermal cells is determined by various factors that 
influence the differentiation potential of these cells (Figure 20).  
 
 
 
Figure 20. Factors influencing differentiation of the endoderm into liver, extra-hepatic bile 
ducts and pancreas. Liver induction signals in mammalian liver are illustrated. STM (Septum 
transversum),CM (Cardiac mesoderm), BMP (Bone morphogenenic protein, FGF (Fibroblast 
growth factor, Pdx1 (Pancreatic and duodenal homeobox 1), Hes1 (Haematopoietically 
expressed homeodomain) and Ngn3 (Neurogenin 3).  
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The liver arises in the form of a diverticulum from the ventral surface of that portion of the 
gastrointestinal tract which later forms the descending part of the duodenum. The 
diverticulum grows upward and forward into the septum transversum and gives off two 
solid buds of cells which represent the right and the left lobes of the liver. The liver buds 
grow into columns or cylinders, termed hepatic cylinders, which branch and anastomose to 
form a close meshwork. The vitelline and umbilical vessels are invaded by this network, 
which disrupts these vessels into a series of capillary-like vessels termed sinusoids. These 
sinusoids ramify in the meshes of the cellular network and ultimately form the venous 
capillaries of the liver.  
 
 
Figure 21. Budding of the liver out of the endoderm. The diagram schematizes the changes in 
morphology of the liver when it buds out of the endoderm.  
By the continued growth and ramification of the hepatic cylinders the mass of the liver is 
gradually formed. The original diverticulum from the duodenum forms the common bile 
duct, and from this the cystic duct and the gall bladder arise as solid outgrowths which later 
acquire a lumen.  
As liver development progresses and the liver undergoes enlargement, it together with the 
ventral mesogastrium of the forgut are gradually differentiated from the septum 
transversum. The liver projects downward into the abdominal cavity from the under surface 
of the septum transversum.  
About the third month of embryonic development, the liver almost fills the abdominal 
cavity, and its left lobe is nearly as large as the right. From this period the relative 
development of the liver is less active, more especially that of the left lobe. The left 
eventually undergoes a degree of degeneration and becomes smaller that the right.  
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1.3.2.1 Developmental stages and molecular mechanisms that regulate liver 
development  
 
Development of the hepatic parenchyma takes place in distinct developmental stages, 
although intertwining and overlap between the stages is highly likely (Duncan 2003). The 
molecular mechanisms involved in the different stages of liver development are detailed 
below: 
A. Competency and specification  
Competency depicts the innate ability of a cell type to follow a given developmental 
pathway provided it is exposed to the appropriate inductive cues (Gilbert 2003) (pg 142-
144).  
Tissue interactions define the precise location and timing of hepatogenesis during 
embryonic development. Large changes in the patterns of gene expression accompany the 
differentiation of the multipotent ventral endodermal cells towards a hepatic phenotype. In 
rodent embryos the onset of liver ontogeny is at embryonic day (E) 8.5.  
Nicole Le Douarin demonstrated using the chick model, that the ventral endoderm had to be 
in close contact with precardiac splanchnic mesoderm and the septum transversum 
mesenchyme for it to follow a hepatic fate (Douarin 1975). This discovery was later 
validated by other reports (Fukuda 1979; Fukuda-Taira 1981). It was later noted that 
fibroblast growth factors (FGF1-, -2 and 8) produced by cardiac mesoderm and bone 
morphogenic proteins (BMPs) produced by the septum transversum act in concert to trigger 
the onset of hepatogenesis and make the ventral endoderm competent to interpret and 
respond to signals that induce the hepatic development program (Jung, Zheng et al. 1999; 
Rossi, Dunn et al. 2001).  
Zaret et al reported the transcription factors HNF3 (FoxA) and Gata4 could modulate 
competency intracellularly (Gualdi, Bossard et al. 1996; Zaret 1998; Chaya, Hayamizu et al. 
2001). These factors are switched on after induction by the surrounding tissues. It has been 
shown that both transcription factors resulted in opening of compact chromatin (Cirillo, Lin 
et al. 2002) and hence promote gene transcription. Two members of the FOXA family, 
FoxA1 (HNF3α) and FoxA2 (HNF3β), are expressed throughout the definitive endoderm 
preceding the potentiators that specify the hepatic fate within the ventral endoderm (Ang, 
Wierda et al. 1993; Monaghan, Kaestner et al. 1993; Sasaki and Hogan 1993). Although 
Gata-4 has been shown to bind to Albumin enhancer, it has yet to be demonstrated that 
Gata-4 is expressed in the endoderm during the onset of hepatogenesis as well.  
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Once the ventral endoderm had been rendered hepatic competent, the mechanisms by which 
the cells of the endoderm actually follow and adopt a hepatic fate are a sequence of 
intracellular responses to these signaling events. This leads to specification of the committed 
ventral endoderm and simultaneous inhibition of pancreas formation in the proximal 
endoderm.  It is worth noting that pancreatic programme is the default for this domain of the 
endoderm.  
 
 
 
 
 
 
 
 
 
 
Figure 22. Competency and specification of the ventral endoderm. The septum transversum 
produces BMP (Bone morphogenic proteins) which in association with FGFs (Fibroblast 
growth factors) trigger the onset of hepatogenesis and make the ventral endoderm competent 
to interpret and respond to signals that induce the hepatic development program. This hepatic 
induction in the proximal endoderm is coupled with inhibition of pancreatic development from 
the endoderm. Ventral endoderm cells sufficiently distal to the cardiogenic mesoderm escape 
the latter inhibitory effect and initiate the pancreatic gene programme ((Zaret 2002).  
 
 
 
 
 
Introduction: The Liver  
 83 
B. Liver bud formation 
After hepatic endoderm has been specified, it undergoes transitions that are elicited by 
signals that specify the endoderm. At approximately rodent E9.0-9.5, the hepatic endoderm 
begins to extend towards the midgut and the cells become columnar in shape. Various 
transcription factors promote the earliest steps of liver-bud emergence and morphogenesis: 
Hex (Haematopoietically expressed homeodomain) and Prox1 (prospero-related homeobox) 
genes. The septum transversum expresses various factors that regulate the synthesis of 
paracrine morphogens needed for hepatoblast growth. These include: Hlx (H2.0-like 
homeodomain protein), HGF (Hepatocyte growth factor), Smad2 and Smad3 
(transcriptional mediators of TGF-β signalling pathway (Zaret 2002). Endothelail cells, 
which eventually form the vascular supply of the liver, have been shown to be a pivotal 
growth stimulus to the hepatic bud enabling the hepatoblasts to proliferate and migrate into 
the surrounding septum transversum (Matsumoto, Yoshitomi et al. 2001). At this stage the 
hepatic epithelial cells are referred to as bipotent hepatoblasts and express Gata4, HNF4α, 
HNF6, AFP and albumin and biliary cytokeratins (Ck17, Ck19) (Kinoshita and Miyajima 
2002; Lemaigre and Zaret 2004; Zhao and Duncan 2005; Shafritz, Oertel et al. 2006).  
 
 
 
 
Figure 23. Post specification and liver 
bud formation. After the hepatic 
endoderm has been specified it begins 
to extend towards the midgut. At the 
same time hepatic endoderm cells 
become columnar in shape. Cells such 
as STM (Septum transversum 
mesenchyme) cells, primitive 
endothelial cells, signalling molecules 
(such as BMP, HGF and VEGFR2) 
and transcription factors (such as Hex, 
Prox1, Hlx and c-Met) are essential to 
promote morphogenesis of the liver 
bud itself. BMP (bone morphogenic 
protein), c-Met (HGF receptor), HFG 
(hepatocyte growth factor), VEGFR2 
(Vascular endothelail growth factor 
receptor 2) (Zaret 2002). 
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C. Differentiation and functional maturation  
At rodent E11-12, the liver primarily becomes a haematopoietic organ. HSCs originating 
from extra-hepatic organs colonize the liver bud and emit growth signals for further 
development of the liver. Consequent, hepatoblasts continue to proliferate and commitment 
to hepatocyte and/or biliary epithelial lineages is initiated (Snykers, De Kock et al. 2009). 
Expression data of marker genes are consistent with hepatocytes and bile duct cells 
(cholangiocytes) being derived from hepatoblast (Shiojiri 1984; Germain, Blouin et al. 
1988). Hepatocyte nuclear factor 6 (HNF6) promotes hepatocyte over biliary cell formation 
in early development but positively controls later differentiation of biliary epithelia and the 
morphogenesis of the bile duct and the gall bladder. HNF4 directly promotes hepatocyte 
gene expression and the formation of hepatocyte epithelial morphology (Zaret 2002).  
Differentiation along cholangiocyte lineage is promoted by Notch signaling pathways 
(Lemaigre and Zaret 2004; Zhao and Duncan 2005; Clotman and Lemaigre 2006). 
Mesenchymal cells or non-parenchymal liver cells excrete HGF which antagonizes 
differentiation along cholangiocytic lineage and supports the growth and differentiation of 
foetal hepatocytes. The hormone insulin synergistically promotes this effect. Subsequently, 
OSM mostly produced by HSCs, and glucocorticoids induce partial hepatic maturation and 
suppression of embryonic haematopoiesis. OSM fails to induce differentiated liver 
phenotype on its own, implying the importance of glucocorticoids as trigger for hepatic 
maturation (Snykers, De Kock et al. 2009). At this point, although the cells continue to 
proliferate, most of them are unipotent and irreversibly committed to either the hepatocytic 
or cholangiocytic lineage. Complete functional hepatic maturation ultimately takes place 
after birth aided by HGF, produced by surrounding non-parenchymal liver cells (sinusoidal, 
stellate and endothelial cells (Lemaigre and Zaret 2004; Shafritz, Oertel et al. 2006; 
Snykers, De Kock et al. 2009).  
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Figure 24. Final differentiation and liver bud formation. Liver-bud morphogenesis is marked 
by remodeling of the extracellular matrix around the hepatoblasts and of E-cadherin-based 
connections between the cells, and proliferation and migration into the surrounding STM 
(septum transversum mesenchyme) (beige). The outgrowth of the liver bud is promoted by 
surrounding primitive endothelial cells (or angioblasts). These endothelial cells eventually 
coalesce around spaces in the loose STM and create vesicles that fuse to form blood vessels (not 
shown). Haematopoietic cells then invade the growing liver and the organ becomes distinct 
from the gut epithelium (Zaret 2002).  
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Figure 25. Schematic representation of foetal liver development. The establishment of fully 
functional liver tissue is accomplished only after postnatal stages and follows a sequential 
array of tightly regulated intra- and extracellular signaling pathways. To distinguish the level 
of expression and/or regulating role among diverse liver-enriched transcriptional factors, 
different letter sizes have been used in this diagram. ALB (albumin), AFP (α-fetoprotein), 
BMP (bone morphogenic proteins), FGF (fibroblast growth factors), GGT (γ-
glutamyltransferase), HGF (Hepatocyte growth factor), HNF (Hepatocyte nuclear factor), OC-
2 (Onecut transcription factor), ST (Septum transversum), TGF (Transforming growth 
factor). (Snykers, De Kock et al. 2009) 
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1.3.3 Hierarchy of Transcription Factors that regulate liver-specific gene 
expression during liver development 
The figure below summarizes the chief transcription factors involved in hepatogenesis.  
These transcription factors belong to various familes: HNF1α and HNF1β belong to the 
variant homeodomain-containing proteins; HNF3α (FoxA1) belongs to winged helix protein 
family; HNF4α is a member of nuclear hormone receptor family and HNF6 is from the 
onecut homeodomain protein family of transcription factors.  
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Figure 26. Transcriptional regulation of liver-specific gene expression during hepatogenesis. 
Hepatocyte HNF-6 
Specification of liver 
Lineage (expressed in 
endodermal progenitor 
cells) 
Hepatoblast differentiation  
Hepatocyte differentiation  
  (Cereghini, Ott et 
al. 1992) 
  (Duncan 2000) 
  (Zaret 2002) 
(Cirillo, Lin et 
al. 2002) 
(Lemaigre and 
Zaret 2004) 
(Lee, Friedman 
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1.3.4 Liver disease- global health burden  
Liver disease is highly prevalent worldwide. The World Health Organization estimated in 
2006, that approximately 20 million people worldwide suffered from cirrhosis of the liver 
and/or mitotic lesions of the liver, the majority arising from the 500 million persons 
(approximately 10% of the world population) who are victims of hepatitis B (HBV) or 
hepatitis C (HCV) viral infections (Rozga 2006). Hepatic failure alone, accounts for 1-2 
million deaths per annum, and is nominated the 5th leading cause of death around the globe. 
Decompensated liver function and ultimate failure has many culprits including: excessive 
alcohol consumption, aggressive forms of fatty liver disease, fibrosis, inflammatory liver 
conditions and unregulated ingestion of common over-the-counter medication, such as 
acetaminophen (Tynelol) (Rozga 2006). Within the UK, acetaminophen over dosage 
contributes to 48% of poisoning admissions to hospitals and is involved in an estimated 100-
200 death per year (Hawkins, Edwards et al. 2007).  
1.3.4.1 Mechanism of liver damage and ultimate fate  
 
The liver is an exceptional organ; in an event of parenchymal cell loss, the mammalian liver 
can cite at least three apparently distinct cell lineages to contribute to regeneration and 
repair after damage (Figure 27). First line of defence is provided by 
hepatoblasts/hepatocytes which are themselves believed to be functional stem cells of the 
liver (Shafritz and Dabeva 2002; Fiegel, Park et al. 2003). More severe liver damage calls 
upon activation of a potential stem cell compartment located within the intrahepatic biliary 
tree, giving rise to cords of bipotential cells that ultimately differentiate to hepatic or biliary 
epithelial cells. These hepatic stem/progenitor cells are referred to by different names 
including ‘oval cells’ and ‘small hepatocyte-like progenitors’ (SHPCs) in rodents (Gordon, 
Coleman et al. 2000; Roskams, Theise et al. 2004) and ‘intermediate cells’ in humans 
(Roskams, Theise et al. 2004; Roskams 2006). This cell population has been shown to have 
‘bipotential characteristics’ expressing morphological and immunophenotypic features 
typical of both hepatic and biliary epithelial cells. Wilson and Leduc, 1958, were the 1st to 
describe activation of this ‘reserve cell compartment’, which in humans is described as 
‘ductular activation’ or ‘progenitor cell activation’ (Leduc 1958). A third population of stem 
cells with hepatic potential resides outside the liver in the bone marrow. These 
haematopoietic stem cells may contribute to the low renewal rate of hepatocytes, but in the 
face of severe and/or extensive damage can contribute significantly to regeneration under 
very strong positive selective pressure (Petersen, Bowen et al. 1999; Alison, Poulsom et al. 
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2000; Theise, Badve et al. 2000; Theise, Nimmakayalu et al. 2000; Kleeberger, Rothamel et 
al. 2002) 
Under conditions where the insult to the liver is extensive and/or chronic, the liver is 
crippled by hepatocyte senescence due to telomere shortening that is associated with 
ongoing proliferation during the prolonged chronic history of disease. During incidents 
where the intrinsic proliferative and clonogenic capacity of inherent 
hepatocytes/hepatoblasts is affected, extrinsic stem cells with hepatogenic potential are 
chemo-attracted towards to the site of liver injury, finding a niche and attempt to salvage the 
liver. It should be noted, however, that in the diseased liver, there may be lack of the major 
growth stimulus and/or absence of substantial growth advantage for haematopoietic stem 
cells to correct and repair the damaged tissue. Another important factor is the intrinsic 
genetic regulation of stem cells (Geiger, Rennebeck et al. 2005). In addition, there are many 
other regulatory systems involved, which dictate the replacement of damaged, aged or 
diseased tissue with new cells. Stem cells secrete factors which act through a paracrine 
system and play a role in regulating tissue regeneration. Systemic factors are also important 
in modulating signaling pathways critical to activate tissue specific stem cells (Conboy, 
Conboy et al. 2005). Liver cells (hepatocytes, cholangiocytes, and progenitor cells), 
mesenchymal cells (Kupffer cells, endothelial cells, hepatic stellate cells) and the liver 
stroma collectively form the liver ‘stem cell niche’ that regulates stem cell proliferation, 
maintenance and cell fate decisions. The importance of such cellular and non-cellular 
interactions was demonstrated by Kon et al, who elegantly illustrated in vitro differentiation 
of small rat liver progenitor cells into hepatocytes upon co-culture with non-parenchymal 
supporting cells (Kon, Ooe et al. 2006). Additionally, the fact that hepatocytes, which have 
a great growth potential in vivo, when isolated and put in culture pose a huge challenge to 
maintain alive and differentiated also further re-enforces the importance of such niches 
(Scharschmidt, Waggoner et al. 1975) . Even if stem cells did tend to retain much of their 
intrinsic proliferative potential when old, age-related changes in the systemic environment 
and niche in which stem cells reside preclude full activation of these cells for productive 
tissue regeneration 
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Figure 27. Three different cell lineages that contribute to liver regeneration and repair after 
injury. First line of defense in the face of injury is provided by bipotential hepatoblast which 
are capable of differentiating into hepatocytes and cholangiocytes. These are believed to be 
functional stem cells of the liver and are capable of self-renewal after loss. When hepatocyte 
renewal is compromised, or the liver damage is more severe, this calls upon activation of 
bipotential stem/progenitor cells in the canal of Hering, located in the intra-hepatic biliary tree 
that take over the burden of regeneration. Under conditions where the insult to the liver is 
extensive and/or chronic or the intrinsic proliferative capacity of the liver is compromised, 
extrinsic stem cells from the bone marrow harbor to the site of injury and provide a third line 
of repair and regeneration. It should be noted, however, that systemic factors also play a 
pivotal role in modulating signaling pathways critical to tissue regeneration.  
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1.3.5 Current mode of management of liver disease- restrictions and 
limitations 
Despite the worldwide prevalence and significant morbidity and mortality associated with 
severe liver disease,  medical advancement so far allows successful treatment of 
compromised liver function through resection and transplantation surgeries only (Belle, 
Porayko et al. 1997; Fong, Sun et al. 1999). This is an invasive procedure and is limited by 
the availability of donor organs. Less that 30% of patients on a waiting list receive a 
transplant (Ascher, Lake et al. 1993; Lee 1993). Non-treatable and/or incurable liver 
conditions impending transplantation, are subject to supportive and palliative modes of 
management. These comprise non-biological and biological liver support systems. These 
supportive modalities have been introduced to standard therapy since 1950s, to bridge 
patients awaiting organ transplant.  
1.3.5.1 Non-biological or artificial liver support systems  
 Non-biological systems primarily provide detoxification/purification by removing toxins of 
hepatic failure. The repertoires of known substances that accumulate in the blood in hepatic 
failure aggravate injury to the liver. These substances inhibit the natural ability of the liver 
parenchyma to regenerate and simultaneously suppress the ability of residual hepatocytes to 
perform organ-specific functions (sick cell syndrome). Additionally, these substances cause 
neurological abnormalities and failure of the immune system and other organs (kidney and 
lung). These substances include not only small molecular weight toxins (ammonia, phenols, 
false neurotransmitters, free bile acids, etc.) but also mediators of inflammation (cytokines, 
chemokines, anaphylatoxins, etc.). Vasoactive substances, endototoxins, cell growth 
inhibitors (e.g TGFβ1) and other known and currently unknown harmful substances are also 
included (Rozga 2006).  Some of the latest advancements in blood purification technologies 
include: MARS ® (Molecular adsorbent recycling system), SPAD (Single-pass albumin 
dialysis) and SEPET (Selective plasma filtration), but their utility is limited by their inability 
to provide missing liver functions. 
1.3.5.2 Bio-artificial livers (BAL) - hepatocyte-based extracorporeal devices  
Bio-artificial or hepatocyte-based devices represent advancement in the management of 
hepatic disorders. These cellular-dependent (animal or human cells) systems are able to 
provide whole liver functions, including detoxification, biosynthesis and biotransformation. 
However, it is worth noting that in addition to the risk of xenosis in the animal cell-based 
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systems (mainly of porcine origin) additional well-conducted studies are warranted to better 
demonstrate safety and proof of concept of these devices (Rozga 2006).  
Thus far, development of an effective liver assist technology has proven challenging 
because of the complexity of liver functions that must be replaced, as well as the 
heterogeneity of the patient population. 
Alternatively cellular therapies including hepatocyte transplantation can be used either to 
replace or increase the number of functional hepatocytes. The current source of hepatocytes 
is from discarded livers not suitable for whole organ transplantation, yet again limiting its 
accessibility. These cells are also used to establish primary cultures. Such primary cultures 
of hepatocytes have been hindered by their short lifespan and the rapid loss of hepatic 
function under in vitro conditions. There is still a great need for new sources of 
stem/progenitor cells with an ability to differentiate into functional liver cells. Isolation of 
an expandable population of adult human pluripotent stem cells will be an attractive 
alternative for current therapies. Before that, however, we need to better understand the 
cellular and molecular (genetic and epigenetic) mechanisms responsible for liver cell 
differentiation. Therefore, adequate in vitro platforms and animal models of liver disease are 
of great importance.  
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1.3.6 Cellular therapy of liver disease- Regenerative medicine, an 
alternative approach in healthcare 
Liver transplantation is currently the only successful treatment for acute hepatic failure or 
end stage liver disease. However, as noted earlier a major limitation to its use is serious 
donor shortage. For this reason, considerable attention has recently been focused on 
identifying alternatives modes of management for fatal liver disorders with regenerative 
medicine occupying the limelight. The following section elaborates briefly on the different 
cell sources that have been exploited in regenerative therapy of liver diseases.  
A. Hepatocyte transplantation  
Hepatocyte transplantation was believed to be a potential solution to this problem. Several 
reports demonstrated in animal models, rescue from lethal hepatic failure post primary 
hepatocyte transplantation. This was achieved through efficacious donor chimerism 
(Makowka, Rotstein et al. 1980; Rajvanshi, Kerr et al. 1996; Rajvanshi, Kerr et al. 1996; 
Gagandeep, Rajvanshi et al. 2000). Two clinical trials have previously demonstrated the 
effectiveness of hepatocyte transplantation for the treatment of liver-based congenital 
metabolic disorders. Fox et al, transplanted allogeneic hepatocytes into the liver of a patient 
with Crigler-Najjar syndrome type I (Fox, Chowdhury et al. 1998). The patient survived for 
11 months with partially corrected hyperbilirubinemia. Additionally, Dhawan et al, reported 
transplantation of cryopreserved hepatocytes into patients with inherited factor VII 
deficiency resulting in gradual reduction in their requirement for recombinant factor VIIa 
until, after 8 to 10 weeks, requiring only 20% of their original dose (Dhawan, Mitry et al. 
2004). It is still questionable, however, whether hepatocyte transplantation can contribute to 
the rescue of liver-based metabolic disorders over long-term. Furthermore, ex vivo 
expansion of mature hepatocytes is not feasible because long-term cultivation of 
hepatocytes is associated with hypofunction of hepatocyte metabolism.  It would, therefore, 
be greatly valuable if functional hepatocytes could be generated from stem cells, which 
could be propagated in vitro.  
B. Foetal liver progenitor cells  
Research looking into the role of stem cell application in liver disease has, unfortunately, 
been subject to various confines (table 6). Liver progenitor cells have been identified in 
embryonic and foetal livers and have been successfully differentiated into hepatocyte or bile 
epithelial cells (Rogler 1997; Lazaro, Rhim et al. 1998; Kubota and Reid 2000). Such 
studies have been restricted by the low yield of cells and the inadequate in vitro expansion 
after isolation (Czyz, Wiese et al. 2003). Sandhu et al and Oertel et al, both demonstrated in 
rat models that foetal hepatic stem/progenitor cells exhibited potency for reconstitution of 
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adult liver but only under a particular set of conditions (Sandhu, Petkov et al. 2001; Oertel, 
Menthena et al. 2008). Thus, it still remains unclear whether adult hepatic stem cells or 
progenitor cells, can reconstitute recipient livers not subjected to genetic modification. To 
answer this question, therapeutic transplantation of hepatic stem cells must be carried out 
using minimal pre-treatment and without genetic modification of the recipients.  
To overcome the problem of low cell yield, attempts were made by several groups to 
immortalize hepatocytes using viruses (Cai, Ito et al. 2000; Allan JE 2002) or the enzyme 
telomerase (Wege, Le et al. 2003). These approaches allowed expansion of hepatocytes but 
were compromised by phenotypic changes and karyotypic abnormalities over prolonged 
culture durations (Delgado, Parouchev et al. 2005).  
C. Embryonic stem cells  
The introduction of embryonic stem cells (ESC) provided another potential source of human 
hepatocytes. Mouse embryonic stem cells (mESCs) have been shown to be able to 
differentiate down the hepatocyte lineage which can integrate into liver tissue and produce 
albumin (Chinzei, Tanaka et al. 2002; Yamamoto, Quinn et al. 2003; Teratani, Quinn et al. 
2005; Cai and Grabel 2007). Similar work has been demonstrated in human embryonic stem 
cells (hESCs) as well (Baharvand, Hashemi et al. 2006; Hay, Zhao et al. 2007). Although 
ESCs have brilliant proliferation and differentiation properties they cannot be used in the 
clinic because of their genetic instability and a high risk of tumour formation. ESCs are also 
limited by the ethical issues that surround the use of human embryos associated with the fact 
that their retrieval requires destruction of an embryo. The scientific realism surrounding 
ESCs is that the production of large quantities of homogenous cells/tissue for clinical 
application are difficult and there could be potential complications associated with the 
animal feeder layers on which human ES cells tend to rely on in addition to the risk of 
teratomas. Hence it is unlikely that embryonic stem cell (ESC)-derived treatments will be 
available for clinical use anytime soon.  
D. Induced pluripotent stem cells  
Recently developed techniques by Takahashi and Yamanaka for pluripotency induced in 
adult fibroblast gives an interesting alternative for ESC (Takahashi and Yamanaka 2006) . 
These induced pluripotent stem cells can be generated without ethical concerns, but their 
genome instability and low efficiency of cell production raises the same concerns as for 
ESCs when considering their clinical use.  
E. Adult stem cells  
Adult stem cells (predominantly bone marrow stem cells) have been extensively 
investigated as a potential source of liver stem cells and as a means to regenerate the 
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diseased liver. This attention was fuelled by the identification of a population of liver stem 
cells in rodent (oval cells) that expressed HSC markers (e.g. Thy-15). And, hence it was 
postulated that these cells most probably originated from the bone marrow (Petersen, Bowen 
et al. 1999). Subsequently, BM transplants in animal models of liver disease were carried 
out and analysis suggested that BM could contribute to a mature hepatocyte population 
(Alison, Poulsom et al. 2000; Theise, Badve et al. 2000). These exciting results lead to 
further investigation of this resourceful stem cell population but the results obtained were 
contradictory with little evidence for a significant repopulation of the liver parenchyma by 
BM-derived cells (Kanazawa and Verma 2003; Menthena, Deb et al. 2004; Thorgeirsson 
and Grisham 2006; Vig, Russo et al. 2006). Additionally, proponents suggested that any 
rescue resulting from BM transplantation was the result of cell fusion of the BM-derived 
cells with the diseased hepatocytes, resulting in a form of cellular gene therapy. 
Furthermore, it was suggested that the unique selection pressure seen in these animal models 
triggered the fused cells to divide to repopulate the liver (Willenbring, Bailey et al. 2004). It 
is worth noting that a selection pressure of this magnitude is unlikely to be available for 
most clinical applications.  
Mesenchymal stem cells (MSCs) derived from various tissues including bone, fat and dental 
tissue have also been explored as an alternative source of donor cells. Animal studies have 
previously demonstrated the ability of human adipose tissue MSC-derived hepatocytes to 
restore some liver function in nude mice with acute liver failure (Banas, Teratani et al. 
2009). Additionally, van Poll et al, showed that systemic infusion of soluble factors secreted 
from MSCs provided a survival benefit and prevented the release of liver injury biomarkers 
(van Poll, Parekkadan et al. 2008). Thus it may be argued that the transplanted MSCs did 
not play a crucial role in reconstitution of the recipient liver, but instead, the soluble factors 
that they secreted were liver protective. Additionally, contradictory results have 
demonstrated that MSCs do not differentiate in to hepatocytes in rat livers (Popp, Slowik et 
al. 2007). Such apparently contradictory results have been commonly seen in this field and 
probably reflect a combination of factors, including the use of varying cell derivation and 
differentiation protocols, and the fact that the models of liver injury are often differing and 
rarely repeated. Although, more in vivo research is definitely needed to address these issues, 
MSCs do appear to ameliorate liver injury in some way or the other. Moreover, it may be 
that both the exact derivation and pre-conditioning of the starting cells and the host liver 
environment will determine the resulting phenotype of the transplanted cells. 
The clinical studies reported for BM therapy for liver disease involve infusion of the 
enriched haematopoietic cell fraction (CD133+, CD34+ or monocytes) (am Esch, Knoefel et 
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al. 2005; Terai, Ishikawa et al. 2006; Lyra, Soares et al. 2007). Interestingly, the majority of 
in vitro and in vivo experimental work suggests that the MSC population in BM are 
inducible into hepatocyte-like phenotype, and there is very few data suggestive that HSCs 
have a similar potential. The logic, however, for using the haematopoietic cell fraction in 
cirrhotic liver conditions may be due to the modulating and remodelling effect of the 
monocyte-macrophage population on scar tissue (Duffield, Forbes et al. 2005). As pointed 
out, the results achieved from ADS research as an alternative cell source for the 
management of liver disease has been exciting but, has also simultaneously highlighted 
many grey areas that need further investigationS.    
A novel stem cell source that has been explored more recently is the umbilical cord and cord 
blood. This stem/progenitor cell reserve provides a very abundant and valuable resource that 
still remains to be exploited therapeutically in the management of liver injury and disease. 
As far as cell therapy of end-stage liver disease is concerned, it may be safe to conclude that 
stem/progenitor cells that can be efficiently differentiated into a hepatocyte phenotype can 
be used for ex vivo purposes, such as liver support devices, toxicology studies and drug 
testing. For transplantation procedures, however, it is essential to ensure that the cells 
infused are pre-programmed to either differentiate into or remain as hepatocytes in vivo post 
transplantation, and research thus far is some way short of this mark. Additionally, it is 
worth considering what the best treatment approach would be. Would it prove more fruitful 
to transplant hepatocyte-like cells in the extremely harsh environment of a cirrhotic liver, 
where endogenous professional hepatocytes find it hard to survive or to modify the cellular 
and extracellular milieu, to allow the endogenous hepatocytes and progenitor cells to 
regenerate the liver? The latter may well be a more realistic medium-term goal for cell 
therapy.  
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Table 6. Limitations of various stem/progenitor cells with potential for management of liver 
disease. 
 
 
Embryonic/foetal 
liver progenitor cells 
 
Immortalized 
hepatocytes 
Viruses/enzyme 
(telomerase) 
 
Embryonic stem 
cells 
 
Induced 
pluripotent 
stem cells 
 
Adult stem cells  
Bone 
marrow/peripheral 
blood 
 
a)  Low yield of cells 
 
 
b) Inadequate in 
vitro expansion 
 
(Campard, Lysy et 
al. 2008) 
 
a) Compromised by 
phenotypic changes 
and karyptype 
abnormality over 
prolonged culture 
durations. 
 
(Airey, Almeida-
Porada et al. 2004) 
 
a) Problems of 
genetic 
instability 
 
b) High risk if 
teratoma 
 
c) Ethical issues 
 
d) Difficulties to 
produce large 
quantities of 
homogenous 
cells/tissue 
 
e) Complications 
associated with 
feeder layers 
 
(Campard, Lysy 
et al. 2008,35) 
 
 
a) Genetic 
instability 
 
b) Low 
efficiency of 
cell 
production 
 
(Airey, 
Almeida-
Porada et 
al.) 
 
 
a) Invasive 
collection 
procedures 
 
b) Differentiation 
potential widely 
studied but 
proponents question 
the very existence 
of the process 
claiming that cell 
fusion is 
responsible for the 
phenomena. 
 
(Alexander, Roberts 
et al. 1996) 
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Figure 28a. Schematic illustration of hepatocyte sources for cellular therapies for in vitro 
modelling of liver disease. Ex vivo adult hepatocytes can be isolated from healthy donor livers, 
yet these cells are scarce due to donor shortage and upon isolation have a limited proliferation 
capacity and lose functionality. Alternatively, adult and foetal liver progenitor cells can be 
extracted from healthy donors and in vitro directed hepatocyte differentiation induced. 
Modified from (Dalgetty, Medine et al. 2009) 
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Figure 28b. Schematic illustration of hepatocyte sources for cellular therapies for in vitro 
modelling of liver disease. Human embryonic stem cells derived from healthy blastocyst 
undergo expansion and differentiation into hepatocyte-like cells by employing extracellular 
signals to mimic human liver development. Human induced pluripotent stem (IPS) cells can be 
generated by reprogramming healthy somatic fibroblast cells from healthy donors followed by 
induction of hepatocyte-like cell differentiation. Both the above sources of hepatocytes are 
associated with complications  in terms of clinical applicability. A much safer and more 
resourceful alternative are the stem/progenitor cells extracted from the umbilical cord and 
cord blood. This primitive cell source provides an ethically sound and unlimited supply of 
stem/progenitor cells that can be exploited in in vitro hepatocyte differentiation systems and 
hence provides an ideal model to study liver development and simultaneously offers a valuable 
tool for cellular therapy of liver diseases.    
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1.3.7 Hepatic differentiation properties of adult stem cells 
Work done on adult stem cells is in close context of ageing, cell repair strategies and 
haematopoiesis. Previous studies have shown the possibility of turning bone marrow (BM) 
and umbilical cord blood (UCB) stem cells into hepatic-like cells in vivo and in vitro (Di 
Campli, Piscaglia et al. 2004; Lee, Kuo et al. 2004; Aurich, Koenig et al. 2005; Hong, Gang 
et al. 2005; McGuckin, Forraz et al. 2005; Nonome, Li et al. 2005; Baharvand, Hashemi et 
al. 2006; Kang, Zang et al. 2006; Tang, Zhang et al. 2006; Zhan, Wang et al. 2006; Hay, 
Zhao et al. 2007). The ability of bone marrow to contribute to hepatocytes was first 
demonstrated by Petersen et al., who showed that bone marrow cells transplanted into 
lethally irradiated mice engrafted in the recipient's liver and differentiated into liver stem 
cells (called oval cells in mice) or mature hepatocytes (Petersen, Bowen et al. 1999). Soon 
after, Alison et al and Theise et al also illustrated in rodents and in humans that hepato-
biliary cells could be derived from bone marrow (Alison, Poulsom et al. 2000; Theise, 
Badve et al. 2000; Theise, Nimmakayalu et al. 2000). With Y-chromosome staining and 
liver specific markers they detected bone marrow-derived hepatocytes in livers of irradiated 
mice and humans after gender-mismatched bone marrow transplantation. Gordon et al,  
reported that human CD34+ cells mobilized in peripheral blood by administration of G-CSF 
(Granulocyte- Colony Stimulating Factor) followed by leukapheresis and re-infusion of 
these cells in patients with liver insufficiency, resulted in improved liver function in patients 
(Gordon, Levicar et al. 2006).  These interesting results, however, were not reproducible by 
several groups including Wagers et al, Kanazawa et al and Cantz et al (Wagers, Sherwood 
et al. 2002; Kanazawa and Verma 2003; Cantz, Sharma et al. 2004). Even when results were 
replicable by groups, as Lagasse et al (Lagasse, Connors et al. 2000),  they were noted not 
to be the result of direct differentiation but rather occurring due to fusion of haematopoietic 
stem cells with recipient hepatocytes in the animal models (Vassilopoulos, Wang et al. 
2003; Wang, Willenbring et al. 2003).  
Although the exact mechanism for the effect on liver function is not clear and little is known 
as to which bio-molecular and biochemical pathways regulate such differentiation, such data 
may reflect activation of genes corresponding to a hepatocyte differentiation program upon 
exposure to the injured liver environment. 
Although proponents see ADS as an attractive alternative to the use of embryonic stem cells 
in regenerative medicine, opponents have questioned the very existence of the process 
claiming that cell fusion is probably responsible for the phenomenon. Several critics have 
challenged the concept of stem cell plasticity. Issues have included the inability to reproduce 
data, and the suggestion that some apparently reprogrammed ADS could be engrafted cells 
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fusing with cells in their new location. This opinion is based on experiments exploring the 
outcome of co-culturing BM with highly volatile embryonic stem cells, but not ADS, and 
noting occasional tetraploid cells from the fusion of the two cell types (Alison, Poulsom et 
al. 2003; Preston, Alison et al. 2003). A better understanding of the mechanisms of lineage 
specific differentiation and plasticity of pluripotent stem cells would provide critical clues 
for the use of stem cells in regenerative medicine. For this purpose the scientific community 
needs to develop reliable in vitro and animal models that will allow for better understanding 
of how to efficiently differentiate ADS and UCB stem cells into functional hepatic tissue. A 
new approach of liver tissue-engineered constructs in 3-dimensional environment in vitro 
gives a unique tool for preclinical and toxicological studying of ADS and UCB for their 
clinical applications in a future. Hence, as previously elaborated earlier it may be safely 
concluded that, umbilical cord and cord blood-derived stem cells offer multiple advantages 
over truly adult stem cells and over embryonic stem cells for liver differentiation.  
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1.3.8 Can Cord and Cord Blood Stem Cells Regenerate Liver Tissue? 
Taking into consideration the superiority of umbilical cord blood stem cells over bone 
marrow derived cells; several groups explored the potential of human umbilical cord blood 
to generate hepatocyte and biliary epithelial cells. These experiments were performed using 
mononucleated cells from cord blood for in vivo transplantation in animal models. In vivo 
studies were first performed in sheep by Almeida-Poroda et al and then in rodents by 
Newsome et al, Wang et al and Ishikawa et al, by transplanting cells into sub-lethally 
irradiated NOD-SCID mice (Ishikawa, Drake et al. 2003; Newsome, Johannessen et al. 
2003; Wang, Ge et al. 2003; Almeida-Porada, Porada et al. 2004). Although these recent 
publications highlight the differentiation potential of human UCB cells and were able to 
produce hepatocytes, further characterization of these differentiated cells was demanded. In 
2005, Sharma and colleagues, for the first time characterized these human UCB-derived 
hepatocyte-like cells after in vivo experiments in mouse animal models, and demonstrated 
the ability of these cells to express human albumin and human hepatocyte-specific antigen, 
Hep Par1 (Sharma, Cantz et al. 2005). They compared BM cells with human UCB 
mononucleated cells in parallel controlled studies and showed that cord blood was superior 
to BM in its differentiation potential. It could have been argued that because neonatal UCB 
stem cells are different from BM stem cells and may have a reservoir of preformed hepatic 
progenitors, which may not be present in the BM preparation, they demonstrated better 
results (Mayani and Lansdorp 1998; Kubota, Storms et al. 2002). However, to avoid such 
questions, Sharma et al performed the experiments using both adult and neonatal BM cells 
for transplantation but were unable to illustrate an increase in frequency of BM-derived 
hepatocytes in the model livers of neonatal BM transplantation (Sharma, Cantz et al. 2005).  
Until 2005, all the research done on human cord blood was performed using cord blood-
derived mononucleated cells and the studies were executed in animal models. 
Mononucleated cells, constitutes the entire white blood cell/leukocyte compartment of 
blood, of which stem cells are a component. Although, UCB demonstrates a better tolerance 
for Human leukocyte Antigen (HLA) mismatch compared to ADS, perhaps due to the 
immaturity of its immune cells, the production of a purified population of stem cells from 
cord blood for transplantation would further reduce any risk of immune-related graft 
rejection. Mcguckin et al reported the world’s first production of haematopoietic cells, 
expressing embryonic stem cell markers, from cord blood. These cells were termed Cord 
Blood-derived Embryonic-like stem cells (CBEs) and were produced by exposing UCB to 
an immuno-magentic cell separation technology that allows sequential removal of nucleated 
granulocytes, haematopoietic myeloid/lymphoid progenitors and erythrocytes, leaving 
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behind a purified population of very immune naive stem/progenitor cells (McGuckin, Forraz 
et al. 2005). Subsequently other reports concerning the existence of circulating embryonic 
stem cell-like cells during foetal development were generated (Jiang, Vaessen et al. 2002; 
Korbling and Estrov 2003). McGuckin et al further demonstrated the differentiation 
potential of these cells and showed that these cells were capable of generating endodermal 
tissues, including hepatocyte-like cells in 2-dimensional and 3-dimensional culture systems, 
expressing hepatocyte-specific markers (McGuckin, Forraz et al. 2005) as well as 
pancreatic-like cells testing positive for insulin and C-peptide (Denner, Bodenburg et al. 
2007). This was achieved by thoroughly studying classic liver biology and development and 
creating an artificial culture system that closely resembles the natural micro-environment 
that is needed for normal development of the liver (Figure 29).  Similar protocols have been 
reported in human embryonic stem cell-derived hepatic cells but not in cord blood studies 
(Baharvand, Hashemi et al. 2006). A few other research groups have also been able to 
successfully differentiate cord MSCs into hepato-bilary cells (Hong, Gang et al. 2005; 
Kang, Zang et al. 2005). Campard and colleagues are amongst the few research groups that 
demonstrated differentiation of cord matrix (Wharton’s jelly) MSCs into hepatocyte-like 
cells (Campard, Lysy et al. 2008).  
 It is worth noting, that since the isolation MSCs from cord blood is inefficient, extraction of 
haematopoietic stem/progenitor cells may prove more resourceful when using cord blood, as 
irrespective of the size of the cord blood units these cells can be isolated from nearly every 
cord blood specimen processed. The umbilical cord, on the other hand, is a brilliant resource 
for MSCs.  However, one of the limitations of MSCs is their strict dependence on selected 
lots of foetal bovine serum that has limited clinical applicability of ex vivo expanded MSCs. 
This drawback, however, may be overcome by restoring to low serum or serum-free culture 
systems as demonstrated by Reinisch et al, who for the first time demonstrated propagation 
of  both BM and UCB MSCs in bovine serum-free systems using human platelet lysate-
conditioned medium (Reinisch, Bartmann et al. 2007). Both these aspects: (i) generation of 
artificial liver tissue in vitro and (ii) use of defined culture media for stem cells 
differentiation, are crucial for establishing a reliable in vitro platform for studying cellular 
and molecular mechanisms of stem cell differentiation towards liver. 
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Figure 29. Hepatocyte microenvironment  in vitro and in vivo. Artificial culture systems are 
created by closely studying physiological liver biology and replicating it in vitro. Modified from 
(Snykers, De Kock et al. 2009) 
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1.3.9 Liver tissue-engineering 
It is worth noting that most in vitro hepatic tissue models available for research and 
development use 2-dimensional culture systems. These systems fail to represent the physical 
cell-cell interactions of a 3-dimensional human liver and also do not always produce 
scientific data that can be fully translated to physiological interpretation. The quest for an 
efficient cellular technology that can be exploited for the management of end-stage liver 
diseases has paved the way for 3-dimensional tissue engineering. Such technology employs 
synthetic biodegradable porous scaffolds and rotational cell culture systems, also referred to 
as bioreactors, which allow cells to grow and differentiate in a 3-dimensional environment 
facilitating cell-cell interaction. Groups like Baharvand et al have utilized scaffolds to effect 
3-D hepatic differentiation of human embryonic stem cells (Baharvand, Hashemi et al. 
2006) and Mcguckin et al have demonstrated similar results from umbilical cord blood by 
employing the microgravity bioreactors (McGuckin, Forraz et al. 2005).  
1.3.10 Clinical trials  
After several reports in animal models , Theise et al was the first to confirm the ability of 
bone marrow to generate hepatocytes and cholangioctyes in humans by evaluating archival 
autopsy and biopsy liver specimens obtained from gender mismatched therapeutic BM 
transplantations and from orthotopic liver transplantations (Theise, Nimmakayalu et al. 
2000). Approximately 11 BM stem cell transplantation clinical trials for treatment of liver 
diseases in humans have been published thereafter (Houlihan and Newsome 2008). These 
include work done by Mohamadnejad and colleagues in 2007, which carried out autologous 
bone marrow enriched CD34+ haematopoietic stem cell transplantation into hepatic arteries 
of four decompensated liver cirrhosis patients. Although a mild degree of improvement of 
liver function was noted in two out of four patients, one died due to radiocontrast 
nepropathy and hepatorenal failiure. Thus they concluded that intra-hepatic artery is not a 
safe mode of stem cell transplantation but could not preclude the use of CD34+ cells via 
other routes of administration (Mohamadnejad, Namiri et al. 2007). Conversely, clinical 
trials performed on similar patients by Lyra et al (Lyra, Soares et al. 2007; Lyra, Soares et 
al. 2007) and Gordon et al (Gordon, Levicar et al. 2006), using mononucleated cell- 
enriched BM cells, reported intra-hepatic artery route of infusion safe and feasible. 
Mohamadnejad et al further reported on the safety and feasibility of autologous bone 
marrow mesenchymal stem cell transplantation in patients with liver decompensation due to 
cirrhosis. This time, however, the stem cells were administered via a peripheral vein in four 
patients. No post-operative side effects were noted and all patients showed evidence of 
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improvements of liver function and a better quality of life (Mohamadnejad, Alimoghaddam 
et al. 2007). The efficiency of intravenous infusion was confirmed by studies performed in 
mice by Kou et al (Kuo, Hung et al. 2008).  Terai et al and Gordon et al, reported 
transplantation of autologous BM stem cells and human CD34+ stem/progenitor cell 
populations mobilized into the blood by granulocyte colony-stimulating factor respectively, 
and both noted improvement of liver functions in patients post transplantation (Gordon, 
Levicar et al. 2006; Terai, Ishikawa et al. 2006). It seems clear that trials of BM stem cells 
treatment in patients with liver disease are still at a preliminary stage and a better 
understanding of the physiology and mechanism of action of BM stem cell in animal models 
of liver disease is needed. The results of these clinical trials are, however, very exciting and 
open the roads for exploring the potential of umbilical cord and cord blood stem cells for 
cellular therapy of liver disease. In addition to intra-hepatic delivery of stem cells for 
treatment of liver disease, tissue engineering offers novel opportunities for the generation of 
extracorporeal liver devices. Such technology would allow temporary replacement of liver 
function buying time till a suitable organ is available for transplantation. 
Thus far the research done into exploring the potential of the umbilical cord and cord blood 
for regenerative management of end-stage disease is commendable. Although the outcome 
of the various studies highlights extra-embryonic tissues as an indispensable reserve with 
immense potential for liver therapy, limitations such as lack of consensus in 
immunophenotype of liver progenitor cells, uncertainty of the physiological role of reported 
candidate stem/progenitor cells, long-term efficacy and safety challenge the use of these 
cells in humans. Current molecular techniques of stem cell identification are confounded by 
cell fusion, horizontal gene transfer, incomplete differentiation and chimera formation. It is 
exciting to note that stem cell transplantation and phase 1 trials of bone marrow 
transplantation in humans for liver diseases (Mohamadnejad, Alimoghaddam et al. 2007; 
Mohamadnejad, Namiri et al. 2007) are underway but require more robust verification. 
More research is definitely demanded to help identity the best source of stem/progenitor 
cells that can transferred from the bench to the bedside for the management of patients with 
severe or life-threatening liver disorders.  
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Goals and scope of this study 
The scope and ambition of this study was to harness the multi-potential property of 
umbilical cord and cord blood stem/progenitor cells to engineer human 2-dimensional and 
3-dimensional functioning hepatic tissue models. These models are to be used as a platform 
to better understand the biology of liver development, to be exploited in bio-artificial liver 
assist technology, used in biotechnology and pharmaceutical applications  (drug toxicology 
studies) and finally to be applied in regenerative medicine for advancement in cell therapy 
for liver disease.  
Stages of the project included:  
 Umbilical cord and umbilical cord blood collection only after written informed 
consents. 
 Selection of cord blood stem/progenitor cell populations.  
 Isolation of umbilical cord Mesenchymal stem cells.  
 Optimization of expansion protocol facilitating commitment of cord blood stem cells 
to meso-endodermal lineages. 
 Directed 2-D umbilical cord and UCB stem cell in vitro differentiation into 
hepatocytes and cholangiocytes (biliary epithelium) driven by growth factors, amino 
acids, minerals, extracellular matrices and cell culture media combinations. 
  Hepatic cell characterization by morphology and phenotyping. 
 Umbilical cord and cord blood derived differentiated stem/progenitor cells were 
compared with other liver cell populations at different stages of development 
including:  
o HepG2 (liver cancer cell line) 
o Human foetal liver cells 
o Human adult liver cells 
 Progression from 2-D cell culture to 3-D tissue engineering. Integration of cells, 
bioscaffolds/biomaterials, bio-chemical and physical cues to engineering 3-D hepatic 
tissue constructs, using 3D bioreactor technology. 
 Functional characterization: assessment of some key functions of the engineered 
hepatic tissue constructs.  
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2 Materials and Methods  
2.1 Consent and collection of umbilical cord and cord blood 
2.1.1 Informed consent 
Written informed consents were obtained from all participants (Appendix A). Uniform 
standards for collection of cord blood units were observed without alterations of safe 
obstetric practice.  
2.1.2 Cord blood collection 
Umbilical cord blood (UCB) specimens were collected from full-term third stage of labour 
deliveries after elective caesarean sections. All specimens were collected according to the 
Royal Victoria Infirmary (RVI) and Newcastle university ethical regulations. The protocols 
followed, were reviewed by the National Health Service local ethics committee. Cord blood 
units were collected at the maternity unit in the Royal Victoria Infirmary, Newcastle upon 
Tyne. 
Blood samples were collected in 250ml blood collection bags (Baxter PL146-CPDA-1-
35ml; Baxter, Derrfeild, IL, USA) containing 35ml anticoagulant (Citrate Phosphate 
Dextrose-A, CPD-A). 
Cord blood collection was only instigated after completion of the third stage of labour with 
no interference with the timing of cord clamping and disconnection of the placenta and 
umbilical cord from the newborn.  
The umbilical cords were clamped by the performing surgeon at three positions along the 
length of the cord (Figure 30). Upon receipt of the cord, blood gases were collected between 
clamps one and two. These samples are sent off for analysis to determine the level of gases 
in the neonate. Subsequently cord blood collection for research was commenced. Blood 
collections were performed under strict sterile conditions. Cord blood was collected between 
clamps two and three (Figure 30). Blood was collected only from the umbilical vessels and 
not from the placenta. Placental manipulation and milking of the cord were not performed 
during the collection procedure. Gravity and natural movement was used to facilitate 
drainage of the umbilical vessels.  
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Figure 30. Clamping of the umbilical cord after the third stage of labour. (A and B) Blood gases 
were collected between clamp 1 (C1) and clamp 2 (C2) and (B) cord blood was subsequently 
collected between clamp 1 (C2) and clamp 3 (C3).  
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Figure 31. Collection of umbilical cord blood after the third stage of albour. 
 (A) Apparatus used for cord blood collection. (B) Clamping of umbilical cord by the obstetric 
surgeons. (C and D) Placenta and cord transferred to funnel-shaped instrument and 
suspended to allow gravity to facilitate cord blood collection. (E and F) Cord blood collection 
between clamp 2 (C2) and clamp 3 (C3). (G) 250ml blood collection bag (Baxter) containing 
anticoagulated cord blood.  
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2.1.3 Cord collection  
Once all the blood from the umbilical cord vessels was drained, the first two clamps were 
removed from the cord and 10cm of the cord was cut from the distal end using a sterile 
scalpel. The piece of cord was then transferred into Hanks’ Balanced Salt Solution (x1) 
(HBSS) (Invitrogen; 1600 Faraday Ave, Calsbad, CA) in a 50ml falcon tube until 
processing was undertaken.  
2.1.4 Criteria for transport and storage of samples prior to processing  
Transport of cord and cord blood units from remote collection sites to the processing and 
storage facility is a quality concern due to time and temperature sensitivity of the samples. 
Both parameters play an important role in the potential decline in cell viability. The samples 
utilized for this project were all transported at room temperature and processed within 24 
hours of collection. Wada et al noted a 1 per cent drop in cell viabilities for every 4 hours 
increase in transit time (Wada, Bradford et al. 2004). And, Hubel et al reported that cord 
blood units processes within 24 hours after collection exhibited very little loss of cell 
viability (Hubel, Carlquist et al. 2004).    
2.1.5 Tissue Culture standards  
To evade bacterial and fungal contamination all tissue culture including processing of 
umbilical cord and cord blood samples as well as preparation of reagents, was performed in 
a specialised tissue  culture facility with class II vertical laminar flow hoods, with or without 
fitted dissection microscopes (Zeiss), observing sterile methodology throughout. These 
facilities were sterilised by fumigation biannually. Additionally, all reagents, equipment, 
materials and hoods were sprayed with 70% ethanol. All waste liquids and cells were treated 
with VirkonTM  (Medisave, VK734) )before disposal. All Culture media was filtered with a 
0.2µm acrodisc syringe filter (PALL Life Sciences, 0.2µm supor membrane, PN 4612, 
PALL corporation, Ann Arbor, USA) and was used or disposed of within four weeks of 
preparation. Cells were routinely examined with a Zeiss Axiovert 200M fluorescence 
microscope to assess cell viability and state of culture. To minimize cell stress from cold 
temperatures or acidic pH changes, all media was warmed to 37°C, and CO2 equilibrated by 
placing in an water bath for 30 minutes prior to usage. All wash buffers utilized were made 
fresh to avoid potential contamination between experiments.  
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2.2 Isolation of mononuclear cell fraction from cord blood 
Recent successful clinical reports have implied the use of UCB in the management of 
several disease conditions. In addition, UCB may alleviate some of the problems associated 
with adult stem cell transplantation. Cord blood banks could minimize the problems 
connected with finding suitable stem cell donors and incidence of graft rejection would be 
diminished. Several different methods of cord blood separation are available today and in 
this study we have analysed the most recent and frequently applied techniques in an attempt 
to indentify the most efficient method for separation and cryopreservation.  
2.2.1 Density gradient method of cord blood separation 
Density gradient method of cell separation exploits the differences in densities to separate 
blood into its various components. 
Thorsby and Bratile (1970) slightly modified the technique pioneered by Bǿyum for 
isolation of Lymphocytes from blood using sodium diatrizoate (9.1%) and polysaccharide 
(5.7%). This technique was pioneered by Bǿyum in 1968. Other authors, Harris and 
Ukayiofo (1969), Ting and Morris (1971) have emphasized the reliability of this technique 
for separation of lymphocyte preparation from anti-coagulated blood stored at room 
temperature for up to 6 hours.  
Ficoll-Paque PREMIUM (GE Healthcare Bio-Science AB; Cat no. 17-5442-02, Sweden) is 
a ready made, sterile solution for the isolation of pure lymphocyte suspensions. This density 
gradient media is manufactured according to GMP compliant measures. This media is 
composed of polysucrose and sodium diatrizoate. It illustrates the following physical 
characteristics: density 1.077 +_ 0.001 g/ml, osmolality 290 +/- 15 mOsm.  
Ficoll causes aggregation of RBC, thereby increasing their sedimentation rate. The 
sedimentation of leucocytes is only slightly affected and can be collected from the upper 
part of the tube when the erythrocytes have settled.  
In this study anti-coagulated blood samples were transferred from blood bags to 50ml 
skirted funnel tubes and diluted in equal volumes of Dulbeco’s Phosphate buffered salt 
solution (PBS) (PAA laboratories GmbH, Cat no. H15-002, Strass 1, Pasching, Austria). 
Four volumes of diluted blood was then overlaid onto one volume of Ficoll (GE Healthcare  
Bio-Sciences AB, Cat. No. 17-5442-02, Sweden) prior to centrifugation (Jouan CR422. St-
herblain, France) (400g (1350rpm), 30 minutes, 4°C, Acceleration 1, Deceleration 0). 
Centrifugation aids in accelerating the density gradient separation. The buffy layer of white 
blood cells (WBCs) is at the interface between the plasma and Ficoll (Figure 32).  Ficoll 
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preserves the functional and morphological integrity of the cells. Additionally, this method 
does not penetrate biological membranes (http://www4.gelifesciences.com, 2007). 
The mononucleated cell (MNC) layer was collected with a sterile Pasteur pipette, washed 
once in PBS and pelleted (500g, 10mins) before re-suspension in PBS. Cell aliquots were 
taken for viability/enumeration using Trypan blue (0.25% in PBS, Sigma- Aldrich, and 
Poole, UK).  
It has, however, been suggested that in order for Ficoll to work at its optimal potential it 
should be used in conjunction with a hydroxyethyl starch separation.  This is because the 
modified two-step approach gives a superior WBC/MNC recovery (median 94.2 ±2.44% 
Vs. 90.2±5.8%) (Schwinger, Benesch et al. 1999). Lymphoprep offers a similar approach to 
Ficoll, but it uses a mixture of metrizote and polysaccharide (http://www.axis-shield.com, 
2007).  
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Figure 32. Density gradient method for cord blood cell separation. (A) Umbilical cord blood 
samples transferred from blood bags to 50ml skirted falcon tubes and diluted in equal volumes of 
(x1) Earle’s basic salt solution (EBBS). (B) Four volumes of diluted blood was then overlaid onto 
one volume of Ficoll. (C) Samples immediately after overlaying on Ficoll (*) and post 10 minutes 
standing at rtp (♣). Note density dependent RBC sedimentation to the bottom of the falcon tubes. 
(D) Pre and post centrifugation of the blood samples. Centrifugation aids in accelerating the 
density gradient cell separation. Note the buffy layer (WBC rich) at the interface between the 
plasma and Ficoll.  (E) Post centrifugation the buffy layer (WBC rich) was collected with a sterile 
pasteur pipette and washed once with (x1) PBS and pelleted.  
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2.2.2 Hetastarch- Hydroxyethy Starch method for cord blood separation 
The umbilical cord blood units were transferred to 150 ml transfer bags (Baxter, R4R2001) 
then HES (Baxter 1001999959, 6 % Hetastarch in 0.9 % Sodium Chloride) was added to the 
UCB at a concentration of 20 % blood volume.  The bag was then centrifuged at 125 x g for 
10 mins, with the brake off (Jouan CR422. St-herblain, France). This stops disruption of the 
RBC pellet. Using a plasma expresser (Fenwal BM-1. Lake Zurich IL, USA), the 
supernatant containing the desired nucleated cells was expressed off into a second transfer 
bag (Figure).  The second bag was then centrifuged at 400 to 500 x g for 10 mins (Jouan 
CR422, St-herblain, France). Again using plasma expresser, the supernatant was removed 
into a third transfer bag and this time discarded, leaving the pellet of nucleated cells in the 
second bag.  These nucleated cells were then resuspended in Human Serum Albumin (HSA) 
(Bio Products Laboratory PL08801/006. Elstree, UK).   
2.2.3 PrepaCyte-CB method for cord blood separation  
PrepaCyte-CB is the first product originated from BioE's patented PrepaCyte technology 
platform. PrepaCyte is manufactured under U.S. FDA cGMP regulations.  PrepaCyte-CB's 
negative selection process leaves desired cells unmodified.  Preliminary results have shown 
PrepaCyte-CB improves TNC (total nucleated cell) and CD34+ cell recoveries when 
compared to Hetastarch-based methods (Basford, Forraz et al. 2009).  In addition, 
PrepaCyte-CB removes more than 98 percent of red blood cells from the final product. 
In this study Cord blood samples were thoroughly mixed on a blood collection mixer 
(Genesis CM-735; Hackensack, NJ, USA) and then transferred to the PrepaCyte-CB kit as 
illustrated in figure 33. The cord blood collection bag was connected with the PrepaCyte-CB 
system with a connecting tube thus allowing blood to drain into the PrepaCyte system. For 
optimal recovery of cells, a portion of the reagent-cord blood mixture was drained back into 
the collection bag, mixed and the contents were transferred back into the PrepaCyte system. 
Tubing between the cord blood bag and the PrepaCyte kit was the heat-sealed and the blood 
collection bag discarded. The PrepaCyte kit containing the reagent-blood mixture was the 
mixed on a rocker for 3-5 minutes, 15-20 rocks/min. After mixing, the PrepaCyte was 
suspended on a plasma expressor (Fenwal BM-1) for 30 minutes at room temperature to 
allow unwanted cells to aggregate and sediment to the bottom of the processing bag by 
causing an antibody dependent agglutination of red cells. The TNC-rich Supernatant 
containing the entire white cell compartment of cord blood was transferred to the next bag 
for centrifugation at 400-500 g for 10 minutes, with low break to avoid disruption of the 
pellet (Jouan CR422). After centrifugation, TNC and stem cell fraction was pelted thus 
Materials and Methods 
 116 
allowing unwanted second supernatant (predominantly plasma compartment of blood) to 
drain back through the system into the first processing bag already containing the unwanted 
agglutinated red blood cell compartment of the cord blood sample.  The TNC and stem cell 
fraction was then either transferred into the cryopreservant bag or used in the laboratory for 
tissue culture purposes. The entire processing protocol took approximately 60 minutes to 
complete.  
 
 
 
 
 
 
 
 
 
 
 
Figure 33. Schematic diagram of the PrepaCyte-CB bag set. Once the UCB unit is added to the 
bag set, it flows sequentially through as the process progresses until the desired nucleated cells 
reach the cryopreservation bag. (Basford, Forraz et al. 2009) 
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2.2.4 Plasma depletion method of cord blood separation  
Plasma depletion is a non-red blood cell-depleted cord blood processing technique. It allows 
substantial plasma depletion from the UCB unit but does not remove red blood cells 
(RBCs). In this study, blood collection bags were connected to sterile 300ml Baxter transfer 
bags (transfer bag 1).   Cord blood was allowed to flow through.  The tubings were heat 
sealed and the collection bag removed. The pre-processing sampling was then performed in 
a biological safety cabinet. The blood units were thoroughly mixed prior to removing 
samples for analysis. A weighing scale was employed to balance the bags prior to 
centrifugation for 10 minutes at 2400rpm (temp 15-26°C). The bags were then carefully 
removed from the centrifuge and placed on a plasma extractor. The transfer bag 1 was then 
connected with a second sterile 150ml transfer bag (transfer bag 2). This bag was placed on 
an electric weighing scale and the scale was set to zero. The tubing of transfer bag 2 was 
clamped with a haemostat. Once the integrity of both bags was checked, the handle of the 
extractor was gently released to close the plate and the haemostat on the tubing was slowly 
released. The volume of the plasma expressed into transfer bag 2 was calculated by the 
weight of the bag. The tubing between the bags was re-clamped before any RBCs entered 
the tubing. The handle of the extractor was then released. Any air remaining in the blood 
bag after removal of the plasma was extracted with a syringe.  Transfer bag 2 containing the 
expressed plasma was then heat sealed and removed. The content of transfer bag 1 was then 
thoroughly mixed and a sample was removed for further analysis. A cryobag was then 
attached to transfer bag 1 containing the plasma depleted UCB unit. The UCB was 
transferred into the cryobag using sterile technique. The extra tubing and transfer bag 1 were 
heat sealed and removed. The cryobag was the stored in an upright position at 2-8°C for a 
minimum of 30 minutes before being transferred to the control rate freezer in cold 
aluminium cassettes.  
2.2.5 Sepax- fully automated sterile system for cord blood processing  
This was a new fully automated, functionally closed and therefore sterile system, which is 
controlled by computer software (Figure 34).  It permits isolation of the haematopoietic 
stem cell (HSC) rich buffy-coat of an UCB unit to a final volume of 10 to 90 ml.  Each unit 
is separated with a single use kit, which is inserted into the machine.   
The UCB unit was introduced into the machine where it filled the central chamber. Whilst 
filling, the system simultaneously sediments the UCB unit.   The sample was then 
centrifuged at speeds of up to 1900 x g and the blood components were separated 
concentrically.  Then, using optical sensors and motorised stopcocks the blood components 
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were directed to individual blood bags and extracted from the UCB unit. 
(http://wwwbiosafe.ch 2007).  This method was recently validated by the Besançon Cord 
Blood Bank in France.  They found that TNC recoveries were higher with the Sepax system 
than with Hetastarch (HES) separation methods (80.3 ± 7.7% versus 76.8 ± 9.1%) and that 
CD34+ cell recovery was also higher with Sepax (86 ± 11.6% versus 81.5 ± 12.5%) 
(Lapierre, Pellegrini et al. 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Sepax- fully automated sterile system for cord blood separation. This is a versatile 
cell separation technology which consists of the compact Sepax main processing unit (A) and 
single-use kits (B) allowing the controlled separation of cellular products in a fully automated 
and closed environment- no other equipment is required. 
(http://www.sinarvin.ir/index_files/sepax_kits.htm).  
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2.3 Umbilical Cord processing 
The piece of umbilical cord previously collected was immersed in HBSS (Gibco, cat. no. 
14170120) until further processing was initiated. Two separate methods of cord processing 
were investigated and the manual dissection of the cord proved to be an easier and more 
efficient technique. 
2.3.1 Isolation of stem/progenitor cells from umbilical cord Wharton’s jelly  
2.3.1.1 Enzymatic digestion of the cord 
 
The piece of cord (approximately 10cm in length) was transferred into a petri dish half filled 
with HBSS. Sterile forceps and a scalpel were used for the cord dissection. The cord was cut 
along its length with a scalpel and the vessels were removed using the forceps. The cord and 
its matrix (including the Wharton’s jelly) were cut into small 4-6mm pieces and transferred 
into a 50ml falcon tube filled with HBSS. The tube was centrifuged at 250g for 5 minutes. 
The supernatant was discarded and the cord pieces were washed in serum-free DMEM 
(Invitrogen, Cat. no. 11039-021) and centrifuged at 250 x g for 5 minutes. The cord pieces 
were then transferred into a Petri dish and incubated with Collagenase (2mg/ml) overnight 
in an incubator at 37°C. The cord pieces were then washed with serum-free DMEM and 
incubated with 2.5% Trypsin at 37°C for 30 minutes with regular agitation. Fetal bovine 
serum (FBS) was introduced to inhibit the enzymatic reaction. The cord pieces were washed 
in serum-free DMEM and then cultured in DMEM-F12 10% FBS.  
2.3.1.2 Manual dissection of the cord  
The piece of cord was dissected in a similar method to the enzymatic digestion protocol. 
The 1-3mm cord pieces were then immediate transferred into culture medium (DMEM-F12 
10% FBS, 1% penicillin-streptomycin (Invitrogen, Cat. no. 15140-122), 1% fungizone 
(Invitrogen, Cat. no. 15290-026) in 6 well plates.  
In both methods, medium was not changed until 5 days after isolation. This allowed 
adequate time for the cord stem/progenitor cells to migrate out and adhere to the culture 
plates.  
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Figure 35. Processing of umbilical cord specimens. (A) Transverse section of umbilical cord 
showing two umbilical arteries (A) and an umbilical vein (V). (B) Measurement of umbilical 
cord specimen prior to processing. (C) Umbilical cord pieces post dissection in HBSS. (D) The 
umbilical cord specimens were dissected resulting in 4-6mm long pieces which were then 
transferred into culture medium for Mesenchymal stem cell isolation.  
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2.4 Sample analysis post cord blood and umbilical cord processing 
2.4.1 Enumeration of cell samples  
2.4.1.1 Haemocytometer 
Cells were enumerated and assessed for viability by diluting cells with Trypan blue solution 
(0.25% in PBS). Cells were then counted with a Neubauer standard haemocytometer. 
The Trypan blue solution allows discrimination between dead cells (staining blue due to 
impaired membrane integrity) and viable cells (remaining translucent) to be made. 
 
Formulation: 
Cell number 
Cells in central and four corner squares counted. This represents cells * 105 / ml  
% viability  
Viable cells/ total cell count * 100  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. The haemocytometer. The haemocytometer 
glass counting chamber comprises grids that are etched 
onto the surface of the glass. The grids consist of five large 
1mm squares, four corner squares and one middle square. 
Upon mounting with a coverslip the height between each 
square and the coverslip is 0.1mm. Consequently, the 
volume above each square is 1mm x 1mm x 0.1mm, which 
equals 0.1mm3 = 0.1µl = 10-4 ml. To avoid repetitive 
scoring, cells placed on the left and top borders and inside 
the square were counted. 
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2.4.1.2 Differential cell count 
 
Differential cell counts on the UCB units was done using a COULTER® AC.T diff 2TM 
Analyzer (Beckman Coulter, Inc. Fullerton, CA 92835). This is a compact system that 
features low-volume automated one step sample processing and haematological analysis. 
The analyzer provides a complete blood count (CBC) together with a comprehensive 
differential count of the cord blood samples. A sample of 1ml was applied to the machine. 
The WBC count and differential determined the number of WBCs and the percentage of 
each type of WBC in each unit of blood.  
 
2.4.2 Colony forming unit (CFU)  
Mononuclear cells from cord blood were counted using the Beckman Coulter analyzer for 
the pre- and post-processed samples. 1x106 cells from each sample was added to Iscoves’s 
Modified Dulbecco’s Medium (IMDM) (Gibco/Invitrogen 21980-032, Daisley, UK) + 20% 
FCS + supplements to make a final volume of 0.5ml. This was then added to 3.5ml aliquot 
of methyl cellulose culture medium (Stem cell Technologies 04534, USA) to make a total 
volume of 4ml. Gentle mixing with a 20ul pipette was performed to avoid frothing. Three 
small gridded petri dishes (Nunc brand, VWR 734-2114, Westchester, PA, USA) were 
labeled and placed in a large petri dish (Figure 37). 1ml of the cell mix was transferred 
gently into two of the small petri dishes using a pipette.  One of the small petri dishes was 
filled with a volume of sterile distilled water (not more that 2/3 full). The dishes were 
incubated at 37°C (95% O2 and 5% CO2) for 14 days. The number of Granulocyte-
Macrophage colonies and other lineages present were assessed using an inverted light 
microscope. If the growth was plentiful the number of colonies in only 20 squares was 
noted. This was achieved by counting the number of colonies in every eight square of the 
grid until 20 squares had been counted.  This figure was multiplied by 11.25 to give the total 
number of cells in the whole plate. If the colony growth was poor then all the colonies in all 
the squares were counted.   The colony numbers of the three test plates were averaged.  And 
the number of colonies per 105 cells was calculated.        
E.g. if cells were plated at 1.0 x106 per plate and resulted in 85 colonies per plate 
then: 
 
 Colonies per 105 cells = 85 ÷ 10 
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Figure 37. Colony forming unit assay. Three small gridded petri dishes were placed in a larger 
petri dish. One was filled with sterile water and the other two with 1ml of cell suspension in 
methyl cellulose culture medium. The dishes were incubated at 37◦C (95% O2 and 5% CO2) 
for 14 days.  
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2.4.3 Flowcytometric analysis  
Cellular characterisation (extra- and intra-cellular) and antigen expression profiles of the test 
samples was investigated by flowcytometry. For the purpose of this project flow cytometric 
analysis was carried out using a Becton Dickinson FACS calibre flow cytometer (Becton 
Dickinson, Franklin Lakes, NJ, USA).  
Sample Preparation  
Samples were prepared as follows:  
Cord blood analysis: samples were prepared in 9 tubes. 100µl of blood (200µl in tube 6 as 
the population examined in this tube was very small) and 50µl of respective antibody 
mixture were added to each of the nine tubes. Tubes were then incubated at room 
temperature, in the dark, for 20 minutes. After incubation, the cells were lysed and washed 
using the BD FACS Lyse/Wash Assistant. The samples were then ready to be analysed on 
the flow cytometer.  
Table 7. Antibody cocktails in each FACS tube used to characterize cord blood derived 
stem/progenitor cells 
Tube 
Number 
Tricolour  
(antibody 
cocktails)- 
Cluster of 
Determinants 
(CD)  
1 45/14/7ADD 
2 3/4/45 
3 3/8/45 
4 3/56/45 
5 3/19/45 
6 34/7ADD 
7 25/4/45 
8 Lin1/11c/ 
HLA-DR 
9 Lin1/123/ 
HLA-DR 
 
Each antibody is detailed in the table 8 
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Table 8. Details of antibodies used to characterize cord blood-derived stem/progenitor cells 
Antibody  (CD) Immunoglobulin  
Subtype  
Fluorochrome  Source 
3 IgG1 FITC 555332; BD Pharmingen, 
Franklin Lakes, NJ, USA  
4 IgG1 PE  347327; BD Pharmingen, 
Franklin Lakes, NJ, USA  
8 IgG1 PE S340055; 
Caltag/Invitrogen, 
Paisley, UK 
11c IgG1 PE 555392; BD Pharmingen, 
Franklin Lakes, NJ, USA  
14 IgG1 PE MHCD 1404-4; 
Caltag/Invitrogen, 
Paisley, UK  
19 IgG1 PE 555413; BD Pharmingen, 
Franklin Lakes, NJ, USA 
25 IgG2b FITC 558689; BD Pharmingen 
Franklin Lakes, NJ, USA  
34 IgG1 PE 345802; BD Pharmingen 
Franklin Lakes, NJ, USA  
45 IgG1 FITC 555482; BD Pharmingen, 
Franklin Lakes, NJ, USA 
56 IgG1 PE 345802; BD Pharmingen, 
Franklin Lakes, NJ, USA 
123 IgG1 PE 340545; BD Pharmingen 
Franklin Lakes, NJ, USA  
7AAD IgG1  559925; BD Pharmingen 
Franklin Lakes, NJ, USA  
HLA-DR IgG2 PE-Cy5 555813; BD Pharmingen 
Franklin Lakes, NJ, USA  
Lin 1 IgG1/2b FITC 340546; BD Pharmingen 
Franklin, Lakes, NJ, USA 
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Mesenchymal stem cell analysis: samples were prepared as follows: 1-2 x106 cells in PBS 
were incubated with 5µl of each antibody (table 9) in the respective tubes. The tubes were 
incubated and the subsequently washed as for the cord blood samples before analysis on the 
LSRII. 
 
Table 9. Antibody cocktails used to characterize umbilical cord derived Mesenchymal stem 
cells. 
Tube Number Multi-Colour (antibody cocktails)- 
Cluster of Determinants (CD)  
1 29/34/44/45/73/105/166 
 
2 44/45/90/106/133 
 
 
Each antibody is detailed in the table 10.  
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Table 10. Details of antibodies used to characterize umbilical cord-derived Mesenchymal stem 
cells. 
Antibody  (CD) Immunoglobulin  
Subtype  
Fluorochrome  Source 
14 IgG2a Pacific-Blue  558121; BD 
Pharmingen 
Franklin, Lakes, NJ, 
USA 
34  IgG1 PE-Cy7 348791; BD 
Pharmingen 
Franklin, Lakes, NJ, 
USA 
29 IgG1 Alexa Fluor 700 
(A700) 
303020; BioLegend 
 
44  IgG2b Pacific Blue 103020; BioLegend 
 
45 IgG1 APC-Cy7 557833; BD 
Pharmingen 
Franklin, Lakes, NJ, 
USA 
CD 73 IgG1 PE 550257; BD 
Pharmingen 
Franklin, Lakes, NJ, 
USA 
90 IgG1 FITC 555595; BD 
Pharmingen 
Franklin, Lakes, NJ, 
USA 
133/1 IgG1 APC 130-090-826; 
Miltenyl Biotech 
GmbH 
105 IgG1 Alexa Fluor 647 
(A647) 
 
323212; BioLegend 
 
106 IgG1 PE/Cy5 305808; BioLegend 
 
166 IgG1 FITC ab33403; AbCam 
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2.5 Selection of a homogenous stem/progenitor cell population from 
mononuclear cell fraction  
The antigen profile of haematopoietic stem/progenitor cells (HSPC) is utilized by most 
investigators to either positively or negatively select HSPC from heterogeneous blood 
samples. Positive selection relies on monoclonal antibodies (conjugated to various 
compounds) designed specifically against markers expressed on primitive HSPC. CD34 and 
CD133 antigens are amongst these antigenic markers, which are commonly aimed for the 
selection of HSPC away from developing and differentiated cells. Inversely, negative 
selection (also known as 'depletion') exploits monoclonal antibodies or chemicals with 
specific affinity for mature and differentiated cell markers, eliminating the differentiated 
haematopoietic lineages from a restricted group of lineage negative (LinNeg) HSPC 
population (Civin, Strauss et al. 1990; Miltenyi, Muller et al. 1990; Engelhardt, Lubbert et 
al. 2002).  
2.5.1 Separation of non-haematopoietic lineage negative cell population 
(CBE) from mononuclear cells applying in-house LinNeg protocol 
A negative immuno-magnetic selection strategy was employed for the depletion of desired 
MNC from differentiating and mature haematopoietic cells. This technique allows a 
primitive and more homogenous source of haemopoietic and possibly non-haemopoietic 
stem/progenitor cells to be obtained. This immuno-magnetic technique separates cells 
according to the presence or absence of cell surface molecules recognized by a monoclonal 
antibody coupled to magnetic beads either primarily or via a secondary antibody (Figure 
38). 
MNC obtained after Ficoll treatment of whole cord blood samples were incubated for 20 
minutes at 4°C with human gammaglobulins (2% in PBS). This allows blocking of non-
specific Fc receptors. Cells were then incubated for 30 minutes at 4°C with the following 
mouse monoclonal anti-human antibodies (all IgG isotypes): (i) anti-CD45 (MEM 28, 
Autogen Bioclear), (ii) anti-glycophorin-A (JC159, Dako, UK), (iii) anti-CD33 (WM53, 
Autogen Bioclear, UK) and (iv) anti-CD7 (WM31, Autogen Bioclear). Centrifugational 
washes in dextrose-albumin were then applied (400g, 10 minutes, 4°C). 
Cells were subsequently secondarily labelled with Dynabeads human IgG4 monoclonal anti-
pan mouse IgG (Dynal, Invitrogen,) for 30 minutes. Cell fraction was then applied to a 
Dynal Magnetic Particle Concentrator. Application to the magnetic field causes retention of 
the positive cell fraction (magnetic bead labelled fraction) whilst eluting the negative 
fraction. The negative cell fraction, termed 'Lineage Negative' cells (LinNeg) were collected 
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with a sterile Pasteur pipette. After centrifugation (400g, 10 minutes, 4°C), LinNeg cells 
were counted with a haemocytometer and assessed for viability. The LinNeg protocol 
although valuable for selection of a very small non-haematopoietic progenitor cell 
population, proved to be very expensive, time consuming and labour intensive. Thus, 
commercial kits from StemSep were resorted to for the enrichment of progenitor cell 
population from cord blood units post Ficoll treatment.  
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http://www.invitrogen.com/downloads/IVGN_SC_Capabilities_Jan_2006.pdf 
 
 
 
 
 
 
 
 
 
Figure 38. Negative immuno-magnetic selection strategy. The figure illustrates a negative 
immuno-magnetic selection strategy employed for the isolation of a primitive and more 
homogenous source of stem/progenitor cells from differentiated and mature haematopoietic cells. 
Cells are separated according to the presence or absence of cell surface molecules recognized by 
monoclonal antibodies coupled to magnetic beads. The monoclonal antibodies utilized in this study 
include: anti-glycophorin-A, anti-CD45, anti- CD33 and anti-CD7. Cells are subsequently 
secondarily labelled with Dynabeads human IgG4 monoclonal anti-pan mouse IgG and cell 
fraction applied to the magnetic field causing retention of the positive cell fraction whilst eluting 
the negative fraction. The negative fraction ' Lineage Negative' constitutes the desires cell fraction.  
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2.5.2 Haematopoietic stem/progenitor cell extraction using commercial kits– 
Human Primitive Haematopoietic Progenitor Cell enrichment Kit 
(StemSep)  
Mononuclear cells (MNC) obtained post Ficoll processing were pelleted and re-suspended 
in separation medium (PBS+2% FBS) (07905; StemCell Technologies) within the 
acceptable range 2-8 x 107 cells/ml, as recommended by the kit (StemSep; 14057 (14067), 
StemCell Technologies). StemSep Enrichment Coctail containing mouse derived 
monoclonal  bispecific tetrameric antibody complexes (IgG1) against cell surface antigens 
on human haematopoietic cells and dextran (CD2, CD3, CD14, CD16, CD19, CD24, CD36, 
CD38, CD45RA, CD56, CD66b, glycophorin A) (14057C; StemCell Technologies) was 
added to the cell suspension at concentration of 100µl/ml of cells. The cells were mixed well 
by pipetting and incubated at 4°C for 30 minutes (Figure 40). Magnetic colloid (colloidal 
suspension of magnetic dextran iron particles in saline pH 7.0-7.5) (10051; StemCell 
Technologies) was added to the cell-antibody suspension at a concentration of 60µl/ml of 
cells, mixed well and incubated at 4°C for 30 minutes. During the incubation period the 
cooled MACS separation columns were prepared. These columns have been developed for 
the gentle depletion of magnetic microbead labelled cells. They come in different sizes 
depending on the number of magnetically labelled cells (LD columns, capacity 1-5 x108 
cells, 130-0742-901; LS columns, capacity 108 cells, 130-042-401; MS columns, capacity 
107 cells, 130-042-201). The columns contain an optimized matrix and when placed in a 
permanent magnet allow a high-gradient magnetic field to be generated. This permits the 
microbeads, which are extremely small, superparamagnetic particles to be retained from the 
cell suspension.  The columns were prepared by washing them from top down with 2ml of 
priming medium (PBS). This allowed the hydrophilic coating of the columns to be rinsed 
out and thus avoided rapid filling of the columns with cell suspension. The magnetically 
labeled cell suspension was mixed properly by pipettimg several times and applied to the 
column. The cell suspension runs through the column matrix at a rate of approximately 0.2-
0.25ml/min and the effluent was collected. The column was then washed with PBS twice 
with 2ml of separation medium (PBS+2% FBS) (07905; StemCell Technologies) and the 
total effluent was collected as the depletion fraction. The depletion fraction was then 
characterized by flow cytometric analysis using antibody cocktails mentioned in section 
2.4.3, to observe whether the kit allowed enrichment of the desired stem/progenitor cell 
population. 
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Figure 39. Schematic diagram of StemSep demonstrating tetrameric antibody complexes 
(TAC) magnetic labeling of human cells. StemSep® Human Hematopoietic Progenitor Cell 
Enrichment Kit 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
 133 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
StemSep 
Enrichment 
Cocktail  
Cell suspension  
Incubate 30 minutes at 
4◦C 
Add 
StemSep 
Magnetic 
Colloid  
Incubate 30 minutes 
at 4◦C 
Prime Column 
Wash and Cell 
Separation 
Load Sample (Gravity 
Feed) 
Magnet  
Collect 
Sample  
Priming 
Medium 
Figure 40. StemSep human progenitor 
cell enrichment kit. The schematic 
diagram illustrates the steps involved in 
extraction and isolation of 
haematopoietic stem/progenitor cells 
using the commercial StemSep kit.  
http://www.stemcell.com/en/Products/Al
l-Products/StemSep-Human-Primitive-
Hematopoietic-Progenitor-Cell-
Enrichment-Kit.aspx 
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2.6 Expansion and commitment of isolated stem/progenitor cell populations 
One of the biggest clinical disadvantages of stem/progenitor cells derived from cord blood is 
that there are not adequate cells in a single cord blood unit to meet the needs of an adult 
patient. Consequently, several groups have made efforts at attempting to expand cord blood 
stem cells. A part of this study was also dedicated to this task. 
MSCs from umbilical cord, however, are blessed with a high proliferation potential and thus 
can be expanded efficiently ex vivo.  
2.6.1 Expansion of Mesenchymal stem/progenitor cells from umbilical cord 
Post isolation of MSCs from umbilical cord these cells were cultured in Mesenchymal stem 
cell growth medium (MSCGM) 10% fetal bovine serum (FBS) (Invitrogen, 16000-036). 
This medium was formulated by adding MSCGM SingleQuots (Lonza, Cat. no. PT-4105, 
Walkersville, MD, USA) to Mesenchymal stem cell basal medium (MSCBM) (Lonza, Cat. 
no. PT-3238, Walkersville, MD, USA) to make MSCGM. The media was supplemented 
with Penicillin-streptomycin (Invitrogen, Cat. no. 15140-122) and Fungizone (Invitrogen, 
Cat. no. 15290-026) both at a concentration of 1:100 to evade bacterial and fungal 
contamination. The first medium change was carried out 4 days after initial plating of cells 
to allow the cells adequate time to adhere to the plate forming a monolayer. The cells were 
expanded in MSCGM for two weeks and then transferred to DMEM-F12 (Gibco, Cat. no. 
11039-021) 10% FBS for further propagation and passaging.  
2.6.2 Expansion and commitment of Haematopoietic and non-haematopoietic 
stem/progenitor cells  
The yield of selected stem/progenitor cell population isolated from cord blood MNCs is 
usually very low and depends of the volume and quality of the cord blood unit. In addition 
the tolerance of these cells to the artificial in vitro culture conditions and hence the resulting 
cell viability is low. A part of this project was focused to trying to devise a system whereby 
these cells could be simultaneously expanded and committed along the desired endodermal 
cell lineage. The cytokines used in this effect are listed in the table 11. 
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Table 11. Expansion and endoderm commitment medium for cord blood stem/progenitor cells 
Reagents  Morphogen Supplier and 
Code  
Final volume  
DMEM-F12 (1:1) Invitrogen, Gibco 
11039-021 
22832.5µl 
5% FBS (Stock 100%) Invitrogen 
16000-036 
1250µl 
ITS liquid media supplement 
(100x)  
Sigma 
13146 
250µl 
Heparin Sodium Salt  
(2.5µg/ml) 
Sigma-Aldrich 
 
H4784 
125µl (500µg/ml stock) 
Collagen IV- from human 
placenta, acid soluble   
(1µl/ml) 
Sigma-Aldrich 
C5533 
25µl 
Penicillin-streptomycin  
(1:100) 
Invitrogen 
15140-122 
250µl 
Fungizone  
(1:100) 
Invitrogen 
15290-026 
250µl 
Recombinant Stem Cell Factor 
(rh SCF) 
20ng/ml 
ImmunoTools  
11343407 
5µl (100µg/ml stock) 
Recombinant Hepatocyte 
Growth Factor (rh HGF) 
 
20ng/ml 
ImmunoTools 
 
11343415 
5µl (100µg/ml stock) 
Recombinant human Fibroblast 
Growth Factor- acidic (rh FGF-
acidic) 
 
20ng/ml 
ImmunoTools 
 
11343555 
5µl (100µg/ml stock) 
Recombinant thrombopoietin 
(rh TPO) 
10ng/ml 
ImmunoTools 
11133345 
2.5µl (100µg/ml stock) 
Final Volume   25000µl 
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2.7 Passaging of cells  
When cells reach confluency, they must be passaged or subcultured. Failure to subculture 
confluent cells results in a reduced mitotic index and eventually ends in cell death. 
Passaging of cells starts with detachment of attached cell monolayers from the surface of 
primary culture by either: enzymatic detachment (Trypsinization or Accutase) or by 
mechanical means (cell scraping) (Greiner bio-one GmbH, Cat. no. 541 070, Germany).  
Trypsinization was performed using Trypsin-EDTA (0.25% Trypsin, 0.02% EDTA; 59428C 
Sigma-Aldrich) for 5-7minutes at 37 °C in the incubator. Once the cells had detached FBS 
(26140 Gibco, lot.366182; Grand Island, N.Y. U.S.A) was added to inactivate the enzyme 
reaction and then the Trypsin-EDTA solution with the cell suspension was transferred into a 
centrifuge tube. The flask was rinsed out with a pipette-full (3-5ml) of PBS (x1) and that 
was transferred into the same centrifuge tube (Jouan CR422). This minimized cell loss. The 
cell suspension was then centrifuged at 1500 rpm for 5 minutes. The supernatant was 
discarded leaving behind 200-500µl supernatant to re-suspend the cells in.  
Alternatively, Accutase (in Dulbecco’s PBS containing 0.5mM EDTA; L11-007, PAA 
Laboratories GmbH; Haidmannweg) was used. Accutase is a mixture of proteolytic and 
collagenolytic enzymes from invertebrate species. Its non-mammalian source makes 
Accutase guaranteed free of BSE, Parvovirus and other viruses that may be found in 
Trypsin. It is a ready to use solution for detachment of cells. Accutase was used in the same 
manner as Trypsin EDTA solutions were used to detach adherent cells but did not require 
foetal bovine albumin for enzyme inactivation. Accutase allowed a more gentle enzymatic 
detachment meaning that the cells could be incubated with Accutase for up to 45 minutes.  
Mechanical detachment was performed using cell scrappers (Greiner bio-one GmbH. Cat. 
no. 541 070, Germany). This can be applied as the sole method of cell passaging or in 
combination with enzymatic detachment.  
2.8 Growth curve 
To evaluate the growth characteristics of the isolated cell populations growth curves were 
carried out. The rate of growth of each cell population was calculated by counting the total 
number of cells in duplicate wells every day for 4 weeks. The results were plotted on a log-
linear scale.  
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2.9 Cytogenetic analysis of expanded cells- analysis of genetic stability 
2.9.1 Cell preparation  
The protocol for cytogenetic analysis of cells was provided by Dr Simon Zwolinski, 
Cytogenetics department, Institute of Human Genetics, Centre for Life.  
Cells for cytogenetic analysis were cultured as monolayers in flasks. 200µl of 1/5 Colcemid 
(Demecolcine) was introduced into the culture medium. Colcemid is related to colchicine 
but is less toxic. It depolymerises microtubules thus limiting microtubule formation 
(inactivates spindle fibre formation). This leads to cell cycle arrest in metaphase. 
After the 3 hours incubation period, the supernatant in the flasks (medium containing 
colcemid) was transferred into a labelled centrifuge tube. The cells are then trypisinized 
Trypsin-EDTA (0.25% Trypsin, 0.02% EDTA; 59428C Sigma-Aldrich). The cell 
suspension was then centrifuged at 500 x g for 5 minutes. The supernatant was discarded 
leaving behind 200-500µl supernatant to re-suspend the cells in. 100µl of 0.075M KCL 
(5.59g of KCL in 1L of dd water) was then added to the cell suspension. The cells were 
given a gentle mix with a pipette and the tube was topped up with 0.075M KCL. The cell 
suspension was then placed in a 37°C water bath for 5 minutes and then centrifuged at 500 x 
g for 5 minutes. The KCL was carefully decanted without disrupting the pellet. A few drops 
of fixative (3:1 Methanol: Acetic acid) was then added to resuspend the cells. The centrifuge 
tube was topped up with fixative and then centrifuged at 500 x g for 5minutes. The fixative 
was pipetted off gently. A few drops of fresh fixative were added to the cells and the cells 
were then stored at -20°C until slide preparation was undertaken.  
2.9.2 Slide preparation  
The slide preparation was courtesy of Dr Simon Zwolinski, Cytogenetics department, 
Institute of Human Genetics, Centre for Life. Once the slides were prepared they were 
stained using a G banding protocol. The staining was kindly performed by Simon 
Zwolinski. 
2.9.3 Slide Analysis  
The microscope used to analyse the slides was Nikon Eclipse E400. The capture software 
was CytoVision version 3.93 (supplied by Applied Imaging 2007). Slide analysis was done 
courtesy of Dr Simon Zwolinski.  
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2.10 Cryopreservation of cells  
2.10.1 Cryopreservation of umbilical cord blood 
Umbilical cord blood unprocessed and post processing units, were cooled to 4°C before 
being transferred to a cryostore bag (CS250n, Quest Biomedical, Solihull, UK). Dimethyl 
sulphoxide (DMSO) (Origen 210002, Origen, Austin, TX, USA) mixed with Dextran 40 
(Baxter Healthcare B5043) was used as the cryopreservant for the cord blood samples. The 
cryopreservant was also cooled to 4°C, and then was introduced to the cells at a 
concentration of 10%. The samples were cryopreserved in a control rate freezer (Planar 
Kryo 560-16, Sunbury-on-Thames, UK) using the following protocol: Start temperature = 
4°C, step I = hold at 4°C for 10 minutes, step II = -2°C/min to -5°C, step III = -1°C/min 
to   -40°C and step IV= -5°C/min to -100°C. Samples were then transferred to the gaseous 
phase of a liquid nitrogen Dewar vessel. Cord blood units were cryopreserved for a 
minimum of 14 days before thawing and further analysis was carried out.  
2.10.2 Cryopreservation of Cord Mesenchymal stem cells (MSCs) 
Dimethyl sulphoxide (DMSO) (Origen 210002, Origen, Austin, TX, USA) mixed with 
foetal bovine serum (26140 Gibco, lot.366182; Grand Island, N.Y. U.S.A) were used as the 
cryopreservant for MSCs. The cryopreservant was cooled to 4°C and then introduced to the 
cells at a concentration of 10% in 1.8ml round bottom Nunc Cryo Tubes (363401; Nunc, 
ThermoFisher Scientific; Nunc GmbH & Co. KG; Langenselbold, Germany). The cells were 
frozen at a concentration of 1 x 10^6 cells/ml of cryopreservant.  
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2.11 Thawing protocol  
2.11.1 Thawing of umbilical cord blood  
The thaw protocol applied in this project was derived from Rubinstein’s method 
(Rubinstein, Dobrila et al. 1995). The cord blood samples, both unprocessed and processed 
units, in cryostore bags (CS250n, Quest Biomedical, Solihull, UK) were removed from 
liquid nitrogen Dewar vessels and transferred to a water bath at 37°C. The blood units were 
then gently manipulated in the water to allow the sample to defrost slowly. Once completely 
thawed, the cryostore bag was connected to two separate transfer bags (Baxter PL1813) 
using aseptic technique. The first bag (Bag 1) was empty and the second bag (bag 2) 
contained 100ml Dextran 40 (Baxter Healthcare B5043)/ Albumin (Bio Products Laboratory 
PL08801/006) solution, in a 1:1 ratio. Half of the Dextran/Albumin solution in transfer bag 
2 was then transferred to the thawed unit in the cryostore bag and mixed thoroughly. This 
mixed solution was then transferred to the first transfer bag (bag 1). The remainder of the 
Dextran/Albumin solution was then transferred to the cryostore bag to rinse out any residual 
thawed blood sample and this was then also transferred into transfer bag 1. Transfer bag 1 
was then heat sealed and detached from the cryostore bag and transfer bag 2, which were 
disposed of. The sample in transfer bag 1 was then centrifuged (Jouan CR422) at 500 x g for 
10 minutes. This transfer bag was then connected to a third transfer bag (bag 3) which was 
used for drainage of the supernatant post centrifugation with the help of a plasma expressor 
(Fenwal BM-1). The pellet in bag 1 was the resuspended in Dextran/Abumin to its original 
post processing volume.  
2.11.2 Thawing of Mesenchymal stem cells  
Mesenchymal stem cells in Nunc Cryo Tubes (363401; Nunc, ThermoFisher Scientific; 
Nunc GmbH & Co. KG; Langenselbold, Germany) were thawed in a 37°C water bath 
similar to the umbilical cord blood samples. Once completely thawed the samples were 
transferred to a centrifuge tube containing 10-15mls of PBS and centrifuged at 500 x g for 5 
minutes. The supernatant was then decanted and the cell pellet was re-suspended in 1ml of 
culture media (DMEM-F12) or PBS.  
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2.12 Liver specific differentiation culture system in vitro  
2.12.1 Culture conditions 
In vitro differentiation was performed in 2-D and 3-D culture systems. 2-D differentiation 
experiments were performed in plastic culture flasks (T25cm2 and T75cm2, canted neck, 
ventilated culture flasks; Iwaki, Scitech DIV, Asahi Techno glass, Japan), 6-well, 24-well 
and 96-well plates (Techno Plastic Products, Switzerland). Cells were also seeded on Slide 
Flasks (Nunc, Rochester, NY, USA) and extra-cellular matrix (ECM) coated 30mm cover 
slips (Thermanox ® plastic coverslips, Nunc, Rochester, NY, USA) positioned in 24-well 
plates for ease of subsequent immunocytochemistry analysis.  
The ECM proteins utilized for coating: 
1. Fibronectin (Human) (Invitrogen, Cat. No. 33016015) 
2. Gelatin (Tissue culture grade, BioReagent, Type B, sterile) ( G1393, Sigma-Aldrich, 
Aryshire, UK) 
After 1 week of ex vivo expansion UCB-derived stem/progenitor cells were stimulated with 
a range of differentaitive hepatic and biliary cues for 1week. The morphogens and growth 
factors exploited to drive stem/progenitor cells towards hepatic differentiation were added to 
medium. Cells were differentiated both in EGF supplemented and EGF depleted media.  
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Table 12. Differentiation medium 
Reagents  Morphogen Supplier and 
Code 
Working Concentration 
DMEM-F12 (1:1) Invitrogen, Gibco 
11039-021 
47167.5µl 
B27 supplement (x50) (1:50) Gibco-Invitrogen 
17504-044 
 
1000µl 
N-2 Supplement (x100) 
(1:100) 
Gibco-Invitrogen 
 
17502-048 
500µl 
Collagen IV- from human 
placenta, acid soluble 
(1µl/ml) 
Sigma-Aldrich  
C5533 
50µl 
Heparin Sodium Salt 
(2.5µg/ml) 
Sigma-Aldrich 
H4784 
250µl (500µg/ml stock) 
Penicillin/streptomycin 
(1:100) 
Invitrogen 
15140-122 
500µl 
Fungisone  
(1:100) 
Invitrogen  
15290-026 
500µl 
Recombinant Hepatocyte 
Growth Factor (rh HGF) 
(20ng/ml) 
ImmunoTools 
11343415 
10µl (100µg/ml stock) 
Recombinant human 
Fibroblast Growth Factor- 
acidic (rh FGF-acidic) 
20ng/ml ♣ 
ImmunoTools 
11343555 
10µl (100µg/ml stock) 
Recombinant Epidermal 
Growth Factor ( rh EGF) 
20ng/ml 
ImmunoTools 
11343407 
10µl (100µg/ml stock) 
Recombinant Stem Cell 
Factor (rh SCF) 
5ng/ml 
Immuno Tools 
11343325 
2.5µl (100µg/ml stock) 
Final volume   50000µl 
 
♣ In EGF depleted culture system EGF cytokine was omitted from the culture medium. 
The cells were then transferred to maturation medium for a further 1week. Cells were 
checked and photographed at different stages of differentiation and maturation.  
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Table 13. Maturation medium 
Reagents Morphogen supplier and 
Code 
Final volume 
DMEM-F12 (1:1) Invitrogen, Gibco 
 
11039-021 
46067.5µl  
B27 supplement (x50)  
(1:50) 
Gibco-Invitrogen 
 
17504-044 
 
1000µl 
N-2 Supplement (x100) 
 
(1:100) 
Gibco-Invitrogen 
 
17502-048 
500µl 
Collagen IV- from human 
placenta, acid soluble 
 
 (1µl/ml) 
Sigma-Aldrich  
 
C5533 
50µl 
Heparin Sodium Salt 
 
 (2.5µg/ml) 
Sigma-Aldrich 
 
H4784 
250µl (500µg/ml stock) 
Penicillin/streptomycin  
 
(1:100) 
Invitrogen 
 
15140-122 
500µl 
Fungisone  
 
(1:100) 
Invitrogen  
 
15290-026 
500µl 
Dexamethasone (10-6M) 
 
1µmol/L 
Sigma-Aldrich 
 
D4902 
1000µl 
Recombinant, human 
Oncostatin M (OSM) 
 
20ng/ml 
Sigma-Aldrich 
 
O 9635 
100µl (10µg/ml stock) 
Recombinant Hepatocyte 
Growth Factor (rh HGF) 
 
20ng/ml 
Immuno Tools 
 
11343415 
10µl (100µg/ml stock) 
Recombinant human 
Fibroblast Growth Factor- 
acidic (rh FGF-acidic) 
 
20ng/ml 
ImmunoTools 
 
11343555 
10µl (100µg/ml stock) 
Recombinant Epidermal 
Growth Factor ( rh EGF) 
 
20ng/ml 
Immuno Tools 
 
11343407 
10µl (100µg/ml stock) 
Recombinant Stem Cell 
Factor (rh SCF) 
 
5ng/ml 
Immuno Tools 
 
11343325 
2.5µl (100µg/ml stock) 
Total volume   50000µl (50ml) 
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2.12.2  Seeding of cells onto plates   
Sterile tissue culture flasks and plates were seeded with the following cell concentrations: 
 
Table 14. Seeding density of cells onto tissue culture flasks and plates 
Plate Format  Surface Area 
(cm2) 
Volume/well (µl) Cell Density (cells/ml) 
T75cm2 
 (75cm2/canted Neck, slim-
type; 3123-075, Iwaki, 
Scitech DIV, Asahi Techno 
glass, Japan) 
75cm2 10000µl MNC 
 
10x10^6/ml 
MSC 
 
0.1x10^6/ml 
T25 cm2 (25cm2/canted Neck, 
slim-type; 3103-025, Iwaki, 
Scitech DIV, Asahi Techno 
glass, Japan  
25cm2 5000µl MNC 
 
5x10^6/ml 
 MSC 
 
0.02x10^6/ml 
6-well plate (Zellkultur Test 
Platte 6; 92006, Techno 
Plastic Products, Switzerland) 
8.962 cm2 2000µl MNC 
 
0.5x10^6/ml 
MSC 
 
1500-
5000/ml 
24-well plate (Zellkultur Test 
Platte 6; 92024, Techno 
Plastic Products, Switzerland) 
1.862cm2 500-1000µl MNC 
 
0.5x10^6/ml 
MSC 
 
1000/ml 
96-well plate (round bottom, 
Zellkultur Test Platte 96; 
92096, Techno Plastic 
Products , Switzerland)  
0.36cm2 100-200µl MNC 
           50000-80000/ml 
♣ used predominantly  for 
culturing of LinNeg or StemSep 
selected cells were cell yield is 
very low   
Slide Flask   Nunc, 
Rochester, NY, USA 
9 cm2 2500-5000 µl MNC 
 
0.5x10^6/ml 
MSC 
 
1500-
5000/ml 
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2.12.3 Three-Dimensional (3D) culture system 
2.12.3.1 Scaffolds 
 
Scaffolds are three-dimensional structures that play a pivotal role in ex vivo tissue 
engineering. Synthetic scaffolds are typically engineered to demonstrate a surface chemistry 
and microstructure adapted to facilitate cellular attachment, proliferation and differentiation. 
They also allow simultaneous inter-cellular communication and excretion of extracellular 
matrix components needed for the tissue formation. Biodegradable scaffolds are favored for 
tissue regeneration as they disintegrate without undesirable by-products and leave behind 
the cells they were meant to deliver.  
2.12.3.2   Types of scaffolds 
 
Scaffolds used in this study were: 
- OPLA (Open-Cell Polylactic Acid) (3D OPLA Scaffold, 354614, Becton and Dickinson 
Biosciences, France) - synthesized from D, D-L, L Polylactic acid. These scaffolds are 
white/neutral in color and sponge/non-compressible in texture. They measure approximately 
5mm x 3mm x 0.039cm3 with a hydration capacity of 30µl and an average pore size of 100-
200µm and weight 5.2-34mg. These scaffolds demonstrate facetted architecture, which is 
effective for culturing high density cell suspensions.  
- Macroporous hydrogels (Protista): these cryogels were white/neutral in color and 
sponge/compressible in texture. They measured 12.5mm x 7.1mm with a pore size of 
approximately 10-120 microns. These scaffolds were sliced with a cryostat and then 
sterilized before use. The hydrogels applied in this study were:  
- Fibrinogen-gelatin- composed of Fibronectin from human plasma, gelatin and 
glutaraldehyde 
- Laminin-Dextran- composed of Laminin, dextran-LLA-HEMA (L-lactide-hydroxyethyl 
methacrylate)   
These cryogels were provided non sterile and were sterilized by incubating them in 70% 
ethanol for at least 24 hours and then rinsed with (x1) PBS to remove ethanol prior to their 
application in tissue culture (as recommended by the supplier).  
2.12.3.3   Seeding of cells on scaffolds   
Scaffolds were gently placed into a small volume of culture medium in a culture dish. 
Scaffolds equilibrated with the medium were then transferred into the wells of a 24-well 
plate (1 scaffold per well) and gently dried with sterile cotton pads. Cells suspended in 
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culture medium were then directly injected with a 100µl pipette into the centre of the top of 
each scaffold at a density of 105per ml.  Partially dehydrated scaffolds re-swell upon 
addition of the cell suspension.  Scaffolds equilibrated with the cell suspension were left in 
dry wells for 1 hour in the incubator at 37°C and 5% CO2. . This ensured cell adherence to 
the porous walls of the scaffolds. After 1 hour incubation the wells with scaffolds were 
filled with growth medium (2ml per well) and the plates were returned to the incubator.  
2.12.3.4   Rotatory cell culture system (RCCS) or Bioreactor 
 
The original concept of the rotatory cell culture system (RCCS) was conceived as a means 
of studying the effects of microgravity at the cellular level. The goal was to gain insight into 
the molecular mechanisms of the effects of microgravity on the astronauts, and to formulate 
counter measures. This technology was developed at NASA’s Johnson Space Centre in 
1996 (Navran 2004 ). The original purpose of the RCCS was to maintain cell cultures on the 
space shuttle before and during lift off. But ever since the usefulness of this technology 
became apparent in ground-based experiments, the RCCS has been exploited as a 
microgravity simulator in cell culture. Thus, allowing cells to be cultured in a 3 dimensional 
environment with minimal shear stress on the cells. The RCCS was designed with several 
features intended to minimize fluid shear (Hammond and Hammond 2001).  
 Biomechanics  
 
In practice, the rotational speed of the bioreactor vessel is set so that the sedimentation rate 
of a cell in the cell culture medium is minimized (Figure 41).  The medium properties 
(viscosity and density) are not varied.  
 
 
 
 
 
 
 
 
 
 
Figure 41. Vector velocity diagram. The 
diagram illustrates the forces acting on a 
particle (P) rotating in a fluid. Gravity-
induced sedimentation Vs is resolved into 
radial Vsr and tangential Vst 
components. Centrifugal force results in 
an outwardly directed particle velocity, 
Vcr. The Coriolis motion Vct is 
tangential to the particle (Navran 2004 ).  
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Mass transport of nutrients and gaseous exchange is accomplished by a combination of bulk 
flow and diffusion, excluding the harmful influences of fluid shear stress on the cells.   
 Limitations of the RCCS 
The drawback of the RCCS is that as particle (cell) size increases, the rotational speed must 
also increase to keep the particles in suspension. Centrifugal force is then increased, causing 
particle collision on the vessel wall. The augmented rotation also causes an increase in shear 
stress. These two factors generate cell damage and limit the size of cell aggregates to less 
than 1cm in diameter (Navran 2004 ).  
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2.13 Phenotypic analysis of differentiated cells  
2.13.1 Light microscope – Differential interference contrast (DIC) 
imaging 
All DIC images were taken with Zeiss Axiovert 200M fluorescence/live cell imaging 
microscope (Carl Zeiss AG International, Germany). Software Axiovision version 4.5.  The 
following objectives were used:  
Plan Neofluar 5x/ 0,15 
Plan Apochromat 10x /0,32 Ph1 
LD Achroplan 20x/ 0,40 Korr Ph2 
LD Achroplan 40x/ 0,60 Korr Ph2 
LD Achroplan 63x/ 0,75 Korr Ph2 
 
2.13.2 Immunocytochemistry (ICC)/Immunohistochemistry (IHC)  
Immunocytochemistry and Immunohistochemistry were used for in situ visualization of 
cellular proteins. During the course of this project cellular proteins were labeled with 
fluorescent markers and visualized using confocal laser scanning microscopy.  
Immunocytochemistry protocol 
To allow precise appreciation of cellular morphology by microscopy, cells were grown on 
gelatin coated glass cover slips in 24 well plates. This manoeuvre permitted passaging and 
the subsequent need to resort to cytospin slides to be excluded, both of which may be 
associated with loss of original cellular morphology. Use of cover slips also had the added 
advantage of minimizing the total volume of antibody usage.  
Adherent cells were washed with PBS once and not for more than 5 minutes. Cells were 
then fixed with a formalin free fixative, Accustain (A5472; Sigma-Aldrich Biotechnology 
LP and Sigma-Aldrich) for 20 minutes at room temperature for fixation of intra- and 
extracellular markers. The cells were then washed three times with PBS, 10 minutes each 
time. Cells could then be stored in PBS at 4°C for up to 72 hours before proceeding with the 
protocol. The cells were then permeabilized with 1% Triton X-100 (Sigma, Cat. no. T8787) 
(5ml of 100% Triton X in 495ml of (x1) PBS) for 15 minutes. This step was only needed for 
internal markers and was not necessary for the detection of surface markers. The cells were 
then blocked with blocking buffer (5% BSA (Albumin Solution from Bovine Serum, cell 
culture tested, 30% in DPBS, A9576, Sigma), 5% Goat serum (10% Non-Immune Goat 
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Serum, 50-0627, Zymed Laboratories, Invitrogen, Carlsbad, CA 92008, USA) in 0.1% 
Triton-X) for 1 hour. For surface markers the same blocking solution was used but without 
the addition of Triton X. The cells were then incubated with the primary antibody overnight 
at 4°C. The primary antibody working concentrations are listed in table (Table 15).  Dual 
staining was performed by pre-mixing and adding the relevant primary antibodies together. 
Control immuno-labeling was carried out in all cases by excluding primary antibodies. 
After the overnight incubation with primary antibody the cells were washed three times with 
PBS (x1), 10 minutes each time. The cells were then incubated with the appropriate 
secondary antibody for 60 minutes at room temperature. Post incubation the cells were 
washed three times with PBS (x1), 10 minutes each time. Nuclear DNA was counterstained 
by incubating cells with 500nM 4’, 6-diamidino-2-phenylindole dilactate (DAPI) (D9564; 
Sigma-Aldrich) in PBS (x1) for 5 minutes. Cells were subsequently washed once in 
PBS(x1). Post-staining, cells cultured on cover slips were mounted on glass slides using 
anti-fade reagent (Gel Mount Aqueous Medium, G0918, Sigma-Aldrich) and they were 
analyzed using Confocal laser scanning microscopy.  
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Immunohistochemistry protocol  
Paraffin embedded foetal and adult liver tissue sections were used as positive controls for 
immunocytochemistry data generated from cord and cord blood differentiated progenitor 
cells.  
Paraffin embedded foetal liver tissue sections were provided courtesy of Steve Lisgo, 
Human Development Biology Resource (HDBR) department, a MRC-Wellcome Trust 
funded resource, run at two sites: the Institute of Human Genetics, Newcastle University 
and Institute of Child Health, University College London (http://www.hdbr.org/).  
Paraffin embedded adult liver tissue sections were provided courtesy of Dr Mathew Wright, 
School of Biomedical Sciences, Newcastle University.  
Tissue sections were de-waxed by immersing them in Histo-clear (Histological clearing 
agent) (HS-200; National Diagnostics) twice, 10 minutes each time. The sectioned were 
then gradually rehydrated by immersing them in ethanol (VWR International, EC no. 200-
578-6, Leicester, UK) in descending order: 100%, 70% and 50%, 2 minutes each, followed 
by equilibration in Tris Buffered Saline (TBS) (100ml 1M Tris-HCL pH 7.5 (125g Trisma 
base, 600ml double deionised (dd) water, ph to 7.5 with concentrated HCL, made up to 1 
litre), 30ml 5M NaCl, 870ml dd water) for 5 minutes. After tissue rehydration antigen 
retrieval was carried out to enhance staining intensity of antibodies. Pre-treatment with 
antigen retrieval reagents, in this case citrate buffer allowed breakage of the protein cross-
links formed by formalin fixation and thereby uncovered hidden antigenic sites. The tissue 
sections on slides were positioned in a slide rack in a large beaker and covered with citrate 
buffer pH 6.0 (3.84g citric acid-Na3 salt, 2L dd water, pH to 6.0 with HCL). The beaker was 
covered with cling film which was pierced for venting. The slides were then heated in the 
microwave for 5 minutes and then allowed to cool by placing them under gently running tap 
water for 3 minutes. The tissue sections were then permeabilized in TBS-TX (1L TBS and 
5ml Triton X-100) for 15 minutes and subsequently placed in blocking solution (10% FCS 
in TBS-TX) in a humid chamber for 1 hour at room temperature. The sections were then 
covered with primary antibody solutions (approximately 200µl per slide) and covered with 
parafilm. This allowed the antibody solution to cover the entire surface area of the slide and 
minimized evaporation. The sections were incubated with primary antibodies overnight at 
4°C. Consequently the slides were washed in TBS-TX, three times, 10 minutes each time 
and then the secondary antibody was introduced. The secondary antibody was added in 
similar manner as the primary antibody but incubated in a humid chamber for 1 hour at 
room temperature. The slides were then washed in TBS-TX, three times, 10 minutes each 
time and then visualised with confocal laser scanning microscopy.  
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Tissue imaging  
The cells and tissue sections were visualized with a confocal laser scanning microscope 
(CLSM) (Leica TCS SP2 UV, Leica Microsystems, Heidelberg, GMBH, Germany). The 
software used was LCS 2.61. The lens used was the HCX Plan Apo NA 1.32.  
Imaging and software operation was performed by Dr Trevor Booth (Bio-Imaging Manager, 
Institute of Cellular Medicine, Newcastle University).  
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Table 15. List of antibodies utilized for immunocytochemistry/immunohistochemistry 
Antibody Immunoglobulin  
Subtype  
Supplier 
and Code 
Specificity 
of 1° 
Antibody 
Source of 
1° 
antibody 
Working 
conc. of 
1° 
Antibody 
2° Antibody/ 
Supplier/ Code/ 
Working conc. 
Anti-Human 
albumin 
IgG Sigma-
Aldrich 
A 0433 
Reacts 
with 
human 
albumin 
Rabbit IgG 
fraction of 
antiserum 
1:16 Alexa 488/Goat 
anti-rabbit IgG 
A11008  
FITC/1:500 
 
Anti-Human 
albumin 
 
IgG Sigma-
Aldrich 
A 7544 
Reacts 
with 
human 
albumin 
Goat 
delipidized 
whole 
antiserum 
1:16 Alexa 594/ 
Rabbit anti-goat 
IgG A11012 
TxRed/1:500 
Monoclonal 
anti-human 
α-
fetoprotein  
IgG2a Sigma-
Aldrich 
A8452 
Recognizes 
α- 
fetoprotein 
present in 
human. No 
cross 
reaction 
with 
human 
serum 
albumin 
Mouse 
ascites 
fluid 
1:500 Alexa 594/ Goat 
anti-mouse 
IgG2a 
A21135 
TxRed/1:500 
Polyclonal 
anti- Ck 7 
 
IgG Abcam 
Ab31014 
Reacts 
with 
human 
Ck7 
Rabbit 1:100 Alexa 488/Goat 
anti-rabbit IgG 
A11008 
 FITC/1:500 
Monoclonal 
anti-Ck 18 
IgG1 Sigma-
Aldrich 
C 1399 
Reacts 
with Ck18 
in human-
derived 
epithelial 
cells 
Mouse 
ascites 
fluid 
1:100 Alexa 647/Goat 
anti-mouse IgG1 
A21240  
Cy5/ 1:500 
Monoclonal 
Anti-Ck 8 
IgG1 Abcam 
Ab9023 
Reacts 
with 
human and 
mouse 
Mouse 1:100 Alexa 647/Goat 
anti-mouse IgG1 
A21240  
Cy5/ 1:500 
Monoclonal 
anti-Ck19 
IgG2a Sigma-
Aldrich 
C 6930 
Reacts 
with 
human 
Ck19 
Mouse cell 
culture 
supernatant 
1:100 Cy™5/ Goat 
anti-mouse 
IgG2a 115-175-
206 
Cy5/1:500 
Monoclonal 
anti-  
Vimentin 
IgM Sigma-
Aldrich 
V2258 
 Mouse  
Ascites 
fluid 
1:200 Alexa 594/Goat 
anti-mouse IgM  
A21044 
TxRed/1:500 
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Antibody Immunoglobulin  
Subtype  
Supplier 
and Code 
Specificity 
of 1° 
Antibody 
Source of 
1° 
antibody 
Working 
conc. of 
1° 
Antibody 
2° Antibody/ 
Supplier/ Code/ 
Working conc. 
Polyclonal  
Anti-   
Gata 4 
IgG SantaCruz 
Biotech 
Sc-9053 
Reacts 
with 
mouse, rat 
and human  
Gata-4 
Rabbit  1:100 Alexa 594/ Goat 
anti-rabbit IgG 
A11012 
FITC/1:500 
 
Polyclonal 
anti- CPS1 
 
IgG 
 
Abcam  
ab3682 
 
Reacts 
with 
mouse, rat 
and human  
CPS1 
 
Rabbit  
Anti-serum 
 
1:5000 
 
Alexa 594/ Goat 
anti-rabbit IgG 
A11012 
FITC/1:500 
Monoclonal 
anti-HGFR 
IgG Abcam  
ab51067 
Recats 
with 
human 
HGFR 
Rabbit  1:100 Donkey anti-goat 
IgG 
NorthernLights™ 
NL493/ NL003 
Light green 
/1:500 
Polyclonal  
Anti-LDLR 
IgG Abcam 
Ab30532 
Reacts 
with 
Mouse, Rat 
and human 
LDLR 
Rabbit 1:100 Alexa 594/ 
Rabbit anti-goat 
IgG A11012 
TxRed/1:500   
Polyclonal 
Anti-Oct4 
IgG Abcam 
ab27985 
Reacts  
with 
Mouse, Rat 
and human  
Goat  1:500 Goat anti-mouse 
IgG2b Red™-X 
 115-295-207  
Rhodamine/1:500 
Monoclonal  
Anti-Sox2 
IgG2a R&D 
MAB2018 
 Mouse 1:50 Cy™5/ Goat 
anti-mouse 
IgG2a 115-175-
206 
Cy5/1:500 
Polyclonal  
Anti-Nanog 
IgG R&D 
AF1997 
 Goat 1:20 Donkey anti-goat 
IgG 
NorthernLights™ 
NL493/ NL003 
Light green 
/1:500 
Polyclonal 
Anti-GFAP 
IgG Abcam 
 ab7779 
 Rabbit 1:1000 Alexa 594/ 
Goat anti-rabbit 
IgG A11012 
TxRed/1:500 
Monoclonal  
Anti-Nestin  
IgG1 R&D 
MAB1259 
 Mouse 1:100 Alexa 488/ Goat 
anti-mouse IgG1 
A21121 
FITC/1:500 
 
 
All antibody working concentrations were made in PBS 
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2.14 Protein Analysis- SDS-PAGE and Western Blotting  
Western blot or alternatively protein immunoblot is an analytic procedure used to detect 
specific proteins. It depends on the ability to resolve the individual proteins 
(macromolecules) in a size-dependent manner. The method was pioneered by George stark 
(Renart, Reiser et al. 1979) and refined by Towbin (Towbin, Staehelin et al. 1979) and 
named by Burnette (Burnette 1981). Western blot is a sequential protocol that was executed 
as follows: 
2.14.1 Tissue preparation 
A combination of mechanical and biochemical techniques are employed to denature protein 
samples. The target proteins investigated in this project were predominantly located in the 
cytoplasm and mitochondria so RIPA (RadioImmuno Precipitation Assay) buffer was used 
for lysate preparation.  
RIPA buffer contains the ionic detergent sodium deoxycholate as an active constituent. As 
soon as lysis occurs, proteolysis, dephosphorylation and denaturation begin. These events 
are slowed down by keeping the samples on ice (4°C) throughout the lysis procedure and 
appropriate inhibitors were added fresh to the lysis buffer. In this case 100µl of 
Phenylmethylsulfonyl Fluoride (PMSF) (protease inhibitor) and one protease inhibitor 
cocktail tablet (Roche Diagnostics, GmbH, Cat. no. 11 836 170 001, Mannheim, Germany) 
were added to 10ml of RIPA buffer. 100µl of lysis buffer was used for lysis of 1x106 cells. 
The cell-lysis buffer mixture was incubated on ice for 30 minutes with gentle regular mixing 
with a pipette. The lysed sample was then centrifuged at 12000 rpm for 20 minutes at 4°C. 
The supernatant was then aspirated and transferred to a new tube and the pellet discarded. 
The samples were then stored on ice before proceeding to the next stage.   
 
2.14.2 Protein quantification 
Bradford (Coomassie Blue G-250 dye-binding) assay was used for measuring total protein 
concentration. The method applied was adapted from Bradford M.M., 1976 (Bradford 
1976).  
The method is based on the proportional binding of the dye to proteins. It is a colorimetric 
assay; as the protein concentration increases, the colour of the test sample becomes darker. 
Coomassie absorbs at 595nm. The protein concentration of the test samples were 
determined by comparison to that of a series of protein standards know to reproducibly 
exhibit a linear absorbance profile in this assay. Bovine serum albumin (BSA) was used as a 
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standard protein in this project.  Cell lysates and standards 0-1mg/ml (table 16) were plated 
in duplicates (10µl per well) in a 96-well clear flat bottom ELISA plate (Techno Plastic 
Products, Cat. no. 92096, Switzerland) leaving column 1 blank. Dilution of the protein 
samples (1:10) was required for the resulting absorbance to fall within the linear range of 
the assay. 200µl of diluted Bradford reagent (Bio-Rad Protein Assay; 500-0006, bio-Rad 
Laboratories GmbH, HeidemannstraBe 164, 80938 Mϋnchen) (diluted with water 4:1) was 
introduced to each well and allowed to stand for 5 minutes at room temperature. The 
Multiskan was switched on for at least 10 minutes prior to reading the plate and the optimal 
density of the samples was read at 595nm. The results generated were used to construct a 
standard curve to which the unknown values obtained could be compared to determine their 
concentration.  The curve and the data from Bradford were used to determine the unknown 
protein concentration. Once the protein concentration in each sample was determined the 
samples were frozen at -20°C or -80°C for later use.  
 
Table 16. Standards created from Bovine Serum albumin (BSA) stock 1mg/ml 
Volume of Stock BSA Volume of (Double distilled)  
water  
Final concentration of 
Standard 
0µl  30µl  0.0 mg/ml 
1.5µl 28.5µl 0.05 mg/ml 
3µl 27µl 0.1mg/ml 
7.5µl 22.5µl 0.25 mg/ml 
15µl 15µl 0.5 mg/ml 
22.5µl 7.5µl 0.75 mg/ml 
30µl 0µl 1 mg/ml  
 
 
 
2.14.3 Denaturation and reduction of the protein   
The fraction of the protein recognized by antibodies is the epitope and this domain may 
reside within the 3D conformation of the protein. To enable antibodies to access this portion 
it is necessary to unfold the protein structure, i.e. denature it.  This procedure was carried 
out by using a loading buffer with the ionic detergent sodium Dodecyl sulphate (SDS), and 
the mixture was boiled at 95-100°C for 5 minutes. The volume of loading buffer added was 
equal to the volume of the cell lysate. 
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Table 17. Reducing loading buffer (LBR) 
Reagent  Volume  Supplier  
(Double distilled) Water  4ml   
0.5M Tris pH 6.8 
(60.5g Trizma base in 1L dd 
water, pH to 6.8 with conc. 
HCL) 
1ml Trizma base  
Sigma-Aldrich 
T1503 
Glycerol  0.8ml  Sigma-Aldrich 
G8773 
10%  Sodium Dodecyl Sulfate 
(SDS) 
(10g SDS in 100ml dd water)  
1.6ml Sigma-Aldrich 
L3771 
0.05% Bromophenol Blue 
(BPB) 
(5mg of BPB in 10ml dd water)  
0.6ml Sigma-Aldrich 
B0126 
1M DTT (DL-Dithiothreitol) 80µl  Sigma-Aldrich 
D9779 
 
Samples were mixed by vortexing (Vortex-Genie, Jencons- PLS, Scientific Industries INC, 
Model G-560E, Serial no. 2-109523) both before and after heating for good resolution.  SDS 
denatures proteins by wrapping around the polypeptide backbone and hence confers a 
negative charge to the polypeptide in proportion to its length. The denatured polypeptides 
thus lose their complex secondary and tertiary structures and become rods of negative 
charge clouds with equal charge densities per unit length. Reduction of disulphide bridges 
by β-mercaptoethanol or dithiothreitol (DTT) is necessary before proteins can adopt the 
random-coil configuration necessary for separation by size. In this case DTT was used at a 
concentration of 150µl of 1M DTT per 1ml of LBR.  In denaturing SDS-PAGE separations, 
therefore, migration is determined not by intrinsic charge of the polypeptide, but by 
molecular weight.  
To enable visualization of the migration of proteins, an anionic dye molecule (bromophenol 
blue) was included in the loading buffer. Since the dye molecule is small, it migrates faster 
than any of the components in the mixture to be separated and hence provides a migration 
front to monitor the separation progress. Glycerol was also included in the loading buffer to 
increase the viscosity of the sample to be loaded and hence allowed the sample to be 
maintained at the bottom of the well, restricting overflow and uneven gel loading.  
2.14.4 Gel electrophoresis 
The proteins in the samples were separated using one dimensional polyacrylamide gel 
electrophoresis. SDS-PAGE (SDS Polyacrylamide Gel Electrophoresis) maintains 
polypeptides in a denatured state as they run along the gel.  Polyacrylamide gels are formed 
from the polymerization of two compounds, acrylamide and N, N-methylene-bis-acrylamide 
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(Bis-acrylamide). Bis is a cross-linking agent for the gels. Introduction of ammonium 
persulphate along with N, N, N’, N’-Tetramethylethyl-enediamine (TEMED) (Sigma, 
T9281) initiates polymerization of the gel. The gels are neutral, hydrophilic, three-
dimensional networks of long hydrocarbons cross linked with methylene groups. The 
separation of molecules within a gel is determined by the relative size of the pores formed 
within the gel. The resolution and pore size is determined by the total amount of acrylamide 
present (%T) and the amount of bis cross-linker (%C). As the total amount of acrylamide 
increases, the pore size decreases.  
In this project a 4% stacking gel was used, which allowed the proteins to form a nice tight 
band at the interface between the stacking gel and the separating gel. A 9% separating gel 
was utilized for the runs in this study as the proteins investigated rangd in molecular weight 
between 40 and 200 KDalton in size. 
 
Table 18. Polyacrylamide gels 
Reagents  Stacking 
Gel (4%) 
Reagents Separating 
Gel (9%) 
Supplier  
(Double distilled) Water  6.3ml (Double distilled) Water 5.1ml  
0.5M Tris pH 6.8 
(60.5g Trizma base in 1L dd 
water, pH to 6.8 with conc. 
HCL) 
2.5ml 1.5M Tris pH 8.8 
181.65g Trizma base in 
1L dd water, pH to 8.8 
with conc. HCL) 
2.5ml Trizma base 
Sigma-Aldrich 
T1503 
10% SDS 100µl 10% SDS 100µl Sigma-Aldrich 
L3771 
Acrylamide/Bis- acrylamide 
49:1 ratio 
1ml 
 Acrylamide/Bis- 
acrylamide 49:1 ratio 
2.25ml Sigma-Aldrich 
AO924 
Ammonium persulfate 
(APS) 
100µl Ammonium persulfate 
(APS) 
50µl Sigma-
AldrichA3678 
N, N, N’, N’-
Tetramethylethylenediamine 
(TEMED) 
10µl  N, N, N’, N’-
Tetramethylethylenedia
mine (TEMED) 
5µl Sigma-Aldrich 
T9281 
 
 
The wells of the gel were gently flushed with running buffer with an 19G fine needle 
syringe (Syringe, BD 1ml, Terumo, Cat. no 0197, Leuvrn, Belgium) (19G microlance 3, 
BD, Cat. no. 2013-08,Ireland). This was performed to ensure even filling of the wells. 
Protein samples were loaded into the wells in the gel. 10µg of protein was loaded into each 
well. The first well was reserved for the protein ladder (5µl) (PageRuler Plus Prestained 
Protein Ladder, SM1811, Fermentas Life Sciences, Sheriff House, UK). The tank was the 
filled with running buffer (table 19) and voltage applied to the gel. The gels were run at a 
voltage of 120 Volts for 20 minutes (until the protein ladder appeared to separate) and then 
Materials and Methods 
 157 
at a constant voltage of 110 volts for 40 minutes (until the bromophenol blue had migrated 
to the bottom of the gel ensuring that the proteins have separated into various bands in each 
well.  
 
Table 19. Running buffer 
Reagents  X10 Running Buffer  
(Double distilled) Water  1L 
Trizma Base  30g 
Glycine  144g 
SDS 10g 
 
 
 
Figure 42. SDS-polyacrylamide gel electrophoresis. SDS-PAGE maintains polypeptides in a 
denatured state once they have been treated with strong reducing agents to remove secondary 
and tertiary structure and thus allows separation of proteins by their molecular weight. 
Sampled proteins become covered in the negatively charged SDS and move to the positively 
charged electrode through the acrylamide mesh of the gel. Smaller proteins migrate faster 
through this mesh and the proteins are thus separated according to size. The concentration of 
acrylamide determines the resolution of the gel - the greater the acrylamide concentration the 
better the resolution of lower molecular weight proteins. The lower the acrylamide 
concentration the better the resolution of higher molecular weight proteins. Samples are 
loaded into wells in the gel. One lane is usually reserved for a ladder. When voltage is applied 
along the gel, proteins migrate into it at different speeds. These different rates of advancement 
separate into bands within each lane (http://en.wikipedia.org/wiki/Western_blot).  
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2.14.5 Transfer of protein bands from gel onto PVDF membrane 
To make the proteins accessible to antibody detection they are moved from within the gel 
onto a membrane made of polyvinylidene difluoride (PVDF). Transfer was done in wet 
conditions during this project. PVDF membranes (Amersham Hybond-P, RPN303F, Lot. 
NH0031, GE Healthcare, Amersham Place, Little Chalfont, Buckinghamshire) were pre-
treated by soaking the membrane in methanol for 1-2 minutes. This was followed by a quick 
soak in water and then incubation in ice cold transfer buffer for 5 minutes. The wet 
membrane was then placed on top of the gel, and a stack of transfer buffer soaked filter 
papers placed on top of that. This stack was sandwiched between two buffer soaked sponge 
pads and transferred to a tank filled with transfer buffer. The electro-transfer was performed 
in a cold room at a constant voltage of 110 volts for 2 hours.   
Table 20. Transfer buffer 
Reagents  (x1) Transfer Buffer 
(Double distilled) Water 2L 
Trisma Base 6.06g 
Glycine 28.8g 
Methanol 400ml 
 
 
 
Figure 43. Transfer of proteins from gel onto membrane. Electroblotting was used for protein 
transfer. This technique uses an electric current to pull proteins from the gel into the PVDF or 
nitrocellulose membrane. The proteins move from within the gel onto the membrane while 
maintaining the organization they had within the gel (http://en.wikipedia.org/wiki/Western_blot).  
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2.14.6 Visualization of all separated proteins after migration  
Ponceau S dye (P7170-IL, Sigma-Aldrich) was used to visualize the uniformity and overall 
effectiveness of protein transfer from the gel to the membrane. The membranes were 
incubated with Ponceau S dye (1:10 dilution with water) for 3-5 minutes at room 
temperature on an agitator. The protein bands, if transferred effectively, appear as well-
defined reddish-pink bands. The membranes were then washed extensively in (x1) Tris 
Buffered Saline-Tween (TBS-Tween) until the dye was washed off.  
Table 21. (x20) TBS 
Reagents  (x20) Tris Buffered Saline 
Solution (TBS) 
NaCL 234g 
Trizma base  48.4g  
(Double distilled) Water  1L 
 
 
Table 22. (x1) TBS 
Reagents  (x1) Tris Buffered Saline 
Solution (TBS) 
1Litre  
Supplier  
(x20) TBS  50ml   
Tween-20  1ml Sigma-Aldrich 
27,434-8 
(Double distilled) Water 949ml  
 
2.14.7 Blocking of the PVDF membranes 
The membranes with the transferred protein bands were then blocked in blocking buffer for 
1 hour at room temperature on an agitator. Blocking the membranes prevented non-specific 
binding of the primary and/or secondary antibodies to the membrane.   
Table 23. Blocking buffer 
Reagents  Blocking buffer  Supplier  
(x20) Tris buffered Saline 
(TBS) 
2.5ml  
Tween-20  0.6ml Sigma-Aldrich 
27,434-8  
Low-fat milk (Marvel) 2.5g Dried skimmed milk, R. No. 
92962, Marvel, Dublin, 
Ireland 
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2.14.8 Antibody staining  
The membranes were incubated with the primary antibody (diluted in incubation buffer) 
(table 25) overnight at 4°C on an agitator to enable adequate homogenous covering of the 
membrane and prevent uneven binding.  
 
Table 24. Incubation buffer 
Reagents  Incubation Buffer 
(x1) Tris Buffered Saline (TBS)-TX 50mls  
Low-fat milk (Marvel) 150mg 
 
 
Post overnight incubation with primary antibody the membranes were washed in (x1) TBS-
TX, three times, and 10 minutes each time. The washes were done at room temperature on 
an agitator. This step ensured that all excess unbound antibodies were washed off.  
The membranes were then incubated with the appropriate secondary antibody (diluted in 
incubation buffer) for 1 hour at room temperature on an agitator.  
The membranes were then washed in TBS-TX, three times, and 10 minutes each time, to get 
rid of any unbound secondary antibody. 
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Figure 44. Blocking and antibody staining of membranes with transferred proteins. During the 
detection process of proteins, the membranes were "probed" for the protein of interest with 
antibodies which were linked to reporter enzymes, which when exposed to an appropriate 
substrate drives a colourimeic reaction and produces a colour. This was carried out in a two 
step process where the proteins were first probed with primary antibodies overnight at 4◦◦C 
followed by washing and subsequent exposure to secondary antibodies which were conjugated 
to a reporter enzyme, in this case horseradish peroxidase 
(http://en.wikipedia.org/wiki/Western_blot).   
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Table 25. List of antibodies used for western blotting 
Antibody  Immunoglobulin  
Subtype  
Supplier 
and Code 
Specificity 
of 1° 
Antibody 
Source of 
1° 
antibody 
Working 
conc. of 
1° 
Antibody 
2° Antibody/ 
Supplier/ Code/ 
Working conc. 
Anti-Human 
albumin 
 
IgG Sigma-
Aldrich 
A 7544 
Reacts 
with 
human 
albumin 
Goat 
 
1:1000 Donkey anti-goat 
IgG-HRP 
conjugated/ 
1:7000 
Sc-2020, Lot. 
C1207, Santa 
Cruz 
Biotechnology 
Monoclonal 
anti-human 
α-
fetoprotein  
IgG2a Sigma-
Aldrich 
A8452 
Recognizes 
α- 
fetoprotein 
present in 
human.  
Mouse  1:500 Anti-Mouse IgG F 
(ab1 )2 HRP 
conjugated/1:7000 
SAB-100, 
Stressgen Corp 
Bioreagents 
Polyclonal 
anti- Ck 7 
 
IgG Abcam 
Ab31014 
Reacts 
with 
human 
Ck7 
Rabbit 1:2000 Anti-rabbit IgG 
(whole molecule) 
HRP 
conjugated/1:7000 
A-0545 Sigma-
Aldrich  
Monoclonal 
Anti-Ck 8 
IgG1 Abcam 
Ab9023 
Reacts 
with 
human and 
mouse 
Mouse 1:500 Anti-Mouse IgG F 
(ab1 )2 HRP 
conjugated/1:7000 
SAB-100, 
Stressgen Corp 
Bioreagents 
Monoclonal 
anti-Ck19 
IgG2a Sigma-
Aldrich 
C 6930 
Reacts 
with 
human 
Ck19 
Mouse  1:50 Anti-Mouse IgG F 
(ab1 )2 HRP 
conjugated/1:7000 
SAB-100, 
Stressgen Corp 
Bioreagents 
Polyclonal 
anti- CPS1 
IgG Abcam  
ab3682 
Reacts 
with 
mouse, rat 
and human  
CPS1 
Rabbit  
 
1:1500 Anti-rabbit IgG 
(whole molecule) 
HRP 
conjugated/1:7000 
A-0545 Sigma-
Aldrich 
Monoclonal 
anti-HGFR 
 
 
 
 
IgG 
 
 
 
 
 
Abcam  
Ab51067 
Recats 
with 
human 
HGFR 
Rabbit  1:1000 Anti-rabbit IgG 
(whole molecule) 
HRP 
conjugated/1:7000 
A-0545 Sigma-
Aldrich 
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Antibody  Immunoglobulin  
Subtype  
Supplier 
and 
Code 
Specificity 
of 1° 
Antibody 
Source 
of 1° 
antibody 
Working 
conc. of 
1° 
Antibody 
2° Antibody/ 
Supplier/ Code/ 
Working conc. 
Polyclonal  
Anti-
CYP3A4 
IgG Courtesy 
of Dr 
Mattew 
Wright 
♣ 
 Rabbit 1:3000 Anti-rabbit IgG 
(whole molecule) 
HRP 
conjugated/1:7000 
A-0545 Sigma-
Aldrich 
Polyclonal  
Anti-
CYP2A 
IgG Courtesy 
of Dr 
Mattew 
Wright 
♣ 
 Rabbit 1:4000 Anti-rabbit IgG 
(whole molecule) 
HRP 
conjugated/1:7000 
A-0545 Sigma-
Aldrich 
Polyclonal  
Anti-
CYP2E 
IgG Courtesy 
of Dr 
Mattew 
Wright 
♣ 
 Rabbit 1:5000 Anti-rabbit IgG 
(whole molecule) 
HRP 
conjugated/1:7000 
A-0545 Sigma-
Aldrich 
Monoclonal  
Anti-β 
Actin  
IgG Abcam 
Ab8226 
 Mouse 1:1000 Anti-Mouse IgG F 
(ab1 )2 HRP 
conjugated/1:7000 
SAB-100, 
Stressgen Corp 
Bioreagents 
 
♣ Institute of Cellular Medicine, Newcastle University  
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2.14.9 Detection  
ECL Plus western blotting detection system (GE Healthcare, Cat. no. RPN2132, 
Buckinghamshire HP79NA, UK) was used for visualisation of the protein band. The ECL 
detection kit uses an acridan-based substrate that releases a high level of sustained light 
output. In addition, ECL kit generates an intense long-lasting chemifluorescent signal at 
440nm that can be detected on a fluorescence imager with appropriate filters.  
 
 
 
 
Figure 45. Chemiluminnescent detection of proteins. This detection technique depends on 
incubation of the western blot with a substrate that will luminesce when exposed to the 
reporter on the secondary antibody. The light emitted was then detected on a fluorescence 
imager which captured a digital image of the western blot. The substrate used in this project 
was ECL Plus western blotting detection reagent which is acridin-based.  
(http://en.wikipedia.org/wiki/Western_blot) 
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2.15 Molecular analysis 
An RNase-free work environment was used for all molecular methodology. Class II vertical 
laminar flow hoods were used and all work surfaces and materials were wiped with RNase 
Away solution (Invitrogen, Cat. no. 10328-011, CA, San Diego).  
2.15.1 RNA isolation 
RNA isolation from cell pellets was performed with Rneasy Mini and Micro kits supplied 
by Qiagen. The Micro kit (74034, Qiagen GmbH, D40724 Hilden) was applied when the 
cell numbers were 5x105 and below. RNA isolation from cell numbers greater that 5x105 
were done with the Mini kit (74104, Qiagen). The kits were used according to the 
manufacturer’s instructions. The protocols for both kits are available at the following 
websites: Mini Kit (http://www1.qiagen.com/HB/RNeasy/MiniKit_EN) and Micro kit 
(http://www1.qiagen.com/Products/RNeasyMicrokit.aspx#Tabs=t2). In both cases, an 
additional step of in-column DNase digestion was carried out. 10µl DNAse 1 stock (1500 
Kunitz units dissolved in 550µl of RNase-free water) (79254, Qiagen) was diluted in 70µl 
RDD buffer (provided in the Dnase kit) and mixed gently. The DNase 1 mix was then 
introduced directly to the RNeasy MinElute spin column membrane very gently, and placed 
on the bench top for 15 minutes at room temperature (RNeasy Micro Handbook; Page 21; 
http://www1.qiagen.com/Products/RnaStabilizationPurification/RNeasySystem/RNeasyMic
roKit.aspx#Tabs=t2).   Generally, DNase digestion is not required for RNA purified with the 
Qiagen kits. The silica-membrane technology of the columns provides efficient removal of 
the majority of the DNA without DNase treatment. However, complete DNA removal was 
desired as the RNA was used for real-time PCR applications which can be quite sensitive to 
even minute amounts of DNA contamination. 
(http://www1.qiagen.com/Products/Accessories/RNase-FreeDNaseSet.aspx#Tabs=t2).  
2.15.2 RNA quantification- Nanodrop  
To evaluate the purity and the integrity of the mRNA produced the samples were tested on a 
nanodrop. An A260/A280 ratio of 1.9-2.1 was considered as pure RNA.  
2.15.3 cDNA preparation 
First-strand cDNA was generated using SuperScript VILO cDNA Synthesis Kit (11754-050; 
Invitrogen, Carlsbad, CA 92008, USA). This kit comprises: the 10X SuperScript Enzyme 
Mix (SuperScript III RT, RNaseOut Recombinant Ribonuclease Inhibitor and a proprietary 
helper protein) and the 5X VILO Reaction Mix (random primers, MgCl2, and dNTPs in a 
buffer formulation). SuperScript III RT is an engineered version of M-MLV RT with 
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reduced RNase H activity and increased thermal stability. The kit was used as per suggested 
by the manufacturer 
(http://tools.invitrogen.com/content/sfs/manuals/vilo_cdna_synthesis_man.pdf).  
The Thermocycler (Master/Gradient, Eppendorf AG, 22331, Hamburg, Germany) was used 
to run the first-strand cDNA synthesis reactions. The SuperScript VILO cDNA Synthesis 
Kit components were mixed in a tube on ice and then the RNA was included (up to 2.5µg). 
The Thermocycler programme used was as follows:  incubation at 25°C for 10 minutes, 
42°C for 60 minutes, and then the reaction terminated at 85°C for 5 minutes. The resulting 
cDNA was then either used directly or stored at -20°C until further application. The purity 
of the single-strand DNA produced was tested with a nandrop. The ratio of absorbance 
values at 260nm and 280nm gives an estimate of DNA. An A260/A280 ratio of 1.8-2.0 was 
considered as pure cDNA.  
2.15.4  Primers 
A list of the primers used during the course of this study is elaborated in the table 26. All 
primers were self designed using the following web provided programmes: 
- NCBI (National Centre for Biotechnology Information) - the nucleotide database. 
During primer designing, particular attention was focused on trying to ensure, where 
possible, that the mRNA sequence selected included a segment of two exons. This allowed 
application of introns (genomic DNA) during polymerase chain reaction to be avoided.  
http://www.ncbi.nlm.nih.gov/nuccore  
- Primer BLAST (Basic Local Alignment Search Tool) - the selected mRNA sequence 
was then fed into the Primer BLAST software and primers were designed, ranging in length 
between 150-250 bp.  
http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome  
- Nucleotide BLAST- once primers were designed they were checked for any similarities 
with other biological sequences by using the Nucleotide BLAST database. This step helped 
avoid non-specific and unwanted products from being amplified during the PCR.  
http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&BLAST_PROGRAMS=megaBl
ast&PAGE_TYPE=BlastSearch&SHOW_DEFAULTS=on&LINK_LOC=blasthome 
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Table 26. List of  primers applied in this study 
Oligo Name  Sequence (5’-3’) Product 
size (bp) 
Annealing 
Tm° 
Melting 
Tm° 
AFP-F AGCTTGGTGGTGGATGAAAC 248 60° 80° 
AFP-R CCCTCTTCAGCAAAGCAGAC  60° 80° 
Albumin-F
  
AAGCTGCCTGCCTGTTGCCA   156 65° 83° 
Albumin-R GCTCAGGCGAGCTACTGCCC    65° 83° 
CLDN2-F TCGAACCTCATTGTCAGCAG 154 60° 80° 
CLDN2-R  ACGCTGAGGAAGTTCTCCAA  60° 80° 
CYP1B1-F
  
AAGGTGCTTGGAGTTTACCTGGC 251 65° 75° 
CYP1B1- R CTCCGGTAGAAACACAATGAGGG  65° 75° 
CYP2C9-F 
   
TGCATGCAAGACAGGAGCCACAT 429 65° 81° 
CYP2C9-R CGGCACAGAGGCAAATCCATTGA  65° 81° 
CYP2E1-F CCCGAGACACCATTTTCAGAGGA 229 65° 81° 
CYP2E1-R AGAAACAACTCCATGCGAGCCAG    65° 81° 
CYP 3A4 -F 
 
CAAGACCCCTTTGTGGAAAA 
 
175 65° 85° 
CYP 3A4  
 
CGAGGCGACTTTCTTTCATC  65° 85° 
CYP7B1-F 
  
GCCCATAGGACTAAACTACAGCC   
  
256 65° 75° 
CYP7B1-R GGGCTTTGTGACTAAGGACAAAC    65° 75° 
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CYP11B1-F AAACGCCATAGACTGGGTTGCTG   
  
235 65° 81° 
CYP11B1-R AATGCAGGCAGTGCCCTCTTGAA    65° 81° 
CYP20A1-F 
  
CTCGTCCTTTATGCCCTTGGTGT    230 65° 81° 
CYP20A1-R ACCTGTCCCTCCACAGAAAGTAG    65° 81° 
CYP27B1-F
  
CTTTGAGAGGAAGGGTGAAGCCT   256 65° 75° 
CYP27B1-R GGGGCAAACCCACTTAATAGTGG    65° 75° 
GATA-4-F 
  
GCAGCAGCGAGGAGATGCGT    194 65° 85° 
GATA-4-R GGGGAGAGCTTCAGGGCCGA    65° 85° 
HGFR-F CAGGCAGTGCAGCATGTAGT 201 60° 80° 
HGFR-R GATGATTCCCTCGGTCAGAA  60° 80° 
HNF1B-F 
  
TCTGCTCTCCCACGGCTCCC     148   
HNF1B-R GCTGGTCACCATGGCGCTGT    
HNF3B-F
   
TGCCATGCACTCGGCTTCCAG 129 65° 85° 
HNF3B-R CCCAGGCCGGCGTTCATGTT  65° 85° 
HNF4A-F
  
GCCACCCCTGAGACCCCACA    159 65° 85° 
HNF4A-R AGCCCCAGCGGCTTGCTAGA    65° 85° 
LDLR-F GCTTGTCTGTCACCTGCAAA 190 60° 80° 
LDLR-R  AACTGCCGAGAGATGCACTT  60° 80° 
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NANOG-F GATTTGTGGGCCTGAAGAAA 155 65° 82° 
NANOG-R AAGTGGGTTGTTTGCCTTTG 
 
 65° 82° 
OCT-4A-F CGTGAAGCTGGAGAAGGAGA 
 
91 65° 82° 
OCT-4A-R  CTTGGCAAATTGCTCGAGTT 
 
 65° 82° 
PAX6-F GAGGTCAGGCTTCGCTAATG 
 
91 65°  86° 
PAX6-R  TGGTGATGGCTCAAGTGTGT 
 
 65°  86° 
RPL13A-F CCTGGAGGAGAAGAGGAAAGAGA 
 
126 65° 80° 
RPL13A-R  TTGAGGACCTCTGTGTATTTGTCAA 
 
 65° 80° 
SDHA-F TGGGAACAAGAGGGCATCTG 
 
84 65° 76° 
SDHA-R  CCACCACTGCATCAAATTCATG 
 
 65° 76° 
SOX-2-F GGCAGCTACAGCATGATGCAGGACC 
 
131 65°  86° 
SOX-2-R CTGGTCATGGAGTTGTACTGCAGG 
 
 65°  86° 
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2.15.5 Quantitative PCR (real-time) 
Real-time PCR allowing detection and quantification of nucleic acid sequences was 
performed by the 7900HT Fast Real-Time PCR system (Applied Biosystems). SYBR Green 
JumpStart Taq ReadyMix (20 mM Tris-HCl, pH8.3, 100 mM KCl, 7 mM MgCl2, 0.4 mM 
each dNTP (dATP, dCTP, dGTP, TTP), stabilizers, 0.05 unit/ml Taq DNA Polymerase, 
JumpStart Taq antibody, and SYBR Green I) (S4438, Sigma-Aldrich) was used as a 
fluorescent DNA binding dye, that binds all double-stranded DNA and detection is 
monitored by measuring the increase in fluorescence throughout the cycle. SYBR green has 
an excitation and emission maxima of 494nm and 521nm, respectively. The JumpStart Taq 
antibody inactivates the DNA polymerase at room temperature. When the temperature is 
raised above 70°C in the first denaturation step of the cycling process, the complex 
dissociates and the polymerase becomes fully active. This helps prevent non-specific 
product amplification and hence leads to generation of more accurate Ct (Cycle threshold) 
values. The reactions were executed in 384-well clear optical reaction plates (ABI PRISM, 
Applied Biosystems, Cat. no. 4309849, USA). The PCR reaction mix for each primer per 
well was set up as demonstrated in the table below: 
Table 27. PCR reaction mix for each primer 
Reagents Volumes per well  
SYBR green  
(SYBR Green Jumpstart Taq ReadyMix, 
S4438, Sigma) 
5µl 
Forward Primer (10µM) 0.5 µl 
Reverse Primer (10µM) 0.5 µl 
RNase-Free Water  3 µl 
cDNA (2.5-10ng) 1 µl 
Total volume  10 µl 
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Each primer was run in triplicates for all the samples investigated and for each primer tested 
the following controls were applied: 
- Negative control- RNase-free water 
- Positive controls-  
* Foetal liver tissue (7-12 weeks fetal development) 
* Adult liver cDNA (Biobank cDNA kit, PrimerDEsign Ltd BioBank cDNA)- 1.92ng per 
reaction  
* HepG2 (liver carcinoma cell line)  
The plates were centrifuged at 4000 rpm for 5 minutes and then run in a 7900HT Fast Real-
Time PCR Thermocycler. In each case 40 cycle amplification was performed and the 
cycling parameters were as follows: 
Table 28. Real-Time PCR thermocycler parameters 
Initial Denaturation  94°C 2 minutes 
               40 Cycles  
Denaturation  94°C 15 seconds  
Annealing, extension and 
read fluorescence  
60°C or 65°C depending on 
the primer  
1 min  
Hold  4°C (to allow the products to be run on a gel subsequently)  
 
The data generated was visualized in a two-dimensional plot of log of relative fluorescence 
intensity (y-axis) vs. cycle number (x-axis). This is a kinetic PCR amplification curve and is 
used to determine the Ct (cycle threshold) values.  Ct is defined as the number of cycles 
required for the fluorescent signal to cross the threshold (i.e. exceed the background level). 
Ct levels are inversely proportional to the amount of target nucleic acid in the sample and 
are used to determine the amount of template in each sample. Relative quantification of 
gene expression (i.e. the ratio between the amount of target DNA and a reference amplicon, 
usually a house-keeping gene, which illustrates invariant and constitutive expression) was 
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analyzed by inputting the Ct values (Excel format) into the Q-Base software. This software 
permits relative quantification of the genes being studied together with inter-run calibration 
and proper error propagation along the entire calculation track.  
2.15.6 PCR Gel Electrophoresis  
The PCR products (DNA) generated by the real-time thermocycler were analyzed by 
running them on an Agarose Gel. The movement of DNA molecules through the Agarose 
matrix with an electric field allows them to be separated based on their size.  
A 1.5% Agarose gel (Seakem LE agarose, Cat. no. 50004, Lonza, Rockland, Me, USA) 
(1.5g Agarose in 100ml (x1) TAE) was used. 10 µl of GelRed (10,000x in H20, Cat. no. 
41003, Biotium) was added to the gel to allow visualisation of the DNA bands. This nucleic 
acid stain was a safer alternative to ethidium bromide which is a mutagen. GelRed has 
almost identical spectra as ethidium bromide and is nonmutagenic, noncytotoxic and 
environmentally safe.  
The PCR products were pre-mixed with Blue/Orange Loading dye 6X (0.4% orange G, 
0.03% bromophenol blue, 0.03% xylene cyanol FF, 15% Ficoll® 400, 10mM Tris-HCl (pH 
7.5) and 50mM EDTA (pH 8.0) (G1881, Promega). This dye is visible in natural light, co-
sediments with DNA and allows tracking of migration during electrophoresis. 3µl of loading 
dye was mixed with the 10µl of the real-time PCR product and the total volume was then 
loaded into the Agarose gel with GelRed. The first well in the gel was reserved for a 50bp 
step ladder (G4521, Promega). This 50bp DNA Step Ladder consists of 16 DNA fragments 
ranging from 50bp to 800bp in exactly 50bp increments plus a 1,800bp "backbone" 
fragment. The gels were run for 1 hour and 45 minutes at 90 volts. After electrophoresis, the 
gels were visualized with a UV Transilluminator (GeneGenius, Bio Imaging System, 
Syngene, a division of Synoptics LTD). The gels were photographed with a CCD camera. 
Although the stained nucleic acid fluoresces reddish-orange, images are usually shown in 
black and white. The GeneTool analysis software, which comes with the system, was used 
for the analysis of gels.  
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Table 29. (x50) Tris-acetate buffer (1L) 
Reagent  Volume/mass 
Trisma base 242g 
0.5M Na2EDTA ph8.0 100ml 
Glacial acetic acid  57.1ml 
(Double Distilled) water  500ml 
 
Table 30. (x1) Tris-acetate buffer (1L) 
Reagent  Volume/mass 
X50 TAE solution  20ml 
(Double Distilled) water 980ml 
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2.16 Functional assessment of differentiated cells 
2.16.1 Periodic acid Schiff staining 
Periodic Acid Schiff (PAS) staining reagents are commonly used for the demonstration of 
lympocytes and mucopolysccharides. In this project, however, PAS protocol was used to 
examine glycogen deposits in differentiated umbilical cord and UCB-derived progenitor 
cells. A staining kit from Sigma: Periodic Acid Solution, 395-1 (Periodic acid 1g/dL) ; 
Schiff’s Reagent, 395-2 (pararosaniline HCL, 1% sodium metasulfite 4%, in HCL 0.25 
mol/L) ; Hematoxylin solution , Gill No.3, GHS-3 (certified hematoxylin 6g/L, sodium 
iodtae 0.6g/L, aluminium sulphate 52.8 g/L and stabilizer) was utilized and the staining 
procedure was adapted from Kang et al (Kang, Zang et al. 2005) and  according to the 
manufacturer's instructions. It should be noted that the reagents involved in this procedure 
are corrosive and toxic and hence the staining protocol was performed with care.  
When treated with periodic acid, glycols are oxidized to aldehydes. After reaction with 
Schiff’s reagent a pararosaniline adduct is released that stains the glycol-containing cellular 
components bright magenta pink.  
Cells used for this staining procedure were cultured on gelatin coated glass cover slips in 
24-well plates. All stages of this procedure were carried out at room temperature on the 
bench top. Culture media was completely removed from the wells and the cells were gently 
rinsed in (x1) PBS once. The cells were then fixed by incubating them in 100% ethanol for 
10 minutes with gentle agitation on a rocker. The cells were then rinsed in (x1) PBS and 
oxidization reaction was initiated by incubating them with 500µl of PAS reagent for 10 
minutes on a rocker. Once again the cells were rinsed with (x1) PBS, twice, 5 minutes each 
time and 500µl Schiff’s reagent was added to the cells for 15 minutes with gentle mixing on 
the rocker. Subsequently, the cells were rinsed with (x1) PBS, twice, 5 minutes each time. 
Haematoxylin was used to counter stain the nuclei. Cells were stained with Haematoxylin 
for 1 minute and then rinsed twice in (x1) PBS- one quick wash and then on a rocker for 5 
minutes. The cells were then either directly visualized under a light microscope or the cover 
slips were mounted onto a glass slide and then visualized with a light microscope.  
2.16.2 Indocyanine green dye uptake and release test 
Indocyanine green (ICG) is an organic anion that is clinically used as a test to evaluate liver 
function since it is nontoxic and eliminated exclusively by hepatocytes (Branch 1982) (Berk 
PD 1986; Meijer DKF 1988). In this study Indocyanine green dye uptake and release by 
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cultured cells was used to identify functionally differentiated hepatocytes within the culture 
system. The protocol used was adapted from Wang et al, 2005 (Wang, Nan et al. 2005). 
Adherent cultured cells were washed with (x1) PBS and then incubated with ICG 
(Cardiogreen 21980, Standard Fluka) solution (1mg/ml) at 37°C for 20 minutes. It should be 
noted that ICG is not soluble in PBS and hence a (x10) concentrated solution was made in 
sterile water and then diluted to (x1) in culture media (DMEM-F12 plus supplements) 
(Yamada, Yoshikawa et al. 2002). Subsequently the cells were rinsed twice with (x1) PBS 
and replaced with culture media. Cellular uptake of ICG was then examined 
microscopically. The number of cells that had successfully taken up the green ICG dye was 
noted and the cells re-incubated at 37°C for a further 24hrs. The cells were regularly 
examined microscopically to note the time take for the cells to completely excrete the dye.   
2.16.3 Cytochrome P450 Glo-Assay  
A non-selective cytochrome (CY) P450 enzyme assay using a bioluminescent probe 
substrate that cross-reacts with multiple P450 enzymes was used to measure CYP activity in 
differentiated cells. The nonlytic P450-Glo assays measure the activities of CYP enzymes 
from native sources and allow the effects of analytes such as drugs to be tested. The P450-
Glo substrates are CYP enzyme substrates that are derivatives of beetle luciferin {(4S)-4, 5-
dihydro-2-6’-hydroxy-2’-benzothiazolyl)-4-thiazolecarboxylic acid}. The substrate used in 
this study was Luciferin-MultiCYP (Methyl 2-(6-methoxybenzo {d} thiazol-2-yl)-4, 5-
dihydrothiazole-4-carboxylate) (P1731, Promega, 2800 Woods Hollow Road, Madison, 
USA). This chemically synthesized derivative of beetle luciferin is converted to a luciferin 
ester by several members of the CYP family with preference for CYP1A1, -1A2, -1B1 and -
2D6. The luciferin ester produced in a CYP reaction can be detected with Luciferin 
Detection Reagent (LDR) that contains an esterase (V8931: Luciferin Detection Reagent 
(LDR), V859B; Reconstitution Buffer with esterase, V144B). The esterase converts the 
luciferin ester into luciferin and this is converted into light through the action of Ultra-Glo 
Luciferase. The luminescence produced is recorded with a luminometer. The LDR with 
esterase simultaneously stops the initial enzymatic reaction and initiates a stable glow-type 
luminescent signal with a half-life of greater that two hours. The amount of light produced is 
proportional to the amount of luciferin formed and, reflective of the CYP enzyme activity. 
The Luciferin-MultiCYP was used in accordance to the manufacturer’s instructions 
(http://www.promega.com/tbs/tb325/tb325.pdf). It is important to note that the substrates 
and reaction products of the cell-based P450-Glo assays are cell permeable and agreeable 
with a nonlytic format. This property allowed multiplexing with cell viability assays so that 
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CYP P450 activity could be normalized to the number of viable cells in culture. 
Umbilical cord and UCB cells used for this assay were cultured as monolayer in 24-well 
plates. Simultaneous CYP gene induction studies were performed by treating the cells with 
CYP enzyme inducers for 72 hours prior to treating the cells with the MultiCYP 
luminogenic substrate.  The following inducers were used: 
Table 31. Cytochrome P450 gene induction 
Inducer  CYP Enzyme 
Upregulated  
Pathway activated  
Rifampicin (25µM) CYP2C8 
CYP2C9 
CYP2C19 
CYP3A4 
Pregnane X Receptor (PXR) 
Constitutive Androstane 
Receptor (CAR) 
Omeprazole (10µM)♣ CYP 1A1 
CYP1A2 
CYP1B1 
Ary Hydrocarbon Receptor 
(AHR)  
♣ Omeprazole (100mM) was provided courtesy of the company XT (XenoTech) 
The inducers were added to the culture medium and incubated with the cells for 72 hours at 
37°C. After induction the cells were washed with (x1) PBS (this was important as some 
compounds that induce CYP gene expression also inhibit the CYP enzyme activity that has 
been induced) and then replaced with fresh medium containing the MutliCYP substrate 
(0.1mM). To determine background luminescence luminogenic substrate was added in the 
medium to a set of empty wells (no cells). The cells were then incubated with the CYP 
substrate for 1 hour and 30 minutes at 37°C. Intracellular CYP enzymes convert the 
substrate to luciferin, which passes out of the cells into the medium. A small aliquot (50µl) 
of the culture medium from the test wells was removed, and the remaining cells were used 
to analyze cell viability using Trypan Blue and the haemocytometer. The 50µl aliquots of 
medium were transferred to a white-walled luminometer plate (Nunc, Dk-4000, Roskilde, 
Denmark). 50µl of LDR was added to the wells to initiate a luminescent reaction. The plates 
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were incubated at room temperature in the dark for 20 minutes. The luminescence was then 
read using a luminometer (Flouroskan, Ascent FL, Thermo LabSystems). The Flouroskan 
was used according to the manufacturers instruction with an integration time of 0.26 
seconds per well. The net luminescence of each CYP assay was calculated by subtracting 
the luminescence of the minus-cell control wells. Fold changes in net signal from the 
inducer-treated samples as compared to the untreated control samples represented 
upregulation of CYP activity by the inducer.  
Net luminescence of each sample= luminescence (RLU) of sample well- luminescence 
(RLU) of the minus-cell control well 
Fold change after CYP induction= Luminescence (RLU) of induced sample- luminescence 
(RLU) of uninduced sample  
RLU- Relative Light Units  
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3 Introduction  
Many different stem and progenitor cells have been postulated in cord blood with potential 
ranging from embryonic like to lineage-committed progenitor cells. Based on previous 
research (Mayani, Gutierrez-Rodriguez et al. 1998; Erices, Conget et al. 2000; Forraz, 
Pettengell et al. 2002; Bieback, Kern et al. 2004; Kogler, Sensken et al. 2004; McGuckin, 
Forraz et al. 2004; Markov, Kusumi et al. 2007) it was expected that a heterogeneous 
population of stem/progenitor cells could be isolated from cord blood. However, the 
category and quantity of primitive cells derived is governed by various peri-natal and post-
natal parameters which include: gestational age, birth weight and volume of cord blood 
(Ballen, Wilson et al. 2001; McGuckin, Basford et al. 2007) as well as the external factors 
including the method of cord blood processing and the microenvironment in which cells 
grow.  
3.1 Evaluation of five different umbilical cord blood separation techniques  
3.1.1 Introduction 
Since this research project endeavoured to develop clinically relevant protocols for liver 
differentiation, the first step was to evaluate and compare methods for optimal stem cell 
harvest from UCB.  
Ever since the first reported successful reconstitution of the haematopoietic system of a 
child with Fanconi’s anaemia using UCB in 1989 (Gluckman, Broxmeyer et al. 1989) UCB 
has been regarded as an established source of treatment for a range of disorders. Currently 
the most commonly used method of umbilical cord blood separation in many hospitals in the 
world, where small-to-medium amounts of samples are processed, is Hetastarch. However, 
each cord blood bank works to its own criteria for collection, processing and banking, and 
there is no standard operational procedure (SOP) that all cord blood banks abide to.  
A major limitation when considering UCB for transplantation is total nucleated cell (TNC) 
yield recovered from a single cord blood unit of limited volume.  This illustrates the 
importance of maximizing the efficiency of UCB processing. One of the objectives of this 
study was to evaluate the efficiency of some of the more commonly employed methods 
available for UCB processing and to find the best ways forward for hospitals to process cord 
blood prior to clinical application. The different separation systems are elaborated in 
materials and methods chapter (section 2.2). All the separation methods (except plasma 
depletion) have been developed to remove erythrocytes or red blood cells (RBCs) from 
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UCB, but permit recovery of non-erythroid subsets including leucocytes or white blood cells 
(WBCs) encompassing the stem/progenitor cell population and thrombocytes (platelets).  
Plasma depletion only removes the plasma compartment of whole cord blood.  
3.1.2 Multi-parametric analysis of UCB samples pre- and post UCB processing 
and freezing 
UCB samples pre- and post treatment with the different separation techniques were 
investigated and cell populations characterized by flowcytometry (materials and methods; 
section 2.4.3). 
The post-processed samples were subsequently transferred to the gaseous phase of liquid 
nitrogen at -196°C and cryopreserved for a minimum of two weeks before thawing and 
subsequent characterization by flowcytometry. 
3.1.3 Sample  
 A total of 65 UCB units were processed and 120 samples were collected to accomplish this 
number. For logistical reasons and for homogeneity of treatment, samples were collected 
only from Caesarean section births. Under no circumstance was the bith procedure adjusted 
or changed due to our study. Samples were from full-term healthy newborns. The data 
generated related to the following inclusion criteria: all UCB units had to fulfill a negative 
viral profile and infection status; UCB units were processed within 24hrs of collection and 
only if the volume of blood collected exceeded 40ml. The birth weight of the infants 
concerned with the study ranged from 2.41 to 4.42kg (average 3.52kg ± 0.38SD). Since the 
accepted cut-off volume for processing is 40ml (Armitage, Warwick et al. 1999; Van Haute, 
Lootens et al. 2005) the volumes of blood collected ranged from 62.5 to 138.9ml (average 
88.36ml ± 21 SD). For each unit, analysis samples were taken pre and post processing, and 
post cryopreservation/thaw.  
3.1.4 Statistical analysis 
The results generated were statistically analysed using Student t Test where analysis of two 
groups of data was undertaken (2-tailed, paired or unpaired depending on the data analysed). 
A p value of <0.005 was considered as statistically significant. For three or more groups of 
univariate data, single-factor analysis of variation (ANOVA) was used to obtain p values. 
For three or more groups of bivariate data (with replicates), two-factor ANOVA with 
replication was used to obtain p values. Results with p values of less than 0.05 were 
considered statistically significant. 
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3.1.5 Red blood cell reduction efficiency 
To evaluate RBC depletion and consequent volume reduction, erythrocyte counts and 
haemoglobin concentration (g/dl) in pre- and post- processing samples were used as the 
determining criteria. These values were provided by the Coulter cell count machine.  
With regard to eliminating RBCs from the cord blood units, density-gradient separation 
systems (Ficoll-Plaque or Lymphoprep) proved to be the most efficient (Figure 45).  
Treatment with Ficoll resulted in x95.7 fold reduction in RBC number compared to whole 
blood (p=0.000964) and a corresponding x60.9 fold reduction in haemoglobin concentration 
(p=0.000904). Ficoll was the most efficient of the methods tested; superior to PrepaCyte-CB 
(p=7.36974E-06); Hetastarch (p=0.005384); Sepax (p=4.77539E-07) and plasma depletion      
(p=2.81517E-06). Plasma depletion, as expected, was ineffective in getting rid of RBCs 
(Figure 45). 
From the results noted, it may be concluded that density gradient method of cord blood 
separation was the most efficient in RBC depletion. PrepaCyte-CB was second best.  
 
 
 
 
 
 
 
 
 
Conclusion  
 Density gradient method of cord blood separation was the most efficient in RBC 
depletion. PrepaCyte-CB came in as second best.  
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* p< 0.001 
(a) Red blood cell numbers  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46. RBC and corresponding haemoglobin concentrations in cord blood samples post 
processing. (a) The graph illustrates changes in the number of RBCs after treatment with the 
different separation techniques. Density-gradient dependent processing of cord blood proved 
to be the most effective in depleting erythrocytes from the samples. (b) The graph illustrates 
corresponding Haemoglobin levels in cord blood samples post processing. As expected the 
alteration in Haemoglobin levels corresponded to the changes observed in the RBC numbers. 
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3.1.6 Total nucleated cell (TNC) fraction recovery  
Total nucleated cell (TNC) fraction encompasses the entire non-erythroid compartment of 
blood excluding the platelets. TNC recovery was quantified using data from the differential 
cell counter (WBC count, RBC count and WBC differential count) combined with data 
derived from flow cytometric analysis, looking at CD45+ cells (expressed by all leukocyte 
lineage committed cells) and their viability analysed by uptake of 7AAD.  
Plasma depletion yielded the greatest TNC recovery post processing at 86.48% (±29.35 
SD). TNC recovery was significantly more efficient for plasma depletion compared to 
Ficoll/Lymphoprep 19.13% (±10.88 SD) (p<0.005) and Hetastarch 44.94% (±20.06 SD) 
(p<0.005). PrepaCyte-CB 72.03% (±8.48 SD) and Sepax 83.48% (±18.58 SD) were only 
slightly less efficient than plasma depletion in terms of TNC recovery (both p>0.005) 
(Figure 47a) 
Post freezing and subsequent thaw (compared to pre-processing cord blood units) the 
highest TNC recovery was illustrated by Sepax 48.83% (±28.87SD). This recovery was 
significantly superior to results obtained from Ficoll/Lymphoprep 8% (±10.51SD), 
PrepaCyte-CB 5.73% (±4.04 SD) and Hetastarch 9.73% (±5.06 SD) (all illustrating 
p<0.005).  Although plasma depletion also yielded a lower TNC recovery post thaw 
compared to Sepax, the difference was not statistically significant (Figure 47a).  
Corresponding to the previously elaborated post-thaw results, Sepax demonstrated the 
highest TNC recovery 58.48% (±30.74 SD) compared to post-processing cord blood 
samples. Although, the recovery values for the others methods were lower: 
Ficoll/Lymphoprep 42.84% (±32.79 SD), PrepaCyte-CB 7.96% (±6.11 SD), Hetastarch 
21.66% (±6 SD) and plasma depletion 24.75% (±24.89 SD), the difference was only 
significant for PrepaCyte-CB (p<0.005) (Figure 47a).  
 
In conclusion, Plasma depletion yielded the highest total TNC recovery post processing of 
cord blood units, followed closely by Sepax and PrepaCyte-CB. Density gradient proved to 
be the least effective. Post freezing and consequent thawing of the cord blood units, TNC 
recoveries where calculated with respect to both the unprocessed cord blood TNCs as well 
as to the post-processing TNCs. Although, the comparison to post processing TNC is 
interesting to note, what is of greater value is the recovery compared to the starting TNC.  
As a general rule, when comparing post thaw TNCs to post-processing TNCs, the 
recoveries calculated look much better as the post-processing TNCs are usually lower than 
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that of the unprocessed whole blood. In this respect, Sepax yielded the highest post thaw 
recovery compared to whole cord blood, followed by plasma depletion. PrepaCyte-CB was 
the least efficient. Density gradient, although, not very effective, generated results 
comparable to Hetastarch. 
Thus, it may be inferred that for immediate clinical transplantation post cord blood 
processing, plasma depletion might be considered to be the best option. However, it should 
be noted that plasma depletion removes only the plasma fraction of whole blood leaving 
behind the entire cellular compartment, including platelets. Transfusion of platelet 
concentrate may not be desired in a transplantation setting. Based on this, Sepax or 
PrepaCyte-CB might prove to be better alternatives.  
In situations, where processed cord blood units are to be cryopreserved for future use, 
Sepax might be the superlative choice for cord blood separation as it yielded the highest 
TNC recovery post freezing and subsequent thaw.  
For purposes of research in the laboratory, density gradient might be a good option for cord 
blood processing. Although the TNC yield post processing was not brilliant, post thaw 
TNC recovery was comparable to Hetastarch. In addition, density gradient-dependent 
protocols for cord blood processing, have the advantage of being very time and cost 
effective.  
 
 
 
 
 
 
 
 
Conclusion  
 
Immediate requirement for clinical transplantation entails PrepaCyte-CB or Sepax 
as the most appropriate option for cord blood processing.  
 
Sepax is a better choice for cord blood processing if the units are aimed for 
cryopreservation. 
 
For laboratory based research density gradient method of cord blood separation 
provides the most time and cost effective methodology.  
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Figure 47. Recovery of nucleated cell fraction from cord blood post-processing and post-thaw 
for the different techniques investigated. (a) The graph demonstrates the percentage of TNC 
recovery during the different phases of cord blood processing. Post-processed samples 
compared with whole blood (post from pre), and post thaw. Post thaw analysis was done 
compared to pre-processed whole blood (thaw from pre) as well as compared to post-processed 
samples (thaw from post). (b) Dot plot FACS graphs illustrating TNC fraction (CD45) and 
percentage viability of this gated cell fraction (7AAD). 
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3.1.7 Haematopoietic Stem/progenitor cell population recovery  
Haematopoietic stem/progenitor cells (HSC) are integrated in the nucleated cell 
compartment of blood. These cells may be categorized into three developmental stages 
based on expression of cell surface markers (McGuckin, Pearce et al. 2003; Christina 
Basford 2010).  
- Early stage stem cells  (CD45+low/CD34-/CD133+) 
- Mid stage stem cells (CD45+low/CD34+low/CD133+) 
- Late stage stem cells (CD45+high/CD34+/CD133-) 
 
Recovery of CD34+ and CD133+ cells was measured by using the nucleated cell count 
values from the differential cell counter combined with flow cytometric analysis, 
examining the CD34+ and CD133+ cells and their viabilities measured by uptake of 7AAD.  
 
3.1.7.1 Early stage stem cells (CD45+/CD34-/CD133+) 
 
PrepaCyte-CB yielded the highest average recovery of 62.59% (±16.23 SD), followed 
closely by plasma depletion 60.1% (±28.5% SD). In comparison to the other methods: 
Hetastarch 48.4% (±26.25 SD), Sepax 48.5% (±15.66 SD) and Ficoll/Lymphoprep 13.66% 
(±9.36 SD) produced lower recoveries. PrepaCyte was significantly more efficient than 
Ficoll/Lymphoprep (p=8.87921E-07) but the difference in HSC recovery compared to the 
other methods was not statistically considerable (p>0.005) (Figure 48a).  
Post thaw the highest average HSC recovery (compared to the original unprocessed 
samples) was noted in PrepaCyte 25.1% (±21.55 SD) and plasma depletion 25.5% (±10.2 
SD). However, when compared to the other methods the difference was insignificant 
(p>0.005): Ficoll/Lymphoprep 8.16% (±6.67 SD), Hetastarch 20.4% (±19.6 SD) and Sepax 
7.56% (±4.47 SD) (Figure 48a) 
When post thaw counts were compared to the post-processed samples, the highest recovery 
was provided by Hetastarch 50.5% (±29.2 SD). The recoveries generated by the other 
methods were as follows: Ficoll/Lymphoprep 45.89% (±33.28 SD), PrepaCyte-CB 30.5% (± 
25.39 SD), Sepax 23.23% (±20.23%) and plasma depletion 33.5% (±4.6 SD). The variation 
in the HSC recovery was not significant (p>0.005) (Figure 48a).  
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Conclusion 
 
PrepaCyte-CB generated the highest recovery for early-stage HSCs post 
processing. 
 
Density gradient proved to be the least effective in terms of early-stage HSCs 
recovery. 
 
Post cryopreservation and consequent thaw, PrepaCyte-CB, once again, provided 
the highest recovery and density gradient, accompanied by Sepax were the least 
efficient.  
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Figure 48. Recovery of early haematopoietic stems cell population post-processing and thaw. 
(a) The graph demonstrates the percentage recovery of early stage haematopoietic stem cell 
(HSC) population post processing and post thaw. (b) Dot plot FACS graphs illustrating how 
early stage HSC fraction (CD45+/CD34-/CD133+) were selected on FACS analysis. This cell 
population was gated within viable total nucleated cell (TNC) fraction (CD45+). Percentage 
viability (7AAD negative) of each gated cell fraction is illustrated below each corresponding 
graph. (c) Quadrant FACS dot plot illustrating percentage of viable TNCs (CD45+) positive for 
CD34 only (quadrant Q1-3), positive for CD133 only (quadrant Q13) and positive for both 
CD34 and CD133 (quadrant Q2-3).  The cell population we were interested in was the cell 
population positive for CD133 and negative for CD34 (quadrant Q13).  The cell Quadrant 3-3 
is negative for both CD markers. Negative controls for each sample were the unstained 
samples (samples with secondary antibody alone) corresponding to the test sample for analysis.  
** p<0.0000008 (PrepaCyte was significantly more efficient than Density Gradient method) 
♣ p>0.005 (HSC recovery by PrepaCyte was not significantly superior to the other methods 
of cord blood processing) 
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3.1.7.2 Mid stage haematopoietic stem cell (CD45+/CD34+/CD133+) recovery  
 
PrepaCyte yielded the highest recovery for mid stage HSCs 65.83% (±14.22 SD). 
Hetastarch and plasma depletion followed closely with recoveries of 64.21% (±17.89 SD) 
and 60.98% (±14.9 SD) respectively. Ficoll/Lymphoprep provided a recovery of 27.43% 
(±13.37 SD) and Sepax 54.3% (±26.79 SD). Although, both methods provided lower 
recoveries compared to PrepaCyte immediately post processing, the difference was not 
significant (p> 0.005).  
Post thaw (average counts compared to pre-processing samples) the highest average mid 
stage HCS recovery was achieved by Sepax 67.99% (±134.35 SD). This was significantly 
more efficient than plasma depletion 21.78% (± 34.35) (p=0.005) and PrepaCyte 24.33% 
(±14.21 SD) (p=0.005). But, Hetastarch 26.7% (±22.69) and Ficoll/Lymphoprep 45.38% 
(±40.09) although demonstrating lower recoveries, the variance was not significant 
(p>0.005).  
Post thaw average counts compared to post-processing counts showed Sepax to be the 
most efficient in terms of HSC recovery, 76.70% (±16.56 SD). This was significantly more 
efficient than plasma depletion, 26.39% (±15.56 SD) (p=0.005). Ficoll/Lymphoprep 
46.85% (± 23.79 SD), PrepaCyte 37.94% (±28 SD) and Hetastarch 34.31% (±28.51 SD) 
demonstrated recoveries lower than Sepax, the difference did not prove to be statistically 
significant (p> 0.005).  
 
 
 
 
 
 
 
 
 
 
Conclusion  
 
PrepaCyte-CB proved to the most efficient for mid-stage HSC recovery post 
processing. This result was followed closely by plasma depletion and Hetastarch. 
Density gradient was the least efficient. 
 
Post-thaw, Sepax provided the highest recovery, followed by density gradient. Plasma 
depletion was the least effective.  
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Figure 49. Recovery of mid stage haematopoietic stem cell population post-processing and 
thaw. (a) The graph demonstrates the percentage recovery of mid stage haematopoietic stem 
cell (HSC) population post processing and post thaw. (b) Dot plot FACS graphs illustrating 
mid stage HSC fraction (CD45+/CD34+/CD133+). This cell population was gated within viable 
total nucleated cell (TNC) fraction (CD45+). Percentage viability (7AAD negative) of each 
gated cell fraction is illustrated below each corresponding graph. (c) Quadrant FACS dot plot 
illustrating percentage of viable cells positive for CD34 only (quadrant Q1-3), positive for 
CD133 only (quadrant Q13) and positive for both CD34 and CD133 (quadrant Q2-3). 
Quadrant 3-3 is negative for both CD markers. Negative controls for each sample were the 
unstained samples (samples with secondary antibody alone) corresponding to the test sample 
for analysis.  
* p<0.005 (Sepax demonstrated the highest average HSC revovery post thaw and this was 
statistically sginificant when compared to plasma depeltion recoveries) 
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3.1.7.3 Late stage haematopoietic stem cell (HSC) (CD45+/CD34+) recovery 
 
PrepaCyte yielded the highest average recovery for late stage HSCs, 73.92% (±14.42 SD). 
This recovery was appreciably greater than the recoveries achieved by Ficoll/Lymphoprep 
39.18% (±27.03 SD) (p=0.0003), Hetastarch 48% (±29.55 SD) (p=0.001) and plasma 
depletion 45.58% (±23.19 SD) (p=0.0006). Sepax, however, provided an average recovery 
which although slightly less then PrepaCyte, was still comparable in efficiency; 68.70% 
(±19.88 SD) (p=0.406).  
 Late stage HSC recoveries yielded post freeze-thaw (compared to the original unprocessed 
units) demonstrates highest average recoveries for Sepax 53.83% (±15.93 SD). The results 
observed were superior to recoveries obtained by PrepaCyte 30.59% (±17.01 SD) (p=0.001) 
and Hetastarch 24.93% (±24.55 SD) (p=0.004). The recoveries acquired by 
Ficoll/Lymphoprep 26.06% (±35.76 SD) and plasma depletion 25.21% (± 25.81 SD), while 
lower than PrepaCyte were not statistically considerable (p>0.005).    
Post thaw recoveries compared to post processing samples illustrated highest recovery by 
Sepax 63.20% (±17.23 SD). The recoveries obtained by the other four techniques were less 
efficient, but the variance was not major (p>0.005): Ficoll/Lymphoprep 35.96% (±31.78 
SD), Hetastarch 41.89% (±28.11 SD) and plasma depletion 36.20% (±36.97 SD). 
PrepaCyte, however, was significantly less efficient, providing an average recovery of 
38.49% (±19.85 SD) (p=0.004).  
 
Conclusion 
 PrepaCyte-CB proved to be the most efficient for the recovery of late-stage HSCs post 
processing, followed by Sepax. Density gradient was the least effective.  
Post thaw, the highest recovery was noted in Sepax. Density gradient, although 
proving to be the least efficient, generated results that were comparable to the other 
three techniques. 
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Figure 50. Recovery of late stage haematopoietic stem cell population post-processing and 
thaw. (a) The graph demonstrates the percentage recovery of late stage haematopoietic stem 
cell (HSC) population post processing and post thaw. (b) Dot plot FACS graphs illustrating 
late stage HSC fraction (CD45+/CD34+). This cell population was gated within viable total 
nucleated cell (TNC) fraction (CD45+). Percentage viability (7AAD negative) of each gated cell 
fraction is illustrated below each corresponding graph. Negative controls for each sample were 
the unstained samples (samples with secondary antibody alone) corresponding to the test 
sample for analysis.  
* p<0.005 (PrepaCyte yielded highest HSC recovery post processing and this was significantly 
superior to Density Gradient, Hetastarch and plasma depletion) 
♣ p<0.005 (Sepax yieled highest HSC recovery post thaw and this was significantly superior to 
PrepaCyte and Hetastarch)  
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3.1.8 Non-haematopoietic stem cell (Lineage Negative cell fraction) recovery  
 
It has been postulated that cord blood constitutes both haematopoietic as well as non-
haematopoietic stem/progenitor cells. We investigated the non-haematopoietic cell fraction 
by using total nucleated cell counts provided by the differential cell counter and the data 
generated by flowcytometry. The Lineage negative population was characterized as the 
percentage of cells that tested negative for CD235a or Glycophorin-A (RBCs and 
reticulocytes), CD45 (T cells, B cells and monocytes), CD33 (myeloid-specific and some 
lymphoid cells) and CD7 (T cells) on flowcytometric analysis. Cell viability as assessed by 
7AAD uptake was taken into consideration each time. The recovery of this primitive cell 
population was calculated for each processing technique both immediately post cord blood 
separation and post thawing of the cryopreserved processed samples.  
Post-processing the highest recovery was noted in Sepax 77.31% (±45.79 SD). PrepaCyte 
and plasma depletion were the next best in line, with recoveries of 59.44 % (±7.38 SD) and 
57.99% (±22.04 SD) respectively. Ficoll/Lymphoprep 10.02% (±5.36 SD) and Hetastarch 
15.77% (±11.69 SD) were considerably less efficient in terms of LinNeg recovery (p=0.001 
and p=0.003 respectively).  
 
Post thaw (compared to unprocessed samples) the highest LinNeg recovery was also noted 
in Sepax 28.39% (±18.06 SD). This was a lot better that Ficoll/Lymphoprep 0.093% (±0.04 
SD) (p=0.0008), PrepaCyte 0.79% (±0.46 SD) (p=0.0009) and Hetastarch 6.29% (±4.01 SD) 
(p=0.004). Plasma depletion illustrated a recovery of 11.46% (±12.48 SD) which, although 
lower that the recovery noted in Sepax separation, the difference was not statistically 
noteworthy.  
Post thaw (compared to post-processing samples) the highest LinNeg recovery was 
demonstrated by Hetastarch 54.98% (±36.11 SD). The post thaw recoveries noted in all the 
other separation methods was less efficient; Ficoll/Lymphoprep 0.95% (±0.23 SD), 
PrepaCyte 1.29% (±0.66 SD), plasma depletion 25.02% (±29.3 SD) and Sepax 42.56% 
(±30.98 SD). The difference observed was statistically notable for density gradient 
(p=0.001) and PrepaCyte-CB (p=0.001).  
Conclusion 
 
Sepax was the most effective for recovery of lineage negative cells post processing, 
followed by PrepaCyte-CB. Density gradient yielded the least efficient recovery, but 
was comparable to Hetastarch. 
Post thaw, Sepax once again proved to be the most efficient and density gradient was 
the least effective. 
Chapter 3: Selection and Isolation of Stem/Progenitor Cells from Human Umbilical Cord Blood 
 197 
Non-haematopoietic stem cell (Lineage negative cell 
fraction) (CD45-/CD33-/CD7-) recovery
0
20
40
60
80
100
Density Gradient Prepacyte Hetastarch Sepax Plasma Depletion 
R
ec
ov
er
y 
(%
)
post from pre thaw  from pre thaw  from post 
♦ p<0.005 (Hetastarch demonstrated the highest LinNeg yield post thaw when compared with 
post-processed cord blood units). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51. Recovery of  lineage negative cell fraction post-processing and thaw. (b) Dot plot 
FACS graph illustrating Lineage negative cells (cell fraction negative for CD45, CD7 and 
CD33). Controls for each sample were the unstained samples (samples with secondary 
antibody alone) corresponding to the test sample for analysis.  
* p<0.005 (Sepax demonstrated the highest Lineage negative fraction recovery post-processing. This 
was significantly superior to Density Gradient and Hetastarch methods of cord blood separation). 
♣ p<0.005 (Sepax demonstrtaed the hightest post thaw yield compared to pre-processed cord blood.  
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3.1.9 Conclusion 
Taken as a whole, the results generated in this study indicated that the best way forward for 
translational cellular medicine where cord blood transfusion or transplantation is demanded 
immediately is PrepaCyte-CB. PrepaCyte-CB showed very efficient TNC recovery post 
processing of fresh cord blood units. Additionally, this method proved very effective for 
RBC depletion and subsequent volume reduction. Recoveries of HSCs and lineage negative 
cellular fractions were also notably superior to that observed in the other techniques.  
In situations where cord blood units are to be cryopreserved for possible future use then 
Sepax might be a better alternative for the processing of cord blood units. The highest TNC 
recovery post thaw was noted for Sepax. Similarly, the recoveries of both HSCs and non-
haematopoietic stem cells (lineage negative stem cells) were very efficient. The only 
limitation of this processing technique is that it was not very effective in RBC depletion and 
volume reduction, which is a very important issue for cord blood banking. 
In terms of in vitro research, density gradient method of cord blood processing is probably a 
good choice. This method was the most effective in RBC depletion. This is a matter of 
prime importance in cell culture. Remnant RBCs in culture eventually undergo lysis 
releasing various cytokines into the culture media. These cytokines provide signalling cues 
to stem/progenitor cells in culture ushering them towards undesired haematopoietic cell 
fates. Although, this technique proved to be the least effective in terms of TNC, HSC and 
lineage negative cell recovery post processing, the recoveries post thaw were acceptable and 
in some cases comparable to Sepax and PrepaCyte-CB. Furthermore, as noted earlier, 
density gradient was very time and cost effective to use.  
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3.2 Colony forming units  
Clonogenic potential has been used as a measure for more mature haematopoietic progenitor 
cells. Each colony formed represents the progeny of a single pluripotent/multipotent stem 
cell. Hence, operationally, the number of colony forming units is a measure of the numbers 
of stem cells. The clonogenic potential of the cord blood samples, both pre and post-
processing with the different separation techniques, were investigated. PrepaCyte generated 
the highest average CFU potential, 1327 CFU/106 cells post-processing. This was notable 
more efficient than the clonogenic potential noted in Ficoll/Lymphoprep 554.64 CFU/106 
cells (p=0.00024), plasma depletion 859 CFU/106 cells (p=4.78E10-6). Average CFU counts 
in Sepax and Hetastarch treated units were only slightly inferior to PrepaCyte; Sepax 1110 
CFU/106 cells and Hetastarch 1153 CFU/106 cells (both p values > 0.005).  
Post freeze-thaw procedure, CFU capacity was once again highest in PrepaCyte treated 
samples, 922.52 CFU/106 cells. This count was significantly better than the CFU units noted 
in the other techniques: Ficoll/Lymphoprep 133.33 CFU/106 cells (p=9.606E10-6), plasma 
depletion 540 CFU/106 cells (p=3.147E10-6), Sepax 608 CFU/106 cells (p=0.003) and 
Hetastarch 394.37 CFU/106 cells (p=9.29E10-11). 
    
Conclusion 
PrepaCyte-CB yielded the highest average CFUs, followed by Sepax and Hetastarch. 
Density gradient generated the lowest CFU count.   
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Figure 52. Clonogenic potential of cord blood samples post processing and post thaw. (a) A 
graphical presentation of the colony forming unit (CFU) potential of cord blood samples after 
processing and after subsequent thaw. (b) DIC images of CFUs. CFU-E (colony forming unit-
erythroid): clonogenic progenitors that represent the more mature erythroid progenitors. 
They have less proliferative capacity. CFU- G (colony forming unit- granulocytes): clonogenic 
progenitors of granulocytes that give rise to a homogenous population of eosinophils, basophils 
or neutrophils. CFU-GM (colony forming unit- granulocyte, macrophage): progenitors that 
give rise to colonies containing a heterogeneous population of macrophages and granulocytes. 
CFU-GEMM (colony forming unit- granulocyte, erythrocyte, macrophage, and 
megakaryocyte): formed by the most primitive of progenitors in cord blood giving rise to 
erythroid, granulocyte, macrophage and megakaryocyte lineages. Images were taken at 
magnification of x20.  
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a1st place worth 3 points, b2nd place worth 2 points and c3rd place worth 3 points 
 (7 analysis methods evaluated) 
3.3 Analysis Discussion 
During the analysis no one method came out consistently as best; so a league table was 
devised. Each method was rated for all the 7 analysis methods discussed above and was 
awarded 3 points for 1st place, 2 points for 2nd place and finally 1 point or 3rd place.  
As mentioned in the previous section, depending on the primary use of UCB, different 
processing methods may be more applicable than others. Density gradient was the most 
efficient for RBC depletion; Plasma depletion and Sepax provided the highst TNC 
recoveries post processing and PrepaCyte-CB demonstrated the highest recovery for HSC 
populations. Based on the league table, however, PrepaCyte-CB was noted to be the best 
performer for many of the analysis methods. PrepaCyte-CB has the added advantage of 
being a closed system and hence is associated with a much reduced risk of contamination 
during processing. This is of particular importance to the developing world where access to 
a clean room is not economically feasible. Additionally, PrepaCyte does not require 
expensive laboratory equipment and this is a significant issue in less economically 
developed parts of the world where transplants are rarely peformed due to lack of necessary 
resources and facilities. It is worth noting that UCB transplants are currently unavailable to 
large sections of the second and third world countries. Thus, the choice of UCB processing 
should be carefully addressed with the view that UCB is readily available in a suitable form 
for patient treatment.  
Table 32. Processing League Table 
Performance position and frequency 
Methods  1sta 2ndb 3rdc Points 
PrepaCyte-CB 4 2 1 17 
Sepax 1 2 2 9 
Plasma 
Depletion 
1 1 2 7 
Hetastarch 0 2 3 7 
Density 
Gradient 
1 0 0 3 
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3.4 Isolation of stem/progenitor cells from cord blood by negative depletion  
It has been demonstrated in the previous sections (section 3.1.7 and 3.1.8) that regardless of 
the technique utilized to process cord blood units, both haematopoietic and non-
haematopoietic stem/progenitor cells were identified and characterized in cord blood 
samples.  
Our subsequent aim was to investigate whether the desired cell populations could be 
selectively isolated and concentrated using the StemSep ‘human primitive progenitor cell 
enrichment kit’ and our in-house Lineage negative selection protocol.  
The StemSep depletion kit is tailored to highly enrich CD34+, CD36-, CD38- and CD45RA- 
haematopoietic progenitors from fresh cord blood. Antibodies to 12 lineage-specific cell 
surface antigens are used to target mature, fully differentiated cells as well as lineage-
committed progenitor cells for removal. The depletion cocktail includes antibodies to the 
following human cell surface markers:  (CD2, CD3, CD14, CD16, CD19, CD24, CD36, 
CD38, CD45RA, CD56, CD66b, glycophorin A) (14057C; StemCell Technologies).  
Cord blood buffy layer, post processing with Ficoll, was further treated with StemSep kit, 
which effectively rid the samples of any remnant RBCs, including reticulocytes (CD24, 
CD36 and glycophorin A); T cells (CD2, CD3, CD38, CD45RA, CD56); B cells (CD19, 
CD38, CD45RA); Natural killer cells (CD2, CD16, CD56); monocytes and macrophages 
(CD14, CD16, CD36, CD45RA); granulocytes (CD14, CD16, CD66b); lymphoid and 
myeloid precursors (CD24, CD56) and platelets (CD36). The negative selection post 
StemSep treatment contained cells of interest and was investigated for a number of stem cell 
markers by flowcytometric analysis: CD90, CD133, CD34, SSEA-4 (Stage-specific 
embryonic antigen 4). In each case, cell viability with 7-AAD was noted (Figure 53) 
Likewise, buffy cells were treated with in-house Lineage negative selection protocol.  This 
procedure employed glycophorin-A, which rid the samples of RBC remnants post Ficoll; 
CD45, which eliminated T, B cells and monocytes; CD33, which removed myeloid 
derivatives and some lymphoid cells and, CD7, which rid of T cells. Post procedure the 
negative cell selection was analysed for the stem cell markers noted above (Figure 53).  
Both methods resulted in a significant further reduction in CD45 cell population post Ficoll: 
StepSep, an additional 8.7% reduction (p=0.0005) and in-house protocol, an additional 9.3% 
reduction (p=0.0003).  
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Post treatment with StemSep, CD90+ cells (haematopoietic stem cell marker) illustrated a 
relative increase in cell concentration (p=8.17E-06). This was attributable to the selective 
removal of the undesired mature leukocytes and leukocyte precursors, leaving behind the 
cells of interest. Our in-house protocol also demonstrated a similar effect. The CD90+ cell 
concentration, although lower than that noted in StemSep, was not notably inferior 
(p>0.005).  
The CD34 recovery after StemSep treatment was slightly abridged compared to post Ficoll 
but the difference was not noteworthy (p>0.005). This small decrease in cell number was 
probably contributed to the elimination of late stage haematopoietic stem cells, which 
illustrate a strong expression of CD45; leaving behind early and mid-stage haematopoietic 
stem cells and lineage negative cells. Our in-house protocol, however, was unable to 
demonstrate a similar result. We noted a considerable decrease in the number of CD34+ cell 
concentration (p=2.24E-05). This outcome was most likely due to the many washes 
incorporated in this protocol, which lead to cell loss. In addition, the sequential introduction 
of antibodies to the cells lead to prolongation of the protocol and hence contributed to 
decreased cell viability.  
CD133+ cells constitute a very small percentage of the cellular compartment of blood. This 
makes them a challenge to study due to low cell numbers, which undergoes further 
reduction during processing. StemSep failed to show a marked change in CD133+ cell 
population compared to post Ficoll treated samples. Lineage Negative protocol, however, 
demonstrated a modest increase in CD133+ concentration, which although small was 
statistically appreciable (p=0.0015). 
We next examined the expression of SSEA-4, an embryonic stem cell marker. Both methods 
demonstrated a notable relative increase in the concentration of SSEA-4 positive cells post 
processing: StemSep (p=0.0006) and LinNeg (p=3.13E-07). Although, StemSep illustrated 
somewhat better results, the difference was not statistically significant (p>0.005).  
So, it may be concluded that StemSep facilitated the selective isolation of mid-stage HSCs, 
as noted by efficient further reduction of CD45+ cells (considerably eliminating late-stage 
HSCs that show strong CD45 expression) and a relative increase in the concentration of 
CD90 and CD34 positive cells. This kit, however, failed to demonstrate a notable increase 
in CD133+ cell concentration, and thus did not prove very effective in the selection and 
concentration of early HSC populations. The relative increase in the concentration of SSEA-
4 positive cells was impressive, demonstrating the ability of the kit to isolate and 
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concentrate stem/progenitor cells with ES cell attributes.  
Our in-house protocol demonstrated better isolation for early HSCs (more efficient CD133+ 
cell selection) compared to StemSep. Although CD90, CD34 and SSEA-4 positive cell 
recovery was less efficient then StemSep, the difference was not statistically significant. 
 
 
 
 
Conclusion  
Although our in-house protocol did prove effective in the selection and concentration 
of early HSC populations and non-haematopoietic stem cells, taking the overall results 
into view, it was decided that StemSep was a more efficient method.  
StemSep protocol involved fewer steps, fewer washes and less manipulation of cells in 
vitro.  
Lineage Negative protocol, on the other hand, was labour intensive. It was a very long 
protocol involving multiple steps, several washes and more cell manipulation. The 
prolonged ex vivo cell processing procedure involved, in addition to reducing cell 
viability also greatly increased the risk of bacterial and cellular contamination. It was 
for these reasons that it was decided to discontinue the lineage negative method and 
continue with StemSep kit for all further experiments. 
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Figure 53. Percentage of expression of haematopoietic stem cell markers in cord blood post 
isolation using StemSep kit versus in-house Linegae negative protocol. The graph illustrates 
that StemSep facilitated the selective isolation of mid stage HSCs (greater CD45+ cell removal 
decreasing late stage HSC population; these cells demonstrate strong CD45 expression).  
Simultaneous increase in SSEA-4 concentration illustrated the ability of the kit to isolate cells 
with embryonic stem cell attributes. In-house protocol proved to be more efficient for early 
stage HSC selection (more efficient CD133+ cell selection) compared to StemSep. Although the 
resulting cellular expression of CD90, CD34 and SSEA-4 was less efficient than SetmSep the 
difference was not statistically significant (p>0.005).  N=6 
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Figure 53b. Dot plot FACS graphs illustrating gated selection of HSC populations from white 
blood cell fraction isolated from whole blood. Note corresponding cellular viability (7-AAD 
negative cells) from the different stages of cord blood processing. Percentage of expression 
demonstrated is from the total cell population.  
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Figure 53c. Dot plot FACS graphs illustrating gated selection of CD45+ cell population and 
within that population the concentration of CD34+ cells. Percentage of expression 
demonstrated is from the total cell population. 
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Figure 53d. Dot plot FACS graphs illustrating gated selection of CD133+ cellar population 
within CD45+ population.  
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3.5 Characterisation of isolated cord blood stem/progenitor cells  
3.5.1 Immunocytochemistry for pluripotency markers 
The negative selection from the StemSep kit was further analysed for a number of 
embryonic stem cell proteins by immunocytochemistry: Oct4 (Pou5fl), Sox-2, Nanog. These 
transcription factors have been identified as crucial for the efficient maintenance of 
embryonic stem cell identify (Niwa, Miyazaki et al. 2000; Chambers, Silva et al. 2007; 
Masui, Nakatake et al. 2007). The examined cell population tested positive for all three 
pluripotency regulators, which co-localised to the chromatin (Figure 54). This close 
localisation of these three transcription factors in the chromatin has been previously reported 
in human ES cells (Boyer, Lee et al. 2005).  It was reported for the first time, by McGuckin 
et al, that these markers were also expressed in cord blood-derived stem/progenitor cells 
(McGuckin, Forraz et al. 2006). These results were successfully reproduced in this study. 
Several other pluripotency transcription factors: Klf4 (Kruppel-like factor 4), Esrrb 
(Estrogen related receptor βeta) and Tcf4 (T cell factor 4) also share the global localisation 
to chromatin (Chen, Fang et al. 2008; Chen, Xu et al. 2008) but were not investigated in this 
project.  
In addition, the cells were also tested for the presence of Ki-67 (MKI67), which is a cellular 
marker of proliferation (Scholzen and Gerdes 2000). Ki-67 protein is present during all 
active phases of the cell cycle (G1, S, G2 and mitosis), but is absent from resting cells (G0). 
The cells tested positive for this proliferation marker, which too was limited to the nucleus. 
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Figure 54. Expression of pluripotency markers in cord blood cells post StemSep isolation. The 
cells demonstrated positive expression of Oct4a, Sox-2 and Nanog. Cells were also positive for 
Ki-67, which is a proliferation marker.  Cellular nuclei was stained blue with DAPI. 
Red=TxRed, Purple=Cy5 and Green= FITC. Images were taken at a magnification of x10 and 
x20. All positively stained images were acquired by setting negatives (secondary antibody only) 
as a control.  
 
(a) 
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3.6 Expansion of cord blood-derived stem/progenitor cells- a significant 
challenge 
 
One of the chief limitations with cord blood samples is the scarce stem/progenitor cell 
content that is attained from cord blood units of modest volume. Ex vivo expansion and 
maintenance of this cell population would have significant impact for stem cell enrichment 
of grafts deemed unsuitable for transplantation purposes owing to insufficient stem cell 
content. Several groups have made attempts at achieving stem/progenitor cell self-renewal 
in vitro. This includes attempts at optimization of culture systems incorporating growth 
factors and cytokines or by retroviral gene transfer as was done in bone marrow cells 
(Sorrentino 2004). The results observed, however, have been so far modest. In addition, the 
potential deleterious effect of insertional mutagenesis is a subject of great concern and is 
clinically very relevant.  
What occurs in stem cell cultures in vitro, in the absence of any cytokines, is that that the 
cells divide symmetrically and give rise to two daughter cells committed to differentiation, a 
situation that eventually leads to depletion of the cultured stem cell pool in a matter of days. 
This happens because the critical interplay between intrinsic and extrinsic factors that exists 
in vivo, and is essential for the maintenance of stem cells has been disrupted. What is 
desired, however, is the creation of a culture system that will permit symmetrical division of 
the stem cells with one parent cell giving rise to two identical daughter stem cells, hence 
increasing stem cell numbers.  
The ideal expansion system would include as few growth factors or cytokines as possible, 
should be short term and associated with minimal manipulation.  
The expansion regime we formulated involved a limited number of mitogens and 
morphogens, hence obeying the concepts of ‘minimal manipulation’. This was done with the 
perspective of transfer to clinical settings. The cocktail constituted: Dulbeco’s Modified 
Eagle’s Medium, 5 % fetal calf serum, Stem cell factor (SCF) (20ng/ml), acidic Fibroblast 
growth factor (aFGF) (20ng/ml) and Thrombopoietin (TPO) (10ng/ml). These cytokines 
were chosen based on the role that they play in regulation of stem cell niches. The doses 
selected were derived from literature review on previous research done in this area. SCF has 
been shown to play an important role in the regulation of HSCs in the stem cell niche in the 
bone marrow (Broudy 1997). SCF has been shown to contribute to the self renewal and 
maintenance of HSCs in vivo and increase the survival of HSCs in vitro. The expression of 
the receptor for SCF (c-kit) on HSCs at all stages of development stays constant (Kent, 
Copley et al. 2008).  In vivo, the stromal cells that surround HSCs constitute part of the stem 
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cell niche, and release several ligands, including SCF. SCF has been shown to enhance 
adhesion to ECM proteins and stromal cells and thus may contribute to the maintenance of 
HSCs in the niche (Broudy 1997). It has previously been demonstrated that foetal HSCs are 
6 times more sensitive to SCF than HSCs from adults (Bowie, McKnight et al. 2006; Kent, 
Copley et al. 2008). Hence, UCB- derived stem/progenitor cells, being at a more primitive 
developmental stage than adult stem cells were expected to show an effective response to 
SCF in the culture media.  
 Thrombopoietin (TPO), in addition to playing a pivotal in the development of 
megakaryocytes also plays a role in the development of HSCs. Kaushansky et al 
(Kaushansky 2002; Kaushansky and Drachman 2002) demonstrated that when used alone 
TPO does not influence stem cell kinetics, but when used in combination with other 
cytokines, for example SCF, it supports HSC survival and profoundly enhances stem cell 
proliferation. The importance of TPO and its receptor (c-Mpl) in haematopoiesis has been 
demonstrated in in vivo studies in mice by genetically eliminating c-Mpl receptors and 
demonstrating a much less potent stem cell repopulation capacity in the recipient murine 
bone marrow (Solar, Kerr et al. 1998). Congenital amegakaryocytic thrombocytopenia 
(CAMT) is a rare human disorder that further demonstrates the role of TPO in 
haematopoiesis and stem cell biology (Ballmaier, Germeshausen et al. 2001). In this 
disorder faulty signalling response to TPO causes initial faulty megakaryocytes and 
platelets, and with time develops into aplastic anaemia due to failed haematopoiesis and 
deficiency of all haematopoietic progenitors.  
Fibroblast growth factors have also been shown to play an important role in haematopoiesis. 
One of the proposed mechanisms of action of FGF is that it has the ability to interrupt BMP 
signalling which causes differentiation of human ES cells. Hence FGF in culture allows 
maintenance of undifferentiated proliferation of stem cells. This phenomenon has been 
elegantly demonstrated in human embryonic stem cells (Xu, Peck et al. 2005).  
The formulated medium was further supplemented with ITS and heparin sulphate. ITS was 
applied as a maintenance factor and heparin sulphate functions as a modulators of FGF 
activity. Heparin sulphate binding protects FGF from denaturation and proteolytic 
degradation and provides a matrix-bound or cell-surface reservoir of this factor for the cells 
and is required for the activation of FGF high-affinity receptors (Quarto and Amalric 1994).  
In addition to exogenous cytokines, in vitro and in vivo studies have shown that stromal 
cells are also important in providing a microenvironment that enables primitive 
undifferentiated cells to indefinitely self-renew and inhibits differentiation and maturation. 
These cells also provide a rich environment of signals (cytokines, ECM proteins and 
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adhesion molecules) that control proliferation, survival and differentiation decisions. It is 
currently not known whether non-contact conditions are sufficient for ex vivo expansion or 
whether stromal binding is essential (Hofmeister, Zhang et al. 2007). A great deal of work 
has been done to investigate the importance of ECM components on the ex vivo expansion 
of cells. Previous studies have reported successful expansion of BM-derived MSCs on 
plates coated with various ECM: fibronectin, collagen and Matrigel (mixture of ECM 
components), and these cells were able to differentiate into hepatocyte-like cells (Schwartz, 
Reyes et al. 2002; Fiegel, Lioznov et al. 2003). It was suggested that the ECM could 
potentially modulate the local concentration of cytokines available and together with the 
stem cell microenvironment and cytokines regulate stem cell proliferation and 
differentiation fate. Conversely, Kang et al reported that that they were able to culture and 
expand UCB-derived MSCs in plastic culture flasks without treatment with ECM proteins 
and these cells were still able to differentiate into hepatocytes (Kang, Zang et al. 2006). 
Thus, there exists opposing views regarding the role of ECM proteins in in vitro 
stem/progenitor cell expansion.  
 The stem/progenitor cells in this study were cultured on ECM proteins: collagen IV or 
fibronectin coated plastic round bottom 96-well plates. StemSep kit yielded a very low cell 
count post treatment and for this reason culturing in round bottom 96-well plates allowed 
cells to aggregate at the bottom of the plate and permitted liberated inter-cellular 
communication that is required for cell fate decisions and maintenance. These cells grew as 
tight adherent clusters resembling the ‘niche-like’ structures described by Scadden and Sun 
et al (Scadden 2006; Sun, Jeong et al. 2007). This was observed as early as after 1 day post 
seeding and culture (Figure 55). Cell colonies were formed as clusters of small rounded 
cells, 4-5µ in size. These homogenous colonies, in due course, became surrounded by 
spindle-shaped cells and embodied a ‘niche-like’ architecture (Figure 55). This structure 
might be correlated to the hypothesis of Wilson and Trumpp (Wilson, Oser et al. 2007) ; that 
the quiescence stem cells are anchored in the centre of the niche, whereas self renewing 
stem cells are located close to the border separating the niche from the non-niche 
microenvironment, which would provide signals that determine cell fate. The surrounding 
cells play a key role in supporting the centrally located stem cells and provide signals that 
are key players in determining cell fate decisions. The perseverance of this ‘niche’ structure 
appears to be a key factor in survival of the stem cells as it was noted that loss of the 
supporting cells in the ‘niche’ structures resulted in ultimate loss of the stem cell colonies as 
well. 
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The cells were cultured in vitro for 25 days with media changes every other day. The cells 
were trypsinized and counted with a haemocytometer at regular intervals and the results are 
noted in Figure 56. The cells were doubled in number by day 4, but thereafter there was a 
constant decline in cell number till day 13 after which the cell numbers stayed constant at 
very low levels for approximately a week and then cell viability went down to zero. It is 
worth noting that, after the first week in culture the cells that did survive were the ones that 
existed in aggregates.  
In conclusion, the applied expansion system resulted in a very modest increase in cell 
number and was incapable of maintaining the cells in culture for long term applications. 
Consequently, it was decided to limit the expansion period to duration of one week only. 
Since the cell viability decreased rapidly after day 10, commitment of cells towards 
endoderm lineage was undertaken simultaneous with the short-term expansion. This was 
done by the introduction of Hepatocyte growth factor (HGF) (20ng/ml) to the expansion 
media. Analysis with immunocytochemistry at the end of a one week treatment with the 
dual culture system illustrated positive expression for Gata-4 (endodermal marker), albumin 
(earliest hepatic marker) and Ck7 (hepatic stem cell marker) (Figure 57). The cells were 
very weakly positive for ectoderm markers Nestin and GFAP and were negative for Pax6, 
showing commitment towards endo-mesodermal lineage.  This dual culture system 
permitted modest expansion and endoderm commitment of cord blood-derived 
stem/progenitor cells in a short time period.  
 
 
 
 
 
 
 
Conclusion  
 
The applied expansion system resulted in a very modest increase in cord blood 
stem/progenitor cell number and was incapable of maintaining the cells in culture 
for long term applications.  
 
Commitment of stem/progenitor cells towards meso-endoderm lineage was 
undertaken simultaneous with short-term expansion.  
 
The dual culture system permitted modest expansion and commitment of cord 
blood stem/progenitor cells to endoderm and liver lineage.  
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Figure 55. Ex vivo expansion of cord 
blood-derived stem/progenitor cells. 
Figure illustrates stem/progenitor 
cells from StemSep kit cultured in 
DMEM-F12 supplemented with a 
cocktail of mitogens and 
morphogens permitting the 
development of ‘niches’ ex vivo.  
With increased length in culture the 
cell clusters so formed increased in 
size and demonstrated a 
heterogeneous population of cells 
that function in a synergistic way to 
provide signals that determine the 
fate of stem cells. Note that the 
small rounded cells positioned 
centrally (arrow) are the primitive 
stem/progenitor cells which are 
surrounded by spindle-shaped cells 
and occasionally overlie large 
multinucleated osteoclast-like cells 
(♣).  DIC images acquired at 
magnification 10, 20 and 40. 
 
Day 14 
♣ 
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Figure 56. Ex vivo proliferation assay for human cord blood-derived stem/progenitor cells. The 
average doubling time for these cells was four days after which the cellular viability 
deteriorated remarkably resulting in rapid fall in cell number as noted on the 
haemocytometer. (N=3) 
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Figure 57. Simultaneous endoderm commitment of cord blood stem/progenitor cells during in 
vitro expansion. Post treatment with relevant mitogens, cells demonstrated positive expression of 
Gata-4 (endodermal marker) and were also positive for some liver related markers: albumin, 
AFP, Ck7 and Ck19. The cells  were very weakly positive for Nestin and GFAP. Cellular nuclei 
were stained blue with DAPI.  Red= TxRed, Purple=Cy5 and Green=FITC. Images were taken at 
a magnification of x10 and x20. All positively stained images were acquired by setting negatives 
(secondary antibody only) as a control. HPCs (Haematopoietic progenitor cells). N=4  
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3.7 Cytogenetic analysis of cord blood-derived stem/progenitor cells  
One of the major concerns during ex vivo manipulation, culture and propagation of 
stem/progenitor cells is genetic instability and mutagenesis. Thus, karyotype analysis of 
cord blood stem/progenitor cells post isolation, propagation and lineage commitment was 
undertaken.  The cells produced normal karyotype as illustrated in the figure 58.  
 
 
Figure 58. Karyotype of cord blood-derived stem/progenitor cells post short time ex vivo 
expansion. Post expansion cells demonstrated a normal karyotype. (N=2) 
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3.8 Multi-potential of selected stem/progenitor cells  
The selected cord blood stem/progenitor population demonstrated multi-potential capacity. 
In addition to liver commitment (endoderm), other members of the group were able to 
differentiate the same stem/progenitor cell population into pancreatic cells (endoderm), 
neuroglial cells (ectoderm) and cardiac progenitors (mesoderm). Based on this result, it may 
be argued that these cells were pluripotent and capable of generating tissues of all three 
germ layers (Figure 59).  
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Figure 59. Multipotential capacity of cord blood stem/progenitor cells. These cells 
demonstrated the capacity to differentiate along ectoderm lineage (neuroglial differentiation) 
and mesoderm lineage (cardiac progenitor cell differentiation) in addition to endodermal fate. 
Images courtesy of  Hamad Ali, Dr Christina Basford and Marko Strabad. Images were taken 
at magnification of x10, x20 and x40.
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3.9 Chapter discussion 
One of the goals of this study was the selection of stem/progenitor cell populations from 
umbilical cord blood. We have demonstrated here that not only can different 
stem/progenitor cell populations be isolated from cord blood units but have simultaneously 
compared the efficiency of the five most commonly used methods for cord blood 
processing.  Since no one method came out consistenetly as best during analysis, a league 
table was devised and each method was rated for all the 7 analysis methods used. Based on 
the league table PrepaCyte was noted to be the best performer for many of the 
investigations. Additionally, PrepaCyte proved superior in terms of cost effectiveness. This 
closed separation system did not demand expensive laboratory equipment or specialized 
clean rooms. However, it is important to note that depending on the primary use of UCB, 
different processing methods may prove more applicable than others. Thereofore, the choice 
of UCB processing should be cautiuosly tackled with the view that cord blood can be 
readily transferred from the bench to the bedside in a suitable form for patient treatment.  
We further investigated whether the desired stem/progenitor cells populations could be 
selectively isolated and concentrated from UCB. We compared our in-house Lineage 
negative selection protocol with the StemSep ‘human primitive progenitor cell enrichment 
kit’. It was concluded that although our in-house protocol proved effective in the selection 
and isolation of early HSC populations, taking the overall results into view, StemSep proved 
to be the more efficient method. StemSep protocol was time effective, involving fewer 
steps, fewer washes with less manipulation of the cells. All these factors collectively 
contributed to greater cell viability and reduced the risk of contamination in vitro.  
We further investigated the multi-potential capacity of the isolated stem/progenitor cell 
populations. These cells demonstrated the ability to differentiate into cells representing all 
three germ layers. Additionally these cells tested positive for a few ES  cell markers.  
This project also aimed to develop an ex vivo regime obeying the concepts of ‘minimal 
manipulation’ for the expansion of isolated UCB stem/progenitor cells. Our expansion 
system resulted in a very modest increase in cell number and was incapable of maintaining 
the cells in culture for long term applications. Hence, commitment of stem/progenitor cells 
towards endoderm lineage was undertaken simultaneously with the short-term expansion. 
These expanded cells demonstrated a normal karyotype on analysis. This dual culture 
system allowed modest expansion and commitment of stem/progenitor cells to endodermal 
fate.  
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4 Introduction 
A population of non-haematopoietic multipotent stem cells termed mesenchymal stem cells 
(MSCs) have previously been derived from the human umbilical cord (Romanov, 
Svintsitskaya et al. 2003; Wang, Hung et al. 2004; Sarugaser, Lickorish et al. 2005). These 
cells grow adherent to plastic and express specific pattern of cell surface determinants 
(CD105, CD90, CD73, and CD44). This cell fraction is distinct from the haematopoietic and 
pluripotent stem cells present in cord blood and do not express blood-cell determinants 
(CD34, CD45 and CD133). These Mesenchymal stem cells can be expanded very efficiently 
in vitro. Additionally, these multipotent cells (Kang, Zang et al. 2006) have unique 
immunoregulatory features that suppress lymphocyte proliferation in vitro (Gerson 1999) 
and exhibit high self renewal potential (Bartholomew, Sturgeon et al. 2002). MSCs have 
potential to differentiate into tissues of all three germ layers: including bone, cartilage, fat, 
muscle, endothelial cells, neuronal, glial cells and liver cells (Bruder, Jaiswal et al. 1997; 
Kopen, Prockop et al. 1999; Pittenger, Mackay et al. 1999; Erices, Conget et al. 2000; 
Woodbury, Schwarz et al. 2000; Campagnoli, Roberts et al. 2001; Horwitz, Gordon et al. 
2002; Krampera, Glennie et al. 2003; O'Donoghue, Choolani et al. 2003; Lee, Kuo et al. 
2004; Hong, Gang et al. 2005; Li, Qu et al. 2005; Chien, Yen et al. 2006; Lange, Bruns et al. 
2006; Ong, Dai et al. 2006; Snykers, Vanhaecke et al. 2006; Lu, Teng et al. 2007; Paunescu, 
Deak et al. 2007; Tamagawa, Oi et al. 2007; Yen, Chien et al. 2007; Campard, Lysy et al. 
2008; Lu, Dong et al. 2008). 
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4.1  Isolation of Mesenchymal stem cell (MSC)-like cells from human umbilical 
cord and cord matrix  
One of the goals of this study was to isolate MSCs from umbilical cord. We were able to 
accomplish this task with a 100% efficiency (n=15). The manual method of umbilical cord 
dissection and culture proved more effective than the enzymatic technique of cord 
processing (Materials and Methods, section 2.3.1.1) which was carried out by incubating 
cord pieces with Collagenase (2mg/ml) overnight in an incubator. Cord pieces were 
subsequently washed with serum-free DMEM and incubated with Trypsin at 37◦C for 30 
minutes with regular agitation. FBS was then used to inhibit the enzymatic reaction of 
Trypsin. Cord pieces were then washed in serum-free DMEM and cultured in DMEM-F12 
10% FBS. The manual method of umbilical processing (Materials and Methods, section 
2.3.1.2) was less time consuming and involved minimal manipulation. Cells appeared to 
migrate out of the cord pieces and grow in culture as early as day 3 post transfer of 
umbilical cord pieces into culture plates (Figure 60).  
Isolated cells initially displayed a fibroblast-like morphology in culture, with the majority of 
the cells being flat with a wide cytoplasm within which were noted stress fiber patterns 
(Figure 60).  
The abundant availability of umbilical cords as a biological by-product, the efficiency of 
isolation of this cell population and the reproducibility of this technique defines the 
umbilical cord as a valuable resource for regenerative medicine. We have indicated here that 
hospitals could achieve this task with clinical ease with no requirement for specialist labs to 
do this for them.  
 
 
 
 
 
 
 
 
 
 
 
Conclusion  
 
Mesenchymal stem cell-like cells were isolated from human umbilical cord matrix with 100% 
efficiency (n=15).  
 
Manual dissection and transfer of umbilical cord pieces into culture media proved more 
effective than enzymatic digestion of umbilical cord samples.  
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Isolation and expansion of Mesenchymal stem cells (MSC) from human umbilical cord  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 60. Progressive in vitro proliferation of MSCs isolated from umbilical cord matrix over 
duration of 4 weeks. Note that initially post isolation the fibroblastic cells display a flattened 
morphology with wide cytoplasm (          )   but with progressive proliferation they become 
more spindle-like in phenotype with a narrow cytoplasm and a low nuclear to cytoplasmic 
ratio (*).  Images were taken at magnification of x10 and x20.  
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4.2 Characterisation of isolated Mesenchymal stem cell-like cells from 
umbilical cord  
4.2.1 Flowcytometric analysis of umbilical cord Mesenchymal stem cell-like 
cells  
Flow cytometric analysis of the isolated MSC-like cells demonstrated that these cells 
expressed most of the markers that have routinely been used to characterize MSCs in the 
past: matrix markers (CD44, CD105) and integrin markers (CD29), CD73, CD90 but not 
haematopoietic markers (CD45, CD34 and CD133). These cells, however, were negative for 
CD106 and CD166. Other reports have previously noted that the expression of some of 
these markers, for example CD106, might fluctuate between different studies and may 
depend on the precise location (perivascular or intervascular) in the cord where the cells are 
isolated (Sarugaser, Lickorish et al. 2005; Weiss, Medicetty et al. 2006; Campard, Lysy et 
al. 2008). The MSCs were also analysed for the expression of Major Histocompatibility 
Complex (MHC). In humans, MHC is called Human Leukocyte Antigen (HLA) system.  
The cells tested positive for major HLA class I antigens (A, B and C) but were negative for 
HLA class II (DR and DQ) and minor HLA class I antigen G. HLA class I antigens present 
peptides from inside the cell. These peptides are produced from digested proteins that are 
broken down in the proteasomes. HLA-A, B and C are major Class I proteins while HLA-E, 
F and G are minor class I proteins. HLA class II antigens present antigens from outside of 
the cell to T-lymphocytes. These particular antigens stimulate T-helper cells to multiply, and 
these T-helper cells in turn then trigger antibody producing B-cells to produce antibodies to 
that specific antigen. Self-antigens are suppressed by suppressor T-cells.  
The data generated here confirmed previous reports that MSCs (from various sources) do 
not express immunologically relevant cell surface markers including HLA class II  
(Niemeyer, Krause et al. 2006) . This data identified MSCs as being immune privileged. In 
vitro studies have previously demonstrated that HLA-mismatch MSC do not provoke an 
immune response in the host and are even able to suppress allogenic lymphocyte 
proliferation (Le Blanc, Tammik et al. 2003; Le Blanc, Tammik et al. 2003).  This 
phenomena seems to be independent of the major histocompatibility complex and mediated 
by production of cytokines, in particular interleukin-2 (IL-2) and IL-10 (Rasmusson, 
Ringden et al. 2003), HGF and Transforming growth factor-β-1 (TGF-β-1) and not by 
apoptosis (Di Nicola, Carlo-Stella et al. 2002). These features make MSCs an attractive 
candidate for HLA-independent therapeutic strategies. Their immunemodulatory features 
have already contributed to the application of MSCs in the treatment of severe graft-versus 
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host disease (Le Blanc, Rasmusson et al. 2004). Additionally, several groups have already 
demonstrated that the immunosuppressive capacity of MSCs remain even after in vitro 
differentiation (Le Blanc, Tammik et al. 2003; Niemeyer, Seckinger et al. 2004; Niemeyer, 
Krause et al. 2006). This property is very important for tissue engineering procedures and 
HLA-mismatch transplantation. When considering allogenic approach, it is important to 
note that donor age and the disease state of the patient may considerably influence stem cell 
number and quality. Immune privileged MSCs would make it possible to use approved 
MSCs of high quality for transplantation purposes. However, it is important to note that the 
immunemodulating properties of MSCs may provoke potential side effects. In the face of 
allogenic transplantaion, the induced immune suppression may allow local malignant 
growths (Djouad, Plence et al. 2003). Thus, the possible adverse effects of 
immunemodulation caused by allogenic MSCs demand further investigation before these 
cells can be safely translated to the clinical.  
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Flowcytometric analysis of umbilical cord Mesenchymal stem cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 61. Characterisation of umbilical cord Mesenchymal stem cells by flowcytometry. The 
red graphs represent the negative control and the blue is the tested population. (N=4) 
 
Marker % of positive 
cells 
Marker % of positive cells  
CD166 2.34±0.36 CD90 94.41±1.71 
CD73 98.4±0.87 CD105 91.87±3.6 
CD106 0.84±0.91 CD133 0.77±0.97 
CD29 97.6±1.5 CD34 0.2±2.1 
CD44 93.1±1.18 CD45 7.44±4.69 
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Figure 62. Characterization of MSCs for HLA histocompatibility complexes by flowcytometry. 
The cells tested strongly positive for major HLA class I (A,B and C) but were negative for 
minor HLA class I antigen (G) as well as negative HLA  class II (DR and DQ). (N=3) 
 
Marker % of Positive cells  
HLA-ABC 96.57±1.86 
HLA-G 0 
HLA-DR 0 
HLA-DQ 0 
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4.2.2 Expression of embryonic stem cell markers in umbilical cord 
Mesenchymal stem cells  
4.2.2.1 Immunocytochemistry 
 
Undifferentiated umbilical cord MSCs tested positive for Oct4a and Sox-2 by 
immunocytochemistry, but failed to test positive for Nanog (Figure 63).  
4.2.2.2 Flowcytometric analysis  
 
To confirm the presence of these makers we examined these cells by flowcytometry. On 
FACS analysis, the isolated MSCs tested positive for various embryonic markers, including 
TRA-60, TRA-81, SSEA-4, Oct4a as well as Nanog (Figure 64). 
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Expression of Oct4 and Sox-2 in umbilical cord Mesenchymal stem cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oct4a 
Sox-2 
DAPI 
Merge 
Nanog  
Figure 63. Expression of 
embryonic stem cell markers 
in MSCs. (a) Expression of 
Oct4 and Sox-2 in umbilical 
cord Mesenchymal stem cells. 
(b) Mesenchymal stem cells 
tested negative for the 
marker Nanog. Cellular 
nuclei was stained blue with 
DAPI. Red=TxRed, 
Purple=Cy5 and Green= 
FITC Images were taken at a 
magnification of x20. All 
positively stained images were 
acquired by setting negatives 
(secondary antibody only) as 
a control.  
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Flowcytometric investigation of Mesenchymal stem cells for embryonic stem 
cell markers  
 
 
 
 
 
 
 
 
 
 
 
Figure 64. FACS dot plots illustrating the expression of embryonic markers in cord matrix 
derived MSCs. 
 
 
Marker % of positive cells 
TRA-60 2.88% ± 3.22 
Nanog 11.88%±7.44 
TRA-81 2.1%±2.72 
SSEA-4 59.7%±29.19 
Oct-4a 11.82%±11.23 
n=5 
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Conclusions 
 
Human umbilical cord-derived Mesenchymal stem cell-like cells were characterized by 
flowcytometric analysis and expressed most of previously described Mesenchymal stem 
cell markers: CD73, CD29, CD44, CD90 and CD105 
 
These cells tested negative for haematopoietic markers: CD45, CD34 and CD133 
 
MSCs were positive for major HLA class I antigens (A, B and C) but tested negative for 
minor HLA class I antigen (G) and major HLA class II antigens (DR and DQ) 
 
The cells expressed some embryonic stem cells markers: Oct4, Sox2, Nanog, TRA-60, 
TRA-81 and SSEA-4, as noted on immunocytochemistry and flowcytometric analysis  
Chapter 4: Processing of Human Umbilical Cord- Isolation of Mesenchymal Stem Cells  
 
 236 
4.3 In vitro expansion of umbilical cord Mesenchymal stem cells  
Umbilical cord MSCs posed no difficulty to propagation in vitro. Post isolation these cells 
were expanded primarily in Mesenchymal stem cell growth medium (MSCGM) 10% fetal 
bovine serum (FBS) (Invitrogen, 16000-036); MSCGM SingleQuots (Lonza, Cat. no. PT-
4105, Walkersville, MD, USA) formulated in Mesenchymal stem cell basal medium 
(MSCBM) (Lonza, Cat. no. PT-3238, Walkersville, MD, USA) to MSCGM. The media was 
supplemented with Penicillin-streptomycin and Fungizone to evade bacterial and fungal 
contamination. The first medium change was carried out 4 days after initial plating of cells 
to allow the cells adequate time to adhere to the plate forming a monolayer. The cells were 
expanded in MSCGM until the first passaging of cells was undertaken, nearly two weeks 
post isolation (when cells were approximately 80% confluent). The cells were then 
transferred to DMEM-F12 (Gibco, Cat. no. 11039-021) supplemented with 
10% FBS. Penicillin/streptomycin and Fungizone were again added to minimize the chances 
of bacterial and fungal contamination during the prolonged period of proliferation. In this 
culture media the cells underwent 10 successful passages with a doubling time of about a 
week before they reached a stage of growth arrest (Figure 63).  During the period of 
proliferation, the cells acquired the morphology of small very spindly cells with small 
centrally located nuclei. At the stage of cell cycle arrest, a transformation from small spindle 
cells to large flat irregular, occasionally multinucleated cells with wide cytoplasm was 
noted. With regular media changes these cells could be maintained in vitro for several days 
but then gradually showed a decline in cell viability. Interestingly, it was observed that if 
these growth arrested cells were transferred back to Mesenchymal stem cell growth medium 
(MSCGM) (plus supplements) they could be pushed back into proliferation and re-acquire 
the small spindle morphology.  
It may be argued that MSCs demonstrated a better ex vivo expansion and survival than cord 
blood stem/progenitor cells because these cells have been shown to express adhesive ligands 
and soluble factors that support their growth and self-renewal. MSCs have previously been 
used in vitro in co-cultures with unmanipulated cord blood cells and have been shown to 
support haematopoiesis and maintenance of cord blood stem/progenitor cells ex vivo 
(Robinson et al, 2006).  
It must be noted, however, that MSCs from umbilical cord did not produce niche-like 
colonies. This could partly be due to the fact that these cells were a more homogeneous 
population and hence lacked the cellular heterogeneity that is essential for niche formation.  
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Conclusions 
 
Mesenchymal stem cells demonstrated very efficient in vitro proliferation and viability 
 
Mesenchymal stem cell growth medium (MSCGM) (Lonza) was essential for kick starting 
MSC proliferation ex vivo  
 
With prolonged ex vivo expansion in DMEM-F12 10% FBS  MSCs transformed from small 
spindle-shaped cells to large, flat, irregular and occasionally multinucleated cells with wide 
cytoplasm. At this stage the cells were noted to be in cell cycle arrest.  
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Figure 65. Growth curve for human umbilical cord-derived Mesenchymal stem cells during a 6 
week proliferation assay. (a) Six week in vitro proliferation assay for human umbilical cord-
derived MSCs. Average doubling time for the cells was one week . (b) Mitotically active MSCs 
were noted to be small, spindle shaped with small nuclei. Magnification x10 (c) Upon entrance 
into cell cycle arrest, the cells transformed into large, flat, irregular shaped cells with wide 
cytoplasm and were occasionally noted to be multinucleated. Magnification x20. 
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4.4 Cytogenetic analysis post expansion  
Post prolonged ex vivo expansion of Mesenchymal stem cells, cytogenetic analysis was 
undertaken to determine the genetic status of the cells. The cells demonstrated a normal 
karyotype after 14 passages.  
 
P=14 
Figure 66. Karyotype of human umbilical cord Mesenchymal stem cells post prolonged ex vivo 
expansion. N=2 
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4.5 Multi-potential of isolated human umbilical cord Mesenchymal stem cells  
In addition to hepato-bilary differentiation (endoderm), other members of the group were 
able to successfully differentiate umbilical cord-derived MSCs into cells representing the 
other two germ layers: Neuro-glial cells (ectoderm) and cardiac progenitor cells 
(mesoderm).  
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Multipotential characteristic of umbilical cord-derived Mesenchymal stem cells  
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Figure 67. Multipotentiality of umbilical 
cord-derived MSCs. Images taken at 
magnification x10 and x20. Nuclei stained 
blue with DAPI, green= FITC, Red= 
TxRed. Image (b) courtesy of Mr Hamad 
Ali and image (c) courtesy of Dr Christina 
Basford.  
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4.6 Chapter discussion  
One of the goals of this study was to isolate Mesenchymal stem cells from umbilical cord 
samples. We demonstrated this task with 100% efficiency. Manual dissection and transfer of 
umbilical cord pieces into culture media proved more effective than enzymatic digestion of 
umbilical cord samples.  
The isolated MSCs tested positive for most of the markers commonly applied to 
characterize MSCs. These cells tested positive for major HLA class I antigens but were 
negative for HLA class II antigens. Lack of expression of HLA class II identified MSCs as 
being immune priveleged. This feature makes MSCs an attractive candidate for HLA-
independent therapeutic strategies.  
The isolated MSCs were investigated for the expression of some pluripotency factors and 
tested positive for a few ES cell markers. These MSCs demonstrated very efficient in vitro 
proliferation and expansion. Cytogenetic analysis of the cells post expansion demonstrated a 
normal karyotype.  
We further investigated the multi-potential property of these cells. The isolated MSCs were 
able to differentiate into cells representing all three germ layers.  
Thus, it may be concluded that the abundant availability of umbilical cords as a biological 
by-product, the efficiency of isolation and the reproducibility of the manual technique 
applied defines the umbilical cord as a valuable stem/progenitor cell source for regenerative 
medicine.  
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Differentiation of human umbilical cord and cord blood stem/progenitor cells 
towards liver lineage 
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5 Introduction  
This study endeavoured to exploit the multi-potential property of umbilical cord and UCB-
derived stem/progenitor cells to reproduce liver cells ex vivo.  Stimulation with a range of 
hepatic inducting signals resulted in successful commitment of UCB-derived 
undifferentiated stem/progenitor cells and Mesenchymal stem cells along hepatic and biliary 
lineages. A three step protocol encompassing the following stages was applied to effect 
hepatic differentiation from undifferentiated primitive cells:  
 Short-term expansion with meso-endoderm commitment  
 Hepato-bilary differentiation  
 Short-term maturation 
The selected stem/progenitor cell populations have tremendous potential in the management 
and treatment of liver disorders. However, translation from the bench to regenerative 
medicine clinical applications and clinical trials demands certain important concerns to be 
considered. The factors of particular importance include: (1) minimizing in vitro culturing 
time duration, which is important to reduce the risks of bacterial and fungal contamination 
and also to avoid chromosomal abnormalities which have occurred in other stem cell 
populations (Corselli, Parodi et al. 2008); (2) culture systems free of animal products in 
order to diminish zoonosis and the transmission of diseases across species; (3) use of well 
defined media (serum-free) to prevent any effect serum or serum components might have on 
the growth and differentiation pathways (Xu, Peck et al. 2005); (4) development of efficient 
3-dimensional tissue engineering systems incorporating bio-degrable scaffolds. These 
factors constitute the core components of GMP standard and clinical grade tissue 
engineering SOPs (Standard Operational Protocols).   
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5.1 Serum versus serum-free culture systems  
A few research groups have managed to successfully differentiate umbilical cord blood 
stem/progenitor cells and umbilical cord MSCs into hepato-bilary cells. However, the major 
limitation of their techniques was the use of un-defined culture systems that contained 
animal serum and occasionally prolonged ex vivo culture durations, both of which pose 
potential risk for the clinical applicability of these stem cells.  
The system we applied to effect hepato-biliary differentiation of the selected 
stem/progenitor cell populations aimed to abide by the above mentioned GMP standards of 
tissue culture. We used a defined serum-free media during differentiation and maturation 
and a short duration of cell expansion in vitro to minimize the risks of infections and 
chromosomal aberrations. B-27 and N-2 were selected as serum substitutes. Both B-27 and 
N-2 have previously been defined as serum replacements suited for long-term cultures of 
primary embryonic hippocampal and other brain neurons (Brewer 1995). Also, Ali, Jurga et 
al, recently demonstrated successful differentiation of umbilical cord blood stem/progenitor 
cells into neural cells using a defined serum-free culture system (Ali, Jurga et al. 2009). We 
examined the composition of both these media supplements (Table 33 and 34) 
(A.Richardson 2001) . The ingredients did not contain anything that based on literature 
review should be excluded or avoided in hepatic differentiation protocols. Thus we decided 
to use both B-27 and N-2 as serum replacements in our defined serum-free differentiation 
and maturation culture systems.   
During the one week expansion of cells, media was supplemented with FBS 5%. This was 
carried out taking into account that physiologically blood is composed of 55% plasma in 
which the cells circulate. Thus, to avoid rapid changes in the microenvironment of cells, we 
decided to gradually introduce the cells to a serum-free environment. Additionally, serum 
would potentially enhance attachment of cells during initial seeding in culture plates.  At the 
end of expansion, half of the media was replaced with our defined serum-free differentiation 
medium. The culture medium was refreshed on alternate days, every time replacing 50% of 
the old media with fresh serum-free medium, until eventually reaching 0% FBS by day1 of 
maturation.  
Conclusion  
 
A defined serum-free differentiation medium was formulated by replacing serum 
with B-27 and N-2 supplements.  
Serum levels were gradually tapered by transferring cells from low-serum expansion 
medium to serum-free differentiation medium.  
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Table 33. Composition of B-27 supplement  
Components  Final mg/dl  
Hormones 
Corticosterone  0.02 
Progesterone 0.0063 
Retinol, acetate  0.1 
Insulin  4.0 
T3 (triodo-L-thyronine) 0.002 
Vitamins  
Biotin  0.10 
Antioxidants  
D, L-α-Tocopherol (Vit.E) 1.0 
D, L-α-Tocopherol acetate 1.0 
Catalase 2.5 
Glutathione (reduced) 1.0 
Superoxide dismutase 2.5 
Others  
L-Carnitine  2.0 
Ethanolamine  1.0 
Putrescine  16.1 
Selenium  0.016 
Linolenic acid  1.0 
Linoleic acid  1.0 
Albumin, bovine  2500.0 
Transferrin  5.0 
(A.Richardson 2001)  
(Wachs, Couillard-Despres et al. 2003) 
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Table 34. Composition of N-2 supplement 
Component Final mg/L 
Insulin (bovine) 5mg/L 
Progesterone 20nM 
Putrescine  100µM 
Na selenite  30nM 
Transferrin (human) 100mg/L 
(A.Richardson 2001) 
(Wachs, Couillard-Despres et al. 2003) 
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5.2 Hepato-biliary differentiation culture system in vitro  
5.2.1 Introduction 
During embryonic development, early liver formation from embryonic endoderm requires a 
series of inductive signals from at least three different mesodermal cell types. Induction of 
hepatic genes requires fibroblast growth factor (FGF) signaling from the adjacent 
cardiogenic mesoderm, bone morphogenic protein (BMP) signaling from nearby septum 
transversum mesenchyme and interaction with endothelial cells (Schmidt, Bladt et al. 1995; 
Jung, Zheng et al. 1999; Duncan 2000; Duncan 2003; Lemaigre and Zaret 2004). When 
hepatic endoderm is specified and the liver bud begins to grow, the cells are referred to as 
hepatoblasts. These hepatoblasts are bipotent cells and eventually give rise to definitive 
hepatocytes and bile duct epithelial cells (cholangiocytes). Hepatoblasts have a phenotype, 
intermediate between hepatocytes and cholangiocytes. During and after the mid-stage of 
hepatogenesis, surrounding Mesenchymal cells secrete HGF and support the foetal 
hepatocytes (Kinoshita and Miyajima 2002; Zaret 2002). At the developmental phase where 
liver becomes the major site for haematopoiesis, haematopoietic stem cells produce 
Oncostatin M, that in the presence of circulating glucocorticoids promotes hepatic cell 
differentiation and maturation and simultaneously suppresses embryonic haematopoiesis 
(Schmidt, Bladt et al. 1995; Kinoshita and Miyajima 2002; Zaret 2002).  
Post development and in adult life hepatoblasts are replaced by progenitor cells which form 
a reserve cell compartment, also called ‘progenitor cell compartment’, and reside in the 
smallest and most peripheral branches of the biliary tree, the ductules and canals of Hering 
(Roskams, Theise et al. 2004). These canals represent the anatomical and physiological link 
between the parenchyma (intra-lobular canalicular system of hepatocytes) and the portal 
tract mesenchyme (the biliary tree). This reserve compartment is activated when the mature 
epithelial cell compartment of the liver are damaged or inhibited in their replication. 
5.2.2 Formulated differentiation system applied in this study   
The differentiation system applied in this study reflected analogy to mechanisms involved in 
normal mammalian liver development. Additionally, the three-step protocol was deduced 
after extensive literature review into culture systems previously reported to have been 
successful in differentiation of stem/progenitor cells into hepato-biliary cells. The sequential 
approach for the introduction of cytokines to the culture system applied  was  not innovative 
in this field, groups like Snykers et al and others  have tested its effectiveness before (Lee, 
Kuo et al. 2004; Hong, Gang et al. 2005; Chien, Yen et al. 2006; Ong, Dai et al. 2006; 
Snykers, Vanhaecke et al. 2006; Talens-Visconti, Bonora et al. 2006; Yoshida, Shimomura 
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et al. 2007; Campard, Lysy et al. 2008; Kazemnejad, Allameh et al. 2008; Lysy, Campard et 
al. 2008).  
We were able to generate stem cell colonies from UCB similar to the liver ‘stem cell niche’ 
described by Roskam (Roskams 2006) using exogenous differentaiting cues that mimic 
physiological conditions needed for liver development. 
 It has been shown that exogenous FGF and HGF could mimic the hepatic inductive effects 
of cardiogenic mesoderm (Kakinuma, Tanaka et al. 2003; Lee, Kuo et al. 2004; Kang, Kim 
et al. 2005; Kang, Zang et al. 2005; Kang, Zang et al. 2005; Baharvand, Hashemi et al. 
2006; Kang, Zang et al. 2006; Hay, Zhao et al. 2007) . Acidic-FGF (aFGF or FGF1) has 
been shown to constitute autocrine and paracrine regulation of liver development (Kan, 
Huang et al. 1989). Acidic FGF is protein of the FGF family. A-FGF shares 55% DNA 
sequence homology with Basic FGF. These two growth factors are ubiquitously expressed 
and exhibit a wide spectrum of similar biological activities with quantitative differences 
likely due to variation in receptor affinity or binding  (Ledoux, Gannoun-Zaki et al. 1992). 
A-FGF interacts with all 4 FGF receptors. It is known that FGF is essential for the induction 
of endoderm towards liver lineage (Kawasaki, Tamura et al. 2005).  Mouse embryonic stem 
cells grown in medium supplemented with FGF could differentiate into cells expressing 
hepatocyte-specific genes and antigens (Kan, Huang et al. 1989; Jung, Zheng et al. 1999; 
Ruhnke, Ungefroren et al. 2003).  
HGF was first identified as a blood-derived mitogen for hepatocytes. HGF is a ligand of 
tyrosine kinase c-Met (Limaye, Bowen et al. 2008).  HGF and its receptor c-Met are the key 
factor for liver growth and function and its actions are brought about through induction of 
all members of the TGF-β family (Michalopoulos, Bowen et al. 2003).  
In addition to FGF and HGF, epidermal growth factor (EGF) was introduced later in the 
culture system. EGF is a ligand of tyrosine kinase receptor EGFR (Limaye, Bowen et al. 
2008). EGF has been reported to increase the expression of all liver-specific genes and 
stimulates differentiation of foetal liver epithelial cells (Kawasaki, Tamura et al. 2005).  
Akaike et al, reported that EGF signaling was mediated through integrins. They noted that 
primary hepatocyte cultures only proliferated when cultured on collagen (an integrin) matrix 
(Kim and Akaike 2007). Thus, we used collagen IV in our differentiation and maturation 
medium. Previous reports have noted that EGF on its own and in association with HGF and 
dexamethasone induces biliary epithelial formation (Michalopoulos, Bowen et al. 2003; 
Limaye, Bowen et al. 2008). All three factors induce HNF-6 expression, which is important 
in biliary epithelial development.   
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 Initial endoderm commitment of UCB-derived stem/progenitor cell populations was 
achieved using TPO, SCF, acidic-FGF and HGF in low-serum (5% FBS) culture conditions 
for a week. This was followed by differentiation using by a cocktail of acidic-FGF, HGF 
and EGF in serum-free culture conditions which allowed for tapering of serum levels to 
achieve an ultimate serum-free system.  
Umbilical cord derived MSCs, in addition to illustrating very efficient propagation in 
DMEM-F12 and viability in vitro, also demonstrated markers specific to all three germ 
layers at day 0, i.e. in their undifferentiated state post isolation (Figure 71).  Hence, 
endoderm induction of these cells was unnecessary. The aim, however, was to enhance and 
increase the expression of endodermal and liver specific markers in these cells during the 
period of differentiation and maturation.  
 Post cell differentiation we were able to generate bipotent liver progenitor cells from both 
UCB-derived stem/progenitor cells and MSCs. Our findings validated results of previous 
work done in this area (Lee, Kuo et al. 2004; Kang, Zang et al. 2005; Kang, Zang et al. 
2005; McGuckin, Forraz et al. 2005). In addition to bipotent progenitors a heterogenous 
population of liver cells were also noted. Cells displayed a range of phenotypes from 
hepatocytes to biliary epithelail cells. The presence of EGF in the culture induced 
simultaneous biliary epithelial cell development. This action was synergistically enhanced 
by the introduction of corticosteroid (dexamethasone) during the subsequent maturation 
phase of the protocol.  
Maturation of umbilical cord and UCB-derived hepatocyte progenitors was achieved using a 
combination of dexamethasone and Oncostatin M. Oncostatin M is a member of the 
interleukin 6 family cytokines and was originally identified by its ability to inhibit growth of 
A375 melanoma cells (Zarling, Shoyab et al. 1986). Later studies showed that primary 
cultures stimulated with oncostatin M showed a progression of hepatocytic development 
towards maturation (Kamiya, Kinoshita et al. 1999; Kinoshita, Sekiguchi et al. 1999; 
Miyajima, Kinoshita et al. 2000). Dexamethasone, by itself, suppresses growth and induces 
maturation of cells exclusively towards hepatic lineage. This action is exhibited through 
suppression of Il-6, CXC-chemokine receptor, amphiregulin, COX-2 and HIF; and 
induction of HNF4 and C/EBPα expression, both transcription factors needed for hepatocyte 
differentiation (Michalopoulos, Bowen et al. 2001; Michalopoulos, Bowen et al. 2003). But, 
in combination with HGF and EGF, it induces biliary epithelial formation.  
 In the presence of maturation inducers, retraction of the elongated end of MSCs membranes 
was observed and the polygonal morphology of hepatocyte-like cells became more apparent 
with increased length of culture (Figure 71).  Under similar hepatogenic conditions the 
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rounded morphology of UCB-derived colony cells gradually progressed towards the 
polygonal morphology of hepatocytes in a time-dependent manner and became apparent by 
2 weeks post-differentiation (Figure 70) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
 
Short-term ex vivo expansion and simultaneous endoderm commitment of UCB-
derived stem/progenitor cells was executed before exposing the cells to 
differentiation 
 
Umbilical cord MSCs already illustrated commitment to hepatobiliary lineage 
post isolation and hence stimulation of endoderm commitment during ex vivo 
expansion was not necessary.   
 
 The differentiation culture system was designed to further differentiate the 
endoderm committed cells towards hepato-biliary progenitor cells (hepatoblasts) 
with inclination towards hepatocyte differentiation primarily.   
 
The presence of EGF in the culture system induced simultaneous biliary 
epithelial cell formation. This action, however, was synergistically enhanced by 
the introduction of dexamethasone during maturation.  
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5.3 Temporal significance of cytokine introduction in the differentiation 
system  
Liver development is accomplished by a sequential array of biological events, although it is 
important to note that overlap between the stages is greatly possible. Phenotypic 
transformations during liver development are preceded by a chronological cascade of 
molecular events that are tightly regulated and determine the ultimate fate of cells. Various 
extracellular signals, including cytokines and growth factors, as well as cell autonomous 
mechanisms are involved in this sequence of events. The cytokine, EGF, demonstrated this 
phenomena during our ex vivo differentiation protocol.  
Early introduction of EGF in the culture system, i.e. during expansion, resulted in 60% of 
the cells expressing markers of ectodermal lineage (Nestin and GFAP).  Additionally cells 
demonstrated neuronal-like morphology.  In the absence of EGF, however, the expression of 
these markers was minimal post expansion and the cells illustrated a more rounded 
morphology with propensity towards aggregate formation, cell density allowing (section 
3.6, Figure 57). This illustrated that early introduction of EGF favoured ectoderm lineage 
commitment ex vivo. However, when EGF was added to the media later in the protocol, i.e. 
during differentiation, it provided signaling cues that enhanced hepato-biliary 
differentiation.  
To study the influence of EGF on hepato-biliary differentiation in vitro two parallel 
identical differentiation experiments (week one of the differentiation protocol) were set up 
with the only deferring factor being the presence or absence of EGF.  Post differentiation the 
corresponding cells were examined by immunocytochemistry and at the mRNA level. 
Although the cells failed to demonstrate remarkable phenotypic differences on 
immunocytochemistry examination, interesting differences were noted on molecular 
examination.   
In the absence of EGF (media supplemented with aFGF and HGF as well) UCB 
stem/progenitor cells demonstrated an up regulation in genes associated with hepatocyte 
progenitor (Gata-4, CLDN2) and hepatoblast (AFP) phenotypes. The cells also expressed 
some CYP genes at this stage. In paralleling EGF supplemented experiment no Gata-4 and 
AFP expression was detected and CLDN2 was measured at a lower level. CYP genes if 
detectable were expressed at lower levels as well (Section 5.4.7, Figure 85-88). In 
comparison, when EGF was introduced into the media at a later stage in the differentiation 
protocol (week two) a different gene expression profile was noted. Endodermal marker, 
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Gata-4, was no longer detectable; hepatic stem cells marker, CLDN2, was down regulated 
and hepatoblast related genes, HNF4α and AFP, were up regulated. Some CYP genes were 
no longer expressed, whilst others showed an increase in expression.  
Here we have shown that early introduction of EGF into the culture media does not enhance 
hepatocyte differentiation of cord blood stem/progenitor cells. On the other hand, 
supplementation of the differentiation system with EGF at later stage (after initial 
hepatocyte progenitor induction) favours further hepatocyte development and maturation. It 
has previously been reported that bile epithelium formation is dependent on EGF 
(Nishikawa, Doi et al. 2005) and here we demonstrate that EGF signalling early in 
hepatocyte differentiation system does not favour hepatocyte formation.  
MSCs responded differently to the presence of EGF in vitro.  Early introduction of EGF into 
the differentiation system resulted in an up regulation of hepatocyte progenitor genes 
(CLDN2 and HNF4α) and down regulation of CYP genes. In contrast, later introduction of 
EGF during week two of differentiation was associated with down regulation of CLDN2 
and AFP whilst HNF4α and all the studied CYP genes were up regulated (Section 5.4.7, 
Figure 85-88) illustrating a more mature hepatocyte phenotype. In appears that in MSC 
cultures early influence of EGF signalling pathway caused either dedifferentiation of cells 
already committed to hepatobiliary fate causing them to revert to a more primitive hepatic 
stem cell phenotype, or stimulated hepatocyte differentiation towards biliary epithelial cells 
through a transdifferentiation mechanism. If this phenomenon were proven to be true it 
would demonstrate phenotypic plasticity of hepatocytes in vitro. However, more work needs 
to be carried out to enable a better understanding of the role of EGF in hepato-bilary 
differentiation. 
 Here we have shown that although EGF plays a pivotal role in hepato-bilary differentiation,  
the determination of the exact time of cytokine introduction into the differentiation protocol 
is of prime importance.  
Likewise, introduction of maturing factors, dexamethasone and Oncostatin M during 
differentiation, would expectedly hinder the activated differentiation pathways and cause 
premature maturation of cell in culture.   
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Conclusion  
 
The timing of EGF introduction into the differentiation medium was of prime 
importance. 
 
Early introduction of EGF during expansion promoted cells to commit along 
ectoderm lineage. 
 
Later introduction of EGF into the differentiation medium (after endoderm 
commitment) promoted differentiation towards hepatobiliary epithelial cells.  
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In vitro characterization assays on differentiated cells was performed at regular intervals 
post induction and the results are noted in the sections below. 
5.4 Periodic analysis of stem/progenitor cells during differentiation  
One of the challenges of identifying and characterizing non-liver derived hepato-bilary 
cellular populations in vitro is the lack of definite cell markers to classify these cells. Taken 
individually the markers that are frequently used for hepatocyte characterization are not 
limited to the liver. Studies have shown expression of cytokeratins, often used for hepato-
bilary characterization, have also been detected in the gastric cardia, the lung, the skin and 
in the umbilical cord. For example, Ck18, commonly used as a mature hepatocyte marker, 
was observed in the lung. Ck8, also a mature hepatocyte marker, is apparently one of the 
most expressed genes in umbilical cord MSCs. Furthermore, mRNAs for albumin, AFP and 
α-1AT (Alpha-1Antitrypsin) were detected in human pancreas. Cytochrome 3A4 has 
recently been identified in the brain (Robertson, Field et al. 2003). Consequently, we 
decided to use a combination of markers to characterize our umbilical cord and cord blood-
derived differentiated stem/progenitor cells. 
5.4.1 Phenotypic analysis during UCB-derived stem/progenitor cellular 
colony differentiation 
After 1 week of ex vivo expansion, UCB-derived primitive cells were stimulated with a 
range of differentaitive hepatic cues for 2 weeks. Cells were examined and images taken at 
different stages of differentiation and maturation.  Results demonstrated that initial exposure 
to differentiating signals caused a reduction in the size of the cellular aggregates (Figure 68a 
and b). This phenomenon was probably due to the fact that not all cells are able to withstand 
the drastic change in the culture conditions and underwent apoptosis (programmed cell 
death). The ‘niche-like’ structures appeared to be more tolerant to the change in culture 
conditions. With increased length in culture during differentiation, the cell clusters increased 
in size and demonstrated a heterogeneous population of cells that probably function in a 
synergistic way to provide signals that determine the fate of stem cells (Figure 68c).  We 
noted that the small rounded cells were positioned centrally and were surrounded by 
spindle-shaped cells that occasionally overlay large multinucleated osteoclast-like cells 
(Figure 68c and d). These structures were similar to the niches described by Sun et al, 2007; 
rounded cellular colonies formed on large multinuclear cells (osteoclast-like cells), 
surrounded by spindle-shaped cells. With differentiation the cells displayed an increase in 
size and cytoplasmic granularity (Figure 68c). Contact with maturation inducers caused a 
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further increase in size with an increase in nucleus to cell size ratio and cells began to take 
on a polygonal phenotype (Figure 68d). These UCB-derived cells did not survive in vitro 
after 2 weeks of ex vivo differentiation and maturation. 
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Figure 68. DIC images of UCB-derived stem 
cell colonies at different stages of the 
differentiation protocol. (a and b) UCB 
stem/progenitor cell colonies after expansion. 
(b) An initial loss in colony size post exposure to 
differentiation medium. (c and d) During 
differentiation cells retained their rounded 
morphology but demonstrated an increase in 
nuclear to cell size ratio. Differentiated colonies 
were supported by large multinucleated 
osteoclast-like cells (♣) on which the colonies 
were assembled and surrounded by occasional 
spindle shaped cells. Introduction of maturation 
factors  resulted in a further increase in cell size 
and the appearance of polygonal cellular 
morphology. (e) The differentiated colonies 
failed to survive ex vivo more that 2 weeks. 
Apoptosis of the large supporting osteoclast-like 
cells preceded eventual loss of the differentiated 
colonies.  Images were taken at magnifications 
of x5, x10 and x20. UCB (Umbilical cord blood) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     (a)       Day 1 
 (b)        Day 7 
 (c)      Day 10 
   (d)     Day 14 
(e)   Day 16 
 
 
♣ 
Post ex vivo expansion and 
endoderm commitment  
Post 1 week ex vivo differentiation  
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5.4.2 Phenotypic analysis during umbilical cord-derived MSC differentiation  
After ex vivo expansion, UC-derived MSCs were stimulated with a similar range of 
differentaitive hepatic and biliary cues for 1 week and then transferred to maturation 
medium for a further 1-4 weeks. Cells were checked and images taken at different stages of 
differentiation and maturation. Results demonstrated that initial exposure to differentiating 
signals caused a reduction in cell confluency (Figure 67a and b). This phenomenon was 
probably due to the fact that not all cells were able to withstand the drastic change in the 
culture conditions from expansion to differentiation and underwent apoptosis. The cells that 
did survive were the ones that went on to differentiate into hepatic progenitors.  With 
differentiation MSCs illustrated a phenotypic transformation. Retraction of cellular 
appendages was noted and cells demonstrated a transformation in morphology from spindle 
shape to polygonal shape (Figure 69b and c). These transformed cells were noted to form 
dense cellular aggregates surrounded by the yet untransformed spindle shaped MSCs 
(Figure 69c). These MSCs did not display a change in morphology most likely due to lack 
of response to differentaitive signals in culture. With introduction of maturation factors and 
prolonged culture duration these untransformed cells eventually underwent apoptosis. 
Additionally, the cells in the cellular aggregates displayed a more pronounced polygonal 
morphology (Figure 69d) with increased cellular granularity and appearance of 
intracyplasmic inclusion bodies (Figure 69e and f) which may be interpreted as a sign of 
increased metabolic activity. The MSCs were a lot more robust in culture and were able to 
endure the in vitro culture environment for much longer. We were able to maintain these 
cells in culture for 4-5 weeks.  
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Figure 69. DIC images of UC-derived MSC 
cells at different stages of the differentiation 
protocol. (a and b) Exposure to hepatocyte 
differentaitive signals was associated with a 
slight initial loss in cell confluency. (b) Cells 
were exposed to differentiating factors for 1 
week. At the end of differentiation cells 
displayed a noticeable change in 
morphology. Retraction of appendages and 
appearance of polygonal contour could be 
appreciated. (c) Introduction of maturation 
factors was associated with aggregation of 
transformed cells into cellular colonies 
surrounded by untransformed spindle 
shaped MSCs. (d-f) The cells were 
maintained ex vivo in maturation medium 
for 3 weeks.  Prolonged culture during 
maturation resulted in eventual reduction 
in the size of aggregated cellular masses and 
appearance of intracytoplasmic granules 
and inclusion bodies were noted. Images 
were taken at magnifications of x5, x10 and 
x20 
     (a)           Day 1 
  (b)            Day 7 
 (c)           Day 14 
(d)        Day 21 
  (e)          Day 28 
   (f)         Day 35 
Post ex vivo expansion  
Post 1 week ex vivo 
differentiation  
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5.4.3 Antigenic analysis- immunocytochemistry on differentiated UCB-
derived stem/progenitor cells  
The differentiated stem/progenitor cells were examined for a number of liver related 
proteins by immunocytochemistry. 
Differentiated cells exhibited expression of both albumin and AFP. Albumin is one of the 
earliest hepatic markers. AFP is closely related to albumin both genetically and structurally 
and is normally expressed in the foetal liver. As albumin synthesis increases during later 
foetal development, AFP concentrations begin to decline, reaching a trace concentration. 
Further characterization of differentiated cells was performed by using cytokeratins. These 
intermediate filament proteins are cytoplasmic structural proteins represented in human 
epithelial tissues by at least 20 different polypeptides. They range in molecular weight 
between 40 kDa and 68 kDa. The individual human cytokeratins are designated 1 to 20. The 
various epithelia in the human body usually express cytokeratins which are not only 
characteristic of the type of epithelium, but also related to the degree of maturation or 
differentiation within an epithelium. Therefore cytokeratins are considered to serve as good 
lineage markers in identifying epithelia and in tracing cell-of-origin in tumours. Differences 
in the expression of cytokeratins subtypes between human hepatocytes and biliary cells have 
been well studied (Osborn, van Lessen et al. 1986; Ramaekers, Huysmans et al. 1987; Van 
Eyken P 1987). Hepatocytes express Ck-8 and -18, and intrahepatic bile duct epithelial cells 
also express these, in addition to Ck-7 and -19. Ck-7, -8, -18 and -19 were used to 
characterize differentiated cells in this study. Ck-7 is expressed in hepatic stem cells and  in 
bile ductular epithelial cells and is often co-expressed with Ck-19 (Sasaki, Nio et al. 2001). 
Ck-19 is expressed by bi-potential hepatic progenitor cells but is lost as these cells 
differentiate along hepatic lineage. However, expression of Ck-19 should be persistent when 
progenitor cells develop along biliary epithelium (Haque, Haruna et al. 1996). Ck-19 is 
expressed in immature as well as remodeled bile duct cells (Sasaki, Nio et al. 2001).. Sasaki 
et al reported that Ck-20 is another keratin detected only in developing bile duct cells in 
human foetal liver and is absent in late foetal stages (Sasaki, Nio et al. 2001).  
Results obtained indicated that the differentiated cells from UCB were liver progenitor cells, 
expressing Ck-7, Ck-8 and Ck-18 and low levels of Ck-19 post differentiation and 
maturation ex vivo (Figure 70). These findings suggest that differentiated cells can be 
characterized as bi-potential hepatic progenitors expressing both hepatocyte and biliary 
cytokeratins but not yet fully committed to either lineage. These cells were predominantly 
located in the centre of the niches. These cells are similar in morphology and 
immunophenotype to the ‘intermediate cells’ described by Roskam and the ‘small 
Chapter 5: Differentiation of Human Cord and Cord Blood Stem/Progenitor Cells Towards Liver Lineage 
 261 
hepatocytes’ characterized by Kon et al (Kon, Ooe et al. 2006; Roskams 2006). The so-
called ‘small hepatocytes’ are a sub-population of rat hepatocytes that have a high growth 
potential in culture and are two times smaller than normal mature hepatocytes, expressing 
both hepatocytic and biliary characteristics. The importance of the society of liver cells was 
also demonstrated in our culture system by the fact that once the surrounding supporting 
cells of the niche were loss some of the centrally located differentiated stem cells escaped 
from the colony and became suspended in the medium or underwent apoptosis. 
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Immunocytochemistry of 2 week differentiated UCB-derived stem/progenitor cells  
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Figure 70. Confocal images of 
UCB-derived stem/progenitor 
cells post differentiation and 
maturation.. The cells tested 
positive for Albumin, AFP, 
and cytokeratins: Ck-7, Ck-
19, Ck-8 and Ck-18, vimentin, 
CPS1, receptors: LDLR and 
HGFR, Gata-4, embryonic 
marker Sox-2 and weakly 
positive for GFAP. All nuclei 
were stained with DAPI. 
Blue=DAPI (4, 6-diamidino-
phenylindole dilactate), 
green=FITC, red=TxRed, 
magenta=Cy5. Co-
expression= yellow.  Images 
were taken at magnification 
of x10 x40. All images were 
taken against negatives 
(secondary antibody only-
stained cells) which were used 
to set the threshold for 
positive staining.  
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5.4.4 Antigenic analysis- immunocytochemistry on differentiated umbilical 
cord-derived Mesenchymal stem cells  
Characterisation of Mesenchymal stem cells indicated that these cells already displayed 
signs of lineage commitment upon isolation. These cells already expressed some hepatic 
markers exhibiting a partial hepatocyte identity. This suggested hepatogenic potency of 
umbilical cord MSCs. MSCs also tested positive for expression of some embryonic stem 
cell markers and illustrated capacity to differentiate into tissues representing all three germ 
layers. Therefore, it might be safe to assume that these cells occupy a lower position in the 
stem cell hierarchy and must be best referred to as progenitor cells with multipotent capacity 
rather than pluripotent stem cells.  
In addition to testing positive for some liver markers at day 0: albumin, Ck-7, Ck-8, Ck-18, 
CPS1 and Gata-4, undifferentiated MSCs also tested positive for markers of other germ-
layer specific tissues, such as nestin and TUJ (ectodermal) and Nkx2.5 and myocardin 
(mesoderm) (data generated by other members of the group and not shown here). It is 
interesting to note that at day 0 MSCs failed to illustrate expression of AFP, LDLR and 
HGFR.  
The aim of the differentiation protocol was to try to amplify the expression of liver markers 
and down regulate expression of other germ layer markers. Nestin was used as an 
ectodermal marker during immunocytochemistry analysis.  
MSCs were analysed at weekly time points during the three week differentiation and 
maturation protocol. At the end of the first week of differentiation the cells showed an 
increase in the expression of: gata-4 (endodermal marker), albumin (hepatocyte marker), 
Ck-18 (hepatocyte marker) and Ck-19 (hepatic stem cell marker; expression of which 
persists when cells differentiate along biliary epithelium lineage). Expression of Ck-8 
(hepatocyte marker), Ck-7 (hepatic stem cell marker) and nestin (ectodermal marker) was 
reduced. Cells tested negative for AFP (hepatoblast marker), LDLR and HGFR (Figure 71 
and 72). At this stage the antigenic profile of cells showed an increase in the expression of 
some liver markers and demonstrated a heterogeneous liver cell population with propensity 
towards hepatic stem cell phenotype.  
Analysis of the same antigens post two weeks of differentiation and subsequent to 
introduction of maturation markers illustrated the following changes: further increase in the 
expression of albumin, Ck-18 and Ck-19. Expression of Ck-8 also showed an increase at 
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this stage. Expression of gata-4 and CPS1 appears unchanged. Ck-7 was not expressed and 
nestin showed a significant down regulation. AFP, LDLR and HGFR were still negative at 
this stage (Figure 71 and 72). Again antigenic analysis illustrated a heterogeneous 
population consisting of a lower percentage of hepatic stem cells (demonstrated by 
reduction in Ck-7 expression), mature hepatocytes (albumin, Ck-8, Ck-18 and CPS1) and 
biliary epithelium progenitors (albumin, Ck-18, Ck-8 and Ck-19).  
Analysis at week three after prolonged exposure to differentiation and maturation factors 
was associated with remarkable changes in cellular phenotype.  The cells were no longer 
homogenously spindle shaped and in monolayer.  Cellular aggregates of polygonal cells 
surrounded by spindle shaped cells were noted.  The expression of markers in the cells was 
notably different than the previous phases of culture. Expression profiles were no longer 
uniform and generalized. The intensity of expression of albumin in the cells remained the 
same. AFP, which was not expressed earlier, was detected at this stage. The expression 
pattern of this marker, however, was not uniform in the cells. Only the cells located in the 
centre of the cellular masses tested positive for this marker. Ck-7 expression was strikingly 
up regulated at this stage and once again the expression was localized to cells in the centre 
of the cellular aggregates. Ck-8 expression was unchanged compared to week two but was 
only detected in spindle shaped cells situated at the peripherally of the cellular masses. 
Again, Ck-19 expression was not noticeably different than week two but was focused in the 
centrally positioned cells surrounded by Ck-18 positive cells. CPS1 expression was up 
regulated as well. LDLR and HGFR, which were negative thus far, were expressed at this 
stage. Nestin expression was absent at this phase of the protocol demonstrating commitment 
of cells to meso-endodermal lineage and not ectodermal lineage (Figure 71 and 72).  
At week three, cells displayed ‘niche-like ‘structures composed of a heterogeneous cellular 
population. Cells located at the centre of the niches displayed characteristics of primitive 
progenitor cells: small, rounded and illustrated high expression of albumin, Ck-7 and Ck-19 
(hepatic stem cell markers) and AFP (hepatoblast marker). Once again, these cells could be 
compared to the ‘intermediate cells’ described by Roskam and the ‘small hepatocytes’ 
characterized by Kon et al (Kon, Ooe et al. 2006; Roskams 2006). Cells at the periphery of 
the niches tested positive for more mature markers: Ck-8 and Ck-18 (hepatocyte markers). 
Although gata-4 expression was still present, the intensity of expression was reduced 
compared to earlier stages.  
It could concluded that at the end of the protocol we generated a heterogeneous population 
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of liver cells, with progenitor cells (hepatic stem cells and hepatoblasts) located at the centre 
of the niches, surrounded by more mature cells. In our culture system these cells displayed 
characteristics of mature hepatocytes (Ck-8, Ck-18, CPS1, LDLR, and HGFR). Although, 
biliary epithelium progenitor cells were present in culture (Ck-19 and Ck-7 positive cells), 
our formulated culture system supported preferred commitment along hepatocyte lineage 
rather than cholangiocytes.   
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Figure 71a. Expression of hepatic and biliary markers at different stages of Mesenchymal stem 
cell differentiation ex vivo. Day zero (post expansion), day 7 (one week post differentiation), 
day 14 (one week post maturation), day 21 (two weeks post maturation). Confocal images were 
obtained at magnification x10 and x20. Cellular nuclei have been stained blue with Dapi (4’, 6-
diamidino-phenylindole dilactate). AFP, Ck-7 and Ck-19 were stained magenta with Cy5. 
Albumin, Ck-7 and Ck-18 were stained green with FITC. Dual staining (co-expression) is 
represented by yellow staining. All images were taken against negatives (secondary antibody 
only-stained cells) which were used to set the threshold for positive staining.  
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Immunocytochemistry of differentiated UC-derived MSCs 
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Figure 71b. Expression of hepatic and biliary markers at different stages Mesenchymal stem 
cell differentiation ex vivo. Day zero (post expansion), day 7 (one week post differentiation), 
day 14 (one week post maturation), day 21 (two weeks post maturation). Confocal images were 
obtained at magnification x20. Cellular nuclei have been stained blue with Dapi (4’, 6-
diamidino-phenylindole dilactate). Vimentin and LDLR were stained red with TxRed. CPS1, 
HGFR and gata-4 were stained green with FITC. Sox-2 was stained magenta with cy5. Dual 
staining (co-expression) is represented by yellow staining. All images were taken against 
negatives (secondary antibody only-stained cells) which were used to set the threshold for 
positive staining.  
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Figure 72. Expression of Nestin and GFAP at 
different stages of Mesenchymal stem cell 
differentiation ex vivo. Day zero (post expansion), 
day 7 (one week post differentiation), day 14 (one 
week post maturation), day 21 (two weeks post 
maturation). Confocal images were obtained at 
magnification x20. Cellular nuclei have been 
stained blue with DAPI (4’, 6-diamidino-
phenylindole dilactate). GFAP was stained red 
with TxRed. Nestin was stained green with 
FITC. All images were taken against negatives 
(secondary antibody only-stained cells) which 
were used to set the threshold for positive 
staining.  
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5.4.5 Positive controls for immunocytochemistry 
To verify the quality and scope of our ex vivo differentiation system positive controls were 
considered essential. We were able to get hold of three types of cells that have previously 
been used as positive controls in hepatocyte differentiation protocols: 
- HepG2 cell-line 
- Normal foetal liver parenchyma at 9 weeks of gestation (tissue sections on slides) 
- Normal adult liver parenchyma (tissue sections on slides) 
All three cell types were used as controls for immunocyto/histochemistry. Positive control 
for functional analysis of differentiated cells was restricted to HepG2 cell-line. 
 
5.4.5.1 HepG2 
The HepG2 cell line has been isolated from a liver biopsy of a male Caucasian aged 15 
years, with a well differentiated hepatocellular carcinoma. These cells are epithelial in 
morphology, have a model chromosome number of 55 and are not tumorigenic in nude 
mice. The cells secrete a variety of major plasma proteins e.g. albumin, alpha 2-
macroglobulin, alpha 1-antitrypsin, transferrin and plasminogen. They have been grown 
successfully in large scale cultivation systems. HepG2 cells are used routinely for a variety 
of biochemical and cell biological studies, including studies of hepatocyte functions. HepG2 
is the most commonly used cell line for examining the regulation of hepatic protein 
synthesis by cytokines. In this study HepG2 cell line was used as a control for the UCB- and 
umbilical cord-derived differentiated liver cells. All the investigations performed on our 
tested cell populations in culture were repeated on the HepG2 cell line for comparison.  
HepG2 cells were kindly provided by Catherine Mowbray and Professor Barry Hirst 
(Institute of Cell and Molecular Biosciences, Newcastle University, Newcastle upon Tyne, 
UK). The cells provided were at passage 69. We sub-cultured the cells in a well defined 
medium composed of DMEM-F12 supplemented with 10% FBS and penicillin/streptomycin 
and fungizone only. Samples were cryopreserved and subsequently thawed and re-cultured 
for all further analysis during the course of this study. One characteristic of these cancer 
cells was to form mounds or piles during ex vivo expansion. This phenomenon is due to the 
reduction in cell-cell and cell-extracellular matrix adhesion that allows masses of cells to 
form. Cancer cells do not exhibit contact inhibition and thus are able to continue growing 
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even when surrounded by other cells. This alteration in cell adhesion also facilitates cancer 
cells to move and migrate in order to metastasize.  
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
a b 
c 
x40 
Figure 73. HepG2- well differentiated hepatocellular carcinoma culture. (a) A confluent low 
magnification image of HepG2 cells in culture. The cells have a tendency to form piles or mounds as 
they grow (b), rather than growing as monolayers and even when they get confluent, the cell are still 
very piled-up. (c) High magnification image of an individual cell exhibiting classical hepatic cell 
morphology: polygonal and a high nucleus to cytoplasmic ratio and increases granularity. DIC 
images were acquired at magnification of x10, x20 and x40.  
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Antigen analysis of HepG2 cells by immunocytochemistry  
HepG2 cells were examined for the same antigens as UCB- and umbilical cord cells. These 
cells tested positive for all the studied liver markers: Gata-4, albumin, AFP, Ck-7, Ck-8, Ck-
18, Ck-19, HGFR, LDLR, CPS1 and vimentin.  These cells were also positive for 
embryonic markers: Oct4, Sox-2 and Nanog, albeit some at lower levels than others as 
detected on immunocytochemistry. Nestin and GFAP were also positive in the cells.  
The expression of AFP and CK-19 was noted to be predominantly in the centre of the 
cellular mounds or piles that were structured during ex vivo culture of this cell-line (Figure 
74). The pattern of expression of other liver markers in HepG2 cells was very similar to that 
noted in umbilical cord-derived Mesenchymal stem cells post maturation with the important 
difference that the differentiated MSCs showed very low if any expression of Nestin, and 
were negative for the embryonic marker Sox-2.  The expression of embryonic markers in 
these cells was not surprising (Figure 74 and 75). It has previously been noted that cancer 
cells possess traits reminiscent of those ascribed to normal stem cells.  Ben-Porath et al, 
2008 reported previously an unknown link between genes associated with embryonic stem 
cell identity and the histopathological traits of tumours. They claimed that this probably 
supports the possibility that these genes contribute to stem cell-like phenotypes shown by 
many tumours (Ben-Porath, Thomson et al. 2008).  
It is worth noting that these HepG2 cells display a phenotype intermediate between 
hepatocytes and biliary epithelial cells (cholangiocytes). These cells might be comparable to 
early liver progenitor cells; hepatic stem cells and hepatoblasts but not to mature 
hepatocytes. Additionally, the abnormal cell kinetics of these cancer cells should be a factor 
of concern when it comes to interpretation of biomedical studies.  
 
 
Conclusion  
 
On characterisation HepG2 cells displayed a phenotype comparable to hepatocyte 
progenitor cells and not mature hepatocytes.  
 
Lack of mature hepatocyte features suggested that this cell line was not an ideal 
representative for mature hepatocytes and thus not the best in vitro model for 
biochemical and cell biology studies.  
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Figure 74. Expression of hepatic, biliary and embryonic stem cell markers in HepG2 cells. 
Confocal images were obtained at magnification x20 and x63. Cellular nuclei have been 
stained blue with DAPI (4’, 6-diamidino-phenylindole dilactate). AFP, Ck-8, Ck-19, and Sox-2 
were stained magenta with Cy5. Albumin, Ck-7, Ck-18 and gata-4 were stained green with 
FITC. All images were taken against negatives (secondary antibody only-stained cells) which 
were used to set the threshold for positive staining. Scale 50µm 
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Immunocytochemistry of undifferentiated HepG2 cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) ALB/AFP 
   (b) Ck7/Ck8 
(d) Gata-4/Sox-2 
    (c) Ck18/Ck9 
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(e) HGFR/LDLR 
   (f) Nestin/GFAP 
  (g) CPS1/Vimentin 
  (h) Nanog/Oct4a 
Figure 75. Expression of hepatic and some 
embryonic stem cell markers in HepG2 cells. 
Confocal images were obtained at magnification 
x10 and x20. Cellular nuclei have been stained blue 
with DAPI (4’, 6-diamidino-phenylindole dilactate). 
HGFR, Nestin, CPS1 and Nanog were stained green 
with FITC. LDLR, GFAP, vimentin and Oct4 were 
stained red with TxRed. Co-expression is depicted 
by yellow staining. All images were taken against 
negatives (secondary antibody only-stained cells) 
which were used to set the threshold for positive 
staining. Scale 75µm 
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5.4.5.2 Foetal liver tissue sections  
 
Paraffin embedded normal foetal liver tissue sections were provided courtesy of Steve 
Lisgo, Human Development Biology Resource (HDBR) department, a Wellcome 
Trust/MRC-funded resource run at the Institute of Human Genetics, Newcastle University 
and Institute of Child Health, University College London. The liver sections were from 
human embryos at 9 weeks of gestation.   
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 76. Transverse sections of human embryonic liver at 9 weeks gestation. DIC images 
were taken at magnification of x20 and illustrate the primitive portal tract, ductal plate and 
hepatoblasts. Ductal plate is a network of primitive biliary epithelium developing in the 
mesoderm following the portal vein branches and progressive towards the periphery of the 
hepatic parenchyma. The ductal plate is thought to give rise to the intra-hepatic biliary system 
(Godlewski et al, 2004).  Scale 150µm 
 
 
 
 
Ductal plate  
Hepatoblasts  
a b 
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Immunohistochemistry of normal human foetal liver tissue sections 
The foetal liver tissue sections from human embryos at 9 weeks of gestation were examined 
for most of the antigens used to characterize the differentiated umbilical cord and UCB-
derived differentiated stem/progenitor cells.  
The foetal liver cells at this gestational stage exhibited most of the characteristics of bi-
potent hepatic progenitor cells (hepatoblasts). The cells tested positive for albumin, AFP, 
Ck-7, Ck-8, Ck-19, CPS1 and HGFR.  Ck-7 (hepatic stem cell marker) was notably strong 
and expressed in all of the cells examined in the tissue sections (Figure 77b). AFP 
(hepatoblast marker) expression was localized predominantly to the ductal plate (origin of 
the intra-hepatic biliary tree). Ck-19 (another stem cell marker which persists when 
hepatoblasts differentiate into biliary epithelium) displayed limited weak expression (Figure 
77c). Ck-8 and Ck-18 (mature hepatocyte marker) were only barely positive in a small 
percentage of the cells (Figure77b).  CPS1 (rate limiting enzyme of the urea cycle) 
illustrated weak expression in the ductal plate cells and in the hepatoblasts. Gata-4 
(endoderm marker) was weakly positive. This was expected as the endoderm cells at this 
developmental stage have already committed to hepatobilary lineage. Vimentin and LDLR 
were also negative at this stage of liver development.  Weak HGFR expression was noted in 
the cells.  
The albumin+, Ck-7+, Ck-19+, Vimentin– cells in foetal liver represent bipotent progenitor. 
These cells are comparable to HepPar1+, Ck-14+, Ck-19+, Vimentin– cells that Haruna et al, 
1996, proposed as bipotent progenitors in human foetal liver samples (Haruna, Saito et al. 
1996).    
The phenotype of our ex vivo differentiated UC and UCB stem/progenitor cells were 
comparable to the foetal liver hepatic progenitor cells. Our differentiated cells, however, 
also tested positive for Gata-4 (endodermal marker) and Vimentin (mesodermal marker) 
expression demonstrating that they were at a more primitive developmental stage than the 
foetal hepatic progenitors at 9 weeks of gestation which tested negative for both of these 
markers.  
We were unable to obtain primary foetal embryonic liver cell cultures to use as functional 
models in our study. It should, however, be noted that these progenitor cells, being at an 
early developmental stage are highly unlike to serve as good hepatic functional models for 
biochemical and biomedical studies.  
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Conclusion 
Foetal liver tissue sections at different developmental stages serve as a good model 
to check the phases of in vitro differentiation by identifying the acquisition or loss of 
specific protein.  
In this study, human liver tissue sections from embryos at 9 weeks of gestation were 
the youngest developmental stage that we could get hold of.  
The phenotype of our ex vivo differentiated umbilical cord and UCB 
stem/progenitor cells were comparable to 9 week foetal liver hepatic progenitor 
cells albeit, at a slightly earlier developmental stage (Gata-4 and Vimentin positive).   
 The results obtained were only used to represent hepatobilary cells at an 
embryonic developmental stage. These results collectively with the results obtained 
from adult liver tissue sections were used as models to compare our results with.  
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 Figure 77. Confocal immunocytochemistry images of human foetal liver tissue sections at 9 
weeks gestation. (a) Albumin expression was noted throughout the liver section but stronger 
expression in the ductal plate. AFP was expressed predominantly in the ductal plate with 
weaker expression in the hepatoblasts. (b) Strong Ck-7 expression was noted both in the 
hepatoblasts as well as in the ductal plates. Ck-8 expression was weak and localized mainly to 
the hepatoblasts. (c) Ck-18 was very weakly expressed at this stage. Ck-19 expression was very 
weak and only expressed in a few hepatoblasts. (d) Gata-4 was weakly positive with greater 
expression in the ductal plate. (e) CPS1 was positive in both hepatoblasts and ductal plate with 
once again stronger expression in the ductal plate. Vimentin was negative. (f) HGFR was noted 
to be expressed both in hepatoblasts and ductal plate but LDLR was negative. Images were 
taken at magnification of x20. All nuclei were stained blue with DAPI (4’, 6-diamidino-
phenylindole dilactate). Albumin, Ck-7, Ck-18, Gata-4, CPS1 and HGFR were stained green 
with FITC. AFP, Ck-8 and Ck-19 were stained magenta with Cy5. Vimentin and LDLR were 
stained red with TxRed. Dual staining and co-expression appeared as whitish staining on 
imaging. All images were taken against negatives (secondary antibody only-stained cells) 
which were used to set the threshold for positive staining. Scale 150µm 
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5.4.5.3  Adult liver tissue sections  
 
Paraffin embedded normal adult liver tissue sections were provided courtesy of Dr Mathew 
Wright, School of Biomedical Sciences, Newcastle University. Similar to the foetal liver 
tissue sections, these adult tissue sections were used as positive controls for our 
differentiated stem/progenitor cells.  
 
 
  
  
(a)                                                                                                                          
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Figure 78. Confocal immunohistochemistry images of adult liver transverse sections. DIC images were 
taken at magnification of x20 and illustrate the portal triad (portal tract): portal vein, hepatic artery 
and bile duct. (b) Hepatic lobule surrounded by the portal space. Arteries, veins and bile ducts occupy 
the portal spaces. Nerves, connective tissue and lymphatic vessels are also present but not shown in this 
image. Scale 150µm 
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Immunohistochemistry of adult liver tissue sections  
 
The tissue sections from human adult liver samples were examined for the same antigens 
used to characterize the differentiated umbilical cord and UCB-derived differentiated 
stem/progenitor cells and the foetal liver tissue sections. 
The hepatocytes in the paraffin-embedded tissue section tested positive for albumin, Ck-8 
Ck-18 and CPS1; all of which are indicated markers of mature hepatocytes. Ck-18 
expression was notably stronger in hepatocytes in and surrounding the limiting plates 
(distinct row of hepatocytes joined together and forming a row which surrounds the portal 
tract) (Figure 79). Ck-7 was also positive but expression was once again limited to a few 
cells in and in close vicinity to the limiting plate (Figure 79). Based on their location these 
Ck-7+ cells, could either represent a potential hepatic stem cell compartment located within 
the intra-hepatic biliary tree or could be intra-hepatic biliary epithelial cells 
(cholangiocytes). It was expected that the Ck7+ cell population would also test positive for 
Ck-19 but surprisingly Ck-19 expression was negative. The cells were negative for Gata-4 
and vimentin.   
At the end of our ex vivo differentiation protocol, the resulting heterogeneous cellular 
phenotype displayed a percentage of cells that resembled mature hepatocytes and some that 
were comparable to the Ck-7+ cells noted in the adult liver. This cellular population in our 
differentiation system, however, was also positive for Ck-19.  
 
 
Conclusion  
 
Adult human hepatocytes represent the ideal morphological and phenotypical 
positive control for ex vivo hepatic differentiation systems.  
 
Resource for this tissue is limited to cadaveric supply or from post hepatectomy 
specimens, hence making control samples not readily accessible.  
 
Primary mature hepatocytes would be the ultimate functional control for in vitro 
differentiation systems. These cultures, however, are very difficult to maintain in 
culture and have a propensity to undergo phenotype transformations.  
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Figure 79. Confocal immunohistochemistry images of adult liver tissue transverse sections. (a) 
Hepatic lobular cells positive for albumin but negative for AFP. (b) Hepatocytes were diffusely 
positive for Ck-8 but Ck-7 expression was localized to areas of the limiting plate (distinct row 
of hepatocytes joined together forming a row which surrounds the portal tract). (c) Ck-19 was 
not expressed. Ck-18 expression was similar to Ck-7 expression. All cellular nuclei were 
stained blue with DAPI (4’, 6-diamidino-phenylindole dilactate). Albumin, Ck-7 and Ck-18 
were stained green with FITC. AFP, Ck-8 and Ck-19 were stained magenta with Cy5. Images 
were taken at magnification of x20. Dual staining and co-expression appeared as whitish 
staining on imaging. All images were taken against negatives (secondary antibody only-stained 
cells) which were used to set the threshold for positive staining. Scale 150µm 
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Portal triad 
Figure 80. Confocal immunohistochemistry images of adult liver tissue transverse sections.  (a) 
A small percentage of hepatocytes in the hepatic lobule imaged tested positive for CPS1. 
Vimentin was negative. (b) Hepatocytes were negative for Gata-4. No Gata-4 expression was 
noted in the portal tract either.  All cellular nuclei were stained blue with DAPI (4’, 6-
diamidino-phenylindole dilactate). CPS1 and Gata-4 were stained green with FITC. Vimentin 
was stained red with TxRed. All images were taken against negatives (secondary antibody 
only-stained cells) which were used to set the threshold for positive staining.  
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5.4.6 Protein analysis of differentiated cells  
Western bloting was drawn on to verify the presence of the liver related proteins detected on 
immunocyto/histochemistry.  This test, however, could only be carried out on umbilical 
cord-derived Mesenchymal stem cells. This was due to the fact that this assay was less 
sensitive than immunocyto/histochemistry and hence required a comparatively large amount 
of protein for antigen detection which could not be met by the low cell counts yielded from 
umbilical cord blood. Efficient ex vivo expansion of Mesenchymal stem cells, on the other 
hand, provided sufficient cell numbers that could meet the protein requirements of this test. 
In each case, 5-10mg of protein was used for the detection of each antigen. In each run the 
amount of protein from each test sample loaded was the same.  
Protein extracts from cultured cells at different stages of the differentiation protocol were 
used for this technique.  
Undifferentiated Mesenchymal stem cells and embryonic stem cells were used as negative 
controls. Human embryonic stem cells were provided courtesy of Professor Majlinda Lako, 
NorthEast England Stem Cell Institute, Centre for Life, Newcastle University.  HepG2 cells 
and adult liver protein were used as positive controls. Adult liver protein extracts were 
provided courtesy of Dr Matthew Wright.  
ß-Actin was used as a control for integrity of cell in the western blot runs. ß-Actin is one of 
the two non-muscle cytoskeletal actins. Actins are highly conserved proteins that are 
involved in cell motility, structure and integrity.  
The proteins examined by western bloting included: AFP, albumin, Ck-19, C-k7, Ck-8, 
HGFR, CPS1 and CYP450 enzymes (CYP3A4, 2A and 2E).  
AFP was detected only in adult liver and very low levels could be appreciated in HepG2 
cells as well. However, AFP expression in adult liver tissue sections was not noted on 
immunohistochemistry analysis. This may have been because the area of the tissue 
examined microscopically was not periportal where potential progenitor cell populations are 
believed to reside in. AFP expression was not detected in any of the differentiation phases of 
the MSCs, although, on immunocytochemistry AFP expression was noted at week 3 of the 
protocol. A likely explanation is that immunocytochemistry is a more sensitive assay for 
protein detection and the use of a larger quantity of protein extract may have made AFP 
detection possible on western bloting. The negative controls were negative for AFP 
expression (Figure 81).  
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Albumin was detected at all the stages of MSC differentiation as well as in the 
undifferentiated MSC control. Highest albumin expression was noted in adult liver as 
expected. This result corresponds to the results obtained on immunocytochemistry. 
Embryonic stem cell negative control was negative for albumin (Figure 81) 
Ck-19 was positive in undifferentiated MSCs, as well as all other stages of differentiation 
except the final stage (week 3-post maturation). This result once again corresponds with the 
results from immunocytochemistry, except for Ck-19 not being detected at week 3.  It is 
worth noting here that the cell number at week 3 of the differentiation system was 
considerable lower than the cell density at earlier stages of differentiation. The lower cell 
count and hence consequential lower protein content could explain the lack of detection of 
Ck-19 at the final stage of differentiation. Ck-19 expression was noted in both positive 
controls with adult liver demonstrating a lower expression compared with its corresponding 
ß-Actin. This is because Ck-19 expression in the liver post development is restricted to 
biliary epithelium and not hepatic parenchyma.  Embryonic stem cells were positive for Ck-
19. This result was not very surprising as embryonic stem cells have previously been 
reported to test positive for various germ layer markers (Figure 82) 
Ck-8 expression was noted in undifferentiated MSCs as well as all the stages of MSC 
differentiation. These results corresponded to the immunocytochemistry results obtained for 
this protein. HepG2 and adult liver both tested positive for Ck-8. Protein level was slighter 
lower in adult liver but this reflected the comparatively smaller protein content of this 
sample as was depicted by ß-Actin (Figure 83). Embryonic stem cells were positive for Ck-
8.  
CPS1 was detected in undifferentiated MSCs as well as all the stages of MSC 
differentiation. These results yet again corresponded to the immunocytochemistry results 
obtained for this functional protein. Both positive controls tested positive as well. 
Embryonic stem control also demonstrated expression of this protein (Figure 83).  
The results acquired for Ck-7 did not reflect the immunocytochemistry results for this 
protein. Undifferentiated MSCs were positive for Ck-7 on both assays. Differentiated MSCs 
at week 1 and week 2 of differentiation tested positive for Ck-7 on western blotting, but 
were negative for Ck-7 on immunocytochemistry. Similarly, at week 3 of differentiation Ck-
7 was negative on western analysis but was strongly positive on immunocytochemistry. 
HepG2 cells tested negative for Ck-7 whilst the protein displayed a positive expression on 
immunocytochemistry. Adult liver illustrated expression of this cytokeratins, albeit at low 
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levels. Embryonic stem cell controls were also weakly positive for Ck-7 (Figure 82).  
HGFR expression on western blot analysis did not demonstrate complete concurrence with 
immunocytochemistry results either. HGFR was detected in undifferentiated as well as 
differentiated MSCs at week 1, 2 and 3 of the differentiation protocol. On 
immunocytochemistry, however, HGFR expression was only noted at week 3 of MSC 
differentiation and was negative at the earlier stages. HepG2 was negative for HGFR on 
western but tested positive on immunocytochemistry. Adult liver cells were also negative 
for HGFR but there was no corresponding immunocytochemistry data to compare this with. 
Embryonic stem cell controls were weakly positive for this protein (Figure 82). 
The presence of CYP450 enzymes were not tested on immunocytochemistry. On western 
blot protein analysis all the test samples were negative for CYP3A4, except for adult liver. 
CYP2A was positive in undifferentiated MSCs and all stages of differentiated MSCs, albeit 
at low levels. HepG2 and adult liver were positive for this CYP enzyme. CY2E 
demonstrated a more selective pattern of expression- very low levels were noted in 
undifferentiated MSCs as well as week 1 of differentiation and subsequently no more 
protein was expressed. Both positive controls demonstrated CYP2E expression. Embryonic 
stem cells were negative for CYP3A4 but demonstrated low levels of CYP2A and CYP2E 
protein expression (Figure 84).  
 
 
 
 
 
Conclusion  
 
Western blot does not provide quantitative data and hence did not add addition 
information to the data already obtained from immunocyto/histochemistry.  
 
This technique is dependent on adequate protein concentration for detection. 
 
Embryonic stem cells did not prove to be good negative controls for this assay.    
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Figure 81. Western blot assays- chemiluminescent protein detection in differentiated MSCs. 
HepG2 and adult liver protein extracts were used as positive controls. Undifferentiated MSCs 
and Embryonic stem cells were used as negative control. 10mg of protein was loaded into each 
well for protein detection, except for albumin where 5mg was used. Higher concentration of 
this protein resulted in very bright optical density on luminescence, making interpretation 
difficult. All images were obtained after 1-3 minutes of exposure. ß-actin was used as a control 
for cellular integrity in all the runs. Sample numbers are decoded in the legend provided. 
 
 
 
 
 
 
 
 
 
(a) 
(b) 
 
(d) 
(c) 
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Figure 82. Western blot assays for protein detection in differentiated cells. HepG2 and adult liver 
protein extracts were used as positive controls. Undifferentiated MSCs and Embryonic stem cells 
were used as negative control. 10mg of protein was loaded into each well for protein detection.  
Sample numbers decoded in the legend provided.  
 
 
(a) 
(b) 
(c) 
(d) 
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Figure 83. Western blot assays for protein detection in differentiated cells. HepG2 and adult 
liver protein extracts were used as positive controls. Undifferentiated MSCs and Embryonic 
stem cells were used as negative control. 10mg of protein was loaded into each well for protein 
detection. Sample numbers decoded in the legend provided. (b) There are two types of 
cytokeratin 8: Acidic (Type 1) ~ 40-55 KDalton; Neutral to basic (Type II) ~ 56-70 KDalton. We 
were interested in acidic Ck-8 (~45 KDaltons).   
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Figure 84. Western  blot assays for protein detection in differentiated cells. HepG2 and adult liver 
protein extracts were used as positive controls. Undifferentiated MSCs and Embryonic stem cells 
were used as negative control. 10mg of protein was loaded into each well for protein detection.  
Sample numbers decoded in the legend provided. 
 
 
 
 
 
 
 
 
(a) 
(b) 
(c) 
(d) 
1= Undiff MSC 
2= Minus EGF Diff 
3= Plus EGF Diff 
4= 2wk Diff 
5= 3wk Diff 
6= HepG2 
7= Adult liver 
8= Embryonic stem 
cells 
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5.4.7 Molecular analysis of isolated stem/progenitor cells 
 Immunocytochemistry and western blot analysis are useful technique for studying protein 
expression in cells, providing valuable information about the presence and the cellular 
localization of proteins within the cells. However, a limitation of these techniques is that 
they fail to provide quantitative information. Since, a lot of the proteins investigated were 
expressed throughout the various stages of the differentiation protocol (in the case of 
MSCs even prior to differentiation); we decided to study the gene expression profiles of 
some of these proteins at the different stages. We used real-time PCR to quantify the 
studied genes. All the values generated were relative quantities (normalised to house-
keeping genes). This enabled examination of changes in gene expression profiles 
throughout the differentiation and maturation protocol.  HepG2, foetal liver mRNA 
(7weeks and 12weeks) and adult liver cDNA were used as positive controls for all the 
tested genes.   
Undifferentiated umbilical cord MSCs prior to differentiation expressed all the genes 
studies,albeit, some at low levels ♣. This verified our finding at the protein level with 
immunocytochemistry and western blotting. After the first week of differentiation, we 
documented an up regulation of the majority of the genes examined (Gata-4, AFP, 
CLDN2, HNF1α, Albumin and all the studied CYP450 genes). However, HNF4α, HGFR 
and LDLR were noted to be down regulated (Figure 85-87).  
Post week two of differentiation, the expression of all the genes noted was down regulated, 
in some cases to a level even below post expansion. One probable explanation for this 
could be the introduction of a new cytokine (EGF) to the culture media, which may have 
altered the cell kinetics, directing the cell machinery to produce proteins needed for the 
newly activated signalling pathway at the expense of some other genes (Figure 85-87).  
Week three of the protocol, demonstrated the maximum expression of the examined genes. 
This observation reflected an increase in the level of maturity of the cells after exposure to 
dexamethasone and Oncostatin M  
 
♣ Week 1 (1wk) of the protocol was carried out in two parallel experiments, with and without EGF. This 
has been represented as ‘minus EGF’ and ‘plus EGF’ in the graphs. This was done to determine the role 
of EGF in hepatobiliary differentiation ex vivo. This has been discussed in Chapter 5 section 5.3 . In this 
section, however, all references to week 1 are with regards to week 1 of differentiation without EGF 
(minus EGF 1wk). 
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The differentiation system applied to cord blood stem/progenitor cells was of a shorter 
duration taking into account the limited viability of these cells in vitro. Undifferentiated 
haematopoietic stem/progenitor cells also tested positive for the expression of all the genes 
examined, suggesting that they too have hepatogenic potential. The corresponding proteins, 
however, did not test positive on immunocytochemistry analysis.  
After one week of lineage commitment and modest expansion the cells demonstrated down 
regulation of all of the genes, except CLDN2, Gata-4 and CYP2E1. Up regulation of Gata-4 
(endodermal marker) confirms the ability of the culture system to establish an endoderm 
fate. Up regulation of CLDN2 (Hepatic stem cell marker) was suggestive of a hepatic stem 
cell phenotype. The simultaneous up regulation of CYP2E1, however, which is a more 
mature hepatocyte marker, reflected the heterogeneous nature of the cultures (Figure 85-87).  
After differentiation (4 days) and maturation (4 days) we documented an increase in the 
expression profiles of AFP (hepatoblast marker), HNF4α (transcriptional factor necessary 
for hepatocyte differentiation) and CYP20A1. All the other examined genes demonstrated a 
down regulation. Simultaneous suppression of Gata-4 and CLDN2 expression meant that at 
this stage the cells demonstrated a phenotype more mature that hepatic stem cells and less 
mature that hepatocytes; they reflected similarity to hepatoblasts.  
The probability test, Anova two-factor with replication, was used to statistically analyse the 
significance of the changes noted in the level of gene expression during the different stages 
of differentiation. A p value of 0.005 was regarded as statistically significant. We 
documented that the trend of gene expression level changes was significant (n=3) 
(p<0.0001). The Anova test also enabled us to study the level of variability in gene 
expression profiles between different cord blood samples. We reported that even though the 
trend in gene expression profiles during the differentiation protocol was more or less 
consistent, the variability between the cord blood samples was very significant (p<0.00001). 
This significant difference may be attributed to the many parameters that have previously be 
shown to influence cord blood quality: gestational age, age of the mother, number of 
pregnancy, sex of the baby etc (McGuckin, Basford et al. 2007).  
To ensure the specificity of the primers used, end-point PCR gel electrophoresis was 
performed to determine the sizes of the products picked up by the primers (appendix C).  
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Conclusion  
 
Both MSCs and UCB haematopoietic stem/progenitor cells tested positive for the 
examined hepatocyte related genes. This reflected the hepatogenic potential of these 
cells  
 
Hepatocyte differentiated MSCs displayed highest level of hepatocyte gene 
expression post maturation. A heterogeneous population of hepato-biliary cells was 
generated with cellular phenotype ranging from hepatic stem cells to mature 
hepatocyte-like cells. 
 
Haematopoietic stem cell-derived differentiated cells illustrated a phenotype 
analogous to hepatoblasts at the end of the differentiation protocol 
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Figure 85. Real-time PCR analysis of MSCs and haematopoietic stem cells (HPCs) at different 
stages of differentiation. Graphical data is in Logarithmic scale. HepG2, foetal liver at 
gestation age of 7 weeks (FL7wk) and 12 weeks (FL12wks) and adult liver cDNA were used as 
positive controls. RNase-free water was used as negative control. Week 1 (1wk) of the protocol 
was carried out in two parallel experiments, with and without EGF. This has been represented 
as ‘minus EGF’ and ‘plus EGF’ in the graphs. This was done to determine the role of EGF in 
hepatobiliary differentiation ex vivo. This has been discussed in Chapter 5 section 5.3. In this 
section, however, all references to week 1 are with regards to week 1 of differentiation without 
EGF (minus EGF 1wk). (a) Highest level of Gata-4 expression was noted in foetal liver at 
gestational age of 12weeks (FL12wk). Both undifferentiated MSCs and HPCs tested positive 
for Gata-4. In MSCS expression of this gene reached maximum expression at week 3.  In 
HPCs, an up regulation was noted after 1week but thereafter the cells were negative for Gata-
4. (b) Highest level of HNF4α was noted in HepG2, followed by foetal liver. Undifferentiated 
MSCs were positive for HNF4α but undifferentiated HPCs were negative. MSCs demonstrated 
a gradual increase in gene expression, attaining maximum expression at week 3. In HPCs an 
initial down regulation was noted at week 1 followed by a noticeable up regulation. (c) Highest 
CLDN2 expression was noted in adult liver.  Both undifferentiated MSCs and HPCs tested 
positive for this gene. At week 3, MSCs demonstrated highest expression of this gene.  
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FL=foetal liver 
Undiff= undifferentiated 
HPC= Haematopoietic 
stem cells 
MSC= mesenchymal stem 
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Figure 86. Real-time PCR analysis of MSCs and haematopoietic stem cells (HPCs) at different 
stages of differentiation. Graphical data is in Logarithmic scale. HepG2, foetal liver at 
gestation age of 7 weeks (FL7wk) and 12 weeks (FL12wks) and adult liver cDNA were used as 
positive controls. RNase-free water was used as negative control. Week 1 (1wk) of the protocol 
was carried out in two parallel experiments, with and without EGF. This has been represented 
as ‘minus EGF’ and ‘plus EGF’ in the graphs. This was done to determine the role of EGF in 
hepatobiliary differentiation ex vivo. This has been discussed in Chapter 5 section 5.3. In this 
section, however, all references to week 1 are with regards to week 1 of differentiation without 
EGF (minus EGF 1wk). (a) Highest level of AFP expression was noted in foetal liver at 
gestational age of 12weeks (FL12wk). Both undifferentiated MSCs and HPCs tested positive 
for AFP. In MSCs the highest level of this gene was expressed at week 1 (post differentiation). 
This was followed by a slight down regulation but expression picked up again at week 3. In 
HPCs, AFP expression demonstrated a subtle down regulation post differentiation, after which 
levels remained constant. (b) Highest albumin expression was noted in foetal liver samples 
(FL7wk and 12wk). Both undifferentiated MSCs and HPCs tested positive for albumin. In 
MSCs, albumin levels illustrated an up regulation at week 1, then a slight reduction in 
expression level, picking up again and attaining maximum expression at week 3. In HPCs, 
albumin expression remained unchanged after differentation but then was slightly down 
regulated at week 2. (c) Highest HGFR expression was noted in foetal liver (FL12wk). Both 
undifferentiated MSCs and HPCs tested positive for HGFR. MSCs demonstrated a down 
regulation at week 1 and 2 but levels picked up at week 3. In HPCs, after differentiation 
HGFR showed a subtle down regulation at week 1 followed by a further reduction in 
expression at week 2.  
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5: Differentiation of Human Cord and Cord Blood Stem/Progenitor Cells Towards Liver Lineage 
 299 
(a) 
(b)
AFP Expression 
0.1
1
10
100
1000
10000
100000
1000000
10000000
100000000
FL
 
7w
k
FL
12
wk
He
pG
2
Ad
ult
 
live
r
Un
dif
f M
SC
Mi
nu
s E
GF
 
1w
k M
SC
Plu
s E
GF
 
1w
k M
SC
2w
k D
iff M
SC
3w
k D
iff M
SC
Un
dif
f H
PC
Mi
nu
s E
GF
 
1w
k H
PC
Plu
s E
GF
 
1w
k H
PC
2w
k D
iff H
PC
R
el
at
iv
e 
ge
n
e
 
qu
an
tifi
c
at
io
n
 
 
(c)
Albumin Expression
0.1
1
10
100
1000
10000
100000
1000000
10000000
FL
 
7w
k
FL
 
12
wk
 
He
pG
2
Ad
ult
 
live
r
Un
dif
f M
SC
Mi
nu
s E
GF
 
1w
k M
SC
Plu
s E
GF
 
1w
k M
SC
2w
k D
iff M
SC
3w
k D
iff M
SC
Un
dif
f H
PC
Mi
nu
s E
GF
 
HP
C
Plu
s E
GF
 
HP
C
2w
k H
PCR
el
at
iv
e 
ge
n
e 
qu
an
tifi
ca
tio
n
 
 
HGFR Expression 
0.1
1
10
100
1000
10000
7w
k F
L
12
w
k F
L
He
pG
2
Ad
ult
 
liv
er
Un
dif
f M
SC
Mi
nu
s E
GF
 
1w
k M
SC
Plu
s E
GF
 
1w
k M
SC
2w
k D
iff 
MS
C 
3w
k D
iff 
MS
C 
Un
dif
f H
PC
Mi
nu
s E
GF
 
1w
k H
PC
Plu
s E
GF
 
1w
k H
PC
2w
kD
iff 
HP
C
R
el
at
iv
e 
ge
ne
 
qu
an
tifi
ca
tio
n
 
 
 
 
FL=foetal liver 
Undiff= undifferentiated 
HPC= Haematopoietic stem 
cells 
MSC= mesenchymal stem 
cells  
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Figure 87. Real-time PCR analysis of MSCs and haematopoietic stem cells (HPCs) at different 
stages of differentiation. Graphical data is in Logarithmic scale. HepG2, foetal liver at 
gestation age of 7 weeks (FL7wk) and 12 weeks (FL12wks) and adult liver cDNA were used as 
positive controls. RNase-free water was used as negative control. Week 1 (1wk) of the protocol 
was carried out in two parallel experiments, with and without EGF. This has been represented 
as ‘minus EGF’ and ‘plus EGF’ in the graphs. This was done to determine the role of EGF in 
hepatobiliary differentiation ex vivo. This has been discussed in Chapter 5 section 5.3. In this 
section, however, all references to week 1 are with regards to week 1 of differentiation without 
EGF (minus EGF 1wk). (a) LDLR demonstrated highest level of expression in foetal liver 
(FL12wk). Undifferentiated MScs and HPCs, both tested positive for LDLR gene. In MSCs, 
LDLR expression decreased during the first two weeks of differentiation but demonstrated an 
upregulation at week 3. This was the highest level of expression noted during the 
differentiation protocol. HPCs, also illustrated a very slight increase in LDLR expression at 
week 2. (b) Highest level of CYP2E1 was noted in adult liver cells. Undifferentied MSCs were 
negative for this gene. Undifferentiated HPCs, on the other hand tested positive for this CYP 
enzyme. In MSCs, CYP2E1 expression was triggered at week 1 post differentiation followed by 
a gradual increase in expression levels reaching maximum expression at week 2 and expression 
was maintained thereafter. HPCs, demonstrated a very subtle increase in expression at week 1 
but expression was switched off at week 2. (c) Highest CYP3A4 expression was appreciated in 
FL12wk. Both undifferentiated MSCs and HPCs demonstrated CYP3A4 expression. In MSCs, 
this CYP gene was upregulated post differentiation at week 1 and thereafter expression level 
was maintained. In HPCs, CYP3A4 expression at week 1 was unchanged from 
undifferentiated state but at week 2 a down regulation was noted.  
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Figure 88. Real-time PCR analysis of MSCs and haematopoietic stem cells (HPCs) at different 
stages of differentiation. Graphical data is in Logarithmic scale. HepG2, foetal liver at 
gestation age of 7 weeks (FL7wk) and 12 weeks (FL12wks) and adult liver cDNA were used as 
positive controls. RNase-free water was used as negative control. Week 1 (1wk) of the protocol 
was carried out in two parallel experiments, with and without EGF. This has been represented 
as ‘minus EGF’ and ‘plus EGF’ in the graphs. This was done to determine the role of EGF in 
hepatobiliary differentiation ex vivo. This has been discussed in Chapter 5 section 5.3. In this 
section, however, all references to week 1 are with regards to week 1 of differentiation without 
EGF (minus EGF 1wk). (a) Highest level of CYP2C9 expression was noted in adult liver cells. 
Both undifferentiated MSCs and HPCs demonstrated CYP2C9 expression. In MSCs, the 
expression of this gene demonstrated an up regulation throughout the differentiation protocol 
reaching the highest level at week 3. HPCs, on the other hand, demonstrated complete switch 
off of this CYP gene post differentiation. (b) Highest CYP20A1 levels were noted in foetal liver 
cells (FL7wk and FL12wk). Undifferentiated MSCs and HPCs tested positive for this CYP 
gene. In MSCs, CYP20A1 was slightly up regulated at week 1 but levels decreased at week 2. 
At week 3, however, expression picked up reaching maximun level of expression comparable to 
foetal liver cells. HPCs, demonstrated a down regulation of CYP20A1 at week 1 but levels 
increased slightly at week 2, however, not surpassing the expression level at day zero 
(undifferentiated state).  
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5.4.8 Functional analysis   
The umbilical cord and UCB- derived hepatobiliary-like cells displayed morphological and 
immunophenotypical characteristics similar to human liver cell populations. However, as 
Hengstler et al put it, the expression of a few hepatic markers by stem/progenitor cells does 
not make them mature hepatocytes. More importantly, the cells should exhibit signs of 
metabolic activity. Therefore, we examined the differentiated cellular populations for a 
range of hepatocyte functions:  glycogen storage, uptake and excretion of indocyanine green 
dye and cytochrome P450 activity. 
(A) Periodic acid Schiff staining 
 
Liver is a prime organ involved in carbohydrate metabolism in the human body. It plays a 
pivotal role in maintaining blood sugar levels during periods of starvation and post-feeding.  
To assess this crucial function of liver cells Periodic Acid Schiff (PAS) staining was used to 
examine glycogen deposits in differentiated stem/progenitor cells. A staining kit from Sigma 
was utilized and the staining procedure was adapted from kang et al (Kang, Zang et al. 
2005) and according to the manufacturer's instructions.  
Post differentiation both MSC and UCB stem/progenitor cells displayed evidence of 
functional activity (Figure 89 and 90). Glycogen stores were stained magenta pink with 
periodic acid Schiff staining kit (Materials and Methods, section 2.16.1).  
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Positive PAS staining in differentiated cord blood stem/progenitor colonies  
 
 
(a)                                                                         (b) 
 
Figure 89. Periodic acid schiff staining of intracellular glycogen stores in UCB-derived 
hepatocyte-like cells. (a) Differentiated stem/progenitor cells in cellular niches demonstrated 
the presence of intracellular glycogen stores (arrow). Cellular nuclei were stained bluish 
purple with haematoxylin. (b) Higher magnification of image (a). DIC images taken at 
magnification of x10 and x20 respectively. Scale 50µm.  
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Figure 90. Periodic acid schiff staining of intracellular glycogen stores in differentiated 
Mesenchymal stem cells. Glycogen stores were depicted by magenta pink intracellular 
staining. Cellular nuclei were stained bluish purple with haematoxylin dye. (a) 
Undifferentiated MSCs were negative for glycogen stores. (b) After one week of differentiation 
a few cells demonstrated intracellular glycogen granules (arrow). (c) After introduction of 
maturation factors into the culture system, MSCs illustrated notable retraction of cellular 
appendages accompanied by amassing of cells into aggregates. These cellular aggregates were 
positive for glycogen stores (circled area). Surrounding cells were noted to be negative for 
glycogen (*). (d) After three weeks of ex vivo differentiation, Periodic Acid Schiff staining was 
strongly positive. All the cells in culture were stained for intracellular glycogen. DIC were 
taken at magnification of x10 and x20.  
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Positive PAS staining in differentiated Mesenchymal stem/progenitor cells  
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HepG2 cells demonstrate positive Periodic acid Schiff staining 
HepG2 cells were used as a positive control for all functional investigations applied to 
UCB-derived stem/progenitor cells and Mesenchymal stem cells. Primary cultures of this 
hepatocelluar carcinoma cell line were tested for PAS staining (Figure 91). The intensity of 
PAS staining in the HepG2 cells was comparable to PAS staining in differentiated MSCs 
after maturation.  
 
Figure 91. Glycogen storage demonstrated in HepG2 cells. A high fraction of the cells exhibit 
glycogen storage as demonstrated by magenta staining (arrow) with Periodic Acid Schiff (a 
and b). Estimation of the precise percentage of positivity with PAS was difficult due to the 
growth pattern of the cell line in mounds.  It was noted that not all the cells in culture tested 
positive for glycogen storage. Nuclei are counter stained with haematoxylin. Scale 50µm. 
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(B) Indocyanine green dye uptake and release test 
 
Another major function of the liver is elimination of various endogenous and exogenous 
compounds from the circulation. For many of these substances, the clearance process 
involves at least three steps: hepatic uptake, conjunction and biliary excretion (Berk and 
Chamovitz 1969) (Scharschmidt, Waggoner et al. 1975) . This clearance process involves 
basolateral (sinusoidal and lateral) membrane transport systems that mediate the 
hepatocellular uptake of bile acids, organic anions, and organic cations (Meier PJ 1997) 
(Muller and Jansen 1998).  
Indocyanine green (ICG) is an organic anion that is clinically used as a test to evaluate liver 
function since it is non-toxic and eliminated exclusively by hepatocytes (Branch 1982) 
(Berk PD 1986; Meijer DKF 1988). In this study Indocyanine green dye uptake and release 
by cultured cells was used to identify functionally differentiated hepatocytes within the 
culture system. The ICG solution (1mg/ml) was loaded to the cell culture dish and incubated 
for 20 minutes at 37° C. After, the culture plate was rinsed three times with (x1) PBS and 
cellular uptake of ICG was examined stereomicroscopically.  
Both MSCs and UCB-derived differentiated cells exhibited the ability to take up and excrete 
Indocyanine green dye back into the culture media. Within 24 hours of loading the dye in 
culture, cells exhibited ability to excrete most of the dye back into the culture media.  
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Indocyanine green dye uptake by differentiated cord blood stem/progenitor colonies  
 
 
 
 
Figure 92. Indocyanine green dye uptake and release test in differentiated cord blood 
stem/progenitor cellular colonies. (a) Stem/progenitor cellular colonies prior to exposure with 
Indocyanine green dye. (b) Green coloration of cells represented Indocyanine uptake. Note 
that the dye uptake is selective to only a few cells. The majority of isolated cells not in colonies 
have been lost during the assay washes and the remnant ones did not illustrate very efficient 
dye uptake. DIC images were taken at magnification x10 and x20 respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prior to ICG treatment  Post 25minutes of ICG (a) (b) 
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Figure 93. Indocyanine green dye uptake and release test in differentiated Mesenchymal stem 
cells at various stages during the differentiation protocol. (a) Undifferentiated MSCs 
demonstrate weak dye uptake. (b) After 1 week of differentiation, dye uptake by cells had 
increased notably. It should be noted here that similar to cord blood stem/progenitor cells, dye 
uptake was not generalized but selective to some cells. (c) Post week 2 of differentiation 
Indocyanine green dye uptake was just as efficient. Additionally, changes in cellular 
morphology of MSCs were noted. (d) Post maturation, green dye uptake was at its maximum 
intensity and cellular transformation from spindle shaped MSC to polygonal cells was 
appreciated. Once again Indocyanine uptake was selective. DIC images were taken at a 
magnification of x10 and x20.  
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Indocyanine green dye uptake by differentiated Mesenchymal stem cells  
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HepG2 cells demonstrate positive Indocyanine green dye uptake  
HepG2 primary cultures demonstrated ability to take up Indocyanine green dye from 
culture. Uptake of this dye was not universal in all the cells in culture but localized to cells 
localized in cellular colonies (Figure 94). The cells also demonstrated the ability to excrete 
the dye back into the culture medium after several washes. Uptake of Indocyanine dye by 
UCB-derived differentiated stem/progenitor cells and Mesenchymal stem cells were 
comparable to HepG2 cells. In both cell types, uptake of the dye was also not universal and 
limited to cells contained in celluar aggregates or colonies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 94. HepG2 cells exhibited ability to take up Indocyanine green dye. (A) Before exposure 
to green dye. (B) Not all the cells were positive for this functional assay. One hour post assay 
and washing the cells with (x1) PBS. (C) Note most of the cells not in cellular colonies were lost 
during cell washing. 24 hours post assay and washing most of the cells had excreted the green 
dye (D). Images acquired at magnification of x10 and 20. Scale 50µm 
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(C) Cytochrome P450 Glo Assay 
 
Human Cytochrome P450 (CYP450) are membrane-associated proteins located either in the 
inner membrane of the mitochondria or in the endoplasmic reticulum of cells. Cytochromes 
are involved in the metabolism of thousands of endogenous and exogenous chemicals. 
CYP450 enzymes are present in most tissues of the body, and play a pivotal role in hormone 
synthesis and breakdown, cholesterol synthesis, and vitamin D metabolism. CYPs also 
function to metabolize potentially toxic compounds, including drugs and endogenous 
metabolites such as bilirubin, principally in the liver.  CYP enzymes account for 
approximately 75% of the total drug metabolism (Guengerich 2008). The Human Genome 
project has identified 57 human genes coding for the various cytochrome P450 enzymes and 
59 pseudogenes divided among 18 families of CYP450 genes and 43 subfamilies (Nelson 
2002).   
In the liver, Cytochrome P450 activity is one of the metabolic functions used as an 
indication of hepatocyte maturity. Thus, to access the level of maturity in differentiated cells 
we measured CYP enzymes using a non-selective cytochrome (CY) P450 Enzyme Assay. 
This assay uses a bioluminescent probe substrate that cross-reacts with multiple P450 
enzymes. Enzyme activity was studied both in untreated differentiated cells as well as post 
treatment of the cells with CYP enzyme inducers. Omeperazole and Rifampicin were used 
as inducers resulting in selective upregulation of certain CYP enzyme subfamilies (Material 
and Methods, section 2.16.4). HepG2 was used as a positive control for both UCB-derived 
differentiated stem/progenitor cells as well as umbilical cord differentiated MSCs. Cell-free 
cultures were used as negative control.  
The results demonstrated that undifferentiated cord blood cells display CYP activity. This 
probably was the effect of the expression of the prominent CYP subfamily, CYP3A, in 
blood neutrophils and lymphocytes. These blood cells are one of the various extra hepatic 
tissues that express CYP enzymes (Starkel, Sempoux et al. 1999). A point, however, that is 
worth noting is that both these cell lineages are not inducible, contrary to hepatocyte CYP 
enzymes. Gallagher et al, also reported cytochrome P450 mRNA expression in foetal liver 
haematopoietic stem cells . These CD34+ cells are very similar to CD34+ cells circulating in 
blood and serve as the primary organ of haematopoiesis during foetal liver development.  
CYP1A1, CYP2E1, CYP3A4 and CYP3A5 mRNA were measurable in these cells. The 
CYP3A4/5 mRNA expression was accompanied by detectable CYP3A protein as well 
(Shao, Stapleton et al. 2007). Similarly, it may be argued that the selected cord blood 
stem/progenitor cells in this project could also display evidence of CYP enzyme activity.   
Chapter 5: Differentiation of Human Cord and Cord Blood Stem/Progenitor Cells Towards Liver Lineage 
 315 
Upon differentiation, cells failed to illustrate an increase in CYP activity after week one of 
ex vivo simulation with signalling cues, but demonstrated a significant increase in CYP 
levels at week two. This increase in enzyme expression is attributable to greater maturity of 
differentiated cells post introduction of maturation factors (Figure 95a). HepG2 
demonstrated greater evidence of CYP activity (x1.14 fold) compared to our differentiated 
UCB cells.  
Undifferentiated MSCs, although constitutively expressing markers of hepatic lineage, did 
not illustrate significant CYP activity (Figure 95b). After differentiation, measurement of 
CYP enzymes failed to show an increase in enzyme levels during the first two weeks of 
differentiation in vitro. Upon introduction of maturation factors, however, a significant 
increase in enzyme levels was noted on measurement. This was suggestive of increase in 
cell maturity and subsequent metabolic activity in differentiated cells.  Upon maturation 
differentiated MSCs demonstrated a greater level of CYP (x3.27 fold) activity than the 
HepG2 control.  
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Figure 95. Measurement of cytochrome P450 proteins in differentiated UCB-derived and 
MSC-derived hepatocyte-like cells. (a) Undifferentiated cord blood stem/progenitor cells 
displayed evidence of low levels of CYP activity. Post differentiation and maturation a notable 
increase in CYP levels was appreciated on measurement with a luminometer. (b) 
Undifferentiated MSCs displayed very low if at all CYP activity. After differentiation and 
maturation a remarkable up regulation in CYP protein levels was noted at week 3. HepG2 was 
used as a positive control for both cell lineages. Cell-free cultures were used as negative control 
allowing measurement of background luminescence which was taken into account during 
calculation of net luminescence of each cell sample. (*) MSC CYP activity x3.27 folds greater 
that HepG2 control.  
 
(a) 
  * 
(b) 
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After measurement of net luminescence (CYP activity) in differentiated cells, we carried out 
CYP gene induction studies.   Cells were treated with CYP enzyme inducers (Rifampicin 
and Omperazole) for 72hrs prior to treating the cells with the MultiCYP luminogenic 
substrate (Materials and Methods, section 2.16.4). Fold changes in net signal from the 
inducer-treated samples as compared to the untreated control samples represented the 
change in CYP activity upon enzyme induction ex vivo. Once again, HepG2 was used as a 
positive control for this assay.  
Results obtained showed that cord blood-derived cells responded to induction positively 
displaying an up regulation in CYP levels post treatment (Figure 96a). It was interesting to 
note that CYP proteins in undifferentiated cord blood cells were also inducible.  This result 
was contrary to that reported by Starkel, Sempoux et al, who showed that CYP3A in blood 
neutrophils and lymphocytes was not inducible. It should be pointed out that Strakel et al 
looked at only one of the CYP subfamilies (CYP3A) and it may be that other CYP 
subfamilies detectable in haematopoietic cells are capable of induction by CYP gene 
inducers. Although prior to induction HepG2 cells exhibited a greater level of CYP activity 
compared with cord blood-derived hepatocyte-like cells; post induction CYP levels in 
differentiated cells were comparable to HepG2 expression levels with the highest level 
being detected in UCB differentiated cells post maturation.  
Undifferentiated MSCs failed to show a positive response to induction. Differentiated 
MSCs, however, did respond to induction and displayed an up regulation in CYP levels 
(Figure 96b). This reaction was most appreciated in differentiated MSCs post maturation. 
HepG2 cells also responded to induction and displayed a net increase in CYP levels after 
treatment with the inducers.  
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Figure 96. Induction of cytochrome P450 proteins in differentiated UCB-derived and MSC-
derived hepatocyte-like cells. (a) Both undifferentiated and differentiated UCB-derived 
stem/progenitor cells were inducible and displayed a net increase in CYP protein levels upon 
induction. (b) Undifferentiated MSCs were not induced by the CYP gene inducers (*). 
Differentiated MSCs displayed a net increase in CYP luminescence upon induction with 
Rifampicin and Omperazole with maximum results being obtained after maturation of the 
cells in vitro (♣).  
 
(b) 
* 
♣ 
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Conclusion  
 
Undifferentiated UCB-derived stem/progenitor cells displays evidence of CYP 
activity.  
 
UCB-derived differentiated hepatocyte-like cells express cytochrome P450 
proteins after ex vivo differentiation and maturation. 
 
Both undifferentiated and differentiated UCB-derived stem/progenitor cells were 
inducible and displayed a net increase in CYP protein level.  
 
Undifferentiated MSCs showed minimal to no CYP activity.  
 
MSC-derived differentiated hepatocyte-like cells express measurable cytochrome 
proteins only after maturation.  
 
Cytochrome P450 levels were quantitatively higher in MSC-derived hepatocytes 
compared to UCB-derived hepatocytes post maturation.  
 
CYP levels post maturation were higher in differentiated MSCs compared with 
the positive control used (HepG2).  
 
Undifferentiated MSCs were not induced by the CYP gene inducers. 
 
Differentiated MSCs displayed a net increase in CYP luminescence upon 
induction. 
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5.4.9 Progression to three-dimensional (3D) culture system  
The low cost and high speed of testing have made two-dimensional (2D) cell culture a key 
component of in vitro research. However, a major limitation of 2D cell culture is the 
unnatural geometric and mechanical constraints that are imposed on the cells. 2D culture 
systems provide only approximate properties of normal tissue.  A possible reason for this is 
that cells in monolayer cultures on 2D substrates do not realistically mimic the 3-
dimensional morphologies of cells in tissues. The dynamic and complex interactions of cells 
with their supporting extracellular materials seen in 3D morphologies of cells is also absent. 
Furthermore, 2D cell monolayer cultures are generally exposed to a uniform environment 
(Albrecht, Underhill et al. 2006; Griffith and Swartz 2006). Development of 3D polymeric 
scaffolds and rotatory cell culture systems (RCCS) has paved the way for 3D tissue 
engineering that overcomes the limitation of 2D cell culture. These synthetic scaffolds are 
engineered to provide a surface chemistry that facilitates cell attachment and migration. 
Additionally, scaffolds deliver and retain cells and biochemical factors; enable diffusion of 
vital cell nutrients and expressed products as well as exert certain mechanical and biological 
influences that modify the behavior of the cell phase. Biodegradability is an essential 
property of scaffolds that allows them to degrade leaving behind only the bioengineered 
tissue. The rotatory cell culture provides a laminar flow of medium and minimal shear force 
inside the culture vessel. The cells are maintained in suspension by the resolution of the 
centrifugal, gravitation and coriolis forces. Thus the cells experience minimal mechanical 
stresses and high mass transport of nutrients, oxygen etc and thus are able to assemble into 
tissue-like aggregates (http://www.synthecon.com/bibliography/index.p). 3D cell culture 
systems  mimic normal physiological environments for cell development.  
In this study we attempted at reproducing our 2D differentiation in a 3D culture system. We 
used a variety of scaffolds (Materials and Methods, section 2.12.3.2) but only macrophorous 
hydrogel (Fibrinogen-gelatin) scaffolds proved effective. These scaffolds were provided 
through collaboration with Protista International AB Company 
(http://www.protista.se/?id=736). These scaffolds were used either on their own or in 
combination with the rotatory cell culture system or bioreactor provided by Synthecon 
(http://www.synthecon.com/bibliography/index.p).  
Results obtained from cord blood stem/progenitor cells showed that these cells failed to 
survive in vitro post seeding into the scaffolds. This could be due to the low cell number 
generated post processing of cord blood units that limited cell-cell interaction within the 
scaffolds. Mesenchymal stem cells, on the other hand, responded very well to the 3D culture 
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environment. These cells were noted to form cellular aggregrated within 24 hours post 
seeding into scaffolds (Figure 97). In 2D monolayers, these cellular aggregates were not 
noted until 3 weeks post differentiation. When scaffolds were used on their own in culture 
plates, cells propagated both within the scaffold (as cellular aggregates) as well as outside 
the scaffold in the culture plate (Figure 97). This feature was avoided when scaffolds were 
cultured in the bioreactor (Figure 98). Post differentiation (1 week), cells within scaffolds 
were investigated for the presence of liver cell markers by immunocytochemistry. The cells 
tested positive for albumin, Ck-7, -8 and -18 (Figure 99). The pattern of expression of the 
various hepatic cell markers at week 1 in 3D culture was similar to that noted in 2D 
experiments at week 3 of the differentiation protocol. This clearly showed that the 3D 
culture environment facilitated cell differentiation. The Protista scaffolds were provided to 
us in limited numbers thus the only functional test that was performed on the differentiated 
cells in the 3D system was Indocyanine green uptake and release test. Periodic acid schiff 
could not be performed on the scaffolds due to their polysaccharide structure. There were 
not enough scaffolds to allow Cytochrome P450 assays to be carried out. The results of 
Indocynaine green test illustrated that the cells were able to take up the green dye from 
culture (Figure 100) and eventually excrete it back into the medium within 24 hours.  
 
 
\ 
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Progression to 3-dimensional tissue engineering 
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Figure 97. Mesenchymal stem cells cultured 
in macrophorous hydrogel scaffolds. (A) 
Note cellular aggregates (arrows) formed 
within the scaffold (Fibrinogen-gelatin).  
(Band C) Cells growing out of the scaffold 
and into the culture plate as monolayers. 
DIC images were taken at magnification of 
x20.  
Figure 98. Mesenchymal stem cells seeded 
in scaffolds cultured in rotatory cell culture 
system. (A) Note cellular aggregates (arrow) 
with the scaffold. (B and C) Note tissue-like 
cell growth (*) out of the scaffold and into 
the medium in the culture vessel. DIC 
images were taken at magnification x20.  
A B 
C 
A 
B 
Day 7  
* 
* 
Day 7  
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B 
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Figure 99. Confocal immunocytochemistry images of MSCs differentiated in 3D culture 
system. Cellular nuclei were stained blue or red with DAPI (4’, 6-diamidino-phenylindole 
dilactate). Cells tested positive for albumin (B) Ck-7, -8 (D) and Ck-18 (C). Green= FITC, 
Red=TxRed. Images were taken at magnification x10.  
 
 
 
 
 
 
 
Figure100. Indocyanine green dye uptake by MSCs differentiated in 3D culture system. Cells 
demonstrated the ability to take up the green dye from culture medium (arrow) and excrete it 
back into the medium within 24 hours. 
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5.4.10 Specificity of differentiation protocol 
To confirm the specificity of our differentiation system towards meso-endodermal lineage 
we examined our differentiated cells for markers of ectodermal germ layer lineage. As 
pointed out early, some of the isolated stem/progenitor cell populations; specifically 
Mesenchymal stem cells expressed markers of different germ layers prior to induction for 
hepatobiliary differentiation. To certify that our proposed differentiation system restricted 
further development of these progenitor cells only along endodermal and hepatic lineage we 
examined them for ectodermal/neural markers post ex vivo differentiation.  This would also 
prove that differentiation was induced by the in vitro provided signaling cues and not the 
result spontaneous differentiation in culture. Foetal brain mRNA was used as a positive 
control in all the experiments. Also, cord blood-derived neurone differentiated cells 
(produced by other members of the group) were used to compare with our hepatobiliary 
differentiated cells.  Foetal and adult liver mRNA was used as negative controls.  
Differentiated cells were investigated for the following genes: Paired box gene 6 (Pax6), T-
box brain 1 (TBR1) and T-box brain 2 (TBR2).  
- Pax6 gene is involved in the development of ectodermal tissues (Callaerts, Halder et al. 
1997).  
- TBR1 is a putative transcription factor that is highly expressed in glutamatergic early-born 
cortical neurons and its expression is largely restricted to the cerebral cortex (Hevner, Shi et 
al. 2001).  
- TBR2 is specifically expressed in the intermediate (basal) progenitor cells of the 
developing cortex (Sessa, Mao et al. 2008).  
On examination, both UCB-derived and MSC-derived differentiated cells tested negative for 
Pax6. This illustrated that these cells had committed to meso-endodermal lineages (Figure 
101a). Adult liver was also negative for this gene.  
Interestingly, investigation for TBR2 revealed that adult liver tested positive for this gene, 
whilst foetal liver was negative. This phenomena could be explained by the theory of 
plasticity and differentiation potential of adult liver cells that has been reported previously 
in literature (Koenig, Krause et al. 2006). MSC differentiated cells displayed a weak 
expression of this gene but UCB-derived differentiated cells were negative (Figure 101b). 
 TRBR1 expression was negative in both foetal and adult liver cells but weakly positive in 
MSC differentiated cells. Differentiated UCB cells tested negative for TBR1.  
The expression of neural progenitor markers in MSCs post differentiation suggested that 
even after differentiation along a specific developmental pathway these cells had maintained 
some of their original multipotent phenotype. One of the limitations of our proposed 
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differentiation system was that we succeeded in producing a heterogeneous society of liver 
cells with majority displaying a bi-potent liver progenitor cell phenotype rather than mature 
hepatocytes. Further development and maturation of these progenitor cells may lead to a 
more mature hepatobiliary cell phenotype and may cause a down regulation in the 
expression of progenitor markers from other germ layers.  
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(c) TBR1 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 101. Establishment of the specificity of the proposed liver differentiation system. Foetal 
brain mRNA was used as a positive control (←). Foetal and adult liver mRNA was used as 
negative controls. Cord blood-derived neurone differentiated cells were used to compare with 
our hepatocyte differentiated cells. (a) Both adult liver cells and our differentiated cells tested 
negative for Pax6, ectodermal marker. (b) TBR2 expression was detected in adult liver tissue, 
but negative in foetal liver. MSC-derived differentiated cells also tested weakly positive for 
TBR2. (c) TBR1 was negative in both foetal and adult liver but once again weakly expressed in 
differentiated MSCs.   
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5.4.11 Discussion 
The first clinical application of UCB for treatment of acute lymphoblastic leukaemia in 
1970 fuelled a lot of interest in cord blood as a valuable stem cell resource. 20 years later, 
the value of cord blood was internationally appreciated and the concept of cord blood banks 
came into existence in 1990. The majority of research implemented was, however, focused 
on the whole mononucleated cell fraction of cord blood and experiments were 
predominantly peformed in vivo in animal models (Ishikawa, Drake et al. 2003; Newsome, 
Johannessen et al. 2003; Wang, Ge et al. 2003; Almeida-Porada, Porada et al. 2004; Sharma, 
Cantz et al. 2005). Little work was done to characterize the cells in cord blood and very few 
in vitro data was reported. In 2005, McGuckin et al, reported for the first time, the selective 
isolation a stem/progenitor cell population within cord blood that expressed embryonic stem 
cell markers (McGuckin, Forraz et al. 2005). They further went on to characterize these cord 
blood cells (Forraz, Baradez et al. 2006) and demonstrated their multipotential property in 
vitro.  
Taking into account the importance of cord blood banking, one of the goals of this study 
was to compare the most commonly used cord blood processing techniques and to identify 
the most efficient way forward for cord blood banks. Identification of the most effective and 
economical processing and storage methods is of prime importance to some cord blood 
banks that are struggling financially. The two key determining factors for engraftment post 
transplantation are the number of nucleated cells (total nucleated cell count) and CD34+ cells 
infused and the number of HLA differences (Gluckman, Rocha et al. 2004; Kamani, 
Spellman et al. 2008). Total nucleated cell counts (TNC) and haematopoietic (CD133+; 
CD34+) and non-haematopoeitic stem/progenitor cell contents of cord blood immediately 
post processing and after cryopreservation were compared for the various processing 
techniques.  Here we have demonstrated that when cord blood samples are aimed for 
immediate transfusion/transplantation then PrepaCyte-CB would be the technique of choice. 
PrepaCyte demonstrated very efficient TNC recovery post processing, as well as very 
effective RBC depletion. Recoveries of Various stem/progenitor cells were also notably 
superior to the other techniques tested. An added advantage with PrepaCyte-CB was that it 
provided a completely closed system for cord blood processing. This allowed processing of 
cord blood units to be performed in class II laminar flow hoods rather than specialized GMP 
grade clean rooms. This may prove of considerable importance for hospitals and 
transplantation centers where the cost of installation of specialized GMP grade processing 
units is a financial burden.  
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For cord blood banks, where blood units are to be cryopreserved for possible future use then 
Sepax would be a better alternative. Sepax demonstrated the highest TNC post freezing and 
subsequent thaw. Recoveries of both HSC and non-haematopoietic stem/progenitor cells 
were also efficient. The single use kits provided also allowed controlled separation of 
cellular products in cord blood in a fully automated and closed environment. No other 
equipment was required during the processing procedure. The major limitation of this 
technique was the suboptimal RBC depletion and volume reduction compared with the other 
techniques. This is an important issue for cord blood banks.  
Density gradient method of cord blood processing was probably the best option for in vitro 
research in the laboratory. This method demonstrated very effective RBC depletion but was 
the least effective in terms of TNC and stem/progenitor cell recoveries. However, the time 
and cost effectiveness of this technique makes it an attractive method for regular laboratory 
based research.  
The next phase of this study was aimed at demonstrating the selective isolation of a 
stem/progenitor cell population within cord blood that expressed embryonic stem cell 
markers. Isolation of a homogenous stem/progenitor cell population could prove to be of 
great clinical importance. Thorough characterization of isolated cell fractions may 
contribute to better engraftment as well as reduce the chances of tumour formation in the 
patient. Characterization of cell therapy products is becoming increasingly important to 
translate pre-clinical research into clinical trials, as most regulatory agencies want 
guarantees that investigators understand the characteristics of the cells applied in therapy.  
We did this by using our in-house ‘lineage negative selection protocol’ that was previously 
designed by our group (McGuckin, Forraz et al. 2005) and a commercial ‘human primitive 
progenitor cell enrichment kit’ from Stem Cell Technologies. Our in-house protocol proved 
more effective in the selection of early stem/progenitor cells. However, the labour intensive 
nature of this procedure and the extensive cell manipulation involved concluded in opting 
for the StemSep kit for practical reasons and subsequent results were similar to the ones 
obtained with the in-house protocol.  
One of the main restricting factors that deem cord blood units of modest volume unsuitable 
for transplantation is the low yield of stem/progenitor cells. Several attempts have been 
made previously by research groups to achieve self-renewal of stem/progenitor cells in vitro 
but the results have so far been modest (Sorrentino 2004). As a part of this study we 
formulated an ex vivo expansion system for UCB stem/progenitor cells that abided by the 
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concepts of minimal manipulation. The results obtained, however, were unimpressive. The 
cells only demonstrated one doubling in culture after which the cell viability deteriorated. 
Thus, we decided to perform a short (1 week duration) expansion and simultaneous germ 
layer (meso-endoderm) commitment. This would allow any further procedures (eg 
differentiation) to be carried out while the cells were still viable. We demonstrated that at 
the end of this protocol the cells expressed endoderm specific markers (Gata-4) as well as 
some early hepatic markers (albumin, Ck-7 and Ck-19). Cytogenetic analysis on these cells 
demonstrated that the cells had a stable karyotype post treatment. Genome stability is of key 
importance in order to translate these findings into clinical settings.  
The complexicity of cord blood processing and the resulting scarcity of stem/progenitor 
cells generated forced us to look into the umbilical cord for an alternative stem/progenitor 
cell source. We were able to successfully isolate Mesenchymal stem cells from umbilical 
cord matrix (Wharton’s jelly) with ease and 100% efficiency. We have reported that in 
addition to the conventional MSC markers these cells also expressed some embryonic stem 
cell markers. These cells also demonstrated very efficient in vitro proliferation and viability. 
Karyotype analysis post prolonged in vitro expansion demonstrated that the cells were 
genetically stable.  
This study also endeavoured to exploit the multi-potential property of UCB-derived 
stem/progenitor cells and umbilical cord Mesenchymal stem cells to reproduce the liver 
‘stem cell niche’ ex vivo.  These cells could provide an ideal in vitro model that could serve 
as a platform to improve our understanding of the developmental biology of the liver as well 
as be exploited in toxicology studies and in bio-artificial liver devices.  
Stimulation with a range of differentaitive hepatic signals resulted in successful 
commitment of UCB-derived undifferentiated progenitor cells and Mesenchymal stem cells 
along hepato-biliary lineage. A three step protocol encompassing: (I) short-term 
expansion with meso-endoderm commitment, (II) hepato-bilary specific differentiation 
and (III) short-term maturation; was applied to effect hepatic differentiation from 
undifferentiated primitive cells (Figure 103). We were able to successfully generate niche-
like cellular colonies when cord blood stem/progenitor cells were cultured. These ‘niches’ 
were initially composed of colonies of small rounded cells, 4-5µ in size, surrounded by 
spindle-shaped cells. As the colonies enlarged, the heterogeneous nature of the niches 
became more evident and large multinuclear cells were noted on which the colonies rested.  
 Initial endoderm commitment of UCB-derived stem/progenitor cell populations was 
achieved using acidic-FGF, HGF and SCF in low-serum culture conditions for a week 
Chapter 5: Differentiation of Human Cord and Cord Blood Stem/Progenitor Cells Towards Liver Lineage 
 331 
followed by differentiation using a cocktail of acidic-FGF, HGF and EGF in low serum 
culture conditions which was eventually tapered to achieve a serum-free system. Post 
endoderm induction and cell differentiation we were able to generate bipotent liver 
progenitor cells from both MSCs and cord blood primitive cells. Maturation of hepatocyte-
like differentiated cells was achieved using a combination of dexamethasone, Oncostatin M 
and ITS+3 (Insulin 1mg/ml, transferrin 0.55mg/ml, sodium selenite 0.5µg/ml, linoleic acid 
470 µg/ml, oleic acid 470 µg/ml, bovine serum albumin 50 mg/ml). In the presence of 
maturation inducers, a retraction of elongated end of MSCs membranes was observed and 
the polygonal morphology of cord blood-derived hepatocyte-like cells became more 
apparent with increased length in culture.  In vitro characterisation assays of differentiated 
cells illustrated that most of the liver markers showed a slightly higher ratio of expression in 
the MSC cultures compared to the cord blood culture systems. The phenotypic profile of our 
differentiated cells was heterogeneous with a phenotype spectrum ranging from hepatic 
stem cells, hepatoblast and mature hepatocytes and biliary epithelial cells. The majority of 
the cells, however, could be characterized as bipotential hepatic progenitors expressing both 
hepatocyte and biliary cytokeratins but not yet fully committed to either lineage (Figure 
103). This is of particular importance as production of umbilical cord MSCs is highly 
reproducible and less cumbersome than isolating MSC from UCB. 5-10mm3 of the UC can 
produce as much as 1 billion MSCs in 30 days and three passages. Since the average UC 
measures 50cm, this MSC source is likely to become increasingly relevant for cell therapy 
research and applications (Forraz 2010).  
Both differentiated cell lineages in addition to illustrating morphological and 
immunophenotypical characteristics of liver progenitor cells, also exhibited signs of 
functional activity. The cells illustrated active carbohydrate metabolism (positive Periodic 
acid Schiff staining); the ability to take up and excrete Indocyanine green dye and 
cytochrome P450 system activity.  
As a control for our in vitro differentiated cells the following cell sources were used: a well 
known human hepatocellular carcinoma cell line (HepG2); human foetal liver tissue 
(gestational ages 7, 9 and 12 weeks) and human adult liver tissue. The immunocytological 
assays performed on the umbilical cord and UCB- derived cells were repeated on these cell 
lines.  Estimation of an exact ratio of marker expression in HepG2 cell line proved difficult 
due to the nature of the growth of the cell line in piles and mounds instead of monolayer. 
However, it could still be appreciated that in this well differentiated liver cell line the degree 
of expression of liver markers was not 100%. The majority of the cells displayed a 
phenotype comparable to bipotent hepatoblast. Thus, the efficiency of differentiation in our 
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primary cultures was comparable to the data generated from this liver carcinoma cell line. 
However, lack of a mature hepatocyte phenotype in this cell line meant that it was not an 
ideal representative control. This information is of prime importance to drug companies and 
biochemical industries where these cells are frequently resorted to as in vitro hepatocyte 
models for toxicology studies and drug testing.  
Immunocytochemistry data generated from human foetal liver tissue sections (9weeks 
gestation) demonstrated that the phenotype of foetal liver hepatic progenitor cells were 
comparable to the phenotype of our ex vivo differentiated cells. Again, due to the lack of 
mature hepatocyte phenotype, foetal liver tissues at different developmental stages would 
serve as a good model to check the phases and extent of in vitro stem/progenitor cell 
differentiation but do not represent an ideal mature hepatocyte control.  
The ideal control for this liver differentiation study was human adult liver tissue sections. 
Mature hepatocytes represent the perfect morphological, phenotypical and functional 
positive control for ex vivo hepatic differentiation. However, resource for this tissue is 
limited to cadaveric supply or from post hepatotectomy specimens, restricting its 
accessibility.  
mRNA samples from the three control specimens were used as controls for molecular 
analysis of our differentiated cells. This supplemented qualitative protein analysis 
(immunocytochemistry/immunohistochemistry and western blots) with quantitative gene 
level data.  
We were unable to attain primary cultures of human foetal liver cells and human adult 
hepatocytes, thus primary HepG2 cell cultures were used as the sole control for functional 
assays performed. Our UCB and umbilical cord-derived hepatocyte differentiated cells 
displayed a degree of metabolic and functional activity that was comparable to HepG2 cells.         
It may be concluded that the three step protocol utilized in this study permitted the umbilical 
cord and UCB-derived pluripotent/multipotent stem cells to commit to meso-endodermal 
germ layer lineage early in the course of ex vivo culture thus ensuring a higher efficiency of 
in vitro differentiation of these stem cells into liver cell populations. We successfully 
generated bipotent liver progenitor cells similar to in vivo hepatoblasts that expressed both 
hepatic and biliary markers. 
Our staged differentiation protocol was devised in 2D cell culture experiments. This 
provided essential phenotypic, protein and molecular level information throughout the 
protocol. However, the 2D monolayer configuration of the cells in culture did little justice in 
mimicking the physiological 3D environment of cells in vivo. Thus, we ventured to 
investigate the use of scaffolds and rotatory cell culture systems to provide a 3D in vitro 
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culture environment more closely resembling the natural cell environment in the human 
body. Here we report that the 3D culture system enhanced ex vivo cell differentiation 
through improved cell-cell and cell-extracellular matrix interactions. Clinically, these 3D 
engineered tissue constructs may allow direct delivery of cells to the site of tissue 
damage/loss and eventually degrade leaving behind the bioengineered tissue. This route of 
administration may prove more beneficial and effective than intravenous transfusion of stem 
cells and may reduce the dose of immunosuppressants required to dampened graft rejection.  
The scarcity of donor livers and other organs is the driving force behind the emerging field 
of tissue engineering and regenerative medicine. Efforts to build tissues from the ground up 
have proven very challenging and have yet to be translated into transplantable replacement 
organs. The liver, in particular, poses a great challenge for this task. Each hepatocyte 
functions as a metabolic factory demanding constant, direct contact with the vascular 
system. One of the limitations of artificial in vitro tissue engineering so far has been the lack 
of an established vascular system associated with the cultured cells. Attempts at co-culturing 
with endothelial cells have been made but this still did not provide cells with stable vascular 
supply (Talamini, McCluskey et al. 1998). Powerful developments in the multidisciplinary 
field of tissue engineering have yielded a novel set of tissue replacement parts and 
implementation strategies A Latest advancement in the field of tranplantational medicine 
has developed a technique that may someday translate into growth of transplantable 
replacement organs. In 2008, Ott et al performed decellularization of rat hearts leaving 
behind an intact vascular system that facilitated repopulation of the structural matrix and 
subsequent survival and function of introduced cardiac and endothelial cells (Ott, 
Matthiesen et al. 2008). This technique was refined in 2010 and applied to rat liver (Uygun, 
Soto-Gutierrez et al.). This work is a break through in the field regenerative liver therapy. 
Decellularized liver matrix may provide a biocompatible, natural scaffold on which 
stem/progenitor cells can be reseeded. Having the detailed microvasculature of the liver is a 
major advantage to growing liver tissue in a synthetic environment. These results provide a 
proof of principle for the generation of a transplantable liver graft as a potential treatment 
for liver disease. It must, however, be emphasized that although there are very promising 
advancements in the field of liver regeneration, we are still a long way from translating 
research into clinical application.  
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Figure 102. Three stage serum tapering in vitro differentiation system and resulting cellular 
phenotype at each stage.  
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(Schmelzer, Zhang et al. 2007) 
Figure103. A schematic diagram illustrating phenotypic overlap between different liver cells. 
In vitro characterization of our differentiated cells displayed a cellular phenotype expanding 
over a society of liver cells with features in common with: hepatic stem cells, hepatoblasts, 
hepatocytes and cholangiocytes. Thus, it may be safely concluded that we succeeded in 
producing a population of bi-potent progenitor cells displaying both hepatocyte and biliary 
epithelium features but not fully committed to either lineage.  
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6 Summary and Future work 
6.1 The following conclusions were deduced from this study: 
Cord blood processing: 
 PrepaCyte-CB is an appropriate choice for cord blood processing in hospitals and 
transplantation centers where UCB units are demanded for immediate 
transfusion/transplantation. 
  The fully automated sterile system provided by Sepax is an ideal method for processing 
of cord blood units aimed for cryopreservation and long term storage. 
 Isolation and characterization of stem/progenitor cells from cord blood 
 We were ably to successfully isolate and characterize a population of primitive cells 
within the mononucleated cell fraction of cord blood that expressed early haematopoietic 
stem cell markers as well as some embryonic stem cell markers. 
 We were also able to identify a non-haematopoietic stem cell population within cord 
blood.  
 Expansion and Commitment of stem/progenitor cells 
 We devised a short term protocol that achieved a very modest increase in 
stem/progenitor cell number but allowed simultaneous commitment of cells to meso-
endoderm lineage.  
 Isolation and characterization of umbilical cord-derived MSCs 
 We managed to successfully isolate MSCs from umbilical cord matrix (Wharton’s jelly) 
with 100% efficiency. These cells expressed the conventional MSCs markers as well as 
some embryonic stem cell markers. MSCs demonstrated very efficient in vitro proliferation 
and propagation. MSCs demonstrated commitment to hepatic lineage upon isolation  
Ex vivo differentiation of UCB-derived stem/progenitor cells and umbilical cord MSCs 
along hepatobiliary lineage 
 At the end of a three-step differentiation protocol we reported a heterogeneous 
population of differentiated cells that resembled natural human hepatobiliary cells in 
phenotype, protein level as well as genetic profile. These differentiated cells spanned the 
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spectrum of hepatobiliary lineage: hepatic stem cells, hepatoblasts, mature hepatocytes and 
cholangiocytes. The majority of the cells, however, resembled bipotent hepatoblast, 
expressing both hepatocyte and cholangiocyte markers. These cells also demonstrated signs 
of functionality and metabolic activity.  
Progression from 2D to 3D culture system 
 3D culture environment enhanced and promoted liver differentiation ex vivo.  
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6.2 Futher developments 
The results generated in this study are very promising for possible future application as 
translational cell therapy of end-stage liver disease. Upon delivery of these differentiated 
hepatic progenitor cells/hepatoblasts to the site of damage, the local microenvironment 
might determine the ultimate fate of the progenitor cells. It may be argued, however, that the 
heterogeneous nature of the ex vivo differentiated cell population may prove to be a matter 
of concern in terms of graft rejection ad possible malignant transformation. Thus, the need 
for refinement of the differentiation protocol to produce a homogenous population of either 
hepatocytes or cholangiocytes is demanded. Additionally, a homogenous population of 
hepatocytes will provide an ideal platform for ex vivo toxicology studies as well as in bio-
artificial liver-assist devices.  
 
Incorporation of vital liver supporting cells (stellate cells), sinusoidal cells and endothelial 
cells in a co-culture system may provide a more physiological environment for liver cell 
development and hence enhance further maturation of hepatic progenitor cells.  
 
The ultimate aim for transplantation medicine would be to produce bioengineered liver 
tissue constructs that represent normal liver infrastructure. Although this may appear as a 
mammoth task at present, intricate advancements achieved by groups like (Uygun, Soto-
Gutierrez et al.; Ott, Matthiesen et al. 2008) may lessen the complexity of future studies.  
In vitro developed bioengineered liver tissue constructs will need to be tested in animal 
models of liver disease with detailed critical evaluation of subsequent results to determine 
their complete potential. Only then should such research be translated to clinical trials in 
humans.  
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Appendix A- Patient information sheet and consent forms  
Umbilical cord and cord blood units were collected from elective caesarean section 
deliveries at the maternity unit in the Royal Victoria Infirmary, Newcastle upon Tyne. Fully 
explained informed consent was obtained from expecting parents prior to delivery. All the 
ethical requirements required by hospital, university and National Health Service have been 
fulfilled.  
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Appendix B- Details of Flowcytometric analysis  
Flow cytometry is a semi-automated system that allows for the investigation of single cells 
in a continuous fluid stream, enabling simultaneous measurements of multiple extra- and 
intra-cellular characteristics.  
The objective of flow cytometry is very simple: measurement by quantification of photon 
release, components of the membrane, cytoplasm and nucleus of a particular cell or group of 
cells. Cell surface and cytoplasmic measurements are usually cellular antigen expression, 
and the most commonly used probes are monoclonal antibodies directed to specific antigens 
on or in the cell. Dyes may be used that are specific for DNA, such as Hoechst 33342; for 
RNA, such as Pyronin-y; or other intracellular constituents, such as Indo-1 for calcium.  
Multiple antibodies can be used simultaneously within the same sample, provided each 
antibody possesses a spectrally different attached fluorescent reporter molecule. The 
resultant data will give an antigenic profile of each cell, predetermined by the specificity of 
the antibodies used. For the dyes, these are fluorochromes in their own right and will bind to 
the cell constituents specific to each.  
Principles of the flow cytometer – Becton Dickinson LSRII 
A. Flow cell 
The flow cell is where the cellular investigation takes place. Introduction of a single cell 
suspension in combination with hydrodynamic focusing and laminar flow ensures optimal 
excitation of fluorochromes allowing optimal scatter characteristics from cells to be 
acquired. As the cells are introduced into the flow cell they should pass the centre of the 
interrogation point of the laser beam. Once the sample is analysed they go to waste, along 
with the fluid sheath.  
B. Laser investigation at the flow cell  
A 488nm laser beam focuses on the flow cell inducing emission of scattered and/or 
fluorescent lights. The intensity of the light scattered in the forward direction (forward 
scatter light- FSC) is proportional to the square radius of the analyzed sphere hence 
representing the cell size. The 90° side scatter (SSC) is refracted in proportion of the nuclear 
and granular cell content giving indications of the internal cellular complexity and surface 
topography. In addition to providing essential information about physical characteristics of 
cells, flowcytometry also allows measure of fluorescent probes. Currently a single 
instrument is capable of detecting 18 fluorescent probes, allowing a large amount of data to 
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be generated from relatively small number of cells. The excitation and/or emission spectra 
of chosen fluorochromes have to be distinct in order for them to be used simultaneously. 
Insertion of multiple lasers into flow cytometers enables more excitation lines and hence 
widens the choice of fluorochrome.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Principles of Flow Cytometry. Cells are aspirated into the flow cytometer and 
transported in a flow of sheath fluid to the flow cell chamber.  The argon-ion laser produces a 
488nm monochromatic light beam which is condensed by a lens (L) focussing the beam 
through the cells.  The primary light beam passes through the cell and is blocked by a specific 
lens (BL) causing forward scatter light (FSC) which is collected by the detector (D).  The 
488nm side scatter (SSC) as well as fluorescence lights are diffracted at a 90º angle and 
further focussed through a lens.  A series of relevant beam splitters (BS), dichoric mirrors (M) 
and filters ((F) enable specific collection of SSC as well as green, orange and red fluorescence 
lights.  FSC, SSC and fluorescence lights falling upon their respective detectors are converted 
in electrical signals themselves amplified by a set of photomultiplier tubes (PMT) and received 
in five channels (FSC, SSC, FL1, FL2, and FL3).  Another laser producing a 635nm beam is 
also used in the same manner and is in the end received by FL4 channel.  These signals are all 
processed by an analogue-to-digital converter, which allows acquisition and analysis of the 
quantity and intensity of these signals on an attached computer.  The signals are then 
represented on visual display unit as frequency of distribution.  
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Various fluorochromes used allow data to be generated provided that the appropriate 
fluorescent detector (laser) is available. The fluorochromes absorb light from an excitation 
source, which is the laser beam. This allows the electrons of the flurochrome to enter the 
next electron orbit which is an unstable state. For the excited molecule to reach a stable 
conformation, the absorbed energy is dispelled by heat and vibration, resulting in the 
emission of a longer wavelength of photons. This is the emission wavelength for the 
molecule. A point of note is that the maximum excitation of laser required need not be 
exact, for example, 488nm. The excitation of each fluorochrome is in the form of a 
spectrum, thereby enabling lasers of specific wavelengths to excite areas of the excitation 
spectrum away from the peak, although with sub-optimal results. Also, independent of 
excitation wavelength, the emission spectra of each fluorochrome will remain the same.  
It should also be noted that different fluorochromes have different ‘brightness’, determined 
by the extinction coefficient and quantum fluorescence yield of each molecule. In principle, 
the weaker the antigen expression, the fluorochrome applied should be brighter.  
 
 
 
 
 
Figure 2. Grading of brightness of the fluorochromes utilized during the course of this 
research. Becton Dickinson LSRII.  
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 For any given fluorochrome, the intensity of staining is directly proportional to the number 
of antigenic sites available. Any non-specific binding, which is at a much lower intensity 
than the specific binding, is due to complement receptors binding and cross-reactivity of the 
antibody with other antigens.  
C. Accounting for non-specific staining 
 
Detection of negative and positive populations can be done either by the use of an isotype 
control or the use of totally unstained cells.  
In isotype controls, cells are incubated with the same protein concentration, fluorochrome 
and immunoglobulin subtype as the specific test antibody. The drawback, however, is that 
occasionally isotype controls can have very different staining characteristics to the specific 
antibody in terms of non-specific binding. Thus, it may be better to use unstained cells or 
the negative population of the positively-stained sample, to adjust the settings of the 
photomultiplier tube (PMT).  
D. Spectral compensation 
In the event of using more than one fluorochrome, any spectral overlap between the 
fluorochromes has to be removed. This ensures that each fluorochrome signal represents 
only the antigens marked by that particular fluorochrome.  It is also important to measure 
accurately those cells that express more than one fluorochrome, by virtue of more than one 
antigen being expressed on the cell surface.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendices 
 370 
Appendix C- PCR gel electrophoresis 
To ensure the specificity of the primers used for real-time PCR analysis, end-point PCR gel 
electrophoresis was performed to ensure that the sizes of the products picked up by the 
primers were accurate. A positive control (Adult liver cDNA) was used for this analysis. 
Product bands are illustrated in the figure below.    
 
 
 
 
 
 
    
Figure 3.  PCR gel electrophoresis illustrting product sizes for the primers examined. Furthest 
Left hand demonstrates the 50bp ladder applied. 1.5% agarose gel was used. Primers were 
tested on poitive control (Adult liver cDNA from Primer design). SDHA and RPL13A are 
house keeping genes.        
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